[
    {
        "instruction":"已知信息：\n'在药品杂质检查中，用古蔡氏检碑法(Gutzeit'sarsenictestmethod)时，金属锌与盐酸作用产生新生态的氢，与试品中的微量碑盐反应生成具有挥发性的碑化氢，遇澳化汞试纸所产 生的黄色至棕色的斑点。'可被翻译为：In the examination of drug impurities, the Gutzeit'sarsenictestmethod is used to produce new ecological hydrogen by the interaction of metal zinc with hydrochloric acid, which reacts with trace salt in the test to produce volatile stele hydrogen, and meets the yellow to brown spots produced by the mercury test paper.\n\n根据上述已知信息，请将'在实验条件下能与硫代乙酰胺或硫化钠作用显色的金属杂质。如银、铅、汞、铜、镉、秘、睇、锡、碑、锌、钻与镖等。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Metallic impurities capable of acting with thioacetamide or sodium sulfide to produce color under experimental conditions. Such as silver, lead, mercury, copper, cadmium, secret, tin, tablets, zinc, diamonds, darts, etc."
    },
    {
        "instruction":"已知信息：\n'十三、推进医疗服务精细化监管'可被翻译为：13. Promoting fine-grained supervision of medical services\n\n根据上述已知信息，请将'七、推进医疗服务价格动态调整等联动改革'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"7. Promoting interlocked reforms such as the dynamic adjustment of medical service prices"
    },
    {
        "instruction":"已知信息：\n'为规范化妆品生产质量管理，根据《化妆品监督管理条例》《化妆品生产经营监督管理办法》等法律、法规和规章，国家药监局组织制定了《化妆品生产质量管理规范》（以下简称《规范》），并于1月6日发布，自2022年7月1日起施行。'可被翻译为：In order to regulate the production quality management of cosmetics, according to the Regulations for the Supervision and Administration of Cosmetics, Provisions for the Supervision and Administration of Cosmetics Manufacture and Distribution and other laws, regulations and rules, NMPA organized to formulate the Good Manufacturing Practice for Cosmetics (hereinafter referred to as the GMP), which was issued on January 6, and shall enter into force as of July 1, 2022.\n\n根据上述已知信息，请将'为规范化妆品不良反应监测工作，根据《化妆品监督管理条例》《化妆品生产经营监督管理办法》等法规、规章，国家药监局组织制定了《化妆品不良反应监测管理办法》，于2022年2月15日予以公布，自2022年10月1日起施行。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In order to regulate the ADR monitoring for cosmetics, according to the Regulations on Supervision and Administration of Cosmetics and the Provisions for Supervision and Administration of Cosmetic Manufacturing and Distribution, the NMPA formulated the Provisions for the Administration of Adverse Reaction Monitoring of Cosmetics, which was issued on February 15, 2022 and will come into force on October 1, 2022."
    },
    {
        "instruction":"已知信息：\n'如果在混悬剂中因加入电解质使微粒表面的&电位升高，静电排斥力阻碍了微粒之间的碰撞聚集，絮凝状态消失，所加入的电解质称为反絮凝剂。'可被翻译为：If the electrolyte is added to the suspension to increase the potential of the particle surface, the electrostatic repulsion hinders the collision between the particles and the aggregation, the flocculation state disappears, the added electrolyte is called the deflocculant.\n\n根据上述已知信息，请将'在混悬体系中加入电解质使微粒表面J电位升高，这时静电排斥力的增大阻碍了微粒间的碰撞聚集，使得絮凝现象减少的过程。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The addition of electrolyte in the suspension system increases the J potential of the surface of the particles, and the increase of electrostatic repulsion hinders the collision and aggregation of the particles, making the process of reducing the flocculation phenomenon."
    },
    {
        "instruction":"已知信息：\n'1.每批药品均应当有留样；如果一批药品分成数次进行包装，则每次包装至少应当保留一件最小市售包装的成品。'可被翻译为：1) There should be reference samples for each batch. Where a batch is packaged into several distinct packaging operations, at least one reference sample should be taken from each individual packaging operation.\n\n根据上述已知信息，请将'2.留样的包装形式应当与药品市售包装形式相同，原料药的留样如无法采用市售包装形式的，可采用模拟包装。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2) The package of reference samples should be identical to the products in the market. If the package of reference samples of active pharmaceutical ingredients (API) cannot be the same as the form in the market, a simulated package may be adopted."
    },
    {
        "instruction":"已知信息：\n'（四）有与生产的化妆品品种、数量和生产许可项目等相适应的技术人员；'可被翻译为：(4) having technicians who are suited to the varieties, quantity and manufacturing licensed items, etc. of the cosmetics manufactured;\n\n根据上述已知信息，请将'（三）有与生产的化妆品品种、数量和生产许可项目等相适应的生产设施设备且布局合理，空气净化、水处理等设施设备符合规定要求；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(3) having the manufacturing facilities and equipment that are appropriate to the varieties, quantity and manufacturing licensed items, etc. of the cosmetics produced, and having a reasonable layout thereof, and the air purification, water treatment facilities and equipment, etc. that meet the specified requirements;"
    },
    {
        "instruction":"已知信息：\n'将药物与辅料制成的小块状或条状供植入体内的无菌固体制剂。'可被翻译为：A sterile solid preparation in which a drug and excipient are inserted into the body in small chunks or strips.\n\n根据上述已知信息，请将'由药物与赋形剂或单独由药物经热融压制而成的一种供腔道或皮下植入的无菌固体控释制剂。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A sterile solid controlled release preparation made by heat melting of a drug with an excipient or a drug alone for endovascular or subcutaneous implantation."
    },
    {
        "instruction":"已知信息：\n'第九条 国家鼓励体外诊断试剂的研究与创新，对创新体外诊断试剂实行特别审批，促进体外诊断试剂新技术的推广与应用，推动医疗器械产业的发展。'可被翻译为：Article 9 The State encourages the research and innovation of in-vitro diagnostic reagents, implements special review for innovative medical devices, accelerates the popularization and application for new technologies of in-vitro diagnostic reagents and promotes the development of medical device industry.\n\n根据上述已知信息，请将'体外诊断试剂临床试验（包括与已上市产品进行的比较研究试验）是指在相应的临床环境中，对体外诊断试剂的临床性能进行的系统性研究。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The clinical trial of in-vitro diagnostic reagents (including the comparative study made with the marketed products) refers to the systematic study on the clinical performance of in-vitro diagnostic reagents in the corresponding clinical environment."
    },
    {
        "instruction":"已知信息：\n'第二十一条 医疗器械生产企业对召回医疗器械的处理应当有详细的记录，并向医疗器械生产企业所在地省、自治区、直辖市食品药品监督管理部门报告，记录应当保存至医疗器械注册证失效后5年，第一类医疗器械召回的处理记录应当保存5年。对通过警示、检查、修理、重新标签、修改并完善说明书、软件更新、替换、销毁等方式能够消除产品缺陷的，可以在产品所在地完成上述行为。需要销毁的，应当在食品药品监督管理部门监督下销毁。'可被翻译为：Article 21 The medical device manufacturer shall keep detailed records on the handling of recalled medical devices, and report to the food and drug regulatory department of the province, autonomous region or municipality directly under the Central Government where the medical device manufacturer is located. The records shall be kept up to 5 years after the expiration of the Medical Device Registration Certificate, and the handling records of the recall of Class I medical devices shall be kept for 5 years. Where product defects can be eliminated by warning, checking, repairing, relabeling, modifying and improving the instructions for use, software upgrade, replacement, and destruction, the above actions may be completed at the location of the product. The medical devices that need to be destroyed shall be destroyed under the supervision of the food and drug regulatory department.\n\n根据上述已知信息，请将'第三条 本办法所称医疗器械召回，是指医疗器械生产企业按照规定的程序对其已上市销售的某一类别、型号或者批次的存在缺陷的医疗器械产品，采取警示、检查、修理、重新标签、修改并完善说明书、软件更新、替换、收回、销毁等方式进行处理的行为。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 3 The recall of medical devices in these Provisions refers to the handling acts of medical device manufacturers to the defective medical device products of a certain category, model or batch which have gone to the market through warning, checking, repair, relabeling, modifying and improving the instructions for use, software upgrade, replacement, withdrawal, destruction in accordance with the prescribed procedures."
    },
    {
        "instruction":"已知信息：\n'在无菌性测试中所用的每种培养基（THIO和SCD）管在整个检测时间段内均需 直接暴露于测试环境中（例如，层流罩）。或者，实验室可使用节b中详细说明 的琼脂沉淀板。'可被翻译为：Tubes of each medium (THIO and SCD) used in the sterility analysis are exposed to the immediate environment of the test (e.g., laminar flow hood) for the duration of the test. Alternatively, a laboratory may use agar settling plates as detailed in section b.\n\n根据上述已知信息，请将'可以在实验室工作台上进行检测，不需要设置洁净间或层流罩。但是，在使用通用生长培养基和检测微生物时要重视遵守无菌操作技术，防止交叉污染。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Testing can be performed on a laboratory benchtop and does not require setup in a clean room or a laminar flow hood. However, it is important to exercise aseptic technique when working with general growth media and test organisms to prevent cross contamination."
    },
    {
        "instruction":"已知信息：\n'第一百一十六条 违反本办法第二十八条、第三十三条规定，申办者有下列情形之一的，责令限期改正；逾期不改正的，处一万元以上三万元以下罚款：'可被翻译为：Article 116 In any of the following circumstances in violation of Articles 28 and 33 of these Provisions, the sponsor shall be ordered to make corrections; where corrections are not made within the specified timeline, the sponsor shall be imposed a fine of not less than RMB 10,000 but not more than RMB 30,000.\n\n根据上述已知信息，请将'第六十八条 有下列情形之一的，按照《药品管理法》第一百一十五条给予处罚：'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 68 In case of any following circumstances, penalties shall be imposed in accordance with Article 115 under the Drug Administration Law:"
    },
    {
        "instruction":"已知信息：\n'下面列出的分析用所有物品要单独控制。试验中使用的每种培养基都测试了每个高 压灭菌器中的一个设备。因此，对于在THIO和SCD中测试的样品，在每个培养基 中检测来自每个灭菌器（烘箱或高压灭菌器）装载的一个物品，测试中使用的每个 镊子、注射器等总共进行两个控制。'可被翻译为：All equipment items used in the analysis listed below will be controlled individually. One item from each autoclave lot of equipment is tested in each medium used in the test. Therefore, for a sample tested in THIO and SCD, one item from each sterilizer load (oven or autoclave) is tested in each medium giving a total of two controls for each forceps, syringe, etc., used in the test.\n\n根据上述已知信息，请将'或者，完成对这些材料的控制，作为每个歧管的“系统控制”的一部分。这还将 包括薄膜切割器和其他接触产品但无法单独控制的物品。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Alternatively, controls for these materials are accomplished as part of the \"system control\" for each manifold. This will also include membrane cutters, and other items that contact the product but cannot be individually controlled."
    },
    {
        "instruction":"已知信息：\n'亚基'可被翻译为：subunit\n\n根据上述已知信息，请将'蛋白质分子由多个具有三级结构亚基聚集形成的稳定构象。亚基间的聚合主要靠静电荷，并须在空间结构上互补。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A protein molecule is a stable conformation formed by the aggregation of multiple subunits with tertiary structure. The aggregation of subunits depends mainly on electrostatic charge and must be complementary in spatial structure."
    },
    {
        "instruction":"已知信息：\n'第五十八条 承担备案管理工作的药品监督管理部门发现已备案化妆品、化妆品新原料的备案资料不符合要求的，应当责令限期改正，其中，与化妆品、化妆品新原料安全性有关的备案资料不符合要求的，可以同时责令暂停销售、使用。'可被翻译为：Article 58 If the filing drug regulatory department finds that the dossiers of filed cosmetics or new cosmetic ingredients do not meet the requirements, the filing management department shall order that correction be made within a specified timeline; where the data filed that relate to the safety of cosmetics and new cosmetic ingredients do not meet the requirements, the filing management department may at the same time order suspension of their sales and use.\n\n根据上述已知信息，请将'已进行备案但备案信息尚未向社会公布的化妆品、化妆品新原料，承担备案管理工作的药品监督管理部门发现备案资料不符合要求的，可以责令备案人改正并在符合要求后向社会公布备案信息。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"For cosmetics and new cosmetic ingredients that have been filed but the filing dossiers has not yet been released to the public, if the filing drug regulatory department finds that the filing dossiers do not meet the requirements, they may order the filing person to make corrections and release the information to the public when the requirements are met."
    },
    {
        "instruction":"已知信息：\n'薄层色谱或纸色谱展开方式之一。根据展开剂的走向可分为双向展开法和同向多次展开法等。'可被翻译为：One of the development methods of thin layer chromatography or paper chromatography. According to the direction of the development agent can be divided into bidirectional development method and the same direction multiple development method.\n\n根据上述已知信息，请将'在一个薄层色谱板上，采用同样的展开剂，同一展开方向，同样展开距离，单向多次展开后样品斑点直径变小的现象。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"On a thin layer chromatography plate, using the same development agent, the same development direction, the same development distance, the phenomenon that the sample spot diameter becomes smaller after multiple unidirectional development."
    },
    {
        "instruction":"已知信息：\n'第十六条 申办者、临床试验机构和研究者不得夸大参与临床试验的补偿措施，误导受试者参与临床试验。'可被翻译为：Article 16 The sponsor, clinical trial institution and investigator shall not exaggerate the compensation measures for participation in the clinical trial, which may mislead the subjects into participating in the clinical trial.\n\n根据上述已知信息，请将'(1) 有源数据支持以证实所有受试者确实参与了临床试验。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(1) There shall be source data to confirm that all the subjects actually participate in the clinical trial."
    },
    {
        "instruction":"已知信息：\n'(1) 试验样品分析按照分析计划执行， 分析批中样品预处理的过程和检测方法与方法学验证一致， 血药浓度数据与申报资料一致。'可被翻译为：(1) The test sample analysis is conducted according to the analysis plan, the preprocessing and testing method of the samples in the analysis batch are consist with the method validation, and the plasma concentration data is consistent with that in the application dossier.\n\n根据上述已知信息，请将'(5) 试验样品分析过程中如有残留， 对试验样品浓度的影响进行评估并采取具体措施， 与申报资料一致。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(5) If there is residual during the process of test sample analysis, evaluate the impact on the concentration of the test sample and carry out specific measures, consist with the application dossier."
    },
    {
        "instruction":"已知信息：\n'鼓励研制创新 保障供应可及'可被翻译为：Encourage R&D to Ensure Accessible Supply\n\n根据上述已知信息，请将'三、鼓励创新与保障公众用药情况（省略）'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"III. Encouraging innovation and safeguarding medication safety for the public (omitted)"
    },
    {
        "instruction":"已知信息：\n'将目的基因导入病变细胞或其他细胞，不去除异常基因，而是通过基因的非定点整合，使其表达产物补偿缺陷基因的功能或使原有的功能得以加强。目前基因治疗多采用此种方式。'可被翻译为：By introducing the target gene into the diseased cells or other cells, the abnormal gene is not removed, but through the non-site-specific integration of the gene, so that the expression products of the defective gene can compensate for the function of the original gene or strengthen the original function. At present, this method is commonly used in gene therapy.\n\n根据上述已知信息，请将'维持细胞最低限度功能所不可少的基因。如编码组蛋白基因、编码核糖体蛋白基因、线粒体蛋白基因、糖酵解酶的基因等。这类基因在所有类型的细胞中都进行表达，因为这些基因的产物对于维持细胞的基本结构和代谢功能是必不可少的。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Genes that are essential for a cell to function at a minimum level. Such as genes encoding histone proteins, genes encoding ribosomal proteins, mitochondrial protein genes, glycolytic enzymes, etc. Such genes are expressed in all types of cells because the products of these genes are essential for maintaining the basic structure and metabolic function of the cell."
    },
    {
        "instruction":"已知信息：\n'第十七条 临床试验前，申办者应当通过研究者和临床试验机构的医疗器械临床试验管理部门向伦理委员会提交下列文件：'可被翻译为：Article 17 Before the clinical trial, the sponsor shall submit the following materials to the ethics committee through the investigator and the medical device clinical trial management department of the clinical trial institution:\n\n根据上述已知信息，请将'第六十二条 临床试验前，临床试验机构的医疗器械临床试验管理部门应当配合申办者向伦理委员会提出申请，并按照规定递交相关文件。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 62 Before the clinical trial, the medical device clinical trial management department of the clinical trial institution shall coordinate with the sponsor to submit the application to the ethics committee and submit relevant documents according to the regulations."
    },
    {
        "instruction":"已知信息：\n'验证批次：由接收方（RU）为了证明其生产所转移产品符合其预定质量标准的能力，或作为工艺性能确认一部分而生产的批次。'可被翻译为：Validation batches Those batches produced by the receiving unit (RU) to demonstrate its ability to manufacture the transferred product which complies with its predetermined specifications, or as part of process performance quanlification.\n\n根据上述已知信息，请将'1.在拟销售产品的常规生产过程中进行的验证。\n2.在特殊情况下，在用于销售的产品的常规生产期间进行验证，当由于只生产了有限数量的批次、不经常生产批次或由已修改的经过验证的工艺生产批次而无法获得复制生产运行的数据时。在对批次进行全面监控和测试的基础上，可以在验证工作完成之前对单个批次进行评估和放行。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.Validation carried out during routine production of products intended for sale.\n2.Validation carried out during routine production of products intended for sale in exceptional circumstances when data from replicate production runs are unavailable because only a limited number of batches have been produced, batches are produced infrequently or batches are produced by a validated process that has been modified. Individual batches may be evaluated and released before completion of the validation exercise, based on thorough monitoring and testing of the batches."
    },
    {
        "instruction":"已知信息：\n'阶段性生产：在给定的时间内，严格按照既定且经验证的控制措施生产多批次同一产品的生产方式。'可被翻译为：Campaign manufacture - A manufacture of a series of batches of the same product in sequence in a given period of time with strict adherence to established and validated control measures.\n\n根据上述已知信息，请将'在给定的时间内，严格遵守已建立和验证的控制措施，按顺序生产同一产品的一系列批次。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The manufacture of a series of batches of the same product in sequence in a given period of time with strict adherence to established and validated control measures."
    },
    {
        "instruction":"已知信息：\n'（五）可被人体吸收的医疗器械，按照第三类医疗器械管理。'可被翻译为：(5) An absorbable medical device shall be regarded as a class III medical device.\n\n根据上述已知信息，请将'（七）医用敷料如果有以下情形，按照第三类医疗器械管理，包括：预期具有防组织或器官粘连功能，作为人工皮肤，接触真皮深层或其以下组织受损的创面，用于慢性创面，或者可被人体全部或部分吸收的。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(7) In any of the following cases, medical dressings shall be regarded as a class III medical device: the medical dressing is intended to have a function to prevent tissue\/organ adhesion; is used as artificial skin; is to contact with the deep dermis or the injured trauma of tissue below dermis; is used to heal chronic wound, or may be wholly\/partially absorbed by human body."
    },
    {
        "instruction":"已知信息：\n'负责授权进口的国家机构(如贸易部或进出口部门)。'可被翻译为：The national agency responsible for authorizing imports (e.g. the ministry or department of trade or of imports and exports).\n\n根据上述已知信息，请将'（六）进口药材涉及《濒危野生动植物种国际贸易公约》限制进出口的濒危野生动植物的，还应当提供国家濒危物种进出口管理机构核发的允许进出口证明书复印件。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(VI) Where the importation of crude drugs involve the endangered species of wild fauna and flora that are restricted from export and import as specified in the Convention on International Trade in Endangered Species of Wild Fauna and Flora, a copy of the approval document for export and import issued by national authorities for the import and export management of endangered species shall also be provided."
    },
    {
        "instruction":"已知信息：\n'在有关国家或地区的药品管理机构注册过的任何药品中从未出现过的一种活性药物成分。在本指导原则中，一种已批准原料药的新的盐、酯或非共价结合的衍生物也认为是一种需进行稳定性试验的新分子实体。'可被翻译为：An active pharmaceutical substance not previously contained in any drug product registered with the national or regional authority concerned. A new salt, ester, or non-covalent-bond derivative of an approved drug substance is considered a new molecular entity for the purpose of stability testing under this guidance.\n\n根据上述已知信息，请将'一种药物的制剂形式，如片剂、胶囊剂、溶液剂、乳膏剂，它们以前未在地区或成员国注册过。通常是一种药物成份与辅料的组合，但不一定都是。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A pharmaceutical product type, for example, tablet, capsule, solution, cream, etc., which has not previously been registered in a region or Member State, and which contains a drug ingredient generally, but not necessarily, in association with excipients."
    },
    {
        "instruction":"已知信息：\n'经验证的封口温度、整个封口的封口温度均匀性、封口时间和压力的设置、维护和监测（如相关）。'可被翻译为：Setting, maintenance and monitoring of validated sealing temperatures, sealing temperatureuniformity across the seal, sealing times and pressures as relevant.\n\n根据上述已知信息，请将'经验证的成型温度（包括预热和冷却）、成型时间和压力的设置、维护和监测（如相关）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Setting, maintenance and monitoring of validated  forming temperatures (including preheating and cooling),forming times and pressures as relevant."
    },
    {
        "instruction":"已知信息：\n'第十三条 质量风险管理是在整个产品生命周期中采用前瞻或回顾的方式，对质量风险进行评估、控制、沟通、审核的系统过程。'可被翻译为：Article 13: Quality risk management is a systematic process for the assessment, control, communication and review of the risk to quality throughout the entire product life cycle. It can be applied both proactively and retrospectively.\n\n根据上述已知信息，请将'第十条 企业应当采用前瞻或者回顾的方式，对药品流通过程中的质量风险进行评估、控制、沟通和审核。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 10 Enterprises shall assess, communicate, control the quality risks in the process of drug circulation in a prospective or retrospective manner."
    },
    {
        "instruction":"已知信息：\n'无菌测试：如果使用生物指示剂验证和监测灭菌周期，并且该批次通过其他质量 控制测试，则可使用该批次培养基。此外，如果可能，在同时进行其他操作之前， 将部分培养基在指定温度下培养14天。'可被翻译为：Sterility: The media batch may be used if the sterilization cycle is validated and monitored with the use of a biological indicator, and the batch passes other quality control testing. Also, if possible, prior to otherwise concurrently, incubate a portion of the media at the specified temperature for 14 days.\n\n根据上述已知信息，请将'所有批次必须通过的关键质量测试，以提供充分的消费者保护。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The critical tests of quality that all lots must pass in order to provide adequate consumer protection."
    },
    {
        "instruction":"已知信息：\n'已知浓度的溶剂或溶剂混合物中的待测物，用于制备校正标样或QC样品。'可被翻译为：An analyte in a solvent or mixture of solvents at a known concentration, which is used to prepare calibration standards or QCs.\n\n根据上述已知信息，请将'待测物的结构类似物或稳定同位素标记化合物，其浓度已知且恒定地加入到校正标样、QC 样品和研究样品中，以促进目标待测物的定量。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A structurally similar analogue or stable isotope labelled compound added to calibration standards, QCs and study samples at a known and constant concentration to facilitate quantification of the target analyte."
    },
    {
        "instruction":"已知信息：\n'（九）必要时应当将检验用实验动物在使用前进行检验或隔离检疫。饲养和管理应当符合相关的实验动物管理规定。动物应当有标识，并应当保存使用的历史记录。'可被翻译为：9. Animals used for testing should, where appropriate, be inspected and quarantined before use. They should be maintained and controlled in a manner that meets the regulations of lab animal management. They should be identified, and records should be maintained, showing the history of their use.\n\n根据上述已知信息，请将'第六十七条 实验动物房应当与其他区域严格分开，其设计、建造应当符合国家有关规定，并设有独立的空气处理设施以及动物的专用通道。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 67: Experimental animal houses should be well isolated from other areas, and their design and construction should comply with relevant regulatory requirements. There should be dedicated air handling facilities and separate entrance for animal access."
    },
    {
        "instruction":"已知信息：\n'在开始样本检测序列之前，应根据USP<788>进行空白检测。环境空白必须符合USP<788>中所设定的要求方可开始样本检测。'可被翻译为：Prior to initiating the test sequence with a specimen, a blank determination is required and must be carried out according to USP<788> . The environmental blank must meet the requirements set forth in USP <788>in order to initiate testing of the specimen.\n\n根据上述已知信息，请将'在开始检测程序之前，必须根据ORA-LAB.019制备和检测一份环境空白。在得 到合格结果之后，可使用该仪器执行检测程序。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Prior to beginning a test procedure an environment blank must be prepared and tested according to ORA-LAB.019. After passing results have been obtained the instrument can now be used to perform the test procedure."
    },
    {
        "instruction":"已知信息：\n'第十四条 医疗器械生产企业按照本办法第十条、第十二条的要求进行调查评估后，确定医疗器械产品存在缺陷的，应当立即决定并实施召回，同时向社会发布产品召回信息。'可被翻译为：Article 14 After the medical device manufacturer carries out an investigation and assessment in accordance with the requirements of Articles 10 and 12 of these Provisions, if it is confirmed that the medical device product is defective, it shall immediately decide and implement a recall, and disclose the product recall information to the society.\n\n根据上述已知信息，请将'（一）违反本办法第十四条规定，未按照要求及时向社会发布产品召回信息的；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(1) fail to disclose the product recall information to the society in a timely manner as required, which violates Article 14 of these Provisions;"
    },
    {
        "instruction":"已知信息：\n'生产商应釆取所有必要的步骤和预防措施，保证其设施内生产的产品的无菌性。不应仅依靠任何终端工艺或成品检验来确保无菌性或其它质量要素。'可被翻译为：The manufacturer should take all steps and precautions necessary to assure the sterility of the products manufactured within its facilities. Sole reliance for sterility or other quality aspects should not be placed on any terminal process or finished product test.\n\n根据上述已知信息，请将'成品的无菌检验应仅被视为确保无菌性的一系列关键控制措施中的最后一步。成品无菌检验不能用于确保不符合设计、程序或验证参数的产品的无菌性。成品无菌检验方法应使用相关产品进行验证。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The sterility test applied to the finished product should only be regarded as the last in a series of critical control measures by which sterility is assured. It cannot be used to assure sterility of a product that does not meet its design, procedural or validation parameters. The test should be validated for the product concerned."
    },
    {
        "instruction":"已知信息：\n'社会各界高度关注我国常用药、急（抢）救药短缺问题，新修订《药品管理法》对“药品储备和供应”做出专章规定，明确国家实行药品储备制度、国家建立药品供求监测体系、国家实行短缺药品清单管理制度，国家实行短缺药品优先审评制度等，多部门共同加强药品供应保障工作。'可被翻译为：All sectors of the society pay close attention to the shortage of commonly used drugs and emergency (first aid) drugs in China.The newly revised DAL provides a special Chapter on Pharmaceutical Reserves and Supplies, clarifying the state's drug reserve system, drug supply & demand monitoring system, list management system and prioritized drug review system forshort-supplied drugs, involving multiple departments' synergy to strengthen drug supply security.\n\n根据上述已知信息，请将'第九十四条 国家建立药品供求监测体系，及时收集和汇总分析短缺药品供求信息，对短缺药品实行预警，采取应对措施。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 94 The State establishes a drug supply monitoring system to promptly gather, compile, and analyze the supply information of drugs in shortage, implement advance drug shortage warnings, and take countermeasures."
    },
    {
        "instruction":"已知信息：\n'为保证药品注册核查质量，统一核查范围和判定标准， 根据《中华人民共和国药品管理法》《药品注册管理办法》等 法律法规及相关指导原则，特制定《药品注册核查要点与判定原则(药理毒理学研究)(试行)》。'可被翻译为：In order to ensure the quality of drug registration inspection and to unify the scope of inspection and determination standards, in accordance with the Drug Administration Law of the People's Republic of China, Measures for Administration of Drug Registration and other laws and regulations and related guidelines, the Key Points and Determination Principles of Drug Registration Inspection (Pharmacological and Toxicological study) (Trial) is hereby formulated.\n\n根据上述已知信息，请将'2. 药品注册核查要点与判定原则（药理毒理学研究）（试行）'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2.《Key Points and Determination Principles of Drug Registration Inspection(Pharmacological and Toxicological Study)(Trial)》"
    },
    {
        "instruction":"已知信息：\n'1.这是一个不会对产品质量产生任何直接或间接影响的系统。这些系统仅根据GEP进行设计和调试。\n2.一个不会对产品质量产生任何直接或间接影响的系统。这些系统仅根据良好的工程实践进行设计和调试。'可被翻译为：1.This is a system that will not have any impact, either directly or indirectly, on product quality. These systems are designed and commissioned according to GEP only.\n2.A system that will not have any impact, either directly or indirectly, on product quality. These systems are designed and commissioned according to good engineering practice only.\n\n根据上述已知信息，请将'系统内的加工参数或部件，其操作、接触、数据控制、报警或故障将对产品质量产生间接影响或无影响。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A processing parameter or component within a system where the operation, contact, data control, alarm or failure will have an indirect impact or no impact on the quality of the product."
    },
    {
        "instruction":"已知信息：\n'（一）主动申请注销的；'可被翻译为：(1) the cancellation is applied voluntarily;\n\n根据上述已知信息，请将'（一）企业主动申请注销的；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(1) The enterprise takes the initiative to apply for cancellation;"
    },
    {
        "instruction":"已知信息：\n'实验过程中测定温度按照预先设计的速率循序上升从而测定药物反应速度常数的方法。'可被翻译为：A method of determining the drug reaction rate constant by increasing the measured temperature at a predetermined rate during an experiment.\n\n根据上述已知信息，请将'在实验过程中保持测定温度不变，从而测定药物反应速度常数的方法。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A method of determining a drug reaction rate constant by keeping the measurement temperature constant during an experiment."
    },
    {
        "instruction":"已知信息：\n'物质从液态（液体或熔融体）或气态形成晶体的过程。'可被翻译为：The process by which a substance forms a crystal from a liquid (liquid or molten) or gaseous state.\n\n根据上述已知信息，请将'将晶体溶于溶剂或熔融以后，又重新从溶液或熔体中结晶的过程。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The process of re-crystallizing a crystal from a solution or melt after it is dissolved in a solvent or melted."
    },
    {
        "instruction":"已知信息：\n'RU应有能力接收准备转移的活动。'可被翻译为：12.4. The RU should be able to accommodate the intended activity.\n\n根据上述已知信息，请将'应由在GXP领域和准备转移的活动方面具备恰当资质和知识经验的人员组成小组进行评估。建议SU和RU质量部分参与该活动。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"4.3. The assessment should be done by a team of appropriately qualified persons with knowledge and experience in the field of GxP and the activity to be transferred. It is recommended that the quality units of the SU and RU participate in this activity."
    },
    {
        "instruction":"已知信息：\n'第二十二条 口岸药品检验机构收到进口药材口岸检验通知书后，应当在2日内与进口单位商定现场抽样时间，按时到规定的存货地点进行现场抽样。现场抽样时，进口单位应当出示产地证明原件。'可被翻译为：Article 22 Drug control institutions of ports shall, within 2 days after receiving the notice for port testing for importation of crude drugs, negotiate with the importers on site sampling time, and carry out on-site sampling at the specified storage location on time. During on-site sampling, importers shall show the original certificate of the place of production.\n\n根据上述已知信息，请将'第二十三条 口岸药品检验所接到《进口药品口岸检验通知书》后，应当在2日内与进口单位联系，到规定的存货地点按照《进口药品抽样规定》进行现场抽样。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 23 Drug control institutes of port shall, within two days after receiving the Notice of Port Testing for Import Drugs, contact the importer, and carry out on-site sampling at the specified storage location in accordance with the Rules for Import Drugs Sampling."
    },
    {
        "instruction":"已知信息：\n'第七十一条 违反本办法规定，未依法办理第一类医疗器械变更备案或者第二类、第三类医疗器械注册登记事项变更的，按照《医疗器械监督管理条例》有关未备案的情形予以处罚。'可被翻译为：Article 71 Where, in violation of the Provisions, a change of filing for a class I medical device is not performed, or a registration alteration of registry items for a class II or class III medical device is not performed according to law, punishments shall be imposed according to the situation concerning fail in filing in the Regulations on Supervision and Administration of Medical Devices.\n\n根据上述已知信息，请将'第八十一条 违反本办法规定，未依法办理第一类体外诊断试剂变更备案或者第二类、第三类体外诊断试剂注册登记事项变更的，按照《医疗器械监督管理条例》有关未备案的情形予以处罚。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 81 Where, in violation of the Provisions, a change of filing for a class I in-vitro diagnostic reagent is not performed, or a registration alteration of registry items for a class II or class III in-vitro diagnostic reagent is not performed according to law, punishments shall be imposed according to the situation concerning fail in filing in the Regulations on Supervision and Administration of Medical Devices."
    },
    {
        "instruction":"已知信息：\n'应对泵进行评估，以确保其正常工作。如果使用蠕动泵，测试完成后应松开泵管，以防止泵管不必要的磨损，这可能导致流量的变化。蠕动泵管应定期更换，以确保所有池体的流速保持一致。对于自动取样系统，还应检查样管对准，以确保所有样品完全收集到小瓶或试管中，无泄漏、样品捕获失败或因其他原因丢失样品。'可被翻译为：The pump should be evaluated to ensure it is working properly. If a peristaltic pump is used, the tubing should be unclamped once the test has completed to prevent unnecessary wear on the tubing, which may cause variation in the flow rate. Peristaltic pump tubing should be replaced at regular intervals to ensure the flow rate remains consistent across all the cells. For automated sampling systems, sample tube alignment should also be checked to ensure that all samples are entirely collected into the vials or test tubes, without leakage, failure to capture samples, or sample loss for other reasons.\n\n根据上述已知信息，请将'泵的流量应符合试验时使用的流量。对于每分钟微升范围内的流速，建议延长采样时间，以减少液滴粘附在样品线上的影响。如果使用自动化系统，应确保样品管线在小瓶上正确对齐。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The flow rate of the pump should be qualified for the rate used during testing. For flow rates in the microliters-per-minute range, it is recommended to extend the sampling time to reduce the effects of droplets adhering to the sample line. If an automated system is used it should be ensured that the sample lines are properly aligned over the vials."
    },
    {
        "instruction":"已知信息：\n'第一条 为规范药品注册核查(以下简称注册核查)工作行为，加强注册核查与审评工作的衔接，保证注册核查工作质量和效率，根据《药品注册管理办法》《药品生产监督管理办法》,制定本程序。'可被翻译为：Article 1 In order to standardize the work process of drug registration inspection (hereinafter referred to as registration inspection), strengthen the connection between registration inspection and evaluation, and ensure the quality and efficiency of registration inspection, the Procedures is formulated in accordance with the Drug Registration Regulation and Drug Manufacture Regulation.\n\n根据上述已知信息，请将'第十条 核查中心建立注册核查相关质量管理体系，制定注册核查的标准操作程序及相应的《药品注册核查要点与判定原则》,加强检查员队伍建设，建立注册核查检查员库，规范注册核查有关工作。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 10 CFDI shall establish a quality management system related to registration inspection, formulate standard operating procedures for registration inspection and the corresponding Key Points and Determination Principles of Drug Registration Inspection, strengthen the construction of the inspector team, establish a registration inspection inspector database, and regulate the related work of registration inspection."
    },
    {
        "instruction":"已知信息：\n'利用同位素标记的与未标记的抗原或抗体与抗体或抗原发生竞争性抑制反应来测定抗体或抗原含量的方法。'可被翻译为：A method of determining antibody or antigen content using a competitive inhibition reaction between an isotopically labeled antigen or antibody and an unlabeled antigen or antibody.\n\n根据上述已知信息，请将'（一）抗原、抗体等主要材料供应商变更的；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(1) Change of suppliers of main materials such as antigen and antibody, etc.."
    },
    {
        "instruction":"已知信息：\n'对受体有较强亲和力和较强的内在活性(a=l),能产生最大药理效应的药物。如肾上腺素等为完全激动药。药物和受体的相互作用不仅与药物对受体的亲和力有关，还与内在活性有关。内在活性是药物产生最大生物效应的能力。'可被翻译为：a drug that has a strong affinity for the receptor and a strong intrinsic activity (a=l) to produce the greatest pharmacological effect. Complete agonists, such as epinephrine. The drug and receptor interaction is not only related to the affinity of the drug to the receptor, but also to the intrinsic activity. Intrinsic activity is the ability of a drug to produce the maximum biological effect.\n\n根据上述已知信息，请将'以拮抗作用为主，还有一定内在活性，即激动受体的效应的药物。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The antagonistic action is mainly, and there is a certain intrinsic activity, that is, the effect of activating the receptor."
    },
    {
        "instruction":"已知信息：\n'第四十二条 化妆品集中交易市场开办者、展销会举办者应当建立保证化妆品质量安全的管理制度并有效实施，承担入场化妆品经营者管理责任，督促入场化妆品经营者依法履行义务，每年或者展销会期间至少组织开展一次化妆品质量安全知识培训。'可被翻译为：Article 42 The organizers of centralized trading market and expos shall establish a management system for ensuring quality and safety of cosmetics and make effective implementation, undertake the responsibility for managing the participating marketers of cosmetics, urge the participating marketers of cosmetics to perform their obligations according to law, and organize to carry out training on knowledge in quality and safety of cosmetics at least once a year or once during the trade fair period.\n\n根据上述已知信息，请将'（六）有保证化妆品质量安全的管理制度。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(6) having a management system for guaranteeing the quality and safety of the cosmetics."
    },
    {
        "instruction":"已知信息：\n'一种液相色谱一质谱联用的接口。'可被翻译为：The utility model relates to a liquid chromatography-mass spectrometry interface.\n\n根据上述已知信息，请将'一种高效液相色谱一质谱联用的仪器接口。属于大气压电离的范畴，包括电喷雾、离子的形成及离子的传递三个步骤。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"An instrument interface for high performance liquid chromatography-mass spectrometry. It belongs to the category of atmospheric pressure ionization, including electrospray, ion formation and ion transfer three steps."
    },
    {
        "instruction":"已知信息：\n'与剂量和常规药理作用无关的不良反应。其发生与患者体质密切相关，难预测，发生率低。'可被翻译为：Adverse reactions independent of dose and routine pharmacological action. Its occurrence is closely related to the patient's constitution, difficult to predict, and the incidence is low.\n\n根据上述已知信息，请将'又称\"剂量相关性不良反应\"。与剂量密切相关的不良反应。可预测。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Also known as \"dose-related adverse reactions\". Adverse reactions that are closely related to dosage. Predictable."
    },
    {
        "instruction":"已知信息：\n'在一项研究或一组研究中，在人或动物暴露于某物质后任何生物学效应发生频率或严重程度显著增加的最低暴露量。'可被翻译为：The lowest dose of substance in a study or group of studies that produces biologically significant increases in frequency or severity of any effects in the exposed humans or animals.\n\n根据上述已知信息，请将'在特定环境下，某试剂的暴露量不足以导致不良反应的实际发生。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Practical certainty that adverse effects will not result from exposure to an agent under defined circumstances."
    },
    {
        "instruction":"已知信息：\n'（三）持有人药品注册证书、药品生产许可证等行政许可被依法吊销或者撤销的；'可被翻译为：(3) Where the MAH's Drug Approval License, Drug Manufacturing Certificate and other administrative licenses have been revoked or withdrawn in accordance with the law;\n\n根据上述已知信息，请将'（三）《药品生产许可证》被依法吊销或者缴销的；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(3) the Drug Manufacturing Certificate is revoked or withdrawn by law;"
    },
    {
        "instruction":"已知信息：\n'国家药监局 海关总署关于增设长春空港口岸为药品进口口岸的公告'可被翻译为：Announcement of NMPA and General Administration of Customs on the Establishment of Changchun Airport as a Drug Import Port\n\n根据上述已知信息，请将'根据《药品进口规定》、《中国食品药品监督管理总局、海关总署关于印发新设立药品进口口岸原则和标准的通知》、《中国食品药品监督管理总局、海关总署关于印发新设立药品进口口岸评价考核方案的通知》，《国家药品监督管理局综合司关于印发《药品首次进口口岸评审标准》及其他有关规定的通知》经现场评审评估，国家药品监督管理局批准重庆市药品监督管理局关于增加化学品首次进口备案功能的申请，于2月2日发布本公告如下:'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"According to the Provisions for Drug Importation, the Notice of the China Food and Drug Administration and General Administration of Customs on Printing and Issuing Principles and Standards for the Newly Establishment of Drug Import Ports, the Notice of the China Food and Drug Administration and General Administration of Customs on Printing and Issuing the Evaluation and Assessment Scheme for the Newly Establishment of Drug Import Ports, the Notice of the Comprehensive Department of National Medical Products Administration on Printing and Issuing the Evaluation Criteria for the Ports for the First Drug Importation and other relevant regulations, upon the on-site evaluation and assessment, the NMPA has approved the application of the Chongqing Municipal Medical Products Administration for adding the filing function for the first importation of chemicals, and this Announcement was hereby issued on February 2 as follows:"
    },
    {
        "instruction":"已知信息：\n'(1) 试验样品和空白基质由专人管理。接收试验样品的房间具有足够的空间用于样品接收、清点和登记。核对运输、接收、清点、入库、储存、领取、使用、归还、销毁等原始记录，信息记录完整， 有明确的时间及操作人员签名。'可被翻译为：(1) The test sample and blank matrix are specially managed by the designated person, the room for receiving test samples has enough space for sample receipt, inventory and registration. Check the original records of transportation, receipt, inventory, stocking, storage, picking, weighing, use, return, and destruction, and the information and records are intact, with clear time and signature of the operator.\n\n根据上述已知信息，请将'(1) 对照标准物质由专人管理， 来源可靠且可追溯， 在分析证书(CoA) 或同等证明性文件规定的条件下储存和使用。核对运输、接收、储存、领取、称量、使用、归还、销毁等原始记录， 信息记录完整。对于不用于定量的对照标准物质， 提供能证明其适用性的文件。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(1) The reference materials are specifically managed by the designated person, with reliable and traceable source, and are stored and used under the conditions specified by the Certificate of Analysis (CoA) or the equal supporting documents. Check the original records of transportation, receipt, storage, picking, weighing, use, return, and destruction, and the information and records are intact."
    },
    {
        "instruction":"已知信息：\n'《药品注册管理办法》已于2020年1月15日经国家市场监督管理总局2020年第1次局务会议审议通过，现予公布，自2020年7月1日起施行。'可被翻译为：The Provisions for Drug Registration, adopted at the first executive meeting of the State Administration for Market Regulation on January 15, 2020, is hereby promulgated and shall come into force as of July 1, 2020.\n\n根据上述已知信息，请将'《药品生产监督管理办法》已于2020年1月15日经国家市场监督管理总局2020年第1次局务会议审议通过，现予公布，自2020年7月1日起施行。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The Provisions for the Supervision and Administration of Drug Manufacturing, adopted at the first executive meeting of the State Administration for Market Regulation in 2020 held on January 15, 2020, is hereby promulgated and shall come into effect as of July 1, 2020."
    },
    {
        "instruction":"已知信息：\n'第十六条 本办法第十条规定情形以外的药品，口岸药品监督管理局审查全部资料无误后，准予进口备案，发出《进口药品通关单》。同时向负责检验的口岸药品检验所发出《进口药品口岸检验通知书》，附本办法第十三条规定的资料一份。'可被翻译为：Article 16 In the case of drugs other than those specified in Article 10 of the Provisions, a drug regulatory department at ports of entry shall, if all the materials pass examination, approve the importation record filing and issue the Import Drug Note. At the same time, it shall issue the Notice of Port Testing for Import Drugs to the relevant drug control institute of port with one set of the materials specified in Article 13 of the Provisions attached.\n\n根据上述已知信息，请将'对麻醉药品、精神药品，口岸药品监督管理局审查全部资料无误后，应当只向负责检验的口岸药品检验所发出《进口药品口岸检验通知书》，附本办法第十三条规定的资料一份，无需办理《进口药品通关单》。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In the case of narcotic drugs and psychotropic substances, a drug regulatory department at ports of entry shall, if all the materials pass examination, only issue a Notice of Port Testing for Import Drugs to the relevant drug control institute of port with one set of the materials specified in Article 13 of the Provisions attached, where no Import Drug Note is required."
    },
    {
        "instruction":"已知信息：\n'标准操作规程 （SOP）：经过批准的程序，给出执行操作的指令，不一定是某个具体的产品或物料，可能是更为通用的（例如设备的操作、维护和清洁、设施的验证和清洁、环境控制、取样和检查）。特定的标准操作规程可能会被用于补充产品专用的主生产文件和批生产文件'可被翻译为：standard operating procedure (SOP). An authorized written procedure giving instructions for performing operations, not necessarily specific to a given product or material , but of a more general nature (for example, operation of equipment, maintenance and cleaning, validation, cleaning of premises and environmental control, sampling and inspection). Certain standard operating procedures may be used to supplement product-specific master and batch production documentation.\n\n根据上述已知信息，请将'经批准用来指导设备操作、维护与清洁、验证、环境控制、取样和检验等药品生产活动的通用性文件，也称标准操作规程。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Approved documents to guide operations related to the manufacture of drugs, such as equipment operation, maintenance and cleaning, validation, environmental control, sampling, testing, and etc. Also refer to as standard operating procedure (SOP)."
    },
    {
        "instruction":"已知信息：\n'第二十九条 列入国家药品标准的药品名称为药品通用名称。已经作为药品通用名称的，该名称不得作为药品商标使用。'可被翻译为：Article 29 A drug name listed in the national drug standards is an adopted name in China and may not be used as a trademark.\n\n根据上述已知信息，请将'列入国家药品标准的药品名称，为药品通用名称。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A drug name included in the national drug standard shall be the generic name of the drug."
    },
    {
        "instruction":"已知信息：\n'应有关于取消人员在洁净室工作或取消人员无监督进入洁净室资格的系统，基于的依据包括持续评估和\/或识别该人员监测计划的不良趋势和\/或参与的 APS 失败。一旦取消资格，应完成再培训和再次资质确认后才能允许该操作人员进一步参与无菌操作。对于进入 B 级洁净室或执行 A 级干预的操作人员，再次资质确认应包括是否参与成功的 APS。'可被翻译为：There should be systems in place for the disqualification of personnel from working in or given unsupervised entry into cleanrooms that is based on aspects including ongoing assessment and\/or identification of an adverse trend from the personnel monitoring programme and\/or after being implicated in a failed APS. Once disqualified, retraining and requalification should be completed before permitting the operator to have any further involvement in aseptic practices. For operators entering grade B cleanrooms or performing intervention into grade A, this requalification should include consideration of participation in a successful APS.\n\n根据上述已知信息，请将'所有人员，包括执行清洁、维护、监控以及进入洁净室的人员，均应定期接受无菌产品正确生产相关纪律的培训、更衣确认和评估。该培训应包括微生物学和卫生学的基本要素，特别关注洁净室实践、污染控制、无菌技术和无菌产品的保护（对于进入 B 级洁净室和\/或干预 A 级的操作人员）以及产品非无菌对患者的潜在安全性影响。培训水平应基于人员职能以及工作区域的关键程度。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"All personnel including those performing cleaning, maintenance, monitoring and those that access cleanrooms\nshould receive regular training, gowning qualification and assessment in disciplines relevant to the correct manufacture of sterile products. This training should include the basic elements of microbiology and hygiene, with a specific focus on cleanroom practices, contamination control, aseptic techniques and the protection of sterile products (for those operators entering the grade B cleanrooms and\/or intervening into grade A) and the potential safety implications to the patient if the product is not sterile. The level of training should be based on the criticality of the function and area in which the personnel are working."
    },
    {
        "instruction":"已知信息：\n'工艺资格将实际的设施、公用设施、设备(每一个现在都是合格的)和经过培训的人员与商业制造工艺、控制程序和部件相结合，以生产商业批次;确认工艺设计，并证明商业制造工艺按预期执行。'可被翻译为：Process qualification combines the actual facility, utilities, equipment (each now qualified) and the trained personnel with the commercial manufacturing process, control procedures and components to produce commercial batches; confirms the process design and demonstrates that the commercial manufacturing process performs as expected.\n\n根据上述已知信息，请将'(ii)制造工艺的关键步骤和工艺重大变更应进行验证；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(ii) Critical steps of manufacturing processes and significant changes to the process are validated;"
    },
    {
        "instruction":"已知信息：\n'第八条 注册人、备案人在境外的，应当指定我国境内的企业法人作为境内责任人。境内责任人应当履行以下义务：'可被翻译为：Article 8 Overseas registrants and filing persons shall designate an enterprise legal person within the territory of China as the domestic responsible person. The domestic responsible person shall fulfill the following obligations:\n\n根据上述已知信息，请将'第六十一条  进口医疗器械注册人、备案人应当指定我国境内企业法人作为代理人，代理人应当协助注册人、备案人履行医疗器械监督管理条例和本办法规定的义务。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 61 The registrant or filing entity of imported medical devices shall designate the domestic enterprise legal person as the agent, who shall assist the registrant or filing entity to fulfill the obligations prescribed in the Regulations on Supervision and Administration of Medical Devices and these Provisions."
    },
    {
        "instruction":"已知信息：\n'（八）企业产品抽检、监督检查、投诉举报等发现问题的整改落实情况；'可被翻译为：(8) rectification implementation condition of problems discovered from sample testing of the enterprise’s products, supervision and inspection, complaint report, etc.;\n\n根据上述已知信息，请将'（六）企业产品抽检、监督检查、投诉举报等发现问题的整改落实情况；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(6) rectification implementation condition of problems discovered from sample testing of the enterprise’s products, supervision and inspection, complaint report, etc.;"
    },
    {
        "instruction":"已知信息：\n'或者在必要时，实施ORS实验室修订后的医疗器械内毒素萃取和分析。'可被翻译为：Alternatively, if deemed necessary, perform the ORS laboratory modified extraction and analysis of Endotoxin from Medical Devices:\n\n根据上述已知信息，请将'本文件中的说明是 ORS 分析人员的指南。分析人员在执行与药品和医疗器械产品测试相关 的分析时，应使用在所有 ORS 实验室以及 PMM 中标准化和统一的程序和工作表（如有）。 当需要修改或有所偏离时，应根据实验室的质量管理体系完成文件记录。一般来说，这些变化应该源于诸如新产品、异常产品或特殊情况等情况。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The instructions in this document are guidelines for ORS analysts. When available, analysts should use procedures and worksheets that are standardized and harmonized across all ORS labs, along with the PMM, when performing analyses related to product testing of pharmaceuticals and medical devices. When changes or deviations are necessary, documentation should be completed per the laboratory’s Quality Management System. Generally, these changes should originate from situations such as new products, unusual products, or unique situations."
    },
    {
        "instruction":"已知信息：\n'从混合物中分离出某一组分。'可被翻译为：Separate a component from the mixture.\n\n根据上述已知信息，请将'从石油中得到的各种烽的混合物。其中大部分属于饱和泾。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A mixture of various polymers obtained from petroleum. Most of which belong to saturated Jing."
    },
    {
        "instruction":"已知信息：\n'在透析过程中通过半透膜的物质。常含有在溶液中容易扩散的物质。'可被翻译为：A substance that passes through a semi-permeable membrane during dialysis. Often containing a substance that diffuses easily in solution.\n\n根据上述已知信息，请将'含有药物或芳香物质的浓糖水溶液。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"An aqueous solution of concentrated sugar containing a medicinal or aromatic substance."
    },
    {
        "instruction":"已知信息：\n'接触碟限度适用于 A 级和 B 级区内的设备、房间和洁净服表面。C 级和 D 级区通常不需要进行常规工作服监测，具体取决于该区域的功能。'可被翻译为：(b) Contact plate limits apply to equipment, room and gown surfaces within the grade A and grade B areas. Routine\ngown monitoring is not normally required for grade C and D areas, depending on their function.\n\n根据上述已知信息，请将'口服液体和固体制剂、腔道用药（含直肠用药）、表皮外用药品等非无菌制剂生产的暴露工序区域及其直接接触药品的包装材料最终处理的暴露工序区域，应当参照“无菌药品”附录中D级洁净区的要求设置，企业可根据产品的标准和特性对该区域采取适当的微生物监控措施。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The exposed processing areas for oral liquid and solid preparations, drugs applied through tract (including recta), epidermal products, and other non-sterile products, as well as the exposed processing areas for handling immediate packaging materials should be designed as Grade D according to requirements in Annex 1 of GMP for sterile products. The manufacturer may take appropriate measures to monitor the microorganism, in accordance with product specifications and property."
    },
    {
        "instruction":"已知信息：\n'第十八条 药品生产、经营企业和医疗机构应当建立并保存药品不良反应报告和监测档案。'可被翻译为：Article 18 Drug manufacturers, distributors and medical institutions shall establish and maintain archives for ADR reporting and monitoring.\n\n根据上述已知信息，请将'（二）未建立和保存药品不良反应监测档案的；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(II) Having not established and maintained achieves for ADR monitoring;"
    },
    {
        "instruction":"已知信息：\n'细菌产生对抗菌药物不敏感的现象，产生原因是细菌在自身生存过程中的一种特殊表现形式。根\n据发生原因，耐药性可分为固有耐药和获得性耐药。'可被翻译为：The phenomenon where bacteria develop insensitivity to antimicrobial drugs is known as antimicrobial resistance (AMR). The reasons behind this development are special manifestations in the bacteria's natural survival process. Antimicrobial resistance can be classified into intrinsic resistance and acquired resistance based on the cause.\n\n根据上述已知信息，请将'长期应用广谱抗生素后，使敏感细菌受到抑制，不敏感细菌趁机在体内大量繁殖所造成的多种以上的病原微生物感染。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"After long-term application of broad-spectrum antibiotics, the sensitive bacteria are inhibited, and the insensitive bacteria take the opportunity to multiply in the body, resulting in more than a variety of pathogenic microbial infection."
    },
    {
        "instruction":"已知信息：\n'2019年8月26日，经第十三届全国人大常委会第十二次会议修订通过，修订后的《中华人民共和国药品管理法》（以下称药品管理法）自2019年12月1日起施行。国家药监局正在抓紧开展配套规章、规范性文件和技术指南的制修订工作，并将按程序陆续发布。现就贯彻实施新修订的药品管理法有关事项公告如下：'可被翻译为：Revised and adopted by the Twelfth Session of the Standing Committee of the 13th National People's Congress on August 26,2019, the revised Drug Administration Law of the People's Republic of China(hereinafter referred to as DAL) shall be implemented as from December 1,2019. NMPA is stepping up work on the development, formulation and revision of supporting regulations, normative documents and technical guidelines, which will be released in accordance with procedures. We hereby announce the issues pertaining to the implementation of the newly revised DALas follows:\n\n根据上述已知信息，请将'新修订的《医疗器械监督管理条例》（国务院令第739号，以下简称新《条例》），将于2021年6月1日起施行。国家药监局正在组织制修订配套规章、规范性文件和技术指导原则等，将按照程序陆续发布。现就贯彻实施新《条例》有关事项公告如下：'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The revised Regulations for the Supervision and Administration of Medical Devices (State Council Order No. 739, hereinafter referred to as the Regulations) will be implemented as of June 1, 2021. NMPA is organizing the formulation and revision of supporting regulations, normative documents and technical guidances, which will be released one after another in accordance with procedures. The matters related to implementation of the new Regulations are hereby announced as follows:"
    },
    {
        "instruction":"已知信息：\n'《生物制品批签发管理办法》已于2020年11月19日经国家市场监督管理总局2020年第11次局务会议审议通过，现予公布，自2021年3月1日起施行。'可被翻译为：Provisions for the Lot Release of Biological Products, deliberated and adopted at the 11th executive meeting in 2020 of State Administration for Market Regulation on November 19, 2020, is hereby promulgated and shall go into effect as of March 1, 2021.\n\n根据上述已知信息，请将'《化妆品注册备案管理办法》已于2020年12月31日经国家市场监督管理总局2020年第14次局务会议审议通过，现予公布，自2021年5月1日起施行。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The Provisions for Registration and Filing of Cosmetics adopted at the 14th Executive Meeting of the State Administration for Market Regulation on December 31, 2020 is hereby promulgated and shall go into effect as of May 1, 2021."
    },
    {
        "instruction":"已知信息：\n'（三）三级召回：使用该医疗器械引起危害的可能性较小但仍需要召回的。'可被翻译为：(3) Class III recalls: the use of the medical device is less likely to cause hazard but the device still needs to be recalled.\n\n根据上述已知信息，请将'（三）三级召回：使用该药品一般不会引起健康危害，但由于其他原因需要收回的。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(Ⅲ)  Class 3 recall: Use of the drug usually will not cause any harm to health, but the drug has to be recalled due to other reasons."
    },
    {
        "instruction":"已知信息：\n'发布本指南的法律背景：2001\/83\/EC号指令第47条——共同体人用药品规范，以及法规2019\/6——共同体兽用药品规范。本文件为欧盟指令（EU）2017\/1572中的人用药品、指令91\/412\/EEC中的兽用药品，委员会委托条例（EU）2017\/1569中的人用研究用药品提供了药品生产质量管理规范（GMP）原则和指南的技术指导，并补充了法规（EU）536\/2014临床研究中的检查安排。'可被翻译为：Legal context for publishing the detailed guidelines:Article 47 of Directive 2001\/83\/EC on the Community  code relating to medicinal products for human use and Regulation 2019\/6 on the Community code relating to veterinary medicinal products. This document provides technical guidance on the principles and guidelines of good manufacturing practice (GMP) for medicinal products as laid down in Commission Directive (EU) 2017\/1572 for medicinal products for human use,Directive 91\/412\/EEC for veterinary use,and Commission Delegated Regulation (EU)2017\/1569 for investigational medicinal products for human useand arrangements for inspections supplementing Regulation (EU)No536\/2014 on clinical trials.\n\n根据上述已知信息，请将'第4卷欧盟人用和兽用药品生产质量管理规范指南'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Volume 4 EU Guidelines for Good Manufacturing Practice for Medicinal Products for\nHuman and Veterinary Use"
    },
    {
        "instruction":"已知信息：\n'药师应临床科室或医务部门的邀请，出于诊疗需要对患者的药物治疗方案进行优化和药学监护的\n药学服务。'可被翻译为：Pharmacists provide pharmaceutical services by optimizing medication treatment plans and offering pharmaceutical monitoring when invited by clinical departments or medical administrations for the purpose of patient care.\n\n根据上述已知信息，请将'由多个专业的专家组成团队协作诊疗的工作模式，由来自不同学科的专家定期在一起通过会议的\n形式，全面考虑患者的具体情况，制定适合患者的诊疗方案，进而由某一科室或某几个科室联合执行\n诊疗方案。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A collaborative diagnostic and treatment model involves a team of experts from various professions. These experts, representing different disciplines, regularly convene through meetings to comprehensively consider the patient's specific situation. They collaboratively devise a tailored diagnostic and treatment plan. Subsequently, one or several departments jointly execute the implemented plan."
    },
    {
        "instruction":"已知信息：\n'第三条  医疗器械上市许可持有人（以下简称持有人），应当具有保证医疗器械安全有效的质量管理能力和相应责任能力，建立医疗器械不良事件监测体系，向医疗器械不良事件监测技术机构（以下简称监测机构）直接报告医疗器械不良事件。由持有人授权销售的经营企业、医疗器械使用单位应当向持有人和监测机构报告医疗器械不良事件。'可被翻译为：Article 3 Medical device marketing authorization holders (hereinafter referred to as MAHs) shall possess the capacities of quality management and corresponding responsibilities to ensure that the medical devices are safe and effective, establish medical device adverse event monitoring system and directly report medical device adverse events to medical device adverse event monitoring agencies (hereinafter referred to as monitoring agencies). Distributing enterprises and user facility of medical device authorized by MAHs shall report medical device adverse events to MAHs and monitoring agencies.\n\n根据上述已知信息，请将'国家药品监督管理局指定的监测机构（以下简称国家监测机构）负责对收集到的医疗器械不良事件信息进行统一管理，并向相关监测机构、持有人、经营企业或者使用单位反馈医疗器械不良事件监测相关信息。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Monitoring agencies designated by the NMPA (hereinafter referred to as national monitoring agencies) shall be responsible for unified management of all the information of medical device adverse events collected and provide feedback of relevant monitoring information of medical device adverse events to relevant monitoring agencies, MAHs, distributing enterprises or user facilities."
    },
    {
        "instruction":"已知信息：\n'药物与油脂性或水溶性基质混合制成的均匀的半固体外用制剂。'可被翻译为：A uniform semi-solid preparation for external use made by mixing a drug with an oily or water-soluble substrate.\n\n根据上述已知信息，请将'例如：口服或外用的固体、半固体制剂在成型或分装前使用同一台混合设备一次混合所生产的均质产品为一批；口服或外用的液体制剂以灌装（封）前经最后混合的药液所生产的均质产品为一批。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"For example, the homogeneous product that solid or semi-solid preparations for oral or topical use are produced within the same blender by one blending prior to molding or filling should be regarded as one batch. The homogeneous product that liquid preparations for oral or topical use are produced by final mixing prior to filling (sealing) should be regarded as one batch."
    },
    {
        "instruction":"已知信息：\n'第一百一十三条 药品监督管理部门发现药品违法行为涉嫌犯罪的，应当及时将案件移送公安机关。'可被翻译为：Article 113 Upon discovery of illegal behaviors related to drugs which allegedly constitutes a criminal offense, the drug regulatory departments shall promptly forward the case to the public security authorities.\n\n根据上述已知信息，请将'对依法不需要追究刑事责任或者免予刑事处罚，但应当追究行政责任的，公安机关、人民检察院、人民法院应当及时将案件移送药品监督管理部门。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Where it is not necessary to pursue criminal liability in accordance with the law or criminal punishment is not required in accordance with the law, but it is necessary to pursue administrative liability, the public security authorities, the People's Procuratorate and the People's Court shall promptly forward the case to the drug regulatory departments."
    },
    {
        "instruction":"已知信息：\n'简称\"肌松药”。阻滞神经肌肉后膜的N胆碱受体，产生神经肌肉阻滞，使骨骼肌麻痹松弛的药物。根据作用机制不同而分为：①除极化型肌松药，如琥珀胆碱，其作用不能为抗胆碱酯酶药所对抗；②非除极化型肌松药，如筒箭毒碱，其肌松作用可为抗胆碱酯酶药所对抗。'可被翻译为：\"Muscle relaxants\" for short. A drug that blocks N choline receptors in the posterior neuromuscular membrane, producing a neuromuscular block that paralyses and relaxes skeletal muscles. According to the different mechanism of action, it can be divided into: (1) depolarizing muscle relaxants, such as succincholine, whose action cannot be opposed by anti-cholinesterase drugs; ② Non-depolarizing muscle relaxants, such as tubocurarine, whose muscle relaxants can be resisted by anti-cholinesterase drugs.\n\n根据上述已知信息，请将'又称\"胆碱受体阻滞药”。能与乙酰胆碱或外源性拟胆碱药争夺胆碱受体从而产生抗胆碱作用的药物。可分为，①M-胆碱受体阻滞药；②N-胆碱受体阻滞药，包括骨骼肌松弛药和神经节阻滞药；③中枢性抗胆碱药等。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Also known as \"cholinergic blockers\". A drug that competes with acetylcholine or exogenous cholinomimetic drugs for cholinergic receptors to produce anticholinergic effects. They can be divided into: (1) M-cholinergic blockers; ② N-choline receptor blockers, including skeletal muscle relaxants and ganglion blockers; ③ central anticholinergics, etc."
    },
    {
        "instruction":"已知信息：\n'第六十七条 研究者负责招募受试者、与受试者或者其监护人谈话。研究者有责任向受试者说明试验用医疗器械以及临床试验有关的详细情况，告知受试者可能的受益和已知的、可以预见的风险，并取得受试者或者其监护人签字和注明日期的知情同意书。'可被翻译为：Article 67 The investigator is responsible for recruiting subjects and talking with them or the guardians. The investigator shall explain to the subjects the details of the investigational medical device and details about the clinical trial, inform the subjects of possible benefits and known and foreseeable risks, and obtain signed and dated informed consent forms from the subjects or the guardians.\n\n根据上述已知信息，请将'第七十九条 研究者可以根据临床试验的需要，授权相应人员进行受试者招募、与受试者持续沟通、临床试验数据记录、试验用医疗器械管理等。研究者应当对其授权的人员进行相关的培训并形成相应的文件。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 79 The investigator may, according to the needs of the clinical trial, authorize corresponding personnel to recruit subjects, communicate with the subjects, record the clinical data and manage the investigational medical device. The investigator shall carry out relevant training and form the corresponding document for the personnel authorized."
    },
    {
        "instruction":"已知信息：\n'第二十八条 批签发机构根据资料审核、样品检验或者现场检查等结果作出批签发结论。符合要求的，签发生物制品批签发证明，加盖批签发专用章，发给批签发申请人。'可被翻译为：Article 28 The lot release institution shall make decision on lot release based on dossier review, sample test or on-site inspection and other results. If the requirements are met, the institution shall issue a Certificate for Lot Release of Biological Products which is affixed with the special seal for lot release, and send it to the lot release applicant.\n\n根据上述已知信息，请将'在批签发机构作出批签发合格结论前，批签发申请人应当将批签发申请资料补充完整并提交批签发机构。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Before the lot release institution makes any conclusion in lot release, the lot release applicant shall supplement the lot release application dossiers and submit them to the lot release institution."
    },
    {
        "instruction":"已知信息：\n'为规范儿童化妆品生产经营活动，加强儿童化妆品监督管理，保障儿童使用化妆品安全，依据《化妆品监督管理条例》等法律法规，国家药监局组织制定了《儿童化妆品监督管理规定》（以下简称《规定》），于2021年10月8日予以公布，并就《规定》实施有关事宜公告如下：'可被翻译为：In order to regulate the production and distribution activities of children’s cosmetics, strengthen the supervision and administration of children's cosmetics and ensure the safety of children in the use of cosmetics, according to the Regulations for the Supervision and Administration of Cosmetics and other laws and regulations, the National Medical Products Administration has organized to formulate the Provisions for the Supervision and Administration of Children's Cosmetics(hereinafter referred to as the Provisions),which was issued on October 8. The issues related to the implementation of the Provisions are hereby announced as follows:\n\n根据上述已知信息，请将'国家药监局关于发布《儿童化妆品监督管理规定》的公告'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"NMPA Announcement on Issuing the Provisions for the Supervision and Administration of Children's Cosmetics"
    },
    {
        "instruction":"已知信息：\n'第一百三十六条 国家药品标准，是指国家食品药品监督管理局颁布的《中华人民共和国药典》、药品注册标准和其他药品标准，其内容包括质量指标、检验方法以及生产工艺等技术要求。'可被翻译为：Article 136 National drug standards refer to the Pharmacopoeia of the People's Republic of China, drug registration specifications, etc. published by the State Food and Drug Administration, including the technical requirements such as specifications, testing methods and manufacturing processes, etc.\n\n根据上述已知信息，请将'第一百三十七条 药品注册标准的项目及其检验方法的设定，应当符合中国药典的基本要求、国家食品药品监督管理局发布的技术指导原则及国家药品标准编写原则。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 137 The establishment of items and the testing methods for drug registration specifications shall be in conformity with the basic requirements of the Chinese Pharmacopoeia, the technical guidelines and rules for compiling the national drug standards published by the State Food and Drug Administration."
    },
    {
        "instruction":"已知信息：\n'2021年5月1日前申请并取得注册的祛斑美白、防脱发化妆品，注册人应当在2023年5月1日前补充提交人体功效试验报告。'可被翻译为：For the cosmetics for spot correcting, whitening and preventing hair loss with the application submitted and registration completed prior to May 1, 2021, registration persons shall submit the human efficacy test report prior to May 1, 2023.\n\n根据上述已知信息，请将'2021年5月1日至12月31日期间申请并取得注册的祛斑美白、防脱发化妆品，注册人应当于2022年5月1日前补充提交符合要求的人体功效试验报告。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"For the cosmetics for spot correcting, whitening and preventing hair loss with the application submitted and registration completed between May 1 and December 31, 2021, registration persons shall submit the human efficacy test report conforming to the requirements prior to May 1, 2022."
    },
    {
        "instruction":"已知信息：\n'（七）禁忌症、注意事项、警示以及提示的内容；'可被翻译为：(7) Contraindications, precautions, warnings and suggestive descriptions.\n\n根据上述已知信息，请将'第十一条 医疗器械说明书中有关注意事项、警示以及提示性内容主要包括：'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 11 Precautions, warnings and suggestive descriptions in medical device instructions mainly include:"
    },
    {
        "instruction":"已知信息：\n'第一百七十六条 企业发现已售出药品有严重质量问题，应当及时采取措施追回药品并做好记录，同时向食品药品监督管理部门报告。'可被翻译为：Article 176 In case of identifying that a sold drug has serious quality issue, an enterprise shall immediately take measures to retrieve the drug, make records and report to the food and drug regulatory department.\n\n根据上述已知信息，请将'第二百七十七条 企业出现生产失误、药品变质或其他重大质量问题，应当及时采取相应措施，必要时还应当向当地药品监督管理部门报告。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 277: The manufacturer should take actions timely for manufacturing failure, drug deterioration, or any other serious quality problems. If necessary, actions taken should be reported to the local drug regulatory department."
    },
    {
        "instruction":"已知信息：\n'国务院办公厅印发《关于建立职业化专业化药品检查员队伍的意见》'可被翻译为：General Office of the State Council Issued the Opinions on Establishing a Team of Professionalized & Specialized Drug Inspectors\n\n根据上述已知信息，请将'第一百零四条 国家建立职业化、专业化药品检查员队伍。检查员应当熟悉药品法律法规，具备药品专业知识。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 104 The State establishes a professional and specialized team of drug inspectors who are familiar with drug laws and regulations and have professional knowledge of drugs."
    },
    {
        "instruction":"已知信息：\n'与药物具有相同的分子式，但其分子中原子的空间排列不同并且为不能重合的镜像的化合物。'可被翻译为：A compound with the same molecular formula as the drug substance that differs in the spatial arrangement of atoms within the molecule and is a non-superimposable mirror image.\n\n根据上述已知信息，请将'具有相同分子式而分子中原子排列不同的化合物。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A compound having the same molecular formula but with a different arrangement of atoms."
    },
    {
        "instruction":"已知信息：\n'促生长试验；使用现行USP（表1，USP<71>）推荐的微生物菌株。不要使用从 原始主种子批次中传代五代以上的培养物。也可以使用所推荐微生物的商业制备 并标化的稳定悬浮培养物。繁殖体细菌或酵母的试验菌悬液应在2小时内使用， 如果在2-8ºC冷藏，则应在24小时内使用。在2-8ºC冷藏的孢子悬浮液（A巴 西芽孢杆菌，B枯草芽孢杆菌和C孢子芽孢杆菌）可保存至经过验证的时长。如 果使用商业制备的生物体，应遵守生产商的说明。此外，所制备的所有菌悬液和 孢子悬浮液浓度应≤100CFU。使用时必须核查所有细菌数量。'可被翻译为：Growth promotion test; follow the current USP using recommended strains of organisms (Table 1, USP<71> ). Do not use cultures that are more than five passages removed from the original master seed lot. Commercially prepared and standardized stable suspension cultures of the recommended organisms can also be used. Test strains suspensions of vegetative bacteria or yeast should be used within 2 hours, or within 24 hours if refrigerated between 2ºC and 8ºC. Spore suspensions (A. brasiliensis, B. subtilis, and C. sporogenes) refrigerated between 2ºC and 8ºC may be kept for a validated period of time. If using commercially prepared organisms, follow the manufacturer’s instructions. Additionally, all bacterial and spore suspensions should be prepared to yield ≤100CFU. All bacterial counts must be verified at time of use.\n\n根据上述已知信息，请将'对于细菌和真菌，根据USP要求接种至检测容器。确保所用种子批培养物 不超过原始主种子批的五代。公司自己配制的繁殖性细菌和酵母测试菌悬 液应在2小时使用；如果冷藏在2-8 ºC ，则应在24小时内使用。孢子混悬 液（A巴西芽孢杆菌，B枯草芽孢杆菌和C孢子芽孢杆菌）可在2-8 ºC 制 备并保存最长达7天。此外，所有的细菌和孢子悬液应制备为≤100CFU。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"For bacteria and fungi, incubate test vessels according to USP requirements. Ensure that seed-lot cultures used are not more than five passages removed from the original master seed-lot. For in-house prepared test strain suspensions of vegetative bacteria and yeast should be used within 2 hours, or within 24 hours if refrigerated between 2ºC and 8ºC. Spore suspensions (A. brasiliensis, B. subtilis, and C. sporogenes) can be prepared and maintained between 2ºC and 8ºC for up to seven days. Additionally, all bacterial and spore suspensions should be prepared to yield ≤100 CFU."
    },
    {
        "instruction":"已知信息：\n'第八条 有下列情形之一的，食品药品监督管理部门可以开展药品医疗器械飞行检查：'可被翻译为：Article 8 Where any of the following circumstances exists, the food and drug regulatory departments can conduct an unannounced inspection for drugs and medical devices:\n\n根据上述已知信息，请将'第二十条 有下列情形之一的，检查组应当立即报组织实施飞行检查的食品药品监督管理部门及时作出决定：'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 20 Where any of the following circumstances exist, the inspection team shall report promptly to the food and drug regulatory department organizing the unannounced inspection for its timely decisions:"
    },
    {
        "instruction":"已知信息：\n'（六）采用经过验证或已知有效的清洁和去污染操作规程进行设备清洁；必要时，应当对与物料直接接触的设备表面的残留物进行检测。'可被翻译为：6. Using cleaning and decontamination procedures that are validated or of known effectiveness; where appropriate, testing the residue on the surface direct contact with materials;\n\n根据上述已知信息，请将'应适当规定和控制去污染的方法（清洁和消毒，以及适用时生物材料的灭活）。消毒步骤之前的清洁非常重要：任何残留物可能会抑制去污染过程的有效性。还应提供证据证明使用的清洁和消毒剂不会对 RABS或隔离器内生产的产品产生不良影响。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Decontamination methods (cleaning and bio-decontamination, and where applicable inactivation for biological materials) should be appropriately defined and controlled. The cleaning process prior to the bio-decontamination step is essential; any residues that remain may inhibit the effectiveness of the decontamination process. Evidence should also be available to demonstrate that the cleaning and bio-decontamination agents used do not have adverse impact on the product produced within the RABS or isolator."
    },
    {
        "instruction":"已知信息：\n'第三十五条 本办法自2020年1月1日起施行。原国家食品药品监督管理局2005年11月24日公布的《进口药材管理办法（试行）》同时废止。'可被翻译为：Article 35 The Provisions shall come into force as of January 1, 2020. The Provisions for Medicinal Material Import (Interim) promulgated by the former China Food and Drug Administration on November 24, 2005, shall be repealed simultaneously.\n\n根据上述已知信息，请将'《办法》经2019年4月28日国家市场监督 管理总局第8次局务会议审议通过，自2020年1 月1日起实施。原国家食品药品监督管理局2005 年11月24日公布的《进口药材管理办法（试 行）》同时废止。《办法》共7章35条，在进口 药材管理上，严格落实“四个最严”要求，严 格药材执行的标准，加强溯源管理。同时，落 实“放管服”改革要求，对首次进口和非首次 进口药材实施分类管理。重点内容包括：'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The Measures has been adopted upon deliberation at the 8th SAMR Conference on April 28, 2019, and shall enter into force as from January 1, 2020. The Measures for the Administration of Imported Medicinal Materials (Interim), promulgated by the former State Food and Drug Administration on November 24, 2005, shall be repealed simultaneously. The current Measures consists of 35 Articles in 7 Chapters. Regarding the administration of imported medicinal materials, the Four Strictest requirements and the standards for medicinal materials are strictly enforced, and traceability management is reinforced. Furthermore, the Measures embodies the reform requirements of Streamlining Administration, Delegating More Powers to Lower-level Governments and Society, Improving Regulation and Optimizing Services, requiring classified management on initial import and non-initial import of medicinal materials. Highlights include:"
    },
    {
        "instruction":"已知信息：\n'（四）不配合药品监督管理部门和监测机构开展的医疗器械不良事件相关调查和采取的控制措施的。'可被翻译为：(IV) Failing to cooperate with drug regulatory departments and monitoring agencies in relevant investigation of medical device adverse events and control measures to be taken.\n\n根据上述已知信息，请将'（四）不配合药品监督管理部门开展的医疗器械不良事件相关调查和采取的控制措施的；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(IV) Failing to cooperate with the drug regulatory departments in relevant investigation of medical device adverse events and control measures to be taken;"
    },
    {
        "instruction":"已知信息：\n'第二百一十三条 包装期间，产品的中间控制检查应当至少包括下述内容：'可被翻译为：Article 213: In-process control of the product during packaging should include at least the following information:\n\n根据上述已知信息，请将'第二百一十二条 包装材料上印刷或模压的内容应当清晰，不易褪色和擦除。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 212: Printed and embossed information on packaging materials should be distinct and resistant to fading or erasing."
    },
    {
        "instruction":"已知信息：\n'偏离行动限或警戒限的次数增加。'可被翻译为：Increasing numbers of excursions from action limits or alert levels.\n\n根据上述已知信息，请将'可能由共同原因引起的孤立的，有规律的偏离行动限的事件（例如，经常在计划内预防性维护后出现的单次偏离）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Regular but isolated excursion from action limits that may have a common cause, (e.g. single excursions that always follow planned preventative maintenance)."
    },
    {
        "instruction":"已知信息：\n'传送带速度或在灭菌区的滞留时间。'可被翻译为：Belt speed or dwell time within the sterilising zone.\n\n根据上述已知信息，请将'除传送带本身能连续灭菌（如隧道式灭菌器）以外，传送带不得穿越 A 级或 B 级区与低级别工艺区的隔离墙。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A conveyor belt should not pass through a partition between a grade A or B area and a processing area of lower air cleanliness, unless the belt itself is continually sterilised (e.g. in a sterilising tunnel)."
    },
    {
        "instruction":"已知信息：\n'第十八条 开展疫苗临床试验，应当取得受试者的书面知情同意；受试者为无民事行为能力人的，应当取得其监护人的书面知情同意；受试者为限制民事行为能力人的，应当取得本人及其监护人的书面知情同意。'可被翻译为：Article 18 Written informed consent shall be obtained from subjects for vaccine clinical trials; where the subject is a person without capacity for civil conduct, the written informed consent shall be obtained from his\/her guardian; where the subject is a person with limited capacity for civil conduct, the written informed consent shall be obtained from the subject and his\/her guardian.\n\n根据上述已知信息，请将'第二十一条 在受试者参与临床试验前，研究者应当充分向受试者或者无民事行为能力人、限制民事行为能力人的监护人说明临床试验的详细情况，包括已知的、可以预见的风险和可能发生的不良事件等。经充分和详细解释后由受试者或者其监护人在知情同意书上签署姓名和日期，研究者也需在知情同意书上签署姓名和日期。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 21 Before a subject is to be involved in the clinical trial, the investigator shall adequately explain the details of the clinical trial to the subject or the guardians of the subject who is without capacity for civil conduct or with limited capacity for civil conduct, including known and foreseeable risks and possible adverse events. After a full and detailed explanation, the subject or the guardians shall sign and date the informed consent form, and the investigator shall also sign and date the informed consent form."
    },
    {
        "instruction":"已知信息：\n'国家药监局关于发布影像型超声诊断设备同品种临床评价技术审查指导原则等2项注册技术审查指导原则的通告'可被翻译为：NMPA Announcement on Issuing of Two Registration Technical Review Guidelines Including the Guidelines for Technical Review of Clinical Evaluation of Ultrasound Diagnostic Imaging Equipment Based on Predicate Products\n\n根据上述已知信息，请将'国家药监局关于发布以医疗器械作用为主的药械组合产品等2项注册审查指导原则的通告'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"NMPA Announcement on Two Guidelines for Registration Review of Drug-Device Combination Products with Device Taking Primary Mode of Action"
    },
    {
        "instruction":"已知信息：\n'第一百四十九条 违反本法规定，药品监督管理等部门有下列行为之一的，对直接负责的主管人员和其他直接责任人员给予记过或者记大过处分；情节较重的，给予降级或者撤职处分；情节严重的，给予开除处分：'可被翻译为：Article 149 Where a drug regulatory department commits any of the following acts in violation of this Law, the persons directly in charge and other directly responsible persons shall be given a demerit or serious demerit. In relatively serious circumstances, they shall be demoted or removed and in serious circumstances, they shall be dismissed:\n\n根据上述已知信息，请将'第三十四条 食品药品监督管理部门及其工作人员不履行医疗器械监督管理职责或者滥用职权、玩忽职守，有下列情形之一的，由监察机关或者任免机关根据情节轻重，对直接负责的主管人员和其他直接责任人员给予批评教育，或者依法给予警告、记过或者记大过的处分；造成严重后果的，给予降级、撤职或者开除的处分：'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 34 The food and drug regulatory departments and their personnel who fail to perform their responsibilities for medical device supervision and administration, or abuse their powers or neglect their duties, in any of the following circumstances, the supervisory authority or the appointment and dismissal authority shall, according to the seriousness of the circumstances, give criticism and education, or give warning, demerit or major demerit to the persons directly in charge and other directly responsible persons according to law; if serious consequences are caused, demotion, removal or dismissal shall be given:"
    },
    {
        "instruction":"已知信息：\n'已经备案的产品不再生产或者进口的，备案人应当及时报告承担备案管理工作的药品监督管理部门取消备案。'可被翻译为：If the products that have been filed are no longer produced or imported, the filing person shall promptly report to the drug regulatory department responsible for the filing administration for cancelling the filing.\n\n根据上述已知信息，请将'第三十七条 普通化妆品的备案人应当每年向承担备案管理工作的药品监督管理部门报告生产、进口情况，以及符合法律法规、强制性国家标准、技术规范的情况。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 37 The filing person of general cosmetics shall report the production and import status, as well as the compliance with laws and regulations, compulsory national standards, and technical specifications to the drug regulatory department responsible for filing administration on a yearly basis."
    },
    {
        "instruction":"已知信息：\n'（二）特殊药品和疫苗类制品的样品检验：60日；同时进行样品检验和标准复核：90日。'可被翻译为：(2) sample testing of a controlled drug or vaccine: 60 days; sample testing and specifications verification: 90 days.\n\n根据上述已知信息，请将'特殊药品和疫苗类制品的样品检验和药品标准复核应当在90日内完成。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Sample testing and verification of specifications for controlled drugs or vaccines shall be completed within 90 days."
    },
    {
        "instruction":"已知信息：\n'第五条 被检查单位对食品药品监督管理部门组织实施的药品医疗器械飞行检查应当予以配合，不得拒绝、逃避或者阻碍。'可被翻译为：Article 5 The organization being inspected shall provide cooperation, and shall not refuse, delay, deny or limit the unannounced inspection of drugs and medical devices organized by the food and drug regulatory departments.\n\n根据上述已知信息，请将'第二十八条 食品药品监督管理部门有权在任何时间进入被检查单位研制、生产、经营、使用等场所进行检查，被检查单位不得拒绝、逃避。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 28 A food and drug regulatory department has the right to enter at any time into the sites of research and development, manufacture, sales or use and etc. of the organization being inspected to conduct the inspection, and the organization being inspected shall not refuse, delay or deny."
    },
    {
        "instruction":"已知信息：\n'治疗真性红细胞系细胞的肿瘤性增生所造成的红细胞增多症的药物。如羟基脲等。'可被翻译为：Drugs used to treat polycythemia caused by neoplastic hyperplasia of genuine erythrocytic cells. Such as hydroxyurea.\n\n根据上述已知信息，请将'由活生物体或细胞制成的药物（如治疗性蛋白质） 。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Drugs that are made by living organisms or cells (e.g., therapeutic proteins)."
    },
    {
        "instruction":"已知信息：\n'管碟法是最常使用的 USP<81>测试方法。管碟法使用固体培养基（琼脂）证明抗生素活性（即抑菌圈（ZOI））。该方法需要使用 5 点标准曲线【S1】-【S5】、中值标准品【S3】、供试抗生素\/未知样品【U3】、经过确认的接种物、不锈钢小管和含有生长琼脂的培养碟。参见图 1 中一次独立碟法测试及一式三份标准曲线和未知样品琼脂平板的放置示例。'可被翻译为：The Plate Method is the most commonly used USP <81> test. The Plate Method uses a solid \nmedium (agar) to demonstrate antibiotic activity (i.e. zones of inhibitions (ZOIs)). This method \nrequires the use of a five-point standard curve [S1] – [S5], median reference standard [S3], test \nantibiotic\/ unknown sample [U3], verified inoculum, stainless steel penicylinders and petri_x0002_plates containing growth agar. See Diagram 1 for an example of one independent test run for the \nPlate Method and placement of the standard curve and unknown sample onto triplicate agar \nplates.\n\n根据上述已知信息，请将'在加入抗生素之后，同时培养一次检测中制备的所有培养碟。在平板培养期间，抗生素会在琼脂中扩散，在小管周边底下形成清晰的圆圈，该圈称为抑菌圈（ZOI）。ZOI 显示的是稀释后的未知样品【U3】和中值标准品【S3】的抗生素活性。详情参见图 3。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"After dosing, all plates prepared in one independent test run are incubated at the same time. As \nthe plates incubate, the antibiotics diffuse through the agar, creating a zone of clearing below \nand around penicylinder perimeter; this clearing is referred to as the zone of inhibition (ZOI). \nThe ZOI demonstrates the antibiotic activity of the diluted unknown sample [U3] and the \nmedian reference standard [S3]. See Diagram 3 for further details."
    },
    {
        "instruction":"已知信息：\n'第八十九条 试验用医疗器械的使用由临床试验机构和研究者负责，研究者应当保证所有试验用医疗器械仅用于该临床试验的受试者，在试验期间按照要求储存和保管试验用医疗器械，在临床试验后按照国家有关规定和与申办者的协议对试验用医疗器械进行处理。上述过程需由专人负责并记录。研究者不得把试验用医疗器械转交任何非临床试验参加者。'可被翻译为：Article 89 The use of investigational medical devices shall be in the charge of the clinical trial institution and the investigator. The investigator shall ensure that all investigational medical devices are used only for the subjects of the clinical trial, well stored and kept during the trial in accordance with relevant requirements, and properly handled after the clinical trial in accordance with relevant state regulations and the agreement with the sponsor. The above process shall be designated to and recorded by identified personnel. The investigator shall not hand over the investigational medical device to any non-clinical trial participants.\n\n根据上述已知信息，请将'第四十五条 申办者对试验用医疗器械在临床试验中的安全性负责。当发现可能影响受试者安全或者试验实施可能改变伦理委员会对继续试验的批准情况时，申办者应当立即通知所有临床试验机构和研究者，并作出相应处理。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 45 The sponsor shall be responsible for the safety of investigational medical device in clinical trial. When finding it may affect the safety of the subjects or the implementation of the trial may change the approval of the ethics committee for the continuation of the trial, the sponsor shall immediately notify all clinical trial institutions and investigators and make corresponding handling."
    },
    {
        "instruction":"已知信息：\n'化妆品、化妆品新原料注册人未按照本办法的规定重新注册的，依照化妆品监督管理条例第五十九条的规定给予处罚；化妆品、化妆品新原料备案人未按照本办法的规定重新备案的，依照化妆品监督管理条例第六十一条第一款的规定给予处罚。'可被翻译为：If the registrant of cosmetics and new cosmetic ingredients fails to re-register in accordance with requirements of these Provisions, it shall be punished in accordance with Article 59 of the Regulations on Supervision and Administration of Cosmetics; if the filing person of cosmetics or new cosmetic ingredients fails to re-file the filing in accordance with requirements of these Provisions, fines shall be imposed as in the first paragraph of Article 61 of the Regulations on Supervision and Administration of Cosmetics.\n\n根据上述已知信息，请将'第四十九条 化妆品注册证不得转让。因企业合并、分立等法定事由导致原注册人主体资格注销，将注册人变更为新设立的企业或者其他组织的，应当按照本办法的规定申请变更注册。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 49 The transfer of cosmetic registration license is prohibited. The change application of registration shall be followed in accordance with these Provisions, if the registrant is changed to a new company or another organization due to company merger or split causing the cancellation of the original registrant as an entity."
    },
    {
        "instruction":"已知信息：\n'在测试时使用与产品相似的物料。对照物料必须与测试产品有着相同的体 积和相似的包装。在许多情况下，过滤灭菌和高压灭菌的蛋白胨水（USP 流体 A）可用于此目的。'可被翻译为：Use a material similar to the product under test. The control material must be of the same volume, and similarly packaged as the test product. Filter- sterilized and autoclaved Peptone water (USP Fluid A) may be useful for this purpose in many cases.\n\n根据上述已知信息，请将'使用针孔、阀门、连通器等相似的管子或其他容器作为待测产品。使用 USP 流体D冲洗内腔。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Use tubing or other containers similarly fitted with needles, valves, connectors, etc., as the product under test. Use USP Fluid D to flush lumens."
    },
    {
        "instruction":"已知信息：\n'微生物接种到液体培养基培养一段时间后，经微生物代谢合成菌体及分泌产物的液体。'可被翻译为：The liquid in which the microorganisms are inoculated into the liquid medium for a period of time and then metabolized to synthesize the bacteria and secrete the products.\n\n根据上述已知信息，请将'微生物包括细菌、真菌、藻类和原生动物合成并分泌到体外的一种代谢产物。其主要成分为蛋白质，通过破坏细胞或干扰细胞正常代谢对宿主产生损害。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A metabolite synthesized and secreted into the body by microorganisms including bacteria, fungi, algae and protozoa. Its main component is protein, which damages the host by destroying cells or interfering with normal cell metabolism."
    },
    {
        "instruction":"已知信息：\n'药师对患者提供合理用药指导、普及合理用药知识等药学服务的过程，以提高患者用药知识水平，\n提高用药依从性，降低用药错误发生率，保障医疗质量和医疗安全。'可被翻译为：The process of pharmacists providing patients with guidance on rational drug use, disseminating knowledge about appropriate medication practices, and offering pharmaceutical services aims to elevate patients' understanding of medications. This, in turn, enhances medication adherence, reduces the occurrence of medication errors, and safeguards the quality and safety of healthcare.\n\n根据上述已知信息，请将'临床药师在病区内对患者开展以合理用药为目的的查房过程。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Clinical pharmacists conduct ward rounds in the patient care area with the aim of promoting rational drug use."
    },
    {
        "instruction":"已知信息：\n'（一）原辅包的使用必须符合药用要求，主要是指原辅包的质量、安全及功能应该满足药品制剂的需要。原辅包与药品\/制剂关联审评审批由原辅包登记人在登记平台上登记，药品\/制剂注册申请人提交注册申请时与平台登记资料进行关联；因特殊原因无法在平台登记的原辅包，药品\/制剂注册申请人也可在药品\/制剂注册申请时，一并提供原辅包研究资料。'可被翻译为：(1) The use of AEP must comply with the medical requirements, mainly referring to the quality, safety and function of AEP should meet the needs of the pharmaceutical preparation. The review & approval of AEP and drug\/preparation associated registration shall be registered on the registration platform by AEP registrant, and the drug\/preparation registration applicant shall associate the data with the platform registration data when submitting the registration application; for AEPs that cannot be registered on the platform for special reasons, it is also possible for drug\/preparation registration applicants to provide the AEP research dossiers together with the application for drug\/preparation registration.\n\n根据上述已知信息，请将'（十六）原辅包发生变更时原辅包登记人应主动开展研究，并及时通知相关药品\/制剂生产企业（药品上市许可持有人），并及时更新登记资料，并在年报中体现。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(16) Where any change arises for AEP, the AEP registrant shall initiate research on its own initiative, and promptly notify the relevant drug\/preparation production enterprise (Drug Marketing Authorization Holders), update the registration information in a timely manner and specify it in the annual report."
    },
    {
        "instruction":"已知信息：\n'通常，需要在IVRT方法开发过程中对不同的接收介质进行评估（采用与待评估的接收液具有化学兼容性的同一种膜）；根据药物（通常是疏水性的）在接收液中的溶解性和稳定性，接收介质通常是水-醇二元混合体系。接收液取样频率通常是在6个小时的研究中，每小时至少取样一次。'可被翻译为：It is conventional to evaluate different receptor solutions during IVRT method development (all using the same membrane that has broad chemical compatibility with the receptor solutions evaluated); these receptor solutions are frequently binary hydro-alcoholic mixtures selected based upon the solubility and stability of the (frequently hydrophobic) drug in the receptor solution. The receptor solutions are conventionally sampled at least hourly across a 6-hour duration.\n\n根据上述已知信息，请将'选择最佳接收液作为IVRT方法开发初始步骤的一个优点是，在使用接收液对不同膜评估前，可先采用选定的接收液对样品分析方法进行优化。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"One advantage of selecting an optimal receptor solution as an initial step in IVRT method development is that it allows for the sample analysis method to be optimized for the selected receptor solution sample matrix before proceeding to an evaluation of different membranes using that receptor solution."
    },
    {
        "instruction":"已知信息：\n'第六条  药品监督管理部门依法设置或者指定的医疗器械检查、检验、监测与评价等专业技术机构，按照职责分工承担相关技术工作并出具技术意见，为医疗器械经营监督管理提供技术支持。'可被翻译为：Article 6 The drug regulatory departments shall set or designate professional technical institutions for inspection, testing, monitoring, and reevaluation, etc. of medical devices according to law, to assume relevant technical work and issue technical opinions in accordance with division of responsibilities, and provide technical support for supervision and administration of medical device distribution.\n\n根据上述已知信息，请将'第六条  药品监督管理部门依法设置或者指定的医疗器械审评、检查、检验、监测与评价等专业技术机构，按照职责分工承担相关技术工作，为医疗器械生产监督管理提供技术支撑。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 6 The drug regulatory department shall set or designate professional technical institutions for review, inspection, testing, monitoring and reevaluation, etc. of medical devices according to law, to assume relevant technical work in accordance with division of responsibilities, and to provide technical support for supervision and administration of medical device manufacturing."
    },
    {
        "instruction":"已知信息：\n'补料'可被翻译为：feeding\n\n根据上述已知信息，请将'在发酵过程中一边补入新鲜料液，一边以相近的流速放料。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The addition of fresh liquid at a similar flow rate during fermentation."
    },
    {
        "instruction":"已知信息：\n'第四十五条 医疗器械注册证遗失的，注册人应当立即在原发证机关指定的媒体上登载遗失声明。自登载遗失声明之日起满1个月后，向原发证机关申请补发，原发证机关在20个工作日内予以补发。'可被翻译为：Article 45 Where a medical device registration certificate is lost, the registrant shall publish a loss declaration immediately at the media specified by the original certificate-issuing authority, and apply after 1 month of declaration to the original certificate-issuing authority for re-issuing the certificate. The original certificate-issuing authority shall re-grant the medical device registration certificate within 20 workdays.\n\n根据上述已知信息，请将'第五十四条 医疗器械注册证遗失的，注册人应当立即在原发证机关指定的媒体上登载遗失声明。自登载遗失声明之日起满1个月后，向原发证机关申请补发，原发证机关在20个工作日内予以补发。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 54 Where a medical device registration certificate is lost, the registrant shall publish a loss declaration immediately at the media specified by the original certificate-issuing authority, and apply after 1 month of declaration to the original certificate-issuing authority for re-issuing the certificate. The original certificate-issuing authority shall re-issue the medical device registration certificate within 20 workdays."
    },
    {
        "instruction":"已知信息：\n'由于某种原因不能选用首选药用于治疗时，可供选用的药物品种。'可被翻译为：A variety of drugs that can be used for treatment when the preferred drug cannot be used for some reason.\n\n根据上述已知信息，请将'药物治疗中所选用药品单次用量偏大或疗程偏长。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The drug used in drug therapy is too large or the course of treatment is too long."
    },
    {
        "instruction":"已知信息：\n'省、自治区、直辖市药品监督管理部门负责本行政区域医疗器械生产监督管理信息化建设和管理工作，按照国家药品监督管理局的要求统筹推进医疗器械生产监督管理信息共享。'可被翻译为：The drug regulatory department of the province, autonomous region, or municipality directly under the central government shall be responsible for the construction and management of information technology for supervision and administration of medical device manufacturing within the administrative areas, and the coordination and promotion of information sharing on supervision and administration of medical device manufacturing as required by NMPA.\n\n根据上述已知信息，请将'省、自治区、直辖市药品监督管理部门负责本行政区域医疗器械经营监督管理信息化建设和管理工作，按照国家药品监督管理局要求统筹推进医疗器械经营监督管理信息共享。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The drug regulatory department of the province, autonomous region, or municipality directly under the central government shall be responsible for the construction and management of information technology for supervision and administration of medical device distribution within the administrative areas, and the coordination and promotion of information sharing on supervision and administration of medical device distribution as required by NMPA."
    },
    {
        "instruction":"已知信息：\n'本节提供的程序信息可用于动力学分析方法。动力学色度和浊度试剂可通过商业化获取。 分析过程可作为试剂盒采购。控制标准内毒素、检测中所用LAL试剂和无热源水的 COA应保存。其它物料如无热源移液管、微量移液头、试管和96阱微生物碟可从不同 供应商处采购。实验室亦应保存显示这些物料无热源的COA。'可被翻译为：This section provides procedural information that can be applied to kinetic assays. The Kinetic Chromogenic and Turbidimetric reagents are commercially available. Assay may be purchased as a kit. A certificate of analysis should be maintained for the control standard endotoxin, Limulus Amebocyte Lysate (LAL), and pyrogen free water used in the assay. Other materials such as pyrogen free pipettes, micropipettor tips, test tubes, and 96- well microplates may be purchased from various vendors. Certificates of analysis indicating these materials are pyrogen-free should also be maintained by the laboratory.\n\n根据上述已知信息，请将'注：无热源移液管、微量移液头、试管和其它用品均有商业化产品可及。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"NOTE: Pyrogen free pipettes, micropipettor tips, test tubes, and other accessories are commercially available."
    },
    {
        "instruction":"已知信息：\n'染色体数目与原来的染色体单倍体或二倍体不同；对于细胞系，其染色体数目与原型染色体不同。'可被翻译为：Chromosome numbers different from the original haploid or diploid set of chromosomes; for cell lines, chromosome numbers differe nt from the modal chromosome set.\n\n根据上述已知信息，请将'染色体的一部分置换到不同染色体上，或同一染色体的不同位点上。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Part of a chromosome is replaced on a different chromosome, or at a different site on the same chromosome."
    },
    {
        "instruction":"已知信息：\n'有一些与 SUS 有关的特定风险，应作为 CCS 的一部分予以评估。这些风险包括但不限于：'可被翻译为：There are some specific risks associated with SUS which should be assessed as part of the CCS. These risks include but are not limited to:\n\n根据上述已知信息，请将'在 CCS 的制定和维护中进行风险管理，来识别、评估、减少\/消除（如适用）和控制污染风险。风险管理应书面化，并应包括降低风险和接受剩余风险有关决策的理由。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Risk management is applied in the development and maintenance of the CCS, to identify, assess,\nreduce\/eliminate (where applicable) and control contamination risks. Risk management should be documented and should include the rationale for decisions taken in relation to risk reduction and acceptance of residual risk."
    },
    {
        "instruction":"已知信息：\n'二、增加吉林省药品监督管理局为口岸药品监督管理部门，由其承担长春空港口岸药品进口备案的具体工作。'可被翻译为：II. Jilin Medical Products Administration is added as the port drug regulatory authority, which shall undertake the specific drug import filing at Changchun AirPort.\n\n根据上述已知信息，请将'二、增加无锡市市场监督管理局为口岸药品监督管理部门，由其承担无锡航空口岸、江阴港口岸药品进口备案的具体工作。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"II. Wuxi Administration of Market Regulation is added as the port drug regulatory authority, which shall undertake the specific drug import filing at Wuxi Airport and Jiangyin Port."
    },
    {
        "instruction":"已知信息：\n'在 FFS 确认过程中确定的控制措施应与 CCS 保持一致。应考虑的方面包括但不限于：'可被翻译为：The controls identified during qualification of FFS  should be in alignment with the CCS. Aspects to be considered include but are not limited to:\n\n根据上述已知信息，请将'BFS 确认过程中确定的控制措施应与工厂的 CCS 保持一致。应考虑的方面包括但不限于：'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The controls identified during qualification of BFS should be in alignment with the site's CCS. Aspects to be considered include but are not limited to:"
    },
    {
        "instruction":"已知信息：\n'八、本通告自发布之日起实施，《关于药械组合产品注册有关事宜的通告》（原国家食品药品监督管理局通告2009年第16号）和《关于调整药械组合产品属性界定有关事项的通告》（国家药品监督管理局通告2019年第28号）同时废止。'可被翻译为：VIII. The Notice shall be implemented as of the date of issuance. The Notice on Matters Concerning the Registration of Drug-device Combination Products(Former CFDA Notice [2009] No. 16)and the Notice on Matters Concerning the Adjustment of Attribute Definition of Drug-device Combination Products(NMPA Notice [2019] No. 28) shall be simultaneously abolished.\n\n根据上述已知信息，请将'关于调整药械组合产品属性界定有关事项的通告【废止】'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"NMPA issued the Announcement on Adjusting the Relevant Matters Concerning the Definition of the Attributes of Drug\/Device Combination Products"
    },
    {
        "instruction":"已知信息：\n'第五十六条 国家药品监督管理局和省、自治区、直辖市药品监督管理部门组织监督检查时，应当制定检查方案，明确检查标准，如实记录现场检查情况，需要抽样检验或者研究的，按照有关规定执行。检查结论应当清晰明确，检查发现的问题应当以书面形式告知被检查单位。需要整改的，应当提出整改内容及整改期限，必要时对整改后情况实施检查。'可被翻译为：Article 56 When organizing supervision and inspections, the NMPA and the drug regulatory authority of the province, autonomous region or municipality directly under the Central Government shall make inspection plans to clarify the inspection standards, record the on-site inspections truthfully, conduct the inspections in accordance with relevant rules when sample testing or study is required. The conclusion of the inspection shall be clear and unambiguous, and the problems found during the inspection shall be notified to the inspected company in written format. If corrective actions are required, the content and the deadline of corrective actions shall be proposed, and the situation after the remediation shall be inspected if necessary.\n\n根据上述已知信息，请将'第五十八条 现场检查结束后，应当对现场检查情况进行分析汇总，并客观、公平、公正地对检查中发现的缺陷进行风险评定并作出现场检查结论。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 58 After the on-site inspection, the results shall be analyzed and summarized; risks of deficiencies found in the inspection shall be assessed objectively, fairly and impartially, and the on-site inspection conclusion shall be made."
    },
    {
        "instruction":"已知信息：\n'1.一种原料、中间产品或成品被另一种原料或产品污染。\n2.一种原料、中间产品或成品在生产过程中被另一种原料或产品污染。\n3.一种原料、中间产品或成品在生产过程中被另一种原料或产品污染。\n4.污染:一种材料或产品被另一种材料或产品污染\n5.在生产、储存、运输过程中，原料药、中间产品或药品成品被另一原料药或产品污染的。\n6.在生产、储存、运输过程中，原料药、中间产品、药品、医疗产品被其他原料药、产品污染的。'可被翻译为：1.Contamination of a starting material, intermediate product or finished product with another starting material or product.\n2.Contamination of a starting material, intermediate product or finished product with another starting material or product during production.\n3.Contamination of a starting material, intermediate product or finished product with another starting material or product during production.\n4.Contamination of a material or product with another material or product.\n5.Contamination of a starting material, intermediate product or finished pharmaceutical product with another starting material or product during production, storage and transportation.\n6.Contamination of a starting material, intermediate product or ﬁnished pharmaceutical product or medical product with another starting material or product, during production, storage and transportation.\n\n根据上述已知信息，请将'生产过程中原料、辅料、中间产品或成品之间，或与其他的原料或产品的不适当接触而产生的污染。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Pollution resulting from improper contact between raw materials, auxiliary materials, intermediate products or finished products, or with other raw materials or products in the production process."
    },
    {
        "instruction":"已知信息：\n'批生产： 已执行的批记录、放大信息、风险评估、关键工艺参数、中控标准、放大方案和报告、工艺验证'可被翻译为：Batch manufacturing: Master of executed batch record; Scale up information; Risk assessment; Critical process parameters; In-process control specification; Scale up protocol and report; Process validation\n\n根据上述已知信息，请将'其它文件： 拒收批准信息、生物批信息、中试批信息、变更历史和变更管理、保存时间方案和报告'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Other documents: Rejected batch information; Bio-batch information; Pilot batch information; History of changes and change management; Hold time protocols and reports"
    },
    {
        "instruction":"已知信息：\n'第二十九条 疫苗批签发应当逐批进行资料审核和抽样检验。疫苗批签发检验项目和检验频次应当根据疫苗质量风险评估情况进行动态调整。'可被翻译为：Article 29 For lot release of vaccines, dossier review and sample testing shall be conducted lot by lot. The testing items and testing frequency for lot release of vaccines shall be dynamically adjusted according to the vaccine quality risk evaluation.\n\n根据上述已知信息，请将'二是规范批签发管理要求，明确批签发豁免情形、检验项目和频次要求，强化生产工艺偏差管理。依照《疫苗管理法》规定，明确预防、控制传染病疫情或者应对突发事件急需的疫苗，经国家药监局批准，免予批签发。对疫苗产品和其他生物制品批签发方式、检验项目和频次分别作出细化规定，要求疫苗批签发应当逐批进行资料审核和抽样检验。规定在批签发申报时应当提交生产工艺偏差等有关资料，由批签发机构对相关资料进行审核、开展现场检查等。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2. Standardization of administrative requirements for lot release, clarifying the exemptions, inspection items and frequency requirements for lot release, and emphasizing control over production process deviations. According to the Vaccine Administration Law, vaccines that are urgently needed to prevent and control infectious diseases or respond to emergencies shall be exempted, with NMPA approval, from lot release. Detailed regulations have been made on the lot release methods, inspection items, and frequency for vaccines and other biological products, and it is required that the lot release of vaccines should be subject to dossier review and sampling inspection. It is stipulated that relevant dossiers such as production process deviation should be submitted while applying for lot release, to facilitate the competent agency's review and on-site inspections."
    },
    {
        "instruction":"已知信息：\n'第二百三十四条 持续稳定性考察的时间应当涵盖药品有效期，考察方案应当至少包括以下内容：'可被翻译为：Article 234: The protocol for an on-going stability program should extend to the end of the shelf life period and should at least include the following contents:\n\n根据上述已知信息，请将'第二百三十九条 应当根据所获得的全部数据资料，包括考察的阶段性结论，撰写总结报告并保存。应当定期审核总结报告。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 239: A summary of all the data generated, including any interim conclusions on the program, should be written and maintained. This summary should be subjected to periodic review."
    },
    {
        "instruction":"已知信息：\n'1.药物起始原料是一种活性药物成分(API)或赋形剂，预定或指定用于药品生产。\n2.在药品生产中使用的具有一定质量的物质，但不包括包装材料。这包括活性药物成分(api)和药用辅料。'可被翻译为：1.A pharmaceutical starting material is an active pharmaceutical ingredient (API) or an excipient intended or designated for use in the production of a pharmaceutical product.\n2.Any substance of a defined quality used in the production of a pharmaceutical product, but excluding packaging materials. This includes active pharmaceutical ingredients (APIs) and pharmaceutical excipients.\n\n根据上述已知信息，请将'生产、包装和标记活性药物成分(api)的公司。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A company that produces, packages and labels active pharmaceutical ingredients (APIs)."
    },
    {
        "instruction":"已知信息：\n'（一）存放于标志明显的专用场所，并有效隔离，不得销售；'可被翻译为：(I) Such drugs shall be stored in special places clearly marked and effectively isolated, and shall not be sold;\n\n根据上述已知信息，请将'（十）经营非药品应当设置专区，与药品区域明显隔离，并有醒目标志。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(X) A special partition shall be set up for distributing non-drugs, which shall be clearly separated from the drug partition and provided with clear marks."
    },
    {
        "instruction":"已知信息：\n'（六）伤害发生的概率；'可被翻译为：(6) the probability of injury;\n\n根据上述已知信息，请将'1.危害发生的概率与危害严重程度的结合。\n2.伤害发生的概率和伤害的严重程度的组合(15)。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.Combination of the probability of occurrence of harm and severity of the harm.\n2.The combination of the probability of occurrence of harm and the severity of that harm (15)."
    },
    {
        "instruction":"已知信息：\n'境外生产药品的注册申请，药品注册申请受理后需要药品注册检验的，申请人应当按规定要求抽取样品，并将样品、检验所需资料及标准物质等送至中检院。'可被翻译为：For drugs manufactured overseas, where drug registration testing is necessary after the drug registration application is accepted, the applicant shall conduct sampling as required and send the samples, dossiers required for testing and reference standard to the NIFDC.\n\n根据上述已知信息，请将'境外生产药品的注册申请，申请人在药品注册申请受理前提出药品注册检验的，申请人应当按规定要求抽取样品，并将样品、检验所需资料及标准物质等送至中检院。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"For drugs manufactured overseas, where drug registration testing has been proposed before the drug registration application is accepted, the applicant shall conduct sampling as required and send the samples, dossiers required for testing and reference standard to the NIFDC."
    },
    {
        "instruction":"已知信息：\n'（二）按照强制性标准以及经注册、备案的产品技术要求组织生产，实际生产与医疗器械注册备案、医疗器械生产许可备案等内容的一致情况；'可被翻译为：(2) organizing manufacturing in accordance with mandatory standards and registered or filed technical specifications for the products; consistency of  the actual manufacturing with the contents of medical device registration and filing, and medical device manufacturing licensing and filing, etc.;\n\n根据上述已知信息，请将'（一）实际生产与医疗器械注册备案、医疗器械生产许可备案等内容的一致情况；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(1) consistency of the actually manufactured products and the contents of medical device registration and filing, and medical device manufacturing licensing and filing, etc.;"
    },
    {
        "instruction":"已知信息：\n'第八十三条 违反本法规定，疫苗上市许可持有人有下列情形之一的，由省级以上人民政府药品监督管理部门责令改正，给予警告；拒不改正的，处二十万元以上五十万元以下的罚款；情节严重的，责令停产停业整顿，并处五十万元以上二百万元以下的罚款：'可被翻译为：Article 83 In cases where vaccine MAHs' violation of this Law involves any of the following circumstances, the drug regulatory departments of the people's governments at or above the provincial level shall order to make rectification and give a warning; and those who refuse to make rectification shall be subject to a fine of not less than RMB 200,000 yuan but not more than RMB 500,000 yuan; in serious circumstances, the offender shall be subject to an order to stop production for rectification and a fine of not less than RMB 500,000 yuan but not more than RMB 2,000,000 yuan:\n\n根据上述已知信息，请将'第一百三十一条 违反本法规定，药品网络交易第三方平台提供者未履行资质审核、报告、停止提供网络交易平台服务等义务的，责令改正，没收违法所得，并处二十万元以上二百万元以下的罚款；情节严重的，责令停业整顿，并处二百万元以上五百万元以下的罚款。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 131 Where a third party platform provider for online drug transactions fails to perform its obligations, such as examine qualifications, report incidents, and cease to provide online services in violation of this Law, the offender shall be ordered to make correction and subject to a confiscation of illegal income and a fine of not less than RMB 200,000 but not more than RMB 2,000,000. In serious circumstances, the offender shall be ordered to stop production for rectification and be subject a fine of not less than RMB 2,000,000 but not more than RMB 5,000,000."
    },
    {
        "instruction":"已知信息：\n'测量样品从制造过程中转移，并可能返回到工艺流。'可被翻译为：Measurement where the sample is diverted from the manufacturing process, and may be returned to the process stream.\n\n根据上述已知信息，请将'在靠近工艺流的地方进行取样、分离和分析的测量。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Measurement where the sample is removed, isolated from, and analysed in close proximity to the process stream."
    },
    {
        "instruction":"已知信息：\n'风险评估应基于科学知识与经验，包括对工艺和产品的科学知识与经验。'可被翻译为：6.7. The evaluation of the risk should be based on scientific knowledge and experience including that of the process and product.\n\n根据上述已知信息，请将'第十四条 应当根据科学知识及经验对质量风险进行评估，以保证产品质量。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 14: The evaluation of the risk to quality is based on scientific knowledge and experience, to ensure the quality of products."
    },
    {
        "instruction":"已知信息：\n'第六条 进行医疗器械临床试验应当有充分的科学依据和明确的试验目的，并权衡对受试者和公众健康预期的受益以及风险，预期的受益应当超过可能出现的损害。'可被翻译为：Article 6 Medical device clinical trials shall have sufficient scientific basis and clear trial objectives and weight the expected benefits and risks that will pose to the subjects' and public's health and the expected benefits shall exceed the possible damage.\n\n根据上述已知信息，请将'（三）受试者可能遭受的风险程度与试验预期的受益相比是否合适。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(3) Whether the potential severity of risk that the subjects may suffer is appropriate compared to the expected benefits of the trial."
    },
    {
        "instruction":"已知信息：\n'第三十九条 应当根据厂房及生产防护措施综合考虑选址，厂房所处的环境应当能够最大限度地降低物料或产品遭受污染的风险。'可被翻译为：Article 39: Premises should be situated in an environment that, when considered together with measures to protect the manufacturing process, presents minimal risk of causing contamination of materials or products.\n\n根据上述已知信息，请将'第四十三条 厂房、设施的设计和安装应当能够有效防止昆虫或其它动物进入。应当采取必要的措施，避免所使用的灭鼠药、杀虫剂、烟熏剂等对设备、物料、产品造成污染。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 43: Premises and facilities should be designed and equipped so as to afford maximum protection against the entry of insects or other animals. Necessary measures should be taken to avoid the contamination to equipment, materials and products caused by raticide, insecticide, fumigation reagent, etc."
    },
    {
        "instruction":"已知信息：\n'进货查验记录应当保存至医疗器械有效期满后2年；没有有效期的，不得少于5年。植入类医疗器械进货查验记录应当永久保存。'可被翻译为：The inspection records of incoming goods shall be kept till 2 years after expiration of valid term of the medical device; if there is no valid term for such medical device, the records shall be kept for no less than 5 years. The inspection records of incoming implantable medical devices shall be kept permanently.\n\n根据上述已知信息，请将'第三十二条  医疗器械经营企业应当建立进货查验记录制度，购进医疗器械时应当查验供货企业的资质，以及医疗器械注册证和备案信息、合格证明文件。进货查验记录应当真实、准确、完整和可追溯。进货查验记录包括：'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 32 The medical device distributors shall establish procedures for inspecting and recording incoming goods, and when purchasing medical devices, it shall inspect qualifications of the supplier, the Medical Device Registration Certificate, the filing information and qualification certificates. The inspection records of incoming goods shall be authentic, accurate, complete, and traceable. The inspection records of incoming goods shall include:"
    },
    {
        "instruction":"已知信息：\n'采用准确、可靠的方法或直接与一级标准物质相比较的方法，测量标准物质的特性量值，测量准确度满足需要的标准物质。在实验室中通常是指与一级标准物质比对后作为对照使用的工作对照品（标准品）。'可被翻译为：The characteristic quantity value of the standard substance shall be measured by accurate and reliable method or by method directly compared with the first class standard substance, and the standard substance whose measurement accuracy meets the needs shall be measured. In the laboratory, it usually refers to the working reference material (standard material) used as a control after comparison with the primary reference material.\n\n根据上述已知信息，请将'以合理的测量范围，通过与对照品或可溯源标准的比对，证明来自于某一具体仪器或设备的结果符合特定的限度。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The demonstration that a particular instrument or device produces results within specified limits by comparison with those produced by a reference or traceable standard over an appropriate range of measurements."
    },
    {
        "instruction":"已知信息：\n'配制记录、分发与返还记录等完整；'可被翻译为：Records of formulating, distribution, and return, etc. of the test\/control articles should be complete;\n\n根据上述已知信息，请将'4.应完整保留研究所需毒麻药品、造模试剂(药品)等的配制、保存、使用、返还或废弃等记录。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"4. Records of formulating, storage, use, return and disposal of narcotic drugs and modeling reagents (drugs) used in the study should be retained completely."
    },
    {
        "instruction":"已知信息：\n'能产生抗生素等次级代谢产物的微生物。'可被翻译为：Microorganisms that produce secondary metabolites such as antibiotics.\n\n根据上述已知信息，请将'抗生素产生菌快速生长结束之后的次级代谢产物形成期。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The phase of secondary metabolite formation after rapid growth of antibiotic-producing bacteria has ended."
    },
    {
        "instruction":"已知信息：\n'1.生产商根据预定的时间表对生产批次进行的研究，以监测、确认和延长活性药物成分的预计复测期(或保质期)，或确认或延长成品药品的保质期。\n2.生产商根据预定的时间表对生产批次进行的研究，以监测、确认和延长原料药的预计复测期(或保质期)，或确认或延长FPP的保质期。'可被翻译为：1.The study carried out by the manufacturer on production batches according to a predetermined schedule in order to monitor, confirm and extend the projected retest period (or shelf life) of the active harmaceutical ingredient, or confirm or extend the shelf life of the finished pharmaceutical product.\n2.The study carried out by the manufacturer on production batches according to a predetermined schedule in order to monitor, confirm and extend the projected re-test period (or shelf-life) of the API, or confirm or extend the shelf-life of the FPP.\n\n根据上述已知信息，请将'1.根据规定的稳定性协议，对主要批次和\/或承诺批次进行长期和加速(和中间)研究，以确定或确认API或FPP的复测期(或保质期)。\n2.根据规定的稳定性方案对主要批次和\/或承诺批次进行的长期和加速(和中间)研究，以确定或确认活性药物成分的复测期(或保质期)或成品药品的保质期。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.Long-term and accelerated (and intermediate) studies undertaken on primary and\/or commitment batches according to a prescribed stability protocol to establish or confirm the re- test period (or shelf-life) of an API or the shelf-life of an FPP.\n2.Long-term and accelerated (and intermediate) studies undertaken on primary and\/or commitment batches according to a prescribed stability protocol to establish or confirm the retest period (or shelf life) of an active pharmaceutical ingredient or the shelf life of a finished pharmaceutical product."
    },
    {
        "instruction":"已知信息：\n'在色谱分析中，一种通过对照品和供试品色谱峰面积或峰高的比较进行定量的方法。'可被翻译为：In chromatographic analysis, a quantitative method is performed by comparing the chromatographic peak area or peak height of the reference and the test.\n\n根据上述已知信息，请将'进行色谱分析时，在供试品与对照品溶液中添加一定量参比物的定量方法。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"When performing chromatographic analysis, a quantitative method of adding a certain amount of reference substance to the solution of the test product and the control product."
    },
    {
        "instruction":"已知信息：\n'在新药审批期间，其注册分类和技术要求不因国内药品生产企业申报的相同活性成份的制剂在我国获准上市而发生变化。'可被翻译为：In the process of the review and approval of a new drug, the registration classification and technical requirements thereof shall not be changed, even though the preparations of the same active ingredients applied for by domestic manufacturers are approved for marketing in China.\n\n根据上述已知信息，请将'第四十八条 在新药审批期间，新药的注册分类和技术要求不因相同活性成份的制剂在国外获准上市而发生变化。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 48 In the process of the review and approval of a new drug, the registration classification and technical requirements thereof shall not be changed, even though the preparations of the same active ingredients are approved for marketing abroad."
    },
    {
        "instruction":"已知信息：\n'第三十条 化妆品注册人、备案人应当选择符合法律、行政法规、强制性国家标准和技术规范要求的原料用于化妆品生产，对其使用的化妆品原料安全性负责。化妆品注册人、备案人申请注册、进行备案时，应当通过信息服务平台明确原料来源和原料安全相关信息。'可被翻译为：Article 30 Cosmetic registrants and filing persons shall select ingredients that meet the requirements of laws, administrative regulations, mandatory national standards and technical specifications for cosmetic production, and shall be responsible for the safety of cosmetic ingredients they use. When applying for registration and filing for filing, the cosmetic registrant and filing person shall clarify the source of ingredients and relevant information on ingredient safety through the information service platform.\n\n根据上述已知信息，请将'化妆品、化妆品新原料注册人、备案人申请注册或者进行备案时，应当遵守有关法律、行政法规、强制性国家标准和技术规范的要求，对所提交资料的真实性和科学性负责。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Registrants and filing persons of cosmetics and new cosmetic ingredients shall comply with the requirements of relevant laws, administrative regulations, mandatory national standards and technical specifications when applying for registration or filing for filing, and shall be responsible for the authenticity and scientificalness of the submitted dossiers."
    },
    {
        "instruction":"已知信息：\n'第六十条 本程序自2022年1月1日起施行。'可被翻译为：Article 60 The Procedures shall come into force as of January 1, 2022.\n\n根据上述已知信息，请将'第六十六条 本办法自2022年1月1日起施行。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 66 These Provisions shall be effective as of January 1, 2022."
    },
    {
        "instruction":"已知信息：\n'按照创新医疗器械特别审批程序审批的境内医疗器械申请注册时，样品委托其他企业生产的，应当委托具有相应生产范围的医疗器械生产企业；不属于按照创新医疗器械特别审批程序审批的境内医疗器械申请注册时，样品不得委托其他企业生产。'可被翻译为：Where applying for registration of a domestic medical device subject to the special review procedures for innovative medical devices and its sample production is entrusted to another enterprise, the applicant shall entrust a medical device manufacturer having corresponding production range. Where the domestic medical device applied for registration is not subject to the special review procedures for innovative medical devices, the sample production shall not be entrusted to another enterprise.\n\n根据上述已知信息，请将'按照创新医疗器械特别审批程序审批的境内体外诊断试剂申请注册时，样品委托其他企业生产的，应当委托具有相应生产范围的医疗器械生产企业；不属于按照创新医疗器械特别审批程序审批的境内体外诊断试剂申请注册时，样品不得委托其他企业生产。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Where applying for registration of a in-vitro diagnostic reagent subject to the special review procedures for innovative medical devices and its sample production is entrusted to another enterprise, the applicant shall entrust a medical device manufacturer having corresponding production range. Where the domestic medical device applied for registration is not subject to the special review procedures for innovative medical devices, the sample production shall not be entrusted to another enterprise."
    },
    {
        "instruction":"已知信息：\n'第十一条  国务院卫生行政部门和地方各级卫生行政部门负责医疗器械使用单位中与医疗器械不良事件监测相关的监督管理工作，督促医疗器械使用单位开展医疗器械不良事件监测相关工作并组织检查，加强医疗器械不良事件监测工作的考核，在职责范围内依法对医疗器械不良事件采取相关控制措施。'可被翻译为：Article 11 Health administrative departments of the State Council and health administrative departments at all levels shall be responsible for supervision and administration of user facility of medical device related to medical device adverse event monitoring, urge user facility of medical device to carry out relevant medical device adverse event monitoring work and organize inspection, strengthen  assessment of medical device adverse event monitoring, and take relevant control measures for medical device adverse events within their responsibility according to law.\n\n根据上述已知信息，请将'第六十三条  药品监督管理部门应当依据职责对持有人和经营企业开展医疗器械不良事件监测和再评价工作情况进行监督检查，会同同级卫生行政部门对医疗器械使用单位开展医疗器械不良事件监测情况进行监督检查。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 63 The drug regulatory departments shall, based on their responsibilities, supervise and inspect the medical device adverse event monitoring and re-evaluation carried out by MAHs and distributing enterprises, and supervise and inspect the medical device adverse event monitoring by user facility of medical device jointly with the health administrative departments at the same level."
    },
    {
        "instruction":"已知信息：\n'第二十七条 企业应当按照培训管理制度制定年度培训计划并开展培训，使相关人员能正确理解并履行职责。培训工作应当做好记录并建立档案。'可被翻译为：Article 27 Enterprises shall, in accordance with the training management system, formulate annual training plans and carry out training so that relevant personnel can correctly understand and perform their duties. Training shall be well documented and related archives shall be established.\n\n根据上述已知信息，请将'第一百二十八条 企业应当按照培训管理制度制定年度培训计划并开展培训，使相关人员能正确理解并履行职责。培训工作应当做好记录并建立档案。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 128 Enterprises shall, in accordance with the training management system, formulate annual training plans and carry out training so that relevant personnel can correctly understand and perform their duties. Training shall be well documented and related archives shall be established."
    },
    {
        "instruction":"已知信息：\n'(2) 一个分析批中所有样品被处理和提取的顺序与进样顺序一致， 过程可溯源。如有分批处理的情况， 每个处理批应当包括低、中、高浓度质控样品， 并符合事先规定的接受标准。'可被翻译为：(2) All the samples in one analysis batch are processed and extracted in the same order with that of the introduction, and the process is traceable. In the case of batch processing, every processing batch shall contain quality control samples of low, medium and high concentration, and comply with the predefined acceptance criteria.\n\n根据上述已知信息，请将'(3) 一个分析批中所有样品有唯一性编号， 样品按照顺序连续不间断进样， 如中断， 在原始记录中记录中断原因， 与申报资料一致。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(3) Within one analysis batch, all samples have a unique identifier, and are introduced continuously in sequence, if there is interruption, the reason for interruption is recorded in the original records, consist with the application dossier."
    },
    {
        "instruction":"已知信息：\n'编码于DNA或RNA（一些病毒）核昔酸序列中的可遗传的生物信息。'可被翻译为：The heritable biological information encoded in the nucleotide sequence of DNA or RNA (some viruses).\n\n根据上述已知信息，请将'固定有寡核昔酸、基因组DNA或互补DNA等的生物芯片。利用这类芯片与标记的生物样品进行杂交，可对样品的基因表达谱生物信息进行快速定性和定量分析。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Biochips that contain oligonucleotide, genomic DNA, or complementary DNA. By hybridizing these chips with labeled biological samples, rapid qualitative and quantitative analysis of the bioinformation of the gene expression profile of the samples can be performed."
    },
    {
        "instruction":"已知信息：\n'由下级食品药品监督管理部门查处的，组织实施飞行检查的食品药品监督管理部门应当跟踪督导查处情况。'可被翻译为：Where an investigation is conducted by an inferior food and drug regulatory department, the food and drug regulatory department organizing the unannounced inspection shall follow, monitor and direct the investigation and sanction.\n\n根据上述已知信息，请将'下级食品药品监督管理部门应当及时将其组织实施的飞行检查中发现的重大问题书面报告上一级食品药品监督管理部门，并于每年年底前将该年度飞行检查的总结报告报上一级食品药品监督管理部门。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The food and drug regulatory department at inferior level shall timely report the significant issues found in an unannounced inspection which conduction has been organized by itself, to food and drug regulatory department at the next higher level in written form, and submit an annual summary report of unannounced inspection at the end of each year."
    },
    {
        "instruction":"已知信息：\n'电子记录上签署的电子签名和手写签名应关联至其相应的电子记录，以确保无法通过普通手段对电子签名进行删除、复制或其他转移方式而实现电子记录的伪造。'可被翻译为：Electronic signatures and handwritten signatures executed to electronic records shall be linked to their respective electronic records to ensure that the signatures cannot be excised, copied, or otherwise transferred to falsify an electronic record by ordinary means.\n\n根据上述已知信息，请将'签署的电子记录应清楚表明与签名相关的信息，内容包括：'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(a) Signed electronic records shall contain information associated with the signing that clearly indicates all of the following:"
    },
    {
        "instruction":"已知信息：\n'第五十四条 医疗器械注册证遗失的，注册人应当立即在原发证机关指定的媒体上登载遗失声明。自登载遗失声明之日起满1个月后，向原发证机关申请补发，原发证机关在20个工作日内予以补发。'可被翻译为：Article 54 Where a medical device registration certificate is lost, the registrant shall publish a loss declaration immediately at the media specified by the original certificate-issuing authority, and apply after 1 month of declaration to the original certificate-issuing authority for re-issuing the certificate. The original certificate-issuing authority shall re-issue the medical device registration certificate within 20 workdays.\n\n根据上述已知信息，请将'第四十五条 医疗器械注册证遗失的，注册人应当立即在原发证机关指定的媒体上登载遗失声明。自登载遗失声明之日起满1个月后，向原发证机关申请补发，原发证机关在20个工作日内予以补发。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 45 Where a medical device registration certificate is lost, the registrant shall publish a loss declaration immediately at the media specified by the original certificate-issuing authority, and apply after 1 month of declaration to the original certificate-issuing authority for re-issuing the certificate. The original certificate-issuing authority shall re-grant the medical device registration certificate within 20 workdays."
    },
    {
        "instruction":"已知信息：\n'药品零售企业销售药品时，应当开具标明药品名称、生产厂商、数量、价格、批号等内容的销售凭证。'可被翻译为：Where a drug retailer sells drugs, it shall provide sales document indicating drug name, manufacturer, quantity, price, batch number, etc.\n\n根据上述已知信息，请将'第一百六十八条 企业销售药品应当开具销售凭证，内容包括药品名称、生产厂商、数量、价格、批号、规格等，并做好销售记录。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 168 Enterprises shall issue the proof of sales for drugs, including drug name, manufacturer, quantity, price, lot number and strength, and make the sales records."
    },
    {
        "instruction":"已知信息：\n'二、现有《药品生产许可证》在有效期内继续有效。《生产办法》施行后，对于药品生产企业申请变更、重新发证、补发等的，应当按照《生产办法》有关要求进行审查，符合规定的，发给新的《药品生产许可证》。变更、补发的原有效期不变，重新发证的有效期自发证之日起计算。'可被翻译为：2. The current Drug Manufacturing Certificate continues to be valid within the validity period. After the implementation of the Production Provisions, manufacturers' applications for alterations, renewal and re-issuance shall be reviewed in accordance with the relevant Production Provisions. While requirements are met, a new Drug Manufacturing Certificate shall be issued. The original validity period of alteration and reissuance remains unchanged, and the validity period of renewal is calculated from the current date of issuance.\n\n根据上述已知信息，请将'第二十三条 省、自治区、直辖市药品监督管理部门应当将药品生产许可证核发、重新发证、变更、补发、吊销、撤销、注销等办理情况，在办理工作完成后十日内在药品安全信用档案中更新。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 23 The drug regulatory department of the province, autonomous region or municipality directly under the Central Government shall update the information on the activities, including issuance, re-issuance, changes, replacement, revocation, rescission and cancellation, done to the Drug Manufacturing Certificate in the drug safety credit archive of the NMPA within 10 days since the date such activities are conducted."
    },
    {
        "instruction":"已知信息：\n'第三十一条 有因检查需要由核查组抽取样品进行检验的，核查组按照药品抽样的有关要求，抽取样品并封样；抽取的样品按要求送交药品检验机构进行样品检验。'可被翻译为：Article 31 If the inspection team needs to take samples for cause-related inspection, the inspection team shall take samples and seal them in accordance with the relevant requirements for drug sampling; the samples shall be sent to the drug testing institution for sample testing as required.\n\n根据上述已知信息，请将'第十八条 需要抽取成品及其他物料进行检验的，检查组可以按照抽样检验相关规定抽样或者通知被检查单位所在地食品药品监督管理部门按规定抽样。抽取的样品应当由具备资质的技术机构进行检验或者鉴定，所抽取样品的检验费、鉴定费由组织实施飞行检查的食品药品监督管理部门承担。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 18 Where finished products and other materials shall be sampled for testing, the inspection team can take samples in accordance with the relevant regulations for sampling test, or notify the local food and drug regulatory department to take samples as required. The samples shall be tested or identified by certified technical institutions, and the testing or identification fees shall be borne by the food and drug regulatory department organizing the unannounced inspection."
    },
    {
        "instruction":"已知信息：\n'第六十四条 药品检验所应当依据核定的药品标准对抽取的样品进行检验，并在规定的时间内将药品注册检验报告送交国家食品药品监督管理局药品审评中心，同时抄送相关省、自治区、直辖市药品监督管理部门和申请人。'可被翻译为：Article 64 Drug testing institutes shall conduct sample testing according to the verified specifications, and within the specified timeline, provide testing reports to the Center for Drug Evaluation of the State Food and Drug Administration, and copy to the relevant drug regulatory departments of the provinces, autonomous regions, or municipalities directly under the Central Government and the applicants.\n\n根据上述已知信息，请将'第五十四条 接到注册检验通知的药品检验所应当按申请人申报的药品标准对样品进行检验，对申报的药品标准进行复核，并在规定的时间内将药品注册检验报告送交国家食品药品监督管理局药品审评中心，并抄送申请人。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 54 The drug testing institute that receives a notice for the testing for registration shall test the samples according to the drug specifications submitted by the applicant, verify the submitted drug specifications, and submit a certificate of analysis for drug registration to the Center for Drug Evaluation of the State Food and Drug Administration within the specified timeline, and copy to the applicant."
    },
    {
        "instruction":"已知信息：\n'化妆品注册人、备案人使用化妆品新原料生产化妆品的，相关化妆品申请注册、办理备案时应当通过信息服务平台经化妆品新原料注册人、备案人关联确认。'可被翻译为：If cosmetic registrants and filing persons use new cosmetic ingredients to produce cosmetics, the relevant cosmetic registration application and filing shall be associated and confirmed by the registrant or filing person of the new cosmetic ingredient through the information service platform.\n\n根据上述已知信息，请将'化妆品、化妆品新原料注册人、备案人按照规定通过化妆品、化妆品新原料注册备案信息服务平台（以下简称信息服务平台）申请注册、进行备案。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Registrants and filing persons of cosmetics and new cosmetic ingredients shall apply for registration and filing through the information service platform of registration and filing for cosmetics and new cosmetic ingredients (hereinafter referred to as the information service platform) in accordance with regulations."
    },
    {
        "instruction":"已知信息：\n'数据监查委员会（同义词：独立的数据监查委员会、数据 与安全性监查委员会）'可被翻译为：data monitoring committee\n\n根据上述已知信息，请将'毒理学家通过专业评判确定的一个独立因子，用于关联生物测定数据与人体安全性数据。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A factor determined by professional judgment of a toxicologist and applied to bioassay data to relate that data safely to humans."
    },
    {
        "instruction":"已知信息：\n'申请人、备案人对资料的真实性负责。'可被翻译为：The applicant and filing entity shall take full responsibility for the authenticity of the documents submitted.\n\n根据上述已知信息，请将'申请人应当对申报资料的真实性负责。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The applicant shall be responsible for the authenticity of application dossiers."
    },
    {
        "instruction":"已知信息：\n'第一百七十五条 企业应当按照国家有关药品不良反应报告制度的规定，收集、报告药品不良反应信息。'可被翻译为：Article 175 Enterprises shall collect and report the information of ADRs in accordance with national provisions on ADR reporting system.\n\n根据上述已知信息，请将'第一百七十一条 药品广告宣传应当严格执行国家有关广告管理的规定。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 171 Drug advertising shall be conducted in strict accordance with the relevant national regulations on advertising management."
    },
    {
        "instruction":"已知信息：\n'能代替神经递质贮存于神经末梢囊泡中，并为神经冲动所释放的物质。'可被翻译为：A substance that can be stored in nerve end vesicles in place of neurotransmitters and released by nerve impulses.\n\n根据上述已知信息，请将'神经冲动传递介质之后，突触前神经元通过神经递质转运器对神经递质重新吸收的过程。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The process by which a presynaptic neuron reabsorbs a neurotransmitter via a neurotransmitter transporter after the nerve impulse transmission medium."
    },
    {
        "instruction":"已知信息：\n'药物溶解或分散于乳状液型基质中形成的均匀的半固体外用制剂。'可被翻译为：A uniform semisolid preparation for external use in which the drug is dissolved or dispersed in a emulsion type matrix.\n\n根据上述已知信息，请将'大量的固体粉末（一般25%以上）均匀地分散在适宜的基质中所组成的半固体外用制剂。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A semi-solid external preparation composed of a large amount of solid powder (generally more than 25%) uniformly dispersed in a suitable substrate."
    },
    {
        "instruction":"已知信息：\n'以水为溶剂含有一种或-种以上的药物成分的内服液体制剂。'可被翻译为：An ingested liquid preparation containing one or more pharmaceutical ingredients in water as a solvent.\n\n根据上述已知信息，请将'含有一种以上原料药的制剂。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A drug product which contains more than one drug substance."
    },
    {
        "instruction":"已知信息：\n'针对特殊用途、通过劳动或努力生产且上市以满足需求或愿望的一个或多个产品。[HL7 患者安全]'可被翻译为：A thing or things produced by labour or effort for a specific use and marketed to satisfy a need or want. [HL7 Patient Safety]\n\n根据上述已知信息，请将'需要调查的观察结果，包括可能或可能不涉及个人或研究受试者人群的问题。[HL7 患者安全]'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"An observation requiring investigation, and includes problems that might or might not involve individual or groups of investigative subjects.[HL7 Patient Safety]"
    },
    {
        "instruction":"已知信息：\n'国家药监局药审中心关于发布《中药新药复方制剂中医药理论申报资料撰写指导原则（试行）》《古代经典名方中药复方制剂说明书撰写指导原则（试行）》的通告'可被翻译为：NMPA CDE Announcement on Issuing the Guidance for the Preparation of Application Dossiers for TCM Theory of Compound Preparations of New Chinese Medicines (interim) and the Guidance for the Preparation of the Package Inserts of Compound Preparations of Chinese Medicines in Ancient Classic Prescriptions (interim)\n\n根据上述已知信息，请将'为加快构建中医药理论、人用经验和临床试验相结合的中药注册审评证据体系，规范中医药理论申报资料和古代经典名方中药复方制剂说明书相关内容的撰写，在国家药品监督管理局的部署下，药审中心组织制定了《中药新药复方制剂中医药理论申报资料撰写指导原则（试行）》和《古代经典名方中药复方制剂说明书撰写指导原则（试行）》。根据《国家药监局综合司关于印发药品技术指导原则发布程序的通知》要求，经国家药品监督管理局审查同意，于2021年10月15日发布实施。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In order to speed up the construction of the evidence system for TCM registration evaluation combining TCM theory, experiences in human use and clinical trials, and standardize the preparation of application dossiers of TCM theory and the package inserts of compound preparations of Chinese medicines in ancient classic prescriptions, under the deployment of the National Medical Products Administration, the CDE has organized to formulate the Guidance for the Preparation of Application Dossiers for TCM Theory of Compound Preparations of New Chinese Medicines (interim) and the Guidance for the Preparation of the Package Inserts of Compound Preparations of Chinese Medicines in Ancient Classic Prescriptions (interim), which has, per the requirements of the Notice of the NMPA Comprehensive Department on Issuing the Release Procedures for Pharmaceutical Technical Guidance, been issued and implemented on October 15, 2021 upon the review and approval by the National Medical Products Administration."
    },
    {
        "instruction":"已知信息：\n'第八十条 验收药品应当做好验收记录，包括药品的通用名称、剂型、规格、批准文号、批号、生产日期、有效期、生产厂商、供货单位、到货数量、到货日期、验收合格数量、验收结果等内容。验收人员应当在验收记录上签署姓名和验收日期。'可被翻译为：Article 80 Acceptance inspection records shall be taken for drugs under acceptance inspection, including adopted name, dosage form, strength, approval number, lot number, date of production, expiry date, manufacturer, supplier, quantity of arrival, date of arrival, quantity qualified in acceptance inspection and results of acceptance inspection of drugs, etc. The acceptance inspection personnel shall sign his\/her name and indicate the date on the acceptance inspection record.\n\n根据上述已知信息，请将'中药材验收记录应当包括品名、产地、供货单位、到货数量、验收合格数量等内容。中药饮片验收记录应当包括品名、规格、批号、产地、生产日期、生产厂商、供货单位、到货数量、验收合格数量等内容，实施批准文号管理的中药饮片还应当记录批准文号。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Acceptance inspection records of Chinese crude drugs shall include the name of the product, the place of production, the supplier, the quantity of arrival, and quantity qualified in acceptance inspection, etc. Acceptance inspection records of Prepared Slices shall include the name of the product, strength, lot number, place of production, date of production, manufacturer, supplier, quantity of arrival and quantity qualified in acceptance inspection, etc. For Prepared Slices subject to the management of approval number, the approval number shall also be recorded."
    },
    {
        "instruction":"已知信息：\n'A型VDC的受体室应充满受体溶液，在池体顶部组装膜的制备和给药过程中，受体溶液应平衡到目标温度(通常为32°或37°)。在此期间可以运行搅拌子以加速温度稳定。在安装池体顶部组件之前，应测量并确保受体溶液温度在目标温度的±1°范围内。搅拌子可以运行，以帮助加快温度稳定。'可被翻译为：The receptor compartment of the Model A VDC should be filled with receptor solution that is equilibrated to the target temperature (typically 32° or 37°) during the preparation and dosing of the membrane in the cell top assembly. The stirrers can be run during this period to speed up temperature stabilization. The receptor solution temperature should be measured and ensured to be within ±1° of the target temperature prior to mounting the cell top assembly. The stirrers can be run to help speed up temperature stabilization.\n\n根据上述已知信息，请将'温度控制的确认:应平衡每个池体的温度使膜达到目标温度，并且设备的初始确认应验证在使用相关设备和方法参数时，该温度可在测试期间保持。根据VDC或FDC设备的设计，膜温度的测量通常可以方便地使用红外温度计，或使用安装在膜上的热电偶;对于浸没池，可以假设膜上的温度与溶解容器中受体溶液的体积相同，一旦达到平衡和稳定。在测试过程中，每个池体的温度通常应保持在目标温度(通常为32°或37°)的±1°内。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"3. Qualification of Temperature Control: The temperature of each cell should be equilibrated to provide the target temperature at the membrane, and the initial qualification of the equipment should verify that the temperature can be maintained for the duration of the test when using the relevant equipment and method parameters. Depending on the VDC or FDC equipment design, a measurement of the membrane temperature can often be made conveniently using an infrared thermometer, or using a thermocouple mounted with the membrane; for immersion cells, the temperature at the membrane may be assumed to be the same as the bulk volume of the receptor solution in the dissolution vessel, once equilibrated and stabilized. The temperature of each cell should typically remain within ±1° of the target temperature (typically 32° or 37°) during the test."
    },
    {
        "instruction":"已知信息：\n'分析方法应根据现行WHO技术报告系列中发布的指南进行验证。'可被翻译为：10.6. Analytical procedures should be validated according to the guidelines as published in current WHO Technical Report Series (7).\n\n根据上述已知信息，请将'对于清洁程序，应根据现行WHO技术报告系列中发布的指南进行开发和验证。在制订清洁程 序、清洁度研究和设定可接受限度时应考虑在清洁验证中使用HBEL时的考量要点。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"10.5. For cleaning procedures, development and validation should be done in accordance with the guidelines as published in current WHO Technical Report Series (6). Points to consider when using HBEL in cleaning validation (14) should be taken into account in establishing cleaning procedures, cleanability studies and setting acceptance limits."
    },
    {
        "instruction":"已知信息：\n'人员的培训\/资格认证'可被翻译为：a. Training\/qualification of personnel\n\n根据上述已知信息，请将'执行每一步分析操作人员的资格、培训和身份识别'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"8. Qualifications, training and identification of the personnel conducting each step of the analysis"
    },
    {
        "instruction":"已知信息：\n'正式的商业文件，概述了与另一个个人、团体或实体达成的协议的基本条款。这是签订更详细合同的第一步。其他名称包括但不限于谅解备忘录、合作合同或合作协议。'可被翻译为：A formal business document outlining the basic terms of an agreement with another individual, group or entity. It is one of the first steps towards a more detailed contract. Alternative names include, but are not limited to, memorandum of understanding, cooperation contract or collaboration agreement.\n\n根据上述已知信息，请将'1.以特定价格供应货物或从事工作的商业协议。\n2.一份注明日期并由研究者、机构和发起人签署的文件，列出任何关于财务问题和授权\/责任分配的协议。当议定书包含这些信息并签字时，它也可以作为合同。\n3.以一定价格供应货物或从事工作的商业协议;这可以在协议中包含质量要素，也可以在单独的合同中包含质量要素。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.Business agreement for the supply of goods or performance of work at a specified price.\n2.A document, dated and signed by the investigator, institution and sponsor, that sets out any agreements on financial matters and delegation\/distribution of responsibilities. The protocol may also serve as a contract when it contains such information and is signed.\n3.Business agreement for the supply of goods or performance of work at a speciﬁed price; this may include quality elements in the agreement, or in a separate contract."
    },
    {
        "instruction":"已知信息：\n'使设计具备良好地接受新版本输入信息的能力。本概念适用于整个系统、数据通信、协议、文件格式和计算机编程语言。例如，如果按照旧标准设计的产品收、阅读、查看或播放新标准或格式（不包括新功能）下的信息，则认为该产品是具备“向上兼容性”的。'可被翻译为：The ability of the design to gracefully accept input intended for newer versions of itself. The concept can be applied to entire systems, data \ncommunications, protocols, file formats and computer programming languages. For example, if products designed for the older standard can \nreceive, read, view or play the newer standard or format (excluding new functionality), then the product is said to be Forward Compatible.\n\n根据上述已知信息，请将'使设计具备良好地接受旧版本输入信息的能力。本概念可用于整个系统、数据通信、协议、文件格式和计算机编程语言。例如，如果使用新标准设计的产品可以接收、阅读、查看或播放使用旧标准或格式设计的产品信息，那么就说该产品是向下兼容的。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The ability of the design to gracefully accept input created with older versions of itself. The concept can be applied to entire systems, data \ncommunications, protocols, file formats and computer programming languages. For example, if products designed for the new standard can \nreceive, read, view or play older standards or formats, then the product is said to be Backward Compatible."
    },
    {
        "instruction":"已知信息：\n'每天检查所有拭子\/海绵的浊度，如发现混浊则分离并转种培养。所有转种培养必须在 LFH 或 BSC 中进行。如果容器无法观察到混浊，则将所有环境监测样本培养 5-7天。无论之前是否转种培养，所有环境监测样本在 14 天培养之后均要进行转种培养。'可被翻译为：5. Check all swabs\/sponges daily for turbidity and subculture for isolation as turbidity is observed. All subculturing must be performed under LFH or BSC. If container does not allow for turbidity observation to be made, then subculture all environmental samples between Day 5 and 7. All environmental samples will be subcultured following day 14 incubation regardless of previous subculturing.\n\n根据上述已知信息，请将'再培养所有已培养的拭子直到满足全培养时间（14 天）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"7. Re-incubate all cultured swabs until the full incubation (14 days) timeframe are met."
    },
    {
        "instruction":"已知信息：\n'按日期安装'可被翻译为：install by date\n\n根据上述已知信息，请将'仪器、装置或其他必须安装的日期。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The date by which an instrument, device or other has to be installed."
    },
    {
        "instruction":"已知信息：\n'经审评，符合附条件批准要求的，在药品注册证书中载明附条件批准药品注册证书的有效期、上市后需要继续完成的研究工作及完成时限等相关事项。'可被翻译为：Where requirements for conditional approval are met upon review, the Drug Approval License shall specify the validity period of the conditional Drug Approval License, the post-approval studies to be completed, the timeline for completing post-approval studies and other relevant details.\n\n根据上述已知信息，请将'第六十四条 申请附条件批准的，申请人应当就附条件批准上市的条件和上市后继续完成的研究工作等与药品审评中心沟通交流，经沟通交流确认后提出药品上市许可申请。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 64 Where conditional approval is applied for, the applicant shall communicate with the CDE about the conditions for conditional marketing approval and the studies to be completed after marketing. Upon confirmation through consultation and communication, a drug marketing authorization application may be filed."
    },
    {
        "instruction":"已知信息：\n'分析方法在生物基质中存在干扰物质（非特异性干扰）的情况下区分和\n测量待测物的能力。'可被翻译为：Ability of an analytical method to differentiate and measure the analyte in the presence of interfering substances in the biological matrix (non-specific interference).\n\n根据上述已知信息，请将'由于样品中存在意外的待测物或其他干扰物质，而直接或间接改变或干扰响应。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The direct or indirect alteration or interference in response due to the presence of unintended analytes or other interfering substances in the sample."
    },
    {
        "instruction":"已知信息：\n'第四十一条 国务院卫生健康主管部门制定国家免疫规划；国家免疫规划疫苗种类由国务院卫生健康主管部门会同国务院财政部门拟订，报国务院批准后公布。'可被翻译为：Article 41 The competent health department under the State Council shall formulate the national immunization program; vaccine varieties in the national immunization program shall be proposed by the competent health department under the State Council jointly with the financial department under the State Council, and released upon approval by the State Council.\n\n根据上述已知信息，请将'第三十二条 国家免疫规划疫苗由国务院卫生健康主管部门会同国务院财政部门等组织集中招标或者统一谈判，形成并公布中标价格或者成交价格，各省、自治区、直辖市实行统一采购。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 32 For national immunization program vaccines, the centralized bidding or unified negotiation shall be organized by the competent health department under the State Council jointly with the financial and other departments under the State Council. The winning price or transaction price shall be established and released, and each province, autonomous region and municipality directly under the Central Government shall implement unified procurement."
    },
    {
        "instruction":"已知信息：\n'（二）药品生产许可证有效期届满未重新发证的；'可被翻译为：(2) The Drug Manufacturing Certificate has expired but not been re-issued;\n\n根据上述已知信息，请将'第十九条 药品生产许可证有效期届满，需要继续生产药品的，应当在有效期届满前六个月，向原发证机关申请重新发放药品生产许可证。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 19 In the case of continuing the drug manufacturing following the expiration of the Drug Manufacturing Certificate, the company shall apply to the original issuing authority for renewal of the Drug Manufacturing Certificate 6 months ahead of the expiration."
    },
    {
        "instruction":"已知信息：\n'由单体经聚合而成的产物。包括由一种单体聚合而成的均聚物，和由两种或两种以上不同单体聚合而成的共聚物两大类。'可被翻译为：A product formed by polymerization of monomers. Includes homopolymers polymerized from one monomer, and copolymers polymerized from two or more different monomers.\n\n根据上述已知信息，请将'β-内酰胺类抗生素在生产或储存过程中形成的自身聚合产物。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Self-polymerizing products formed during the production or storage of beta-lactam antibiotics."
    },
    {
        "instruction":"已知信息：\n'第一百三十八条 药品零售操作规程应当包括：'可被翻译为：Article 138 The operating procedure for drug retail shall include:\n\n根据上述已知信息，请将'第一百三十八条 申请人应当选取有代表性的样品进行标准的研究工作。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article138 An applicant shall select representative samples for drug registration specifications study."
    },
    {
        "instruction":"已知信息：\n'药物分散于熔融的材料中，再喷于冷气流中凝聚而成球或成囊的方法。'可被翻译为：The method in which the drug is dispersed in a molten material and then sprayed in a cold air stream to condense into a ball or capsule.\n\n根据上述已知信息，请将'药物溶解或分散或包裹于成膜材料中而制成的单层或多层膜状制剂。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A single or multilayer film-like preparation in which the drug is dissolved or dispersed or encased in a film-forming material."
    },
    {
        "instruction":"已知信息：\n'第二十三条 核查中心在注册核查时限内，组织实施注册核查工作，确定核查时间，通知申请人和被核查单位接受注册核查。需要进行动态生产现场核查的，结合申请人动态生产安排确定生产现场核查时间。'可被翻译为：Article 23 CFDI shall organize the implementation of the registration inspection work within the registration inspection time limit, determine the inspection time, and notify the applicant and the inspected institution to accept the registration inspection. If a dynamic manufacturing on-site inspection is required, Manufacturing Site Inspection time shall be determined based on the applicant's dynamic production arrangement.\n\n根据上述已知信息，请将'第十三条 核查报告、核查结果仅针对该注册申请该次核查范围和内容，不覆盖该注册申请全部注册申报资料和相关研制行为的评价。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 13 The inspection report and inspection results are only for the scope and content of the inspection of the registration application, and do not cover all the registration application dossiers of the registration application and the evaluation of related development activities."
    },
    {
        "instruction":"已知信息：\n'机械力克服固体物料内部凝聚力、使之破碎的单元操作。'可被翻译为：Unit operation in which mechanical force overcomes the internal cohesion of a solid material and causes it to break.\n\n根据上述已知信息，请将'用机械力克服固体物料内部凝聚力、使之破碎的设备。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Mechanical force to overcome the internal cohesion of solid materials, so that it is broken equipment."
    },
    {
        "instruction":"已知信息：\n'(viii)批记录和发运记录应当能够追溯批产品的完整历史，并妥善保存、便于查阅；'可被翻译为：(viii) Records of manufacture including distribution which enable the complete history of a batch to be traced are retained in a comprehensible and accessible form;\n\n根据上述已知信息，请将'（七）批记录和发运记录应当能够追溯批产品的完整历史，并妥善保存、便于查阅；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"7. Records of manufacture and distribution, which enable the complete history of a batch to be traced, are retained in a comprehensible and accessible form."
    },
    {
        "instruction":"已知信息：\n'一是细化注册人、备案人管理制度，强化企业主体责任落实。根据《条例》关于注册人、备案人的相关规定要求，细化落实化妆品、化妆品新原料注册人、备案人的责任义务及准入条件，加强对产品责任源头监管。建立新原料安全监测制度，对新原料注册人、备案人和化妆品注册人、备案人应当履行的安全监测义务进行了细化规定。'可被翻译为：1. The elaboration on the administration system for registration and notification persons to potentiate corporate principal responsibilities. In accordance with the related requirements of the Regulations, detailed provisions for responsibilities, obligations and access conditions are applied to registration and notification persons of cosmetics and new cosmetic ingredients to potentiate the supervision and liability of product at its source. A safety monitoring system for new cosmetic ingredients is established with detailed regulations on the safety monitoring obligations of registration and notification persons of cosmetics and new cosmetic ingredients.\n\n根据上述已知信息，请将'三是加强备案后监督管理，确保产品质量安全责任落实到位。明确备案后监督管理责任落实和工作要求，加大对备案产品违法违规行为的惩处力度；实施备案产品分级管理，合理配置监管资源。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"3. The enhancement of supervision and administration of post-notification to ensure that the responsibilities for product quality and safety are in place. The responsibilities and requirements for the supervision and administration of post notification are clarified, with stricter penalties for violations of laws and regulations on filed products, which are subject to classification management to rationally allocate supervision resources."
    },
    {
        "instruction":"已知信息：\n'按照现行版本的USP确定要测试的正确件数以及每件要分析的产品数量。如 果可能，最好测试每件的全部内容。如果实验室政策要求测试的单元数超过 USP要求，则遵循实验室政策。'可被翻译为：Follow the current edition of the USP to determine the correct number of units to be tested and the amount of product to be analyzed from each unit. It is preferable to test the entire contents of each unit if possible. Follow laboratory policy if it requires testing more units than the USP requires.\n\n根据上述已知信息，请将'如果所采集的单元数少于USP要求，则在执行下步操作之前与实验室主管讨论。 有因情形下采集的样本可使用少于USP要求的单元数量进行分析。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"If the number of units collected is less than the USP requirements, discuss with the laboratory supervisor before proceeding. Samples collected in a for-cause situation may be analyzed with a number of units less than the USP requirements."
    },
    {
        "instruction":"已知信息：\n'（七）确保相关信息及其纠正和预防措施已通过高层管理人员的评审。'可被翻译为：7. To ensure that the related information and its CAPA pass the review by the senior management.\n\n根据上述已知信息，请将'（六）确保相关信息已传递到质量受权人和预防问题再次发生的直接负责人。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"6. To ensure that the related information is delivered to the Qualified Person and the person directly in charge of preventing issues from re-occurring;"
    },
    {
        "instruction":"已知信息：\n'某些脂溶性、挥发性的药物通过喷雾或气雾给药方式由呼吸道黏膜或肺泡上皮细胞吸收。'可被翻译为：Certain fat-soluble, volatile drugs are absorbed by respiratory mucosa or alveolar epithelium by spray or aerosol delivery.\n\n根据上述已知信息，请将'药物粉末或溶液被雾化后随气体直接接触呼吸道黏膜或吸入肺的给药方式。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The form of administration in which a powder or solution is atomized and then directly exposed to the respiratory mucosa or inhaled into the lungs."
    },
    {
        "instruction":"已知信息：\n'在培养过程中，连续地向发酵罐中加入培养基，同时以相同的流量从发酵罐中流出培养液的发酵方式。'可被翻译为：In the culture process, the culture medium is continuously added to the fermenter, while the same flow rate from the fermenter flowing out of the culture liquid fermentation mode.\n\n根据上述已知信息，请将'在培养过程中，除了不断进行通气，调节培养液的pH值、系统排出废气外，与外界没有其他交换的发酵方式。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"During the culture process, there is no other fermentation method of exchange with the outside world except for continuous ventilation, adjustment of the pH value of the culture solution, and exhaust gas from the system."
    },
    {
        "instruction":"已知信息：\n'（十一）如果医疗器械的预期目的是明确用于某种疾病的治疗，其分类应不低于第二类。'可被翻译为：(11) A medical device intended for the treatment of a certain disease, its class shall not be lower than class II.\n\n根据上述已知信息，请将'根据调整后的过去消费量或预期的疾病模式和标准治疗，对每种药物的需要量进行仔细评估，预期与实际需求相当吻合。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A careful evaluation of the quantities needed of each medicine, based on either adjusted past consumption or anticipated pattern of diseases and standard treatment, which can be expected to match actual needs reasonably well."
    },
    {
        "instruction":"已知信息：\n'两种以上药物作用等于每一种化合物质单独作用的总和。'可被翻译为：The action of two or more drugs is equal to the sum of the separate actions of each chemical compound.\n\n根据上述已知信息，请将'两种以上物质结合成化合物时互相作用的性质。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The property of interaction between two or more substances combined to form a compound."
    },
    {
        "instruction":"已知信息：\n'第七十三条 药品到货时，收货人员应当核实运输方式是否符合要求，并对照随货同行单（票）和采购记录核对药品，做到票、账、货相符。'可被翻译为：Article 73 Upon arrival of drugs, the receiving personnel shall validate whether the mode of transportation meets the requirements, and check the drugs against the accompanying sheet (bill) and the purchase records to ensure consistency among bills, account and goods.\n\n根据上述已知信息，请将'第一百五十三条 药品到货时，收货人员应当按采购记录，对照供货单位的随货同行单（票）核实药品实物，做到票、账、货相符。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 153 Upon arrival of drugs, the receiving personnel shall, in accordance with the purchase records, check the material objects according to the accompanying sheet (bill) provided by suppliers and ensure that the bills, account and goods are consistent."
    },
    {
        "instruction":"已知信息：\n'本附录旨在为无菌产品的生产提供指导。其中部分原则和指导，例如污染控制策略、厂房设计、洁净室分级、确认、验证、监测和人员更衣等，可用于支持其它非无菌但须控制和减少微生物、微粒和内毒素\/热原污染的产品的生产（例如某些液体、乳膏、软膏和低微生物负载的生物中间体）。如果生产商选择将本指南应用于非无菌产品，则应明确记录所应用的原则，并确认应证明符合这些原则。'可被翻译为：The intent of the Annex is to provide guidance for the manufacture of sterile products. However, some of the principles and guidance, such as contamination control strategy, design of premises, cleanroom classification,\nqualification, validation, monitoring and personnel gowning, may be used to support the manufacture of other products that are not intended to be sterile such as certain liquids, creams, ointments and low bioburden biological\nintermediates, but where the control and reduction of microbial, particulate and endotoxin\/pyrogen contamination is considered important. Where a manufacturer elects to apply guidance herein to non-sterile products, the manufacturer should clearly document which principles have been applied and acknowledge that compliance with\nthose principles should be demonstrated.\n\n根据上述已知信息，请将'包括本附录的一般原则适用的（无菌产品以外的）其它领域。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Includes additional areas (other than sterile products) where the general principles of the annex can be applied."
    },
    {
        "instruction":"已知信息：\n'2.2含有已知活性成份的新剂型（包括新的给药系统）、新处方工艺、新给药途径，且具有明显临床优势的药品。'可被翻译为：2.2 Drugs that contain known active ingredients with new dosage form (including new drug delivery system), new formulation process or new route of administration, and have significant clinical advantages.\n\n根据上述已知信息，请将'药品含有相同的活性成分并且浓度、剂型及给药途径也相同。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The drug contains the same active ingredient in the same concentration, dosage form, and route of administration."
    },
    {
        "instruction":"已知信息：\n'打开一个无菌棉签（或海棉），用润湿剂（无菌水、盐水或 D\/E 中和肉汤）浸湿，按压装有湿润剂的容器挤出多余水分'可被翻译为：a. Open a sterile swab (or sponge). Dampen with wetting agent (sterile water, saline, or D\/E neutralizing broth) and squeeze off excess by pressing against the inside of the container holding the wetting agent.\n\n根据上述已知信息，请将'用于冲洗的无菌水或装在螺帽容器中的无菌盐水'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"f. Sterile water for irrigation or sterile saline held in screw cap containers."
    },
    {
        "instruction":"已知信息：\n'充分描述仪器响应（例如，峰面积或高比或信号）与校正标样中待测物浓度（量）之间关系的数学表达式。响应函数是在给定浓度范围内定义的。另见校正曲线。'可被翻译为：A mathematical expression which adequately describes the relationship between instrument response (e.g., peak area or height ratio or signal) and the concentration (amount) of analyte in the calibration standards. Response function is defined within a given range. See also Calibration Curve.\n\n根据上述已知信息，请将'仪器响应（例如峰面积、峰高或信号）与给定范围内校正标样中的待测物浓度（含量）的关系。也称为“标准曲线”。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The relationship between the instrument response (e.g., peak area, height or signal) and the concentration (amount) of analyte in the calibration standards within a given range. Also referred to as Standard Curve."
    },
    {
        "instruction":"已知信息：\n'第三十三条  医疗器械注册人、备案人、受托生产企业应当建立记录管理制度，确保记录真实、准确、完整和可追溯。'可被翻译为：Article 33 The registrant, filing entity or contract manufacturer of medical devices shall establish record management procedures, to ensure the authenticity, accuracy, integrity and traceability of the records.\n\n根据上述已知信息，请将'医疗器械注册人、备案人、受托生产企业应当建立原材料采购验收记录制度，确保相关记录真实、准确、完整和可追溯。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The registrant, filing entity or contract manufacturer of medical devices shall establish procedures for purchasing, accepting and recording raw materials, to ensure authenticity, accuracy, integrity and traceability of related records."
    },
    {
        "instruction":"已知信息：\n'邮发工作文件征求意见，包括EAP，在WHO官网发布工作文件公开征求意见 2020年12月'可被翻译为：Mailing of working document to the Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations (EAP) inviting comments and posting of the working document on the WHO website for public consultation December 2020\n\n根据上述已知信息，请将'邮发修订后的工作文件征求意见，包括EAP，在WHO官网发布工作文件公开征求意见 2021年4月'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Mailing of revised working document inviting comments, including to the EAP, and posting of the working document on the WHO website for a second round of public consultation. April 2021"
    },
    {
        "instruction":"已知信息：\n'3.采用《中华人民共和国药典》及其他法定标准未收载的检验方法；'可被翻译为：3) Testing method adopted is not included in the Chinese Pharmacopoeia or other official standards;\n\n根据上述已知信息，请将'检验结果超出法定标准及企业制定标准的所有情形。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"All events that the testing results fail to meet the regulatory standards or acceptance criteria established by the manufacturer."
    },
    {
        "instruction":"已知信息：\n'无菌工艺模拟（APS）：对整个无菌生产工艺的模拟， 以确认工艺确保产品无菌性的能力。包括与日常生产相关的所有无菌操作，例如必要的设备装配、配料、灌装、冻干以及必要时的密封工艺。'可被翻译为：Aseptic Process Simulation (APS) - A simulation of the entire aseptic manufacturing process in order to verify the capability  of the  process  to  assure  product  sterility.  Includes  all  aseptic  operations  associated  with  routine manufacturing, e.g. equipment assembly, formulation, filling, lyophilization and sealing processes as necessary.\n\n根据上述已知信息，请将'冻干产品的工艺模拟程序应代表整个无菌工艺链，包括在规定的、有文件记录且经过论证的条件（代表最\n差条件下的操作参数）下的灌装、转移、装载、冻干室停留的具有代表性的时长、卸载和密封。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The process simulation procedure for lyophilized products should represent the entire aseptic processing chain including filling, transport, loading, a representative duration of the chamber dwell, unloading and sealing under specified, documented and justified conditions representing worst case operating parameters."
    },
    {
        "instruction":"已知信息：\n'第三十三条 药品进口备案中发现的其他问题，由口岸药品监督管理局按照《药品管理法》以及有关规定予以处理。'可被翻译为：Article 33 Other issues found in the record filing of drugs to be imported shall be disposed of by the drug regulatory departments at ports of entry in accordance with the Drug Administration Law and relevant regulations.\n\n根据上述已知信息，请将'（五）对进口备案和口岸检验中发现的问题进行监督处理；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(V) to supervise and handle the issues found during importation record filing and port testing; and"
    },
    {
        "instruction":"已知信息：\n'对整个无菌制造过程的模拟，以验证工艺确保产品无菌的能力。APS包括与常规生产相关的所有无菌操作(例如，必要时，设备组装、配方、灌装、冻干和密封过程)'可被翻译为：A simulation of the entire aseptic manufacturing process in order to verify the capability of the process to ensure product sterility. APS includes all aseptic operations associated with routine manufacturing (for example, equipment assembly, formulation, filling, lyophilization and  sealing processes, as necessary)\n\n根据上述已知信息，请将'无菌工艺模拟（APS）：对整个无菌生产工艺的模拟， 以确认工艺确保产品无菌性的能力。包括与日常生产相关的所有无菌操作，例如必要的设备装配、配料、灌装、冻干以及必要时的密封工艺。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Aseptic Process Simulation (APS) - A simulation of the entire aseptic manufacturing process in order to verify the capability  of the  process  to  assure  product  sterility.  Includes  all  aseptic  operations  associated  with  routine manufacturing, e.g. equipment assembly, formulation, filling, lyophilization and sealing processes as necessary."
    },
    {
        "instruction":"已知信息：\n'四、关于医疗器械生物学试验'可被翻译为：IV. Biological test of medical devices\n\n根据上述已知信息，请将'医疗器械生物学评价中涉及生物学试验的，其生物学试验报告由申请人在申请注册时作为研究资料提交。开展生物学试验，应当委托具有生物学试验资质的医疗器械检验机构按照相关标准进行试验。国外实验室出具的生物学试验报告，应当附有国外实验室表明其符合GLP实验室要求的质量保证文件。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"If the biological evaluation of a medical device involves biological test, the applicant should submit the biological test report as part of the study materials when applying for registration. For biological tests, medical device testing institutions qualified for biological test shall be entrusted to carry out such tests according to relevant standards. Biological test reports issued by foreign laboratories should be attached with the quality assurance documents demonstrating its compliance with GLP laboratory requirements."
    },
    {
        "instruction":"已知信息：\n'第一百八十二条 厂房、设备、物料、文件和记录应当有编号（或代码），并制定编制编号（或代码）的操作规程，确保编号（或代码）的唯一性。'可被翻译为：Article 182: Premises, equipment, materials, documents and records should have codes (or reference numbers). Operation procedures should be established for the numbering\/coding system to ensure the uniqueness of the codes (or reference numbers).\n\n根据上述已知信息，请将'第四十二条 厂房应当有适当的照明、温度、湿度和通风，确保生产和贮存的产品质量以及相关设备性能不会直接或间接地受到影响。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 42: Lighting, temperature, humidity and ventilation should be appropriate and such that they do not adversely affect, directly or indirectly, either the product quality during their manufacture and storage, or the accurate functioning of equipment."
    },
    {
        "instruction":"已知信息：\n'（七）药品与非药品、外用药与其他药品分开存放，中药材和中药饮片分库存放；'可被翻译为：(VII) Drugs and non-drugs, drugs for topical use and other drugs shall be stored separately, and Chinese crude drugs and Prepared Slices shall be stored separately;\n\n根据上述已知信息，请将'医疗机构应当将药品与非药品分开存放；中药材、中药饮片、化学药品、中成药应分别储存、分类存放。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A medical institution shall store drugs and non-drug products separately; Chinese crude drugs, prepared slices of Chinese crude drugs, pharmaceuticals, and traditional Chinese medicine preparations shall be stored separately by category."
    },
    {
        "instruction":"已知信息：\n'第一百零四条 企业应当根据药品的温度控制要求，在运输过程中采取必要的保温或者冷藏、冷冻措施。'可被翻译为：Article 104 Enterprises shall take necessary measures for heat preservation, or refrigeration and freezing during transportation in accordance with the temperature control requirements of drugs.\n\n根据上述已知信息，请将'第一百零六条 企业应当制定冷藏、冷冻药品运输应急预案，对运输途中可能发生的设备故障、异常天气影响、交通拥堵等突发事件，能够采取相应的应对措施。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 106 Enterprises shall formulate a contingency plan for the transportation of refrigerated and frozen drugs, and be able to take corresponding measures to deal with such emergencies as equipment failure, abnormal weather influence and traffic congestion that may occur during the transportation."
    },
    {
        "instruction":"已知信息：\n'（八）所有因质量原因造成的退货、投诉、召回及调查；'可被翻译为：8. All quality-related returns, complaints, recalls and the investigations;\n\n根据上述已知信息，请将'(viii)对所有与质量相关的退货、投诉和召回以及当时进行的调查进行回顾；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(viii) A review of all quality-related returns, complaints and recalls and the investigations performed at the time;"
    },
    {
        "instruction":"已知信息：\n'第一百三十三条 违反本法规定，医疗机构将其配制的制剂在市场上销售的，责令改正，没收违法销售的制剂和违法所得，并处违法销售制剂货值金额二倍以上五倍以下的罚款；情节严重的，并处货值金额五倍以上十五倍以下的罚款；货值金额不足五万元的，按五万元计算。'可被翻译为：Article 133 Where a medical institution sells self-made preparations in violation of this Law, it shall be ordered to make correction, and be subject to a confiscation of preparations illegally sold and the illegal gains therefrom and a fine of not less than two times but not more than five times of the value of the illegally sold preparations. In serious circumstances, the offender is subject to a fine of not less than five times but not more than fifteen times of the illegal value. If the illegal values are less than RMB 50,000, it shall be counted as RMB 50,000.\n\n根据上述已知信息，请将'第一百二十条 知道或者应当知道属于假药、劣药或者本法第一百二十四条第一款第一项至第五项规定的药品，而为其提供储存、运输等便利条件的，没收全部储存、运输收入，并处违法收入一倍以上五倍以下的罚款；情节严重的，并处违法收入五倍以上十五倍以下的罚款；违法收入不足五万元的，按五万元计算。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 120 Anyone who knows or should know that drug is counterfeit or inferior or falls under drugs prescribed in paragraph one of item (1) to item (5) in Article 124 of this Law and provides conveniences such as storage and transportation, the income from the illegal storage and transportation shall be confiscated, and a fine of not less than one time but not more than five times the illegal income shall be imposed. In serious circumstances, the offender shall be subject to a fine of not less than five times but not more than fifteen times. If the illegal values are less than RMB 50,000, it shall be counted as RMB 50,000."
    },
    {
        "instruction":"已知信息：\n'单位时间内二氧化碳(CO2)产生量与耗氧量之比值。'可被翻译为：The ratio of carbon dioxide (CO2) production to oxygen consumption per unit time.\n\n根据上述已知信息，请将'应用于医疗及制药中的一些气体。如氧、二氧化碳、氨、氧化亚氮等。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Some gases used in medicine and pharmaceuticals. Such as oxygen, carbon dioxide, ammonia, nitrous oxide, etc."
    },
    {
        "instruction":"已知信息：\n'抗抑郁药'可被翻译为：antidepressants\n\n根据上述已知信息，请将'能抑制单胺氧化酶活性的一类抗抑郁药。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A class of antidepressants that inhibit the activity of monoamine oxidase."
    },
    {
        "instruction":"已知信息：\n'第十四条 企业负责人是药品质量的主要责任人，全面负责企业日常管理，负责提供必要的条件，保证质量管理部门和质量管理人员有效履行职责，确保企业实现质量目标并按照本规范要求经营药品。'可被翻译为：Article 14 The responsible person of an enterprise is the principal person in charge of drug quality, takes full responsibilities for daily management of the enterprise and provides necessary conditions to ensure that the quality management department or quality management personnel effectively fulfill the responsibilities and that the enterprise realizes quality objectives and handles drugs according to the requirements in this GSP.\n\n根据上述已知信息，请将'企业负责人是药品质量的主要责任人，全面负责企业日常管理。为确保企业实现质量目标并按照本规范要求生产药品，企业负责人应当负责提供必要的资源，合理计划、组织和协调，保证质量管理部门独立履行其职责。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The head of the manufacturer is principally liable for product quality and routine operation. In order to achieve the manufacturer’s quality objective and compliance with GMP, the head of the manufacturer should provide necessary resources, make appropriate plan, organization and coordination, and ensure that the quality management department can fulfill its responsibilities independently."
    },
    {
        "instruction":"已知信息：\n'技术转移项目应满足以下通用原则和要求：'可被翻译为：1.6. The technology transfer project should fulfil the following general principles and requirements.\n\n根据上述已知信息，请将'本文提供的是技术转移原则指导。这些原则适用于临床试验用药以及上市药品。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2.1. This document provides guiding principles on technology transfer. The principles apply to investigational products as well as marketed product."
    },
    {
        "instruction":"已知信息：\n'药物配伍时，发生化学反应，而使药物产生不同程度的变质或失效，降低疗效或增加副作用。'可被翻译为：When the drugs are compatible, chemical reactions occur, and the drugs have different degrees of deterioration or failure, reducing the efficacy or increasing side effects.\n\n根据上述已知信息，请将'药物配伍时发生的物理性质改变，因而得不到符合要求的制剂、降低疗效或增加副作用。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Physical properties change when drugs are compatible, so that they can not meet the requirements of the preparation, reduce the efficacy or increase side effects."
    },
    {
        "instruction":"已知信息：\n'不依靠电能或者其他能源，但是可以通过由人体或者重力产生的能量，发挥其功能的医疗器械。'可被翻译为：A medical device of which the effects are achieved not relying on electric or other forms of energy, but may use the energy directly generated by human body or gravity.\n\n根据上述已知信息，请将'任何依靠电能或者其他能源，而不是直接由人体或者重力产生的能量，发挥其功能的医疗器械。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Any medical device that operates on electric or other forms of energy excluding the energy directly generated by human body or gravity."
    },
    {
        "instruction":"已知信息：\n'WHO GMP验证指南，WHO TRS1019附录3附录6确认指南，2019'可被翻译为：9. WHO good manufacturing practices: guidelines on validation. Appendix 6. Guidelines on qualification. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations: fifty-third report. Geneva: World Health Organization; 2019: Annex 3 (WHO Technical Report Series, No. 1019; https:\/\/www.who.int\/medicines\/areas\/quality_safety\/quality_assurance\/WHO_TRS_1019_ An nex3.pdf?ua=1, accessed 30 November 2020).\n\n根据上述已知信息，请将'WHO GMP验证指南，WHO TRS1019附录3 附录3清洁验证，2019'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"6. WHO good manufacturing practices: guidelines on validation. Appendix 3. Cleaning validation. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations: fifty-third report. Geneva: World Health Organization; 2019: Annex 3 (WHO Technical Report Series, No. 1019; https:\/\/www.who.int\/medicines\/areas\/quality_safety\/quality_assurance\/WHO_TRS_1019_ An nex3.pdf?ua=1, accessed 30 November 2020)."
    },
    {
        "instruction":"已知信息：\n'为加强对医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药品监督管理局组织制定并于2020年5月19日发布了《无源医疗器械产品原材料变化评价指南》。'可被翻译为：To strengthen the supervision and guidance over medical device registration and further improve the quality of registration review, NMPA organized to formulate and released on May 19, 2020 the Guidelines for Evaluation of Changes in Raw Materials of Passive Medical Devices.\n\n根据上述已知信息，请将'国家药监局关于发布无源医疗器械产品原材料变化评价指南的通告'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"NMPA Issues Guidelines for Evaluation of Changes in Raw Materials of Passive Medical Devices"
    },
    {
        "instruction":"已知信息：\n'制冷设备'可被翻译为：refrigeration equipment\n\n根据上述已知信息，请将'术语“制冷”或“制冷设备”是指以降低空气和产品温度和\/或控制相对湿度为目的的任何设备。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The term “refrigeration” or “refrigeration equipment” means any equipment whose purpose is to lower air and product temperatures and\/or to control relative humidity."
    },
    {
        "instruction":"已知信息：\n'在受控环境中处理无菌产品、容器或设备，其中空气供应、材料和人员受到调节，以防止微生物、内毒素\/热原和颗粒污染。'可被翻译为：The handling of sterile product, containers or devices in a controlled environment in which the air supply, materials and personnel are regulated to prevent microbial, endotoxin\/pyrogen and particle contamination.\n\n根据上述已知信息，请将'无菌制备\/加工：在受控环境下对无菌产品、容器和\/或器械的处理，受控环境是指送风、物料和人员受到管控以防止微生物、内毒素\/热原和微粒污染。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Aseptic  preparation\/processing  -  The  handling  of  sterile  product,  containers  and\/or  devices  in  a  controlled environment   in   which    the   air    supply,   materials   and   personnel    are   regulated    to   prevent   microbial,\nendotoxin\/pyrogen and particle contamination."
    },
    {
        "instruction":"已知信息：\n'擦拭取样连接到进行产品生产或配料的供气设施的房间空气处理系统的排气（回风）格栅。'可被翻译为：7. Swab the exhaust (return) grid for the room air handling system that is connected to the facility air supply where the product manufacturing or compounding occurs.\n\n根据上述已知信息，请将'擦拭取样取样生产或配料期间人员已用过的实验室外套的外袖口。它们可能挂在更衣间的入口（前厅）处。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"10.Swab the exterior cuffs of the used lab coats worn by personnel during manufacturing or compounding. They may be hanging in the entry (ante) gowning room."
    },
    {
        "instruction":"已知信息：\n'（二）新药生产：150日；获准进入特殊审批程序的品种：120日；'可被翻译为：(2) new drug application for production: 150 days; any drug permitted to enter the special review and approval procedures: 120 days;\n\n根据上述已知信息，请将'（一）新药临床试验：90日；获准进入特殊审批程序的品种：80日；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(1) new drug application for clinical trial: 90 days; any drug permitted to enter the special review and approval procedures: 80 days;"
    },
    {
        "instruction":"已知信息：\n'第六十三条 本办法下列用语的含义：'可被翻译为：Article 63 Terms used in these Provisions are defined as follows:\n\n根据上述已知信息，请将'样品的生产应当符合本办法第六十三条的规定。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The production of samples shall be in conformity with the requirements in Article 63 in the Provisions."
    },
    {
        "instruction":"已知信息：\n'将物料或设备从较低等级别或未分级区域移动到较高级别洁净区时，应进行与风险相称的清洁和消毒，并符合 CCS 的规定。'可被翻译为：The movement of material or equipment from lower grade or unclassified area to higher-grade clean areas should be subject to cleaning and disinfection commensurate with the risk and in line with the CCS.\n\n根据上述已知信息，请将'取样物料（将所有准备带入公司配制\/加工前厅、洁净间或区域的物料进行消毒）'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1. Sampling Materials (Disinfect all materials being brought into the ante-room, cleanroom, or area designated for compounding\/processing by the firm.)"
    },
    {
        "instruction":"已知信息：\n'一类能够模拟肽分子与受体或酶的相互作用，可激活或阻止某种生物活性的非肽、类肽或拟肽化合物。'可被翻译为：A class of non-peptide, peptide-like, or peptide-like compounds capable of mimicking the interaction of a peptide molecule with a receptor or enzyme that can activate or block a biological activity.\n\n根据上述已知信息，请将'生物体中具有特定生物活性的各种肽。包括各种多肽类激素、激肽、神经多肽和与行为有关的肽。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Any of various peptides in an organism that have a specific biological activity. Including various polypeptide hormones, kinins, neuropeptides, and peptides associated with behavior."
    },
    {
        "instruction":"已知信息：\n'通过比较标准品与供试品两者对接种的试验菌产生抑菌圈的大小测定供试品效价的一种方法。'可被翻译为：A method of determining the titer of a test product by comparing the size of the inhibition zone produced by the standard product and the test product against the inoculated test bacteria.\n\n根据上述已知信息，请将'利用抗生素在培养基内的扩散渗透作用，将已知浓度的标准品溶液与未知含量的供试品溶液在同样条件下分别加入放置在含有试验菌的小钢管内，通过比较抑菌圈大小，测定供试品效价的方法。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Using the diffusion and penetration effect of antibiotics in the medium, the standard solution with known concentration and the test product solution with unknown content were added and placed in a small steel tube containing test bacteria under the same conditions, and the titer of the test product was determined by comparing the size of the antibacterial zone."
    },
    {
        "instruction":"已知信息：\n'阀、过滤器、排水设施、取样点和使用点。'可被翻译为：Valves, filters, drains, sampling and user points.\n\n根据上述已知信息，请将'1.储存:将药品和原料储存到其使用点\n2.将药品储存到使用点。\n3.将医疗产品储存至使用点。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.The storing of pharmaceutical products and materials up to their point of use.\n2.The storing of pharmaceutical products up to the point of use.\n3.The storing of medical products up to the point of use."
    },
    {
        "instruction":"已知信息：\n'如果检出微生物，检查生产期间所用 EM 方法的充分性是否具备足够的灵敏度和适用性，例如'可被翻译为：If no microorganisms are detected, check the adequacy of the EM method used during manufacturing for proper sensitivity and applicability, for example\n\n根据上述已知信息，请将'实施并记录中控、检测和检查（例如生物负载检查 pH，混合充分性）'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"d. Implementation and documentation of in-process controls, tests, and examinations (e.g., bioburden determination pH, adequacy of mixing)"
    },
    {
        "instruction":"已知信息：\n'5.瞒报试验方案禁用的合并药物；'可被翻译为：5. Hide concomitant drugs prohibited by the trial protocol;\n\n根据上述已知信息，请将'(5) 研究者按照临床试验方案规定的试验流程和评估方法实施试验(如访视、给药、采血、安全性检查和疗效评估等)，采取措施保证关键步骤实施的准确性， 并保存相关记录， 如偏离试验方案应予以记录和解释， 合并用药或合并治疗与禁用药物的记录符合方案规定的要求。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(5) The investigator implements the trial (such as visit, drug administration, blood drawing, safety examination and efficacy evaluation, etc.) in accordance with the trial procedures and evaluation methods specified in the clinical trial protocol, takes measures to ensure accuracy of the execution of key steps, and keeps the relevant records, for example, deviation from the trial protocol shall be recorded and explained, and records of concomitant medication or concomitant therapy and  prohibited drugs comply with the requirements of the protocol."
    },
    {
        "instruction":"已知信息：\n'第二十二条 医疗器械标准管理中心将审核通过后的医疗器械标准报批稿及审核结论等报送国家食品药品监督管理总局审查。审查通过的医疗器械国家标准送国务院标准化行政主管部门批准、发布；审查通过的医疗器械行业标准由国家食品药品监督管理总局确定实施日期和实施要求，以公告形式发布。'可被翻译为：Article 22 The Center for Medical Device Standardization Administration shall submit the reviewed medical device standards draft for approval and review conclusions to China Food and Drug Administration for examination. Medical device national standards passing the examination shall be submitted to the competent standardization administrative department under the State Council for approval and issuance; for medical device industry standards passing the examination, China Food and Drug Administration shall determine and announce the date and requirements for their implementation.\n\n根据上述已知信息，请将'第二十一条 承担医疗器械标准计划项目的医疗器械标准化技术委员会负责组织对医疗器械标准送审稿进行技术审查。审查通过后，将医疗器械标准报批稿、实施建议及相关资料报送医疗器械标准管理中心进行审核。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 21 The technical committee on medical device standardization that undertakes the medical device standards plan project shall be responsible for organizing the technical review of the proposed draft of the medical device standard. After the proposed draft passes the technical review, the draft for approval, implementation suggestions and relevant materials for medical device standards shall be submitted to the Center for Medical Device Standardization Administration for examination."
    },
    {
        "instruction":"已知信息：\n'对放置膜的供体和受体腔室孔的扩散面积的测量'可被翻译为：1. Measurements of the diffusional area of the orifices of the donor and receptor compartments between which the membrane is mounted\n\n根据上述已知信息，请将'皮肤应切割成适合扩散池的尺寸(大于孔的扩散面积)，以确保孔被完全覆盖。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Skin should be cut to the appropriate size for the diffusion cell (larger than the diffusional area of the orifice) to ensure that the orifice is completely covered."
    },
    {
        "instruction":"已知信息：\n'个体为了获得某些商品、服务或者为避免预期损失而愿意支付的最大金额。'可被翻译为：The maximum amount that an individual is willing to pay in order to obtain certain goods or services or to avoid expected loss.\n\n根据上述已知信息，请将'政府或公司为了给予某个体授权而颁发的执照，或者用于软件规定使用者权利而规定的格式合同。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A license issued by a government or corporation to grant a license to an individual, or a form of contract that specifies the rights of users of software."
    },
    {
        "instruction":"已知信息：\n'第二十五条 根据飞行检查结果，食品药品监督管理部门可以依法采取限期整改、发告诫信、约谈被检查单位、监督召回产品、收回或者撤销相关资格认证认定证书，以及暂停研制、生产、销售、使用等风险控制措施。风险因素消除后，应当及时解除相关风险控制措施。'可被翻译为：Article 25 The food and drug regulatory department may take risk control measures in accordance with laws and regulations, such as rectification within a deadline, issuance of warning letter, warning meeting with the organization being inspected, monitoring of product recall, withdrawal or cancellation of relevant qualification certificates, as well as suspension of research and development, manufacture, sales, use and etc. in accordance with the results of unannounced inspection. After the risk factors are eliminated, the relevant risk control measures shall be terminated timely.\n\n根据上述已知信息，请将'风险消除后，采取控制措施的药品监督管理部门应当解除控制措施。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"After the risks are eliminated, the drug regulatory department that took the control actions shall terminate such actions."
    },
    {
        "instruction":"已知信息：\n'第三节 关联审评审批'可被翻译为：Section III Bundling Review and Approval\n\n根据上述已知信息，请将'关联审评时限与其关联药品制剂的审评时限一致。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The timeline for bundling review is the same as that for the review of the corresponding drug product."
    },
    {
        "instruction":"已知信息：\n'第十条 下列情形的进口药品，必须经口岸药品检验所检验符合标准规定后，方可办理进口备案手续。检验不符合标准规定的，口岸药品监督管理局不予进口备案：'可被翻译为：Article 10 In any of the following cases, the importation record filing of drugs to be imported shall proceed only after they have been tested and confirmed by the drug control institute of port that they meet the prescribed standards. If they do not meet the prescribed standards based on testing, the drug regulatory department at ports of entry shall not approve the importation record filing.\n\n根据上述已知信息，请将'第四十条 进口暂未列入进口药品目录的原料药，应当遵照本办法的规定，到口岸药品监督管理局办理进口备案手续。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 40 To import drug substances which have been imported but have not yet been included in the list of imported drugs for the time being, the importer shall go through the formalities of importation record filing with the drug regulatory department at ports of entry in accordance with the regulations of the Provisions."
    },
    {
        "instruction":"已知信息：\n'当溶液与纯溶剂（或两种浓度不同的溶液）在半透膜隔开的情况下，溶剂（或较稀溶液中的溶剂）通过半透膜向溶液（或较浓溶液）扩散的现象。'可被翻译为：The diffusion of a solvent (or a solvent in a dilute solution) through a semi-permeable membrane into a solution (or a concentrated solution) when the solution is separated from the pure solvent (or two solutions of different concentrations) by a semi-permeable membrane.\n\n根据上述已知信息，请将'在透析过程中通过半透膜的物质。常含有在溶液中容易扩散的物质。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A substance that passes through a semi-permeable membrane during dialysis. Often containing a substance that diffuses easily in solution."
    },
    {
        "instruction":"已知信息：\n'横坐标是质荷比（m\/z）、纵坐标是离子的相对强度，以基峰为100%、经过计算机处理的质谱棒状谱图。'可被翻译为：The horizontal coordinate is the mass charge ratio (m\/z), the vertical coordinate is the relative strength of the ion, with the base peak of 100%, after computer processing of mass spectrum rod-like spectrum.\n\n根据上述已知信息，请将'以质谱图中指定质核比范围内最强峰为100%,其他离子峰对其归一化所得的强度。现在标准质谱图均以离子相对丰度值为纵坐标。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The maximum peak is 100% in the range of the specified mass nucleus ratio in the mass spectrum, and the intensity obtained by the normalization of other ion peaks. Now the standard mass spectrometry is the relative abundance value of ions as the ordinate."
    },
    {
        "instruction":"已知信息：\n'主要研究化学物质对眼的损害及其机制的毒理学分支学科。'可被翻译为：A branch of toxicology that studies the damage to the eye caused by chemical substances and its mechanisms.\n\n根据上述已知信息，请将'在免疫学和毒理学基础上发展起来的一个毒理学分支学科。主要研究外源化学物质和物理因素对机体免疫系统的有害作用及其机制。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A subdiscipline of toxicology that developed out of immunology and toxicology. The study of the harmful effects of foreign chemicals and physical factors on the body's immune system and their mechanisms."
    },
    {
        "instruction":"已知信息：\n'1.产品生命周期的所有阶段，从最初的开发到营销，直到产品停产(ICH Q8 (4))\n2.医疗器械生命周期的所有阶段，从最初的构思到最终的退役和处置。\n3.产品生命周期的所有阶段，从最初的开发到营销，直到产品停产(4)。'可被翻译为：1.All phases in the life of a product from the initial development through marketing until the product’s discontinuation (ICH Q8 (4))\n2.All phases in the life of a medical device, from the initial conception to final decommissioning and disposal.\n3.All phases in the life of a product from the initial development through marketing until the product’s discontinuation (4).\n\n根据上述已知信息，请将'考虑到监管要求，从计算机化系统构思时开始，到系统退役和退役时结束的一段时间。系统生命周期通常包括规划阶段;包括设计阶段和编程测试阶段的开发阶段;包括系统集成和测试阶段的确认和发布阶段;验证阶段;发布阶段;一个运维阶段;最后是系统退役阶段。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The period of time that starts when a computerized system is conceived and ends when the system is retired and decommissioned, taking into consideration regulatory requirements. The system life-cycle typically includes a planning phase; a development phase that includes a design phase and a programming and testing phase; a qualification and release phase that includes a system integration and testing phase; a validation phase; a release phase; an operation and maintenance phase; and, finally, a system retirement phase."
    },
    {
        "instruction":"已知信息：\n'根据《中华人民共和国药品管理法》，经国务院批准，同意增设广西壮族自治区崇左市爱店口岸（以下简称爱店口岸）为药材进口边境口岸。现将有关事项公告如下：'可被翻译为：According to the Drug Administration Law of the People's Republic of China, upon the approval of the State Council, it is agreed to establish Aidian Port, ChongzuoCity, Guangxi Zhuang Autonomous Region(hereinafter referred to as Aidian Port) as a crude drug import port. The relevant issues are hereby announced as follows:\n\n根据上述已知信息，请将'国家药监局 海关总署关于增设广西壮族自治区崇左市爱店口岸为药材进口边境口岸的公告'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Announcement of NMPA and General Administration of Customs on the Establishment of Aidian Port as a Crude Drug Import Port"
    },
    {
        "instruction":"已知信息：\n'用于某些疾病的预防、治疗和诊断的酶。'可被翻译为：Enzymes used in the prevention, treatment, and diagnosis of certain diseases.\n\n根据上述已知信息，请将'用于预防、治疗和诊断疾病的糖胺聚糖。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A glycosaminoglycan used in the prevention, treatment, and diagnosis of disease."
    },
    {
        "instruction":"已知信息：\n'调查应当包括产品质量状况、伤害与产品的关联性、使用环节操作和流通过程的合规性等。自查应当包括采购、生产管理、质量控制、同型号同批次产品追踪等。'可被翻译为：Investigation shall include product quality profile, the correlation between the injury and the product, and compliance of the operation in the use and circulation process. Self-inspection shall include procurement, production management, quality control, and tracking of the same model and same batch of products.\n\n根据上述已知信息，请将'现场检查应当包括生产质量管理体系运行情况、产品质量状况、生产过程、同型号同批次产品追踪等。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The on-site inspection shall include operation of production quality management system, product quality profile and production process as well as the tracking of products of the same model and same batch."
    },
    {
        "instruction":"已知信息：\n'进口第一类体外诊断试剂备案，备案人向国家食品药品监督管理总局提交备案资料。'可被翻译为：To apply for filing of import class I in-vitro diagnostic reagents, the filing entity shall submit the filing documents to China Food and Drug Administration.\n\n根据上述已知信息，请将'进口第一类医疗器械备案，备案人向国家食品药品监督管理总局提交备案资料。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"To apply for filing of import class I medical devices, the filing entity shall submit the filing documents to China Food and Drug Administration."
    },
    {
        "instruction":"已知信息：\n'（一）产品名称和企业内部的产品代码；'可被翻译为：1. The name of the product and the internal code reference;\n\n根据上述已知信息，请将'（一）产品名称以及产品代码；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1. The designated name of the product and the code reference;"
    },
    {
        "instruction":"已知信息：\n'超文本标记语言。通常用于格式化网页。'可被翻译为：Hypertext Mark-up Language. Commonly used to format Web pages.\n\n根据上述已知信息，请将'标准通用标记语言。以平台无关的方式描述结构化信息的 ISO 标准。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Standardized Generalized Markup Language. An ISO standard for describing structured information in a platform independent manner."
    },
    {
        "instruction":"已知信息：\n'以电感耦合等离子体为激发光源的一类光谱分析方法。是由原子发射光谱法衍生而来。'可被翻译为：A class of spectral analysis methods using inductively coupled plasma as excitation light source. It is derived from atomic emission spectrometry.\n\n根据上述已知信息，请将'以电感耦合等离子体为激发光源的发射光谱分析方法。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Method of emission spectrum analysis using inductively coupled plasma as excitation light source."
    },
    {
        "instruction":"已知信息：\n'收集瓶或试管应在空时称重，以确定收集完成后样品的确切体积。'可被翻译为：Collection vials or test tubes should be weighed when empty to determine the exact volume of sample present after collection has completed.\n\n根据上述已知信息，请将'样品收集后，应称量小瓶或试管，以确定所收集受体溶液的确切体积。该体积用于测定每个样品中存在的药物总量。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"After samples have been collected, the vials or test tubes should be weighed to determine the exact volume of receptor solution collected. This volume should be used when determining the total amount of drug present in each sample."
    },
    {
        "instruction":"已知信息：\n'经过指定的培养时间后，取掉小管，灭活（即灭菌）并用肥皂和水清洗。小管再次用于检测之前要加热灭菌。使用手动\/自动读碟器测量每个 ZOI 的直径。ZOI 应由经过资格确认的实验室员工测量。使用手动\/自动读碟器测量 ZOI。手动读碟器的示例包括 Fisher_x0002_Lily 读碟器或手动\/电子圆规；手动读取需要将数据录入（例如手写和\/或电子）纸质记录和\/或电子日志和\/或数据表。自动读碟器的例子包括 OMNICON 或 Trinity V3。与手动读取不同，自动读碟器允许计算机化系统对培养碟进行测量，不需要录入原始数据。'可被翻译为：After the specified incubation time, the penicylinders are removed, decontaminated (i.e. \nautoclaved) and washed with soap and water. The penicylinders are then heat sterilized prior to \nre-use in test. The diameter of each ZOI is measured with a manual\/automatic plate reader. ZOIs should only be measured by qualified laboratory personnel. ZOI measurements are taken with the use of a manual or automatic plate reader. Examples of a manual reader include a Fisher_x0002_Lily zone reader or manual\/electronic calipers; manual reads require data entry (e.g. handwritten and\/or electronic) onto hardcopy and\/or into electronic logbooks and\/or spreadsheets. Examples \nof automated plate readers include OMNICON or Trinity V3. Unlike manual reads, automated \nplate readers allow a computerized system to measure the plates and do not require data entry of \nraw data.\n\n根据上述已知信息，请将'用于对样品进行测量的设备应该有适当的验证和频繁的核查，确保结果可靠和可重复， 此类设备的例子包括称重天平、pH计、灭菌器、微生物计数器、手动\/自动读板器和紫 外可见光分光计。手动和自动读板器更多信息参见标题为抗生素效价测定章节：管碟法。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Equipment used to provide a unit of measurement should have the appropriate validation and frequent verification checks to ensure reliable and reproducible results; examples of such equipment include a weight scale, pH meter, autoclave, micrometer, manual\/automatic plate reader and UV-VIS spectrophotometer. For more information on manual and automatic plate readers, see section titled Antibiotic Potency Testing: Plate Method."
    },
    {
        "instruction":"已知信息：\n'第三百零一条 因产品存在安全隐患决定从市场召回的，应当立即向当地药品监督管理部门报告。'可被翻译为：Article 301: Where a decision is made to recall a product from the market due to its existing or potential safety risks, it should be reported immediately to the drug regulatory department.\n\n根据上述已知信息，请将'第二百九十三条 企业应当建立产品召回系统，必要时可迅速、有效地从市场召回任何一批存在安全隐患的产品。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 293: The manufacturer should establish a recall system, if necessary, to recall promptly and effectively any batch of products with potential safety risks from the market."
    },
    {
        "instruction":"已知信息：\n'实验动物在14〜28天内，每日给予供试品后所引起的毒性效应。'可被翻译为：Toxic effects caused by daily administration of test products in experimental animals for 14 to 28 days.\n\n根据上述已知信息，请将'应用药物后短时间内发生的毒性作用（14天内）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Toxic effects that occur within a short period of time after application of the drug (within 14 days)."
    },
    {
        "instruction":"已知信息：\n'国家为保证药品质量，保证人民群众用药安全、有效、质量可控而制定的技术法典，是药品研制、生产、经营、使用和监管的法定依据。'可被翻译为：The technical Code formulated by the State for the purpose of ensuring the quality of drugs and ensuring the safety, effectiveness and quality control of drug use by the people is the legal basis for the research, production, distribution, use and supervision of drugs.\n\n根据上述已知信息，请将'一个国家记载药品标准、规格的法典，是国家为保证药品质量、保证人民用药安全有效、质量可控而制定国家药品质量控制的技术标准。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A national code recording drug standards and specifications is a technical standard for drug quality control formulated by the State to ensure drug quality and ensure the safety, effectiveness and controllable quality of drug use for the people."
    },
    {
        "instruction":"已知信息：\n'第六十一条 化妆品最后一道接触内容物的工序在境内完成的为国产产品，在境外完成的为进口产品，在中国台湾、香港和澳门地区完成的参照进口产品管理。'可被翻译为：Article 61 Cosmetics of which the last process touching the contents completes in China are domestic products, and those that completes overseas are imported products. Those that completes in Taiwan, Hong Kong SAR and Macau SAR shall be regulated by the reference of imported products.\n\n根据上述已知信息，请将'第六十三条 配制、填充、灌装化妆品内容物，应当取得化妆品生产许可证。标注标签的生产工序，应当在完成最后一道接触化妆品内容物生产工序的化妆品生产企业内完成。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 63 For the preparing, filling and canning of cosmetics contents, an entity shall obtain the Cosmetics Manufacturing License according to law. The manufacturing process of labeling shall be completed in the manufacturer of cosmetics that completes the last manufacturing process of contacting contents of cosmetics."
    },
    {
        "instruction":"已知信息：\n'已灭菌设备、组分和容器在使用前和灌装\/装配过程中的保持时间。'可被翻译为：The holding time for sterilised equipment, components, and containers before use and during filling\/assembly.\n\n根据上述已知信息，请将'已净化环境（例如 RABS 或隔离器）在使用前的保持时间。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The holding time for a decontaminated environment, such as the RABS or isolator before use."
    },
    {
        "instruction":"已知信息：\n'（三）有能对所生产药品进行质量管理和质量检验的机构、人员及必要的仪器设备；'可被翻译为：(3) have the institutions and personnel capable of meeting the quality control and testing requirements for drugs to be produced and the necessary instruments and equipment; and\n\n根据上述已知信息，请将'（四）有能对所生产药品进行质量管理和质量检验的必要的仪器设备；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(4) having instruments and equipment essential for quality management and testing for drugs to be manufactured;"
    },
    {
        "instruction":"已知信息：\n'2.基于制剂学因素的考虑'可被翻译为：2. Considerations based on pharmaceutics factors\n\n根据上述已知信息，请将'对于仿制药制剂学方面评估，需基于药品特点具体问题具体分析。具体如下：'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"For pharmaceutical evaluation of generic drugs, analysis should be based on cases according to drug characteristics. The details are as follows:"
    },
    {
        "instruction":"已知信息：\n'（二）申请事项依法不属于本部门职权范围的，应当即时作出不予受理的决定，并告知申请人向有关行政机关申请；'可被翻译为：(2) Where an application item is not subject to the jurisdiction of the concerned departments by law, it shall be decided not to accept the application in time and informed to the applicant to apply to the relevant administrative departments;\n\n根据上述已知信息，请将'（四）申请事项不属于本行政机关职权范围的，应当即时作出不予受理的决定，并告知申请人向有关行政部门申请。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(4) If the subject matter of the application does not fall within the scope of this administrative authority, a decision of not accepting the application shall be made immediately, and the applicant shall be notified of applying to relevant administrative authority."
    },
    {
        "instruction":"已知信息：\n'第八条 设区的市级、县级药品监督管理部门负责本行政区域内药品不良反应报告和监测的管理工作；与同级卫生行政部门联合组织开展本行政区域内发生的药品群体不良事件的调查，并采取必要控制措施；组织开展本行政区域内药品不良反应报告和监测的宣传、培训工作。'可被翻译为：Article 8 Drug regulatory departments of municipalities with districts and of counties are responsible for management of ADR reporting and monitoring within their respective administrative regions; organize and carry out investigation on ADE clusters occurred within their administrative regions and take necessary control measures in conjunction with the health administrative departments at the same level; and organize and carry out publicity and training on ADR reporting and monitoring within their administrative regions.\n\n根据上述已知信息，请将'第十二条 设区的市级、县级药品不良反应监测机构负责本行政区域内药品不良反应报告和监测资料的收集、核实、评价、反馈和上报；开展本行政区域内严重药品不良反应的调查和评价；协助有关部门开展药品群体不良事件的调查；承担药品不良反应报告和监测的宣传、培训等工作。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 12 The ADR monitoring institutions of municipalities with districts and of counties are responsible for the collection, verification, evaluation, feedback, and reporting of ADR reporting and monitoring data within their respective administrative regions; conduct investigation and evaluation on serious ADRs within their respective administrative regions; assist relevant departments in investigating ADE clusters; and carry out publicity and training on ADR reporting and monitoring."
    },
    {
        "instruction":"已知信息：\n'种物质按照规定的方法测定，由固相融化成液相时的温度。是物质的-项物理常数。'可被翻译为：The temperature at which a substance melts from a solid phase into a liquid phase, as determined by a prescribed method. Is the physical constant of a substance.\n\n根据上述已知信息，请将'利用相溶解度来精确测量测定物质纯度的方法。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A method of using phase solubility to accurately measure the purity of a substance."
    },
    {
        "instruction":"已知信息：\n'（一）拖延、限制、拒绝检查人员进入被检查场所或者区域的，或者限制检查时间的；'可被翻译为：(i) Delaying, restricting and refusing the entering of the inspectors into the sites or areas being inspected, or limiting the inspection time and duration;\n\n根据上述已知信息，请将'（四）拒绝或者限制拍摄、复印、抽样等取证工作的；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(iv) Refusing or restricting the evidence collection activities, such as photos\/videos taking, documents copying, sampling, etc;"
    },
    {
        "instruction":"已知信息：\n'当真空阶段是循环的一部分，或系统在灭菌后返回到低于灭菌柜环境的压力时，灭菌柜应定期（通常为每周）进行泄漏测试。'可被翻译为：Leak tests on the steriliser should be carried out periodically (normally weekly) when a vacuum phase is part\nof the cycle or the system is returned, post-sterilisation, to a pressure lower than the environment surrounding the\nsteriliser.\n\n根据上述已知信息，请将'如果真空或压力系统的回流会对产品造成潜在风险，应采取措施阻止真空系统或压力系统关闭时产生的回流。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Where backflow from vacuum or pressure systems poses a potential risk to the product, there should be mechanism(s) to prevent backflow when the vacuum or pressure system is shut off."
    },
    {
        "instruction":"已知信息：\n'一种由硬件和软件的架构、机制和算法组成的系统，可自动对工艺进行调整使工艺输出维持在预期范围内。例如前馈控制和反馈工艺控制。'可被翻译为：A system consisting of hardware and software architecture, mechanisms, and algorithms that automatically adjust a process to maintain the process output within a desired range. Examples include feedforward and feedback process controls.\n\n根据上述已知信息，请将'一种确定工艺的影响因素与工艺输出之间相互关系 的、系统的、有序的方法，也称为“实验设计”。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A structured, organized method for determining the relationship between factors affecting a process and the output of that process. Also known as “Design of Experiments”."
    },
    {
        "instruction":"已知信息：\n'口岸药品检验机构应当将进口药材检验报告书报送口岸药品监督管理部门，并告知进口单位。'可被翻译为：Drug control institutions of ports shall submit the testing reports of importation of crude drugs to the drug regulatory departments of ports, and notify the importers.\n\n根据上述已知信息，请将'经口岸检验合格的进口药材方可销售使用。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The imported crude drugs can be sold and used only after passing the port testing."
    },
    {
        "instruction":"已知信息：\n'（六）更新疫苗说明书、标签按照规定应当经核准而未经核准。'可被翻译为：(6) implementing updates of vaccine package inserts and labels without approval which shall have been approved as required.\n\n根据上述已知信息，请将'（三）使用未经核准的标签、说明书。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(3) use labels or packaging insert which have not been reviewed and approved."
    },
    {
        "instruction":"已知信息：\n'对于隔离器，应使用证明适合于任务和关键性的方法对手套系统进行检漏。应定期进行测试。一般来说，手套完整性测试至少应在每个批次或阶段性生产的开始和结束时进行。根据经过验证的阶段性生产长短，可能需要进行额外的手套完整性测试。'可被翻译为：For isolators, leak testing of the glove system should be performed using a methodology demonstrated to be suitable for the task and criticality. The testing should be performed at defined intervals. Generally glove integrity\ntesting should be performed at a minimum frequency of the beginning and end of each batch or campaign.\nAdditional glove integrity testing may be necessary depending on the validated campaign length.\n\n根据上述已知信息，请将'应证明手套系统（用于隔离器和 RABS）的材料具有适当的机械和化学抗性。应在 CCS 中规定更换手套的频率。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The materials used for glove systems (for both isolators and RABS), should be demonstrated to have appropriate mechanical and chemical resistance. The frequency of glove replacement should be defined within the CCS."
    },
    {
        "instruction":"已知信息：\n'技术审评机构应当自收到复核申请之日起30个工作日内作出复核结论。'可被翻译为：The technical assessment agency shall make a re-evaluation conclusion within 30 working days from the date of receiving the re-evaluation application.\n\n根据上述已知信息，请将'第十五条 技术审评结论为审评不通过的，技术审评机构应当告知申请人并说明理由。申请人有异议的，可以自收到技术审评结论之日起20个工作日内申请复核。复核的内容仅限于原申请事项以及申请资料。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 15 If the evaluation conclusion is disapproval, the technical assessment agency shall notify the applicant and explain the reasons. If disagreements exist, the applicant may apply for re-evaluation within 20 working days from the date of receiving the evaluation conclusion. The content of the re-evaluation is limited to the original application items and application dossiers."
    },
    {
        "instruction":"已知信息：\n'2018年药品不良反应\/事件报告中，男女患者比为0.86:1，女性略多于男性。14岁以下儿童患者的报告占9.8%；65岁以上老年患者的报告占27.7%（图5）。'可被翻译为：In the 2018 ADR\/ADE reports, the ratio of male to female patients was 0.86:1, with men slightly outnumbered by women.Reports of pediatric patients under 14 years of age accounted for 9.8%; reports of elderly patients over the age of 65 accounted for27.7% (Figure 5).\n\n根据上述已知信息，请将'2019年药品不良反应\/事件报告中，男女患者比为0.86:1，女性略多于男性。14岁以下儿童患者占10.2%；65岁及以上老年患者占29.1%。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In the 2019 ADR\/ADE reports, the ratio of male to female patients was 0.86:1, with men slightly outnumbered by women. Reports of pediatric patients under 14 years of age accounted for 10.2 percent; and reports of elderly patients over 65 accounted for 29.1 percent."
    },
    {
        "instruction":"已知信息：\n'第十二条 申请人对检验结果有异议的，可以依照药品管理法的规定申请复验。药品检验机构应当在复验申请受理后20日内作出复验结论，并报告省级药品监督管理部门，通知申请人。'可被翻译为：Article 12 In the case of any objection to the testing results, the applicant may apply for re-testing in accordance with the provisions of the Drug Administration Law. Drug control institutions shall, within 20 days upon the acceptance of the application for re-testing, draw a re-testing conclusion, report to provincial drug regulatory department and notify the applicants.\n\n根据上述已知信息，请将'（四）批签发申请人书面承诺放弃复验的。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(IV) The lot release applicant makes a written commitment to give up the re-test."
    },
    {
        "instruction":"已知信息：\n'堆积粉体的总体积中，粉体的空隙体积所占的比例。'可被翻译为：The proportion of the void volume of the powder in the total volume of the packed powder.\n\n根据上述已知信息，请将'单位体积粉体的质量。单位多为g\/ml。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The mass of the powder per unit volume. Units are mostly in g\/ml."
    },
    {
        "instruction":"已知信息：\n'第二十条  有下列情形之一的，由原发证部门依法注销医疗器械经营许可证，并予以公告：'可被翻译为：Article 20 In one of the following circumstances, the former license issuing department shall cancel the Medical Device Distribution License according to law, and make announcements:\n\n根据上述已知信息，请将'第二十条 有下列情形之一的，药品生产许可证由原发证机关注销，并予以公告：'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 20 In any of the following circumstances, the original issuing authority shall revoke the Drug Manufacturing Certificate and make an announcement:"
    },
    {
        "instruction":"已知信息：\n'如果医疗器械只有其通道标示为无菌和无热源，则器械通道必须与萃取液体接触，按 USP<161>执行完整的萃取程序。'可被翻译为：If only the device pathways are labeled as sterile and nonpyrogenic, the device pathways must come in contact with the extraction fluid for the entire course of the extraction per USP<161>.\n\n根据上述已知信息，请将'所有仅通道标示为无菌的设备均应采用无菌液体D测试该通道，无菌液体D采用膜过 滤法测试。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"All devices with only the pathways labeled as sterile are to be tested by the pathway with sterile Fluid D and testing the Fluid D via membrane filtration."
    },
    {
        "instruction":"已知信息：\n'将抗体产生细胞与具有无限增殖能力的骨髓瘤细胞相融合，通过有限稀释法及克隆化使杂交瘤细胞成为纯一的单克隆细胞系而产生的抗体。由于这种抗体只针对一个抗原决定簇，又是单一的B细胞克隆产生的，故名。是结构和特异性完全相同的高纯度抗体。'可被翻译为：An antibody produced by fusing antibody-producing cells with myeloma cells with infinite proliferation capacity to make hybridoma cells into a single monoclonal cell line by limited dilution and cloning. This antibody is named because it targets only one antigenic determinant and is cloned from a single B cell. It is a high purity antibody with the exact same structure and specificity.\n\n根据上述已知信息，请将'在制备单克隆抗体过程中，用骨髓瘤细胞和效应B细胞融合而成的细胞。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A cell formed by the fusion of myeloma cells and effector B cells in the process of making a monoclonal antibody."
    },
    {
        "instruction":"已知信息：\n'第七十三条  医疗器械生产的违法行为，医疗器械监督管理条例等法律法规已有规定的，依照其规定。'可被翻译为：Article 73 For illegal acts in manufacturing of medical devices, if there have been provisions prescribed in the Regulations on Supervision and Administration of Medical Devices and other laws and regulations, such provisions shall prevail.\n\n根据上述已知信息，请将'第五十七条 化妆品生产经营的违法行为，化妆品监督管理条例等法律法规已有规定的，依照其规定。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 57 For illegal acts in manufacturing and marketing of cosmetics, if there have been provisions prescribed in the Regulations on Supervision and Administration of Cosmetics and other laws and regulations, such provisions shall prevail."
    },
    {
        "instruction":"已知信息：\n'第一百四十一条 通过计算机系统记录数据时，相关岗位人员应当按照操作规程，通过授权及密码登录计算机系统，进行数据的录入，保证数据原始、真实、准确、安全和可追溯。'可被翻译为：Article 141 In case of recording data through the computer system, personnel at relevant posts shall, in accordance with the operating procedure, log into the computer system with authorization and password to enter the data, so as to ensure that the data are original, authentic, accurate, safe and traceable.\n\n根据上述已知信息，请将'第四十条 通过计算机系统记录数据时，有关人员应当按照操作规程，通过授权及密码登录后方可进行数据的录入或者复核；数据的更改应当经质量管理部门审核并在其监督下进行，更改过程应当留有记录。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 40 In case of recording data through a computer system, relevant personnel shall, in accordance with the operating procedures, enter or check the data only after they have been authorized and logged in with password. The change of data shall be reviewed by the quality management department and carried out under its supervision, which shall be recorded."
    },
    {
        "instruction":"已知信息：\n'每百万人口平均报告数量是衡量一个国家药品不良反应监测工作水平的重要指标之一。2019年我国每百万人口平均报告数为1，130份。'可被翻译为：The average number of reports per million population constitutes one of the major indicators to measure the level of a country's ADR monitoring work. The average number of reports per million population in China marked 1,130 in 2019.\n\n根据上述已知信息，请将'每百万人口平均报告数量是衡量一个国家药品不良反应监测工作水平的重要指标之一。2018年我国每百万人口平均报告数为1119份。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"As one of the important indicators to measure the level of national ADR monitoring, the average number of reports per million people in China marked 1,119 in 2018."
    },
    {
        "instruction":"已知信息：\n'第二百四十二条 变更都应当评估其对产品质量的潜在影响。企业可以根据变更的性质、范围、对产品质量潜在影响的程度将变更分类（如主要、次要变更）。判断变更所需的验证、额外的检验以及稳定性考察应当有科学依据。'可被翻译为：Article 242: For all changes, the potential impact on product quality should be evaluated. The manufacturer should classify the changes (e.g. major or minor) depending on their nature and extent, and the effects these changes may impact on product quality. Scientific evidences should be provided to determine what validation activities, additional tests and stability studies are needed.\n\n根据上述已知信息，请将'第二百四十九条 任何偏差都应当评估其对产品质量的潜在影响。企业可以根据偏差的性质、范围、对产品质量潜在影响的程度将偏差分类（如重大、次要偏差），对重大偏差的评估还应当考虑是否需要对产品进行额外的检验以及对产品有效期的影响，必要时，应当对涉及重大偏差的产品进行稳定性考察。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 249: The potential impact of any deviation on product quality should be assessed. The manufacturer may classify the deviations (e.g. as minor or major) depending on the nature and scope of the deviations and extent of the potential impact on product quality. Additional tests and impact on the shelf life should be considered for the assessment of major deviations, and if necessary, stability studies should also be carried out for products involved in major deviations."
    },
    {
        "instruction":"已知信息：\n'国家药品监督管理局食品药品审核查验中心（以下简称核查中心）组织制定药品检查技术规范和文件，承担境外检查以及组织疫苗巡查等，分析评估检查发现风险、作出检查结论并提出处置建议，负责各省、自治区、直辖市药品检查机构质量管理体系的指导和评估。'可被翻译为：The Center for Food and Drug Inspection (CFDI) of NMPA shall organize the formulation of drug inspection technical standards and documents, undertake overseas inspection and organize vaccine inspection, analyze and assess risks found in inspection, make inspection conclusions and propose handling suggestions, and guide and assess the quality management systems of drug inspection agencies of provinces, autonomous regions and municipalities directly under the Central Government.\n\n根据上述已知信息，请将'国家药品监督管理局食品药品审核查验中心组织拟订医疗器械检查制度规范和技术文件，承担重大有因检查和境外检查等工作，并对省、自治区、直辖市医疗器械检查机构质量管理体系进行指导和评估。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The Center for Food and Drug Inspection of NMPA shall organize and draft medical device inspection system specification and technical documents, assume significant for-cause inspection and overseas inspection, etc., and conduct instruction and evaluation of the quality management system of medical device inspection institutions of the province, autonomous region, or municipality directly under the central government."
    },
    {
        "instruction":"已知信息：\n'（一）申请人对拟上市销售医疗器械的安全性、有效性进行的研究及其结果无法证明产品安全、有效的；'可被翻译为：(I) The research conducted by the applicant and its result cannot prove the safety and effectiveness of the medical device to be sold on the market.\n\n根据上述已知信息，请将'（一）申请人对拟上市销售体外诊断试剂的安全性、有效性进行的研究及其结果无法证明产品安全、有效的；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(I) The research conducted by the applicant and its result cannot prove the safety and effectiveness of the in-vitro diagnostic reagent to be sold on the market."
    },
    {
        "instruction":"已知信息：\n'对于无菌工艺，应在 A 级条件下添加组件，并使用预灭菌的组件以确保关键表面的无菌性。'可被翻译为：For aseptic processes, the addition of components should be performed under grade A conditions, to ensure the sterility of critical surfaces, using pre-sterilised components.\n\n根据上述已知信息，请将'应在工艺条件下评估产品与产品接触表面的吸附性和反应性。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The  adsorption  and reactivity  of the product with product  contact  surfaces  should be  evaluated under process conditions."
    },
    {
        "instruction":"已知信息：\n'蒙脱土'可被翻译为：montmorillonite clay\n\n根据上述已知信息，请将'蒙脱土中的无机阳离子被二甲基双十八烷基铁离子取代后的物质。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A substance in montmorillonite after inorganic cations have been replaced by dimethyl dioctadecyl iron ions."
    },
    {
        "instruction":"已知信息：\n'如果时间紧急，并且上述问题已得到解决，则可在进行产品无菌测试时同步进行方法适用性测试。但是应注意的如果方法适用性试验与产品无菌检测同时进行，方法适用性试验失败，则产品检测结果是无效的，需要适当修改方法，中和抑菌性，再重复进行适用性试验和产品检测。'可被翻译为：Run the method suitability test concurrently with product sterility tests when time is critical, and problems associated with 1. above have been resolved. However, it should be noted that if the Method Suitability Test is run concurrently with the product sterility test and the Method Suitability Test should fail, the results of the product test are invalid and the Method Suitability Test as well as the product test will need to be repeated with proper method modification to neutralize the inhibiting property.\n\n根据上述已知信息，请将'适用性表明所测试的产品在测试条件下对微生物生长没有抑制作用。尽管期望在进行产品分析 前进行适用性试验，但同时进行产品测试和适用性试验也是可以接受的。但应注意的是，如果 同时进行适用性试验和产品测试，适用性试验失败，则产品检测结果是无效的，应对方法进行 适当修改，中和抑菌性，然后再重复进行适用性试验和产品检测方法。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Suitability demonstrates that the products tested do not exhibit inhibitory effects on the growth of microorganisms under the conditions of the tests. Although the intent is to perform the suitability test before performing the analysis of the product, it is acceptable to run the product test and the suitability test concurrently. However, it should be noted that if the suitability test is run concurrently with the product test and the suitability test should fail, the results of the product test are invalid and the suitability test as well as the product test will need to be repeated with proper method modification to neutralize the inhibiting property."
    },
    {
        "instruction":"已知信息：\n'第二条 在中华人民共和国境内销售、使用的医疗器械，其唯一标识系统应当符合本规则。'可被翻译为：Article 2  For medical devices sold and used within the territory of the People's Republic of China, their UDI system shall comply with the requirements of the Rules.\n\n根据上述已知信息，请将'第二条 凡在中华人民共和国境内销售、使用的医疗器械应当使用通用名称，通用名称的命名应当符合本规则。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 2 All medical devices that are sold and used within the territory of the People's Republic of China shall use generic names and their naming shall conform to the Rules."
    },
    {
        "instruction":"已知信息：\n'1.活性药物成分(api)、药用辅料、包装材料或药品根据药典各论的要求或已批准上市许可的规范进行分析。\n2.一套测试制度，以验证产品是否符合规格。'可被翻译为：1.Analysis of active pharmaceutical ingredients (APIs), pharmaceutical excipients, packaging material or pharmaceutical products according to the requirements of a pharmacopoeial monograph or a specification in an approved marketing authorization.\n2.A regime of testing to verify that a lot complies with the specification.\n\n根据上述已知信息，请将'多来源药品批准和上市许可的体内和\/或体外测试要求。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In vivo and\/or in vitro testing requirements for approval of a multisource pharmaceutical product and marketing authorization."
    },
    {
        "instruction":"已知信息：\n'第十一条 药品监督管理部门设置或者指定的药品专业技术机构，承担依法实施药品监督管理所需的审评、检验、核查、监测与评价等工作。'可被翻译为：Article 11 The drug professional and technical institutions established or designated by drug regulatory departments shall perform review, testing, inspection, monitoring and assessment as required by the conduct of drug administration in accordance with the law.\n\n根据上述已知信息，请将'由药品监督管理部门设置或确定，依法实施药品审批和药品质量监督检查所需的药品检验工作的技术部门。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Technical departments set up or designated by drug regulatory departments to carry out drug inspection work required for drug approval and drug quality supervision and inspection according to law."
    },
    {
        "instruction":"已知信息：\n'能够进行可重复的内部生物净化的外壳，其内部工作区域满足A级条件，可将其内部与外部环境(例如，周围洁净室空气和人员)不受损害地连续隔离。隔离器主要有两种类型:\n•□闭式隔离器系统通过与辅助设备的无菌连接来完成物料转移，而不是使用对周围环境的开口，从而排除隔离器内部的外部污染。封闭系统在整个操作过程中保持密封。\n•□开放式隔离系统的设计允许物料在操作期间通过一个或多个开口连续或半连续地进入或流出。开口设计(例如，使用连续超压)以排除外部污染物进入隔离器。'可被翻译为：An enclosure capable of being subject to reproducible interior biodecontamination, with an internal work zone meeting grade A conditions that provide uncompromised continuous isolation of its interior from the external environment (for example, surrounding cleanroom air and personnel). There are two major types of isolators:\n•□Closed isolator systems exclude external contamination of the isolator’s interior by accomplishing material transfer via aseptic connection to auxiliary equipment rather than use of openings to the surrounding environment. Closed systems remain sealed throughout operations.\n•□Open isolator systems are designed to allow for the continuous or semicontinuous ingress or egress of materials during operations through one or more openings. Openings are engineered (for example, using continuous overpressure) to exclude the entry of external contaminant into the isolator.\n\n根据上述已知信息，请将'密闭隔离器系统通过与辅助设备的无菌连接而不是对周围环境开放来完成物料转移，从而阻断外部污染物进入隔离器内部。密闭系统在整个操作中保持密封。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Closed isolator  systems  exclude external  contamination of the  isolator's  interior by accomplishing material  transfer via aseptic connection to auxiliary equipment, rather than use of openings to the surrounding environment.Closed systems remain sealed throughout operations."
    },
    {
        "instruction":"已知信息：\n'在成型容器的挤出、成型或密封过程中，接触容器关键表面的空气或其它气体应进行适当的过滤。所用气体的质量和气体过滤系统的有效性应按照第 6.18 和 6.19 节进行定期确认。'可被翻译为：Air or other gases that make contact with critical surfaces of the container during extrusion, formation or sealing  of  the  moulded  container  should  undergo   appropriate  filtration.  The  quality  of  gas  used  and  the effectiveness of gas filtration systems should be verified periodically in accordance with paragraphs 6.18 and 6.19.\n\n根据上述已知信息，请将'对于气体过滤，应避免过滤器或过滤设备意外润湿或潮湿。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"For gas filtration, unintended moistening or wetting of the filter or filter equipment should be avoided."
    },
    {
        "instruction":"已知信息：\n'一类低等的真核生物，不能进行光合作用，以产生大量抱子进行繁殖，一般具有发达的菌丝体，营养方式为异养吸收型，陆生性较强。'可被翻译为：A class of low eukaryotes, unable to photosynthesis, to produce a large number of arms for reproduction, generally have developed mycelium, trophic mode is heterotrophic absorption type, strong terrestrial.\n\n根据上述已知信息，请将'一类细胞直径约0.5Rm、长度在0.5~5pm,结构简单、细胞壁坚韧、以二等分裂方式繁殖和水生性较强的原核微生物。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A kind of prokaryotic microorganism with a cell diameter of about 0.5Rm and a length of 0.5~5pm. It has simple structure, tough cell wall, reproduction by secondary division and strong water nature."
    },
    {
        "instruction":"已知信息：\n'(4) 所有在仪器中进样的样品均记录在原始记录中， 并对样品分析过程中出现的异常情况进行调查和分析， 与申报资料一致。'可被翻译为：(4) Samples introduced into all the instruments are recorded in the original records, and investigation and analysis are conducted for abnormal circumstances occurred during the process of sample analysis, consist with the application dossier.\n\n根据上述已知信息，请将'(5) 所有在仪器中进样的样品均记录在原始记录中， 并对方法学验证过程中出现的异常情况进行调查和分析， 与申报资料一致。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(5) All samples introduced into the instruments are recorded in the original records, and investigation and analysis is conducted for abnormal circumstances occurred during the process of method validation, which are consist with those in the application dossier."
    },
    {
        "instruction":"已知信息：\n'第三条 药品注册是指药品注册申请人（以下简称申请人）依照法定程序和相关要求提出药物临床试验、药品上市许可、再注册等申请以及补充申请，药品监督管理部门基于法律法规和现有科学认知进行安全性、有效性和质量可控性等审查，决定是否同意其申请的活动。'可被翻译为：Article 3 Drug registration refers to the process where drug registration applicants (hereinafter referred to as \"applicants\") submit applications for clinical trials, marketing authorization and renewal of registration as well as supplementary applications as per statutory procedures and relevant requirements, and where the drug regulatory departments decide whether or not to approve such applications after reviewing the safety, efficacy and quality according to laws and regulations and existing scientific recognition.\n\n根据上述已知信息，请将'第十条 药品注册申请人（以下简称申请人），是指提出药品注册申请并承担相应法律责任的机构。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 10 An applicant for drug registration (hereinafter referred to as applicant) refers to the institution that submits a drug registration application and assumes corresponding legal liability."
    },
    {
        "instruction":"已知信息：\n'(7) 病例报告表、总结报告(或数据库) 中的SAE相关数据记录和报告情况与源数据一致，无漏记、误判和误记。'可被翻译为：The relevant data of SAEs recorded in the case report form and summary report (or database) are consist with the source data, without omission, misjudgment and error in recording.\n\n根据上述已知信息，请将'独立于直接参与试验的人员进行的系统检查，以确定试验的进行是否符合商定的方案，以及报告的数据是否与现场记录一致，例如，病例报告表格中报告或记录的数据是否与医院档案和其他原始记录中的数据一致。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A systematic examination, carried out independently of those directly involved in the trial, to determine whether the conduct of a trial complies with the agreed protocol and whether the data reported are consistent with the records on site, e.g. whether data reported or recorded in the case-report forms (CRFs) are consonant with those found in hospital files and other original records."
    },
    {
        "instruction":"已知信息：\n'第十一条 临床试验应当获得医疗器械临床试验机构伦理委员会的同意。列入需进行临床试验审批的第三类医疗器械目录的，还应当获得国家食品药品监督管理总局的批准。'可被翻译为：Article 11 Clinical trials shall be approved by the ethics committee of the medical device clinical trial institution. Clinical trials shall also be approved by China Food and Drug Administration if the corresponding investigational medical device is included in the class III medical device catalogue which requires clinical trial approval.\n\n根据上述已知信息，请将'第二十四条 第三类医疗器械进行临床试验对人体具有较高风险的，应当经国家食品药品监督管理总局批准。需进行临床试验审批的第三类医疗器械目录由国家食品药品监督管理总局制定、调整并公布。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 24 Where the clinical trial of a class III medical device poses high risks to human body, it shall be subject to approval by China Food and Drug Administration. The catalogue of class III medical devices subject to clinical trial approval shall be compiled, adjusted and published by China Food and Drug Administration."
    },
    {
        "instruction":"已知信息：\n'10.拒绝、不配合核查， 导致无法继续进行现场核查；'可被翻译为：10. Refuse or fail to cooperate with the inspection, resulting in the inability to continue on-site inspection;\n\n根据上述已知信息，请将'8.拒绝、不配合核查，导致无法继续进行现场核查；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"8. Refusing or refusing to cooperate with the inspection, causing the discontinuation of on-site inspection;"
    },
    {
        "instruction":"已知信息：\n'污染控制策略（CCS）应在整个设施内实施，从而明确所有关键控制点，并评估所有用于管理药品质量和安全风险的控制措施（设计，程序性、技术性和组织性措施）和监测措施的有效性。CCS 的综合策略应建立起强有力的污染预防保障。应积极回顾并适当更新 CCS，并应推动生产和控制方法的持续改进。CCS 的有效性应成为定期管理回顾的一部分。如果控制系统已经建立并得到了妥善管理，则这些系统可能不需要更换，但应在 CCS 中提及，并应了解系统之间在相关方面的相互作用。'可被翻译为：A Contamination Control Strategy (CCS) should be implemented across the facility in order to define all critical control points and assess the effectiveness of all the controls (design, procedural, technical and organisational) and monitoring measures employed to manage risks to medicinal product quality and safety. The\ncombined strategy of the CCS should establish robust assurance of contamination prevention. The CCS should be actively reviewed and, where appropriate, updated and should drive continual improvement of the manufacturing and control methods. Its effectiveness should form part of the periodic management review. Where existing control systems are in place and are appropriately managed, these may not require replacement but should be referenced in the CCS and the associated interactions between systems should be understood.\n\n根据上述已知信息，请将'CCS 应考虑污染控制的所有方面，并进行持续、定期的回顾，酌情更新药品质量体系。现行体系如有变更，应在实施前后评估对 CCS 的任何影响。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The CCS should consider all aspects of contamination control with ongoing and periodic review resulting in updates within the pharmaceutical quality system as appropriate. Changes to the systems in place should be\nassessed for any impact on the CCS before and after implementation."
    },
    {
        "instruction":"已知信息：\n'由多个氨基酸借肽键线性连接而成。肽键就是氨基酸的a-竣基与相邻的另一氨基酸的a-氨基脱水缩合的共价键。'可被翻译为：It is formed by a linear connection of multiple amino acids by peptide bonds. a peptide bond is a covalent bond in which the A-carboxyl group of an amino acid is dehydrated and condensed with the A-amino group of another adjacent amino acid.\n\n根据上述已知信息，请将'一分子氨基酸的a-竣基和一分子氨基酸的a-氨基脱水缩合形成的酰胺键，即—CO—NH—。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"An amide bond formed by the dehydration condensation of the A-carboxyl group of an amino acid with the A-amino group of an amino acid, that is, -CO-NH --."
    },
    {
        "instruction":"已知信息：\n'1.使用申请中规定的生产设施中的生产设备按生产规模生产的一批原料药或制剂。\n2.在申请中指定的生产设施中使用生产设备按生产规模生产的一批API或FPP。'可被翻译为：1.A batch of an active pharmaceutical ingredient or finished pharmaceutical product manufactured at production scale by using production equipment in a production facility as specified in the application.\n2.A batch of an API or FPP manufactured at production scale by using production equipment in a production facility as specified in the application.\n\n根据上述已知信息，请将'1.看到一批。\n2.相同设计、颜色、形状、大小和配方的避孕套集合。一个批次必须基本上同时生产，使用相同的工艺、相同规格的原材料、共同的设备、相同的润滑剂和任何其他添加剂或敷料，并使用相同的包装材料包装在同一类型的单个容器中。\n3.基本上在同一时间生产的一批原材料、部件或产品，并有一个批次识别码或编号。需要明确的批号标识和记录，以便在设备出现质量问题时进行有效的产品召回。许多生产的节育器的定义在第3节一般要求中给出。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.See batch.\n2.A collection of condoms of the same design, colour, shape, size and formulation. A lot must be manufactured at essentially the same time, using the same process, same specification of raw materials, common equipment, same lubricant and any other additive or dressing, and be packed in the same type of individual container, using the same packaging materials.\n3.A quantity of raw materials, components or iuds made at essentially the same time and having a single lot identification code or number. Clear lot identification and recording are required to permit effective product recall in the event of a quality problem with the device. The definition of a lot of manufactured iuds is given in section 3 on general requirements."
    },
    {
        "instruction":"已知信息：\n'也称摩尔吸光系数。反映分子对特定波长光的吸收能力（通常表示为 L\/mol\/cm ），并受溶剂等因素的影响。'可被翻译为：Molar Extinction Coefficient (also called molar absorptivity) reflects the efficiency with  which a molecule can absorb a photon at a particular wavelength (typically expressed as L mol-1 cm-1) and is influenced by several factors, such as solvent.\n\n根据上述已知信息，请将'由不对称分子组成的物质是光学各向异性的，即L与R两束圆偏振光在这类物质中的传播速度不相等的现象。假如光学各向异性物质在某一波长有吸收，那将在该时对L光和R光有不同的吸收，如该物质的吸光率是A,而对L光和R光的吸光率是Al和Ar，Al和Ar的差△A=Al-Ar，称为圆二色性。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Substances consisting of asymmetrical molecules are optically anisotropic, that is, the phenomenon that two beams of circularly polarized light L and R travel at different speeds through such substances. If the optical anisotropic substance has absorption at A certain wavelength, it will have different absorption of L light and R light at that time, such as the absorption rate of the substance is A, and the absorption rate of L light and R light is Al and Ar, Al and Ar difference △A= al-ar, called circular dichroism."
    },
    {
        "instruction":"已知信息：\n'第二条 凡在中华人民共和国境内销售、使用的医疗器械应当使用通用名称，通用名称的命名应当符合本规则。'可被翻译为：Article 2 All medical devices that are sold and used within the territory of the People's Republic of China shall use generic names and their naming shall conform to the Rules.\n\n根据上述已知信息，请将'第八条 医疗器械的产品名称应当使用通用名称，通用名称应当符合国家食品药品监督管理总局制定的医疗器械命名规则。第二类、第三类医疗器械的产品名称应当与医疗器械注册证中的产品名称一致。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 8 Product names of medical devices shall adopt general names, which shall meet the rules of nomenclature of medical devices formulated by China Food and Drug Administration. Product names of class II and class III medical devices shall be consistent with the product names in the corresponding medical device registration certificates."
    },
    {
        "instruction":"已知信息：\n'违反本办法第九条第三款的规定，责令限期改正，处5万元以上10万元以下罚款；造成危害后果的，处10万元以上20万元以下罚款。'可被翻译为：In case of violation of the provisions in Paragraph 3, Article 9 of these Provisions, it shall be ordered to make correction within the time limit, and subject to a fine of not less than RMB 50,000 and not more than RMB 100,000; for hazardous consequences, a fine of not less than RMB 100,000 and not more than RMB 200,000 shall be imposed.\n\n根据上述已知信息，请将'第三十八条 违反本办法第十七条第一款的规定，责令限期改正，处3万元以上10万元以下罚款；造成危害后果的，处10万元以上20万元以下罚款。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 38 In case of violation of the provisions in Paragraph 1, Article 17 of these Provisions, it shall be ordered to make correction within the time limit, and subject to a fine of not less than RMB 30,000 and not more than RMB 100,000; for hazardous consequences, a fine of not less than RMB 100,000 and not more than RMB 200,000 shall be imposed."
    },
    {
        "instruction":"已知信息：\n'1.开展临床试验，应当获得药品监督管理部门许可， 生物等效性试验应按照要求完成备案。'可被翻译为：1. To conduct clinical trials, the approval from the drug administration shall be obtained, and the bioequivalence test shall be filed as required.\n\n根据上述已知信息，请将'第三十条 药物的临床试验（包括生物等效性试验），必须经过国家食品药品监督管理局批准，且必须执行《药物临床试验质量管理规范》。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 30 Any drug clinical trial, including bioequivalence study, shall be approved by the State Food and Drug Administration, and shall be in compliance with the Good Clinical Practice."
    },
    {
        "instruction":"已知信息：\n'从事药品生产活动，应当经所在地省、自治区、直辖市药品监督管理部门批准，依法取得药品生产许可证，严格遵守药品生产质量管理规范，确保生产过程持续符合法定要求。'可被翻译为：To carry out drug manufacturing activities, approval should be obtained from the drug regulatory department of corresponding province, autonomous region or municipality directly under the Central Government, the Drug Manufacturing Certificate shall be obtained, and the Good Manufacturing Practice for Pharmaceutical Products (GMP) should be strictly followed to ensure the manufacturing process continuously complies with statutory requirements.\n\n根据上述已知信息，请将'原料药生产企业应当按照核准的生产工艺组织生产，严格遵守药品生产质量管理规范，确保生产过程持续符合法定要求。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Manufacturers of active drug ingredients shall organize manufacturing according to approved manufacturing processes and strictly abide by good manufacturing practice to ensure the drug manufacturing continuously complies with statutory requirements."
    },
    {
        "instruction":"已知信息：\n'第四十条 开展体外诊断试剂临床试验，应当向申请人所在地省、自治区、直辖市食品药品监督管理部门备案。接受备案的食品药品监督管理部门应当将备案情况通报临床试验机构所在地的同级食品药品监督管理部门和卫生计生主管部门。'可被翻译为：Article 40 The clinical trial of in-vitro diagnostic reagents shall be filed with the food and drug regulatory department of the provinces, autonomous regions and municipalities directly under the central government where the applicant is located. The food and drug regulatory department accepting the filling shall report to the food and drug regulatory department and the competent health and family planning department at the same level where the clinical trial institution is located.\n\n根据上述已知信息，请将'接受备案的食品药品监督管理部门应当将备案情况通报临床试验机构所在地的同级食品药品监督管理部门以及卫生计生主管部门。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The food and drug administration department that accepts filing shall inform the local food and drug administration department and the competent health and family planning department of the same level where the clinical trial institution is located."
    },
    {
        "instruction":"已知信息：\n'血浆脂蛋白中密度为0.95〜1.006g\/cn?的脂蛋白。是血浆脂蛋白中密度极低的-类脂蛋白，可用超速离心或电泳法对血浆脂蛋白进行类别分离而确定。'可被翻译为：The medium density of plasma lipoprotein is 0.95 ~ 1.006g\/cn? Is a lipoprotein. Is a very low density of plasma lipoproteins - lipoproteins, which can be determined by class separation of plasma lipoproteins by ultracentrifugation or electrophoresis.\n\n根据上述已知信息，请将'血浆脂蛋白中密度为1.006-1.063g\/cn?的脂蛋白。是血浆脂蛋白中密度较低的-类脂蛋白，可用超速离心或电泳法对血浆脂蛋白进行类别分离而确定。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The medium density of plasma lipoprotein is 1.006-1.063g\/cn? Is a lipoprotein. Is a lower density of plasma lipoprotein - lipoprotein, can be determined by ultra-fast centrifugation or electrophoresis of plasma lipoprotein class separation."
    },
    {
        "instruction":"已知信息：\n'第一百二十五条 本办法规定的期限以工作日计算。'可被翻译为：Article 125 The timelines stipulated in these Provisions shall be calculated in working days.\n\n根据上述已知信息，请将'第七十三条 本办法规定的期限以工作日计算。药品生产许可中技术审查和评定、现场检查、企业整改等所需时间不计入期限。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 73 Timelines specified in these Provisions are calculated based on working days. Time needed for technical review and evaluation, on-site inspection and enterprise remediation in drug manufacturing licensing is not included into the timelines."
    },
    {
        "instruction":"已知信息：\n'本部分不适用于根据本章101.8（d）下取得的电子签名。'可被翻译为：(h) This part does not apply to electronic signatures obtained under 101.8(d) of this chapter.\n\n根据上述已知信息，请将'本部分不适用于根据本章101.11（d）下取得的电子签名。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(g) This part does not apply to electronic signatures obtained under 101.11(d) of this chapter."
    },
    {
        "instruction":"已知信息：\n'快速转移系统\/接口（RTP）：一种用于将物品转移到 RABS 或隔离器中的系统，最大程度降低对关键区的风险。一个例子是具有 a\/β接口的快速转移容器。'可被翻译为：Rapid  Transfer  System\/Port  (RTP)  -  A  System  used  for  the  transfer  of  items  into  RABS  or  isolators  that minimizes the risk to the critical zone. An example would be a rapid transfer container with an alpha\/beta port.\n\n根据上述已知信息，请将'用于将物品转移到RABS或隔离器的系统，以最大限度地降低对关键区域的风险。一个例子是带有alpha\/beta端口的快速转移容器。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A system used for the transfer of items into RABS or isolators that minimizes the risk to the critical zone. An example would be a rapid transfer container with an alpha\/beta port."
    },
    {
        "instruction":"已知信息：\n'第三十九条 违反本办法第十八条的规定，责令限期改正；逾期不改正的，处5万元以上10万元以下罚款；造成危害后果的，处10万元以上20万元以下罚款。'可被翻译为：Article 39 In case of violation of the provisions of Article 18 of these Provisions, it shall be ordered to make correction within the time limit; where correction is not made within the prescribed period, a fine of not less than RMB 50,000 and not more than RMB 100,000 shall be imposed; for hazardous consequences, a fine of not less than RMB 100,000 and not more than RMB 200,000 shall be imposed.\n\n根据上述已知信息，请将'第三十六条 违反本办法第十三条、第十九条第二款的规定，责令限期改正；逾期不改正的，处5万元以上10万元以下罚款。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 36 In case of violation of the provisions in Article 13, Paragraph 2 of Article 19 of these Provisions, it shall be ordered to make correction within the time limit; where correction is not made within the prescribed period, a fine of not less than RMB 50,000 and not more than RMB 100,000 shall be imposed."
    },
    {
        "instruction":"已知信息：\n'第三十五条 本办法自发布之日起施行。'可被翻译为：Article 35 The Provisions shall come into force on the date of issuance.\n\n根据上述已知信息，请将'第三十五条 本办法自2015年9月1日起施行。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 35 The Provisions shall be effective as of September 1, 2015."
    },
    {
        "instruction":"已知信息：\n'证明任何程序、生产过程、设备、物料、活动或系统确实能达到预期结果的有文件证明的一系列活动。'可被翻译为：A documented set of activities that demonstrate that any procedure, production process, equipment, material, activity, or system actually achieves an expected result.\n\n根据上述已知信息，请将'证明任何操作规程（或方法）、生产工艺或系统能够达到预期结果的一系列活动。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A series of actions of proving that any operation procedure (or method), manufacturing process or system actually leads to the expected results."
    },
    {
        "instruction":"已知信息：\n'1.确保原辅料、包装材料、中间产品、待包装产品和成品符合经注册批准的要求和质量标准；'可被翻译为：1) To ensure that all starting materials, packaging materials, intermediate, bulk and finished products meet the registration requirements and specifications;\n\n根据上述已知信息，请将'（二）应当有批准的操作规程，用于原辅料、包装材料、中间产品、待包装产品和成品的取样、检查、检验以及产品的稳定性考察，必要时进行环境监测，以确保符合本规范的要求。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2. Approved procedures are available for sampling, inspection and testing starting materials, packaging materials, intermediate, bulk, and finished products, and stability study, and where appropriate for monitoring environmental conditions, to ensure the compliance with GMP."
    },
    {
        "instruction":"已知信息：\n'2~20个氨基酸残基通过肽键连接形成的肽。'可被翻译为：Peptides formed from 2 to 20 amino acid residues connected by peptide bonds.\n\n根据上述已知信息，请将'由20个以上的氨基酸残基组成的肽。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A peptide consisting of more than 20 amino acid residues."
    },
    {
        "instruction":"已知信息：\n'鼓励中药生产企业优先使用符合本规范要求的中药材。药品批准证明文件等有明确要求的，中药生产企业应当按照规定使用符合本规范要求的中药材。相关中药生产企业应当依法开展供应商审核，按照本规范要求进行审核检查，保证符合要求。'可被翻译为：TCM manufacturers are encouraged to give priority to the use of Chinese crude drugs that meet the GAP requirements. Where there are explicit requirements in the drug approval documents, TCM manufacturers should use the Chinese crude drugs that meet the GAP requirements according to the provisions. Relevant TCM manufacturers should carryout supplier audit according to law and conduct audit and inspection in accordance with the GAP requirements to ensure the compliance with the requirements.\n\n根据上述已知信息，请将'（一）在批准放行前，应当对每批药品进行质量评价，保证药品及其生产应当符合注册和本规范要求，并确认以下各项内容：'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1. Each batch of drugs, prior to release, should undergo quality assessment, so as to ensure that the products and manufacturing comply with the registration requirements and the Provisions, and the following activities should be confirmed:"
    },
    {
        "instruction":"已知信息：\n'三、增加无锡市药品安全检验检测中心为口岸药品检验机构。自本公告发布之日起，无锡市药品安全检验检测中心开始承担无锡航空口岸、江阴港口岸的药品口岸检验工作。'可被翻译为：III. Wuxi Center for Drug Safety Inspection and Testing is added as the port drug inspection agency. As of the date of issuance of this Announcement, WuxiCenter for Drug Safety Inspection and Testing starts to undertake the drug port inspection at Wuxi Airport and Jiangyin Port.\n\n根据上述已知信息，请将'三、增加吉林省药品检验研究院为口岸药品检验机构。自本公告发布之日起，吉林省药品检验研究院开始承担长春空港口岸的药品口岸检验工作。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"III. Jilin Institute for Drug Control is added as the port drug testing institute. As of the date of issuance of this Announcement, Jilin Institute for Drug Control starts to undertake the drug port testing at Changchun Airport."
    },
    {
        "instruction":"已知信息：\n'手性化合物分子含有一个以上不对称中心时，异构体混合物中一个非对映体对其他非对映体的过量。'可被翻译为：When a chiral compound molecule contains more than one asymmetric center, an excess of one diastereomer in the isomer mixture to the other diastereomers.\n\n根据上述已知信息，请将'一类光学活性化合物或结构单元通过暂时参与到一个有机合成中以便能够进行不对称反应，在两个对映体中选择性形成一个对映体。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A class of optically active compounds or structural units that selectively form an enantiomer between two enantiomers by temporarily participating in an organic synthesis in order to perform an asymmetric reaction."
    },
    {
        "instruction":"已知信息：\n'第一百三十二条 在药品储存、陈列等区域不得存放与经营活动无关的物品及私人用品，在工作区域内不得有影响药品质量和安全的行为。'可被翻译为：Article 132 Items and personal belongings irrelevant to drug distribution activities shall not be stored in the storage and display areas of drugs. There shall be no action in the working areas that may affect the quality and safety of drugs.\n\n根据上述已知信息，请将'（十二）药品储存作业区内不得存放与储存管理无关的物品。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(XII) Items irrelevant to storage management shall not be stored in the storage area of drugs."
    },
    {
        "instruction":"已知信息：\n'分子或离子在外界电场作用下，正负电荷中心发生偏移而产生极性或增强极性的现象。'可被翻译为：A phenomenon in which the center of the positive and negative charges of a molecule or ion shifts under the action of an external electric field, resulting in polarity or enhanced polarity.\n\n根据上述已知信息，请将'由于极性键的存在使分子的其他G键电子发生偏移的现象。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Due to the existence of polar bonds, the other G-bond electrons of the molecule are offset."
    },
    {
        "instruction":"已知信息：\n'(良好的贸易和分销规范)是质量保证的一部分，通过对贸易和分销过程中发生的众多活动进行充分控制，确保药品质量得到保持。'可被翻译为：(Good trade and distribution practices are) that part of quality assurance that ensures that the quality of pharmaceutical products is maintained by means of adequate control throughout the numerous activities which occur during the trade and the distribution process.\n\n根据上述已知信息，请将'根据HACCP原则编制的文件，以确保在生产和供应链中对药品质量有重要影响的危害得到控制。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A document prepared in accordance with the principles of HACCP to ensure the control of hazards which are significant for pharmaceutical quality in the production and supply chain."
    },
    {
        "instruction":"已知信息：\n'对批准疫苗注册申请时提出进一步研究要求的，疫苗持有人应当在规定期限内完成研究。'可被翻译为：Where further studies are required when approval is given to a vaccine registration application, the vaccine MAH shall complete the studies within the specified period.\n\n根据上述已知信息，请将'对批准疫苗注册申请时提出进一步研究要求的疫苗，疫苗上市许可持有人应当在规定期限内完成研究；逾期未完成研究或者不能证明其获益大于风险的，国务院药品监督管理部门应当依法处理，直至注销该疫苗的药品注册证书。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Where further study is required when a vaccine's registration application is approved, the vaccine MAH shall complete the study within the prescribed time limit; where the study fails to be completed on time or fails to prove that the benefits outweigh the risks, the drug regulatory department under the State Council shall take actions in accordance with law up to revoke the vaccine's registration certificate."
    },
    {
        "instruction":"已知信息：\n'细胞的冷冻保存'可被翻译为：CRYOPRESERVATION OF CELLS\n\n根据上述已知信息，请将'冷冻保存之前对细胞条件进行优化是获得成功的关键。预冻处理的性质和程度取决于为保存而收获的原始细胞的状态、细胞悬液的组成及冷冻保存的特定处理步骤。预冷冻过程可能包括亚种群的选择、体外扩增或激活或启动因子孵育。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Optimizing the condition of the cells immediately before cryopreservation is critical to a successful outcome. The nature and extent of prefreeze processing depends onthe state of the original cells harvested for preservation, the composition of the cell suspension, and the specific processing steps leading into cryopreservation.Prefreeze processing may include selection of subpopulations, ex vivo expansion, or incubation with activating or priming factors."
    },
    {
        "instruction":"已知信息：\n'一次性系统（SUS）：使用一次性的产品接触组件代替可重复使用的设备的系统，例如不锈钢输送线或散 装容器。本文件中的 SUS 是指那些用于无菌产品生产的 SUS ，通常由一次性组组件组成，例如袋子、过滤器、管子、接头、储瓶和传感器。'可被翻译为：Single Use Systems (SUS) - Systems in which product contact components are used only once to replace reusable equipment such as stainless steel transfer lines or bulk containers. SUS covered in this document are those that are used in manufacturing processes of sterile products and are typically made up of disposable components such as bags, filters, tubing, connectors, storage bottles and sensors.\n\n根据上述已知信息，请将'应建立并执行 SUS 可接受标准，可接受标准应与产品和工艺的风险或关键性相适应。接收时，应对每件 SUS 进行检查以确保其按照已批准的质量标准生产、供应和交付。应在使用前对外包装（例如外包装盒、产品袋的外观）、标签印刷进行目检，审核所附文件（例如，合格证书和灭菌证明），并形成文件记录。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Acceptance criteria should be established and implemented for SUS corresponding to the risks or criticality of the products and its processes. On receipt, each piece of SUS should be checked to ensure that they have been manufactured, supplied and delivered in accordance with the approved specification. A visual inspection of the outer packaging  (e.g.  appearance of exterior carton, product pouches), label printing,  and review  of attached documents (e.g. certificate of conformance and proof of sterilisation) should be carried out and documented prior to use."
    },
    {
        "instruction":"已知信息：\n'清除率'可被翻译为：clearance\n\n根据上述已知信息，请将'附录 B 详细列出了可以使用的不同清除技术，以及不使用洗脱液清除样品中微生物的替代方法。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Annex B has a comprehensive list of the different removal techniques that can be employed and alternatives for samples where removal of microorganisms by elution is not used."
    },
    {
        "instruction":"已知信息：\n'（一）所使用的试验用医疗器械的信息，包括名称、型号、规格、接收日期、批号或者系列号等；'可被翻译为：(1) The information of the investigational medical device, including name, model, specification, date of receipt, lot number or serial number;\n\n根据上述已知信息，请将'（三）每个受试者使用试验用医疗器械的记录，包括每次使用的日期、时间、试验用医疗器械的状态等；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(3) Using records of the investigational medical device by each subject, including the date and time of each use and the state of the investigational medical device;"
    },
    {
        "instruction":"已知信息：\n'如果有足够的测试单元可用，则系统控制的首选是实际产品。为了设计合适的无菌 测试而必须牺牲复杂的医疗器械时，在清洁、重新包装和灭菌后，可以考虑将其用 于系统控制。'可被翻译为：The first choice for the system control is the actual product, if enough test units are available. When complex medical devices must be sacrificed in order to design a suitable sterility test, consider using them for a system control after cleaning, repacking and sterilizing.\n\n根据上述已知信息，请将'在设计无菌检测的“系统控制”时，必须注意尽可能多的复制样品产品的大部分。 以新颖和创新的方式满足这些要求，使系统控制有意义。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In designing \"system controls\" for sterility testing, care must be taken to duplicate the sample product for most aspects, as nearly as possible. Be novel and innovative to meet this requirement and make the system control meaningful."
    },
    {
        "instruction":"已知信息：\n'正交设计'可被翻译为：orthogonal design\n\n根据上述已知信息，请将'研究多因素多水平的一种设计方法。它是根据正交性从全面试验中挑选出部分有代表性的点进行试验，这些有代表性的点具备了\"均匀分散，齐整可比”的特点，正交试验 设计是分式析因设计的主要方法。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A design method to study multi-factors and multi-levels. It is to select some representative points from the comprehensive test according to the orthogonality, these representative points have the characteristics of \"uniform dispersion, uniform comparison\", orthogonal experimental design is the main method of fractional factorial design."
    },
    {
        "instruction":"已知信息：\n'包括可预测地将温度保持在与周围环境不同的水平上，但不是主动或被动地控制在精确的预定义限制内的任何环境。'可被翻译为：Includes any environment in which the temperature is predictably maintained at a level different from that of the surrounding environment, but is not actively or passively controlled within precise predefined limits.\n\n根据上述已知信息，请将'包括温度被主动或被动控制在与周围环境不同的水平上的任何环境，其温度在精确的预定义限制范围内。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Includes any environment in which the temperature is actively or passively controlled at a level different from that of the surrounding environment within precise predefined limits."
    },
    {
        "instruction":"已知信息：\n'2020年1月16日，国家药监局、海关总署和市场监管总局联合发布了《关于实施〈进口药材管理办法〉及有关事项的公告》，明确了关于首次进口药材的申请和审批、进口药材的备案和口岸检验问题。'可被翻译为：On January 16, 2020, the National Medical Products Administration, the General Administration of Customs and the State Administration for Market Regulation issued the Announcement on Implementing the Measures for the Administration of Imported Medicinal Materials and related matters to clarify issues pertaining to the application and approval of initial import, record filing and port inspection of imported medicinal materials.\n\n根据上述已知信息，请将'国家药监局 海关总署 市场监管总局关于实施《进口药材管理办法》有关事项的公告'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Announcement of NMPA, GAC, and SAMR on Implementing the Measures for the Administration of Imported Medicinal Materials"
    },
    {
        "instruction":"已知信息：\n'1类：境内外均未上市的创新药。指含含有新的结构明确的、具有药理作用的化合物，且具有临床价值的药品。'可被翻译为：Class 1: Innovative drugs that have not been marketed in China or overseas. They refer to drugs that contain new compounds with clear structures and pharmacological effects, and have clinical values.\n\n根据上述已知信息，请将'（一）化学药品1类为创新药，应含有新的结构明确的、具有药理作用的化合物，且具有临床价值，不包括改良型新药中2.1类的药品。含有新的结构明确的、具有药理作用的化合物的新复方制剂，应按照化学药品1类申报。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(1) Class 1 chemical drugs are innovative drugs that contain new compounds with clear structures and pharmacological effects and have clinical values. Class 2.1 drugs in modified new drugs are not included. New compound preparations containing new compounds with clear structures and pharmacological effects shall be applied in accordance with Class 1 chemical drugs."
    },
    {
        "instruction":"已知信息：\n'本办法第十条规定情形以外的药品，抽样完成后，口岸药品检验所应当在进口单位持有的《进口药品通关单》原件上注明“已抽样”的字样，并加盖抽样单位的公章。'可被翻译为：In the case of drugs other than those specified in Article 10 of the Provisions, when sampling is completed, the drug control institute of port shall indicate \"Sampled\" on the original Import Drug Note held by the importer, and affix the seal of sampling entity.\n\n根据上述已知信息，请将'第二十三条 口岸药品检验机构应当对产地证明原件和药材实际到货情况与口岸药品监督管理部门提供的备案资料的一致性进行核查。符合要求的，予以抽样，填写进口药材抽样记录单，在进口单位持有的进口药品通关单原件上注明“已抽样”字样，并加盖抽样单位公章；不符合要求的，不予抽样，并在2日内报告所在地口岸药品监督管理部门。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 23 Drug control institutions of ports shall check the consistency of the original certificate of the place of production and actual arrival of crude drugs with the filing materials provided by drug regulatory departments of ports. For those meeting the requirements, the sampling shall be conducted, the sampling record for importation of crude drugs shall be filled out, and the original Drug Import Note held by the importers shall be marked with \"Sampling Completed\" and stamped with the official seal of the sampling unit; for those not meeting the requirements, the sampling will not be conducted and the information shall be reported to local drug regulatory departments of ports within 2 days."
    },
    {
        "instruction":"已知信息：\n'在无菌性测试中所用的每种培养基（THIO和SCD）管在整个检测时间段内均需 直接暴露于测试环境中（例如，层流罩）。或者，实验室可使用节b中详细说明 的琼脂沉淀板。'可被翻译为：Tubes of each medium (THIO and SCD) used in the sterility analysis are exposed to the immediate environment of the test (e.g., laminar flow hood) for the duration of the test. Alternatively, a laboratory may use agar settling plates as detailed in section b.\n\n根据上述已知信息，请将'USP 分析手术敷料\/棉花\/纱布（包装内）的方法要求最少 100 mg，在每种培养基中进行 测试。对于单独包装的一次性用品，建议在每种培养基中对整个单元进行测试。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The USP method for analysis of surgical dressing\/cotton\/gauze (in packages) calls for a minimum quantity of 100 mg, to be tested in each medium. It is recommended that an entire unit shall be tested in each medium for individually packaged single-use articles."
    },
    {
        "instruction":"已知信息：\n'通告进一步声明，2020年10月1日起生产的医疗器械，在其上市销售前，注册人应当按照相关标准或规范要求，将最小销售单元的产品标识及相关数据上传到医疗器械唯一标识数据库；任何相关数据发生变化的，应当保证数据的变更和更新。当医疗器械最小销售单元的产品标识发生变化时，应根据新增的产品标识，将数据上传到医疗器械唯一标识数据库。'可被翻译为：The Announcement further states that, before the sale of medical devices produced since October 1, 2020, the registrant shall, in accordance with the relevant standards or specifications, upload the product identification and related data of the minimum sales unit and higher-level packaging to the unique identification database of medical devices; and ensure data alteration and update where any data related changes arise. When the product identification of the minimum sales unit of the medical device changes, the data should be uploaded to the unique identification database per the newly added product identification.\n\n根据上述已知信息，请将'注册人\/备案人应当在产品上市销售前，将产品标识和相关数据上传至医疗器械唯一标识数据库。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Registrant\/filing entities shall upload UDI-DI and relevant data into the UDID prior to marketing and sales of the product."
    },
    {
        "instruction":"已知信息：\n'专供滴入鼻腔内使用的液体制剂。'可被翻译为：A liquid preparation intended for use by drops into the nasal cavity.\n\n根据上述已知信息，请将'经肛门灌入直肠使用的液体制剂。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A liquid preparation for use by anal injection into the rectum."
    },
    {
        "instruction":"已知信息：\n'1.当档案(申请)基于等效性证据而不是通过体内等效性试验获得批准时，术语生物豁免适用于监管药物批准过程。\n2.当档案(申请)基于等效性证据而不是通过体内等效性试验获得批准时，术语生物豁免适用于监管药品批准过程。'可被翻译为：1.The term biowaiver is applied to a regulatory drug approval process when the dossier (application) is approved based on evidence of equivalence other than through in vivo equivalence testing.\n2.The term biowaiver is applied to a regulatory pharmaceutical product approval process when the dossier (application) is approved based on evidence of equivalence other than through in vivo equivalence testing.\n\n根据上述已知信息，请将'二、申请豁免进行人体生物等效性试验，须在申请表中注明。经评审不能豁免，实质缺陷不能纠正的，不要求申请人提供补充材料，不予批准注册申请。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"II. Applying for exemption from human bio equivalence tests shall be indicated in the application form. If the exemption cannot be made after evaluation, and the substantial defects cannot be corrected, the applicant will not be required to provide supplementary materials, and the registration application shall be disapproved."
    },
    {
        "instruction":"已知信息：\n'违反本法规定，批签发机构未按照规定发给批签发证明或者不予批签发通知书的，由国务院药品监督管理部门责令改正，给予警告，对主要负责人、直接负责的主管人员和其他直接责任人员依法给予降级或者撤职处分；情节严重的，对主要负责人、直接负责的主管人员和其他直接责任人员依法给予开除处分。'可被翻译为：If a lot release institution fails to issue a lot release certificate or a not-release notice in violation of this Law, the drug regulatory department under the State Council shall order to make rectifications and give a warning to the said institution, and give a downgrade or dismissal as punishment to the main responsible person, executive in charge, and other directly responsible personnel according to law; and in serious circumstances, an expulsion from organization.\n\n根据上述已知信息，请将'第八十四条 违反本法规定，批签发机构有下列情形之一的，由国务院药品监督管理部门责令改正，给予警告，对主要负责人、直接负责的主管人员和其他直接责任人员依法给予警告直至降级处分：'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 84 Where a lot release institution has one of the following circumstances in violation of this Law, the drug regulatory department under the State Council shall order to make rectifications and give a warning to the said institution, and give warnings until downgrade as punishment to the principal, director in charge and other directly responsible personnel:"
    },
    {
        "instruction":"已知信息：\n'同样，由于微生物本身的坚固性，它不需要像动物细胞系那样严格地控制冷却速率。因此，冷冻系统或方法的选择对细胞库的生存力影响较小。可简单地将冷冻容器转移到大约-80°的冰箱中过夜，然后转移到气相液氮中。或者，微生物细胞库不使用液氮存储，也可以存储在约-80°冰箱中。但是，如果可以使用液氮对于微生物长期储存（例如，几年）是比较好的选择。如果使用控制速率的冷冻器，那么它应该完全有能力在预期范围内提供统一的冷却速率，例如，1°-5°\/min。'可被翻译为：Again,because of their inherent robustness, microbial cells do not require as strict control of cooling rate as do animal cell lines. Consequently, the choice of freezing system or method has a smaller effect on the viability of the cell bank. Filled cryocontainers simply can be transferred into an approximately −80° freezer overnight followed by transfer to vapor phase liquid nitrogen. Alternatively, microbial cell banks may not use liquid nitrogen storage but can be stored at approximately−80°. However, if liquid-nitrogen storage is available, it is preferred for long-term storage (e.g., years). If acontrolled-rate freezer is employed, then it should be fully qualitied to deliver a uniform cooling rate that is within an expected range, e.g.,1°–5°\/min.\n\n根据上述已知信息，请将'对于微生物细胞而言，控制冷却和升温的速度并不那么重要，但是仍然应使用温水浴（例如30°–35°）尽快融化细胞。可以将温度调节至菌株的孵育温度。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Controllingthe rates of cooling and warming is less critical for microbial cells, but thecells still should be thawed as quickly as possible using a warm water bath(e.g., 30°–35°). Temperatures can be adjusted to the incubation temperature ofthe strain."
    },
    {
        "instruction":"已知信息：\n'第一百六十五条 物料的质量标准一般应当包括：'可被翻译为：Article 165: Specifications for materials should include, if applicable:\n\n根据上述已知信息，请将'第一百八十九条 在生产的每一阶段，应当保护产品和物料免受微生物和其他污染。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 189: At every stage of processing, products and materials should be protected from microbial and other contamination."
    },
    {
        "instruction":"已知信息：\n'第七十七条 企业应当按照验收规定，对每次到货药品进行逐批抽样验收，抽取的样品应当具有代表性：'可被翻译为：Article 77 Enterprises shall carry out sampling inspection for acceptance lot by lot for drugs of each arrival in accordance with the provisions on acceptance inspection, and the samples taken shall be representative:\n\n根据上述已知信息，请将'第七十二条 企业应当按照规定的程序和要求对到货药品逐批进行收货、验收，防止不合格药品入库。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 72 Enterprises shall, in accordance with the prescribed procedures and requirements, receive and inspect the arrived drugs lot by lot, so as to prevent unqualified drugs from being warehoused."
    },
    {
        "instruction":"已知信息：\n'血浆中药物浓度下降一半所需的时间。'可被翻译为：The time it takes for the concentration of the drug in the plasma to drop by half.\n\n根据上述已知信息，请将'在缺乏血小板的血浆中加入过量的组织因子后，凝血酶原转化为凝血酶导致血浆凝固所需的时间。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The time required for the conversion of prothrombin to thrombin resulting in plasma clotting after the addition of an excess of tissue factors to platelet-deficient plasma."
    },
    {
        "instruction":"已知信息：\n'注：无热源移液管、微量移液头、试管和其它用品均有商业化产品可及。'可被翻译为：NOTE: Pyrogen free pipettes, micropipettor tips, test tubes, and other accessories are commercially available.\n\n根据上述已知信息，请将'标准实验室玻璃仪器如烧杯、漏斗、烧瓶、圆颈培养瓶和1-2升的瓶子也是必须的。一 次性无菌设备，如试管 、培养皿和血清移液管，只要不影响效价检测的定量就可以一直 使用。其它设备包括不锈钢瓶、比色皿、血清移液管、单通道微量移液器、pH计、加热 板、可调温水浴锅、培养箱和手动\/自动平板计数器或紫外可见分光光度计。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Standard laboratory glassware such as beakers, funnels, flasks, roux and 1-2 liter bottles are also required. Sterile and disposable equipment such as test tubes, petri-plates and serological pipettes may be used so long as the use of this equipment does not affect the quantitative aspect of potency testing. Additional equipment includes a stainless steel penicylinders, penicylinder dropper, cuvettes, pipettor and micropipette, pH meter, hot plate, adjustable- temperature water bath, incubator and a manual\/automatic plate reader or UV- VIS spectrophotometer."
    },
    {
        "instruction":"已知信息：\n'2019年，国家医疗器械不良事件监测信息系统接收可疑医疗器械不良事件报告39万余份，每百万人口平均报告数为297份，全国96.70%的区县报告了医疗器械不良事件，系统基层注册用户达到31万余家，其中医疗器械注册人达19662家。与2018年相比，全国医疗器械不良事件报告数量保持平稳，系统基层注册用户数量持续增加，新旧医疗器械不良事件监测信息系统实现平稳过渡。'可被翻译为：In 2019, the National Medical Device Adverse Event Monitoring Information System received more than 390,000 reports of suspected medical device adverse events,with an average number of 297 reports per million population; 96.70 percent of districts and counties across China reported medical device adverse events, and the registered users at the grassroots level of the system topped 310,000, covering 19,662 medical device registrants. Compared with 2018, the number of medical device adverse event reports nationwide has remained stable, the number of registered users at the grassroots level of the system has continued to increase, and a smooth transition has been achieved from the old to the new medical device adverse event monitoring information system.\n\n根据上述已知信息，请将'2018年，全国医疗器械不良事件监测信息系统接收可疑医疗器械不良事件报告40余万份，报告质量得到提高。系统基层注册用户达到27万余家，其中生产企业1.3万余家，较去年增长16.44%。全国95.9%的区县报告了医疗器械不良事件，每百万人口平均报告数为305份。此外，国家药品不良反应监测中心完成医疗器械不良事件监测新信息系统的搭建测试，实现了我国医疗器械不良事件在线报告系统的新旧更替，为《医疗器械不良事件监测和再评价管理办法》(以下简称《办法》)的贯彻落实提供有力支撑。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In 2018, the Information System for National Medical Device Adverse Event Monitoring has received more than 400,000 Reports for Suspected Adverse Events of Medical Devices, and the quality of the reports was improved. There are more than 270,000registered users at the grassroots level of the system, of which more than 13,000 are manufacturers, an increase of 16.44% over last year. 95.9% of districts and counties across China reported medical device adverse events,with an average of 305 reports per million people. In addition, the National Center for Adverse Drug Reaction Monitoring completed the establishment of a new information system for monitoring adverse events in medical devices, realizing the replacement of the online reporting system for such events in China,provide strong support for the implementation of the Administrative Measures for Monitoring and Re-evaluating the Adverse Events of Medical Devices (hereinafter referred to as the Measures) ."
    },
    {
        "instruction":"已知信息：\n'第十九条 检查组认为证据可能灭失或者以后难以取得的，以及需要采取行政强制措施的，可以通知被检查单位所在地食品药品监督管理部门。被检查单位所在地食品药品监督管理部门应当依法采取证据保全或者行政强制措施。'可被翻译为：Article 19 Where the inspection team deems that evidence may be lost or difficult to acquire afterwards, and administrative compulsory measures need to be taken, it may notify the local food and drug regulatory department. The local food and drug regulatory department shall take evidence preservation or administrative compulsory measures in accordance with laws and regulations.\n\n根据上述已知信息，请将'需要采取风险控制措施的，被检查单位应当按照食品药品监督管理部门的要求采取相应措施。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Where risk control measures need to be taken, the organization being inspected shall conduct corresponding measures in accordance with the requirements of the food and drug regulatory department."
    },
    {
        "instruction":"已知信息：\n'通过物理作用使菌种发生遗传信息改变的物质。'可被翻译为：A substance that changes the genetic information of a strain by physical action.\n\n根据上述已知信息，请将'通过化学作用使菌种发生遗传信息改变的物质。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A substance that causes the genetic information of a strain to be altered by chemical action."
    },
    {
        "instruction":"已知信息：\n'用元素符号表示物质分子的组成及分子量的化学式。'可被翻译为：A chemical formula in which the constituent and molecular weight of a substance are expressed by an element symbol.\n\n根据上述已知信息，请将'表示物质分子扩散程度的物理量。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A physical quantity indicating the degree of diffusion of the molecules of a substance."
    },
    {
        "instruction":"已知信息：\n'第一百二十四条 省、自治区、直辖市药品监督管理部门应当自受理申请之日起6个月内对药品再注册申请进行审查，符合规定的，予以再注册；不符合规定的，报国家食品药品监督管理局。'可被翻译为：Article 124 Drug regulatory departments of provinces, autonomous regions, or municipalities directly under the Central Government shall review the application dossiers within six months starting from the date of acceptance, and approve the re-registration application if regulations are conformed to, or report to the State Food and Drug Administration if regulations are not conformed to.\n\n根据上述已知信息，请将'第一百二十五条 进口药品的再注册申请由国家食品药品监督管理局受理，并在6个月内完成审查，符合规定的，予以再注册；不符合规定的，发出不予再注册的通知，并说明理由。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 125 The State Food and Drug Administration shall deal with import drug re-registration applications, complete the review within six months, and approve the re-registration application if regulations are conformed to, or issue a non-acceptance notice, in which reasons shall be given, if regulations are not conformed to."
    },
    {
        "instruction":"已知信息：\n'接受了外源遗传物质（如质粒DNA等）使遗传特性发生了改变的细菌。可以通过选择培养液等方法鉴定获得。'可被翻译为：Bacteria that have received foreign genetic material (such as plasmid DNA) that has altered their genetic characteristics. It can be identified by selecting culture medium, etc.\n\n根据上述已知信息，请将'能够进行独立复制的单位，如质粒DNA等。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A unit, such as plasmid DNA, that is capable of independent replication."
    },
    {
        "instruction":"已知信息：\n'在2020年7月1日前，已受理但尚未批准的药品生产许可申请，按照新《生产办法》的有关规定进行办理。'可被翻译为：Applications for drug production licenses that have been accepted before July 1, 2020 but not yet approved afterwards shall be processed in accordance with the relevant provisions of the new Production Provisions.\n\n根据上述已知信息，请将'一、自2020年7月1日起，从事制剂、原料药、中药饮片生产活动的申请人，在申请新的药品生产许可时，应当按照《生产办法》有关规定办理。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1. From July 1, 2020, applicants engaged in the production of preparations, APIs, and TCM slices should follow the relevant provisions of the Production Provisions while applying new for drug production licenses."
    },
    {
        "instruction":"已知信息：\n'第一百七十三条 原版空白的批生产记录应当经生产管理负责人和质量管理负责人审核和批准。批生产记录的复制和发放均应当按照操作规程进行控制并有记录，每批产品的生产只能发放一份原版空白批生产记录的复制件。'可被翻译为：Article 173: The master batch processing records should be reviewed and approved by the heads of production and quality management. The reproduction and issuance should be managed and recorded according to operation procedures, and only one copy of reproduced master records can be issued for the manufacture of each batch.\n\n根据上述已知信息，请将'第一百七十八条 批包装记录应当有待包装产品的批号、数量以及成品的批号和计划数量。原版空白的批包装记录的审核、批准、复制和发放的要求与原版空白的批生产记录相同。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 178: The batch packaging record should carry the batch number and the quantity of bulk product, as well as the batch number and the planned quantity of finished product. The requirements of review, approval, reproducing and issuance of original blank batch packaging record is the same as that of original blank batch processing record."
    },
    {
        "instruction":"已知信息：\n'第六十四条  药品监督管理部门及其工作人员在监督检查中，应当严格规范公正文明执法，严格执行廉政纪律，不得索取或者收受财物，不得谋取其他利益，不得妨碍企业的正常经营活动。'可被翻译为：Article 64 During the supervision and inspection, the drug regulatory departments and their staff shall enforce the law in a strict, procedure-based, impartial and non-abusive manner, and strictly enforce the discipline of clean government, shall not ask for or accept property, seek for other interests, or hinder normal distribution activities of the enterprises.\n\n根据上述已知信息，请将'第七十二条  药品监督管理部门及其工作人员在监督检查中，应当严格规范公正文明执法，严格执行廉政纪律，不得索取或者收受财物，不得谋取其他利益，不得妨碍企业的正常生产活动。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 72 During the supervision and inspection, the drug regulatory departments and their staff shall enforce the law in a strict, procedure-based, impartial and non-abusive manner, strictly enforce the discipline of clean government, and shall not ask for or accept property, seek for other interests, or hinder normal manufacturing activities of the enterprises."
    },
    {
        "instruction":"已知信息：\n'第十七条 药品生产企业在启动药品召回后，一级召回在1日内，二级召回在3日内，三级召回在7日内，应当将调查评估报告和召回计划提交给所在地省、自治区、直辖市药品监督管理部门备案。省、自治区、直辖市药品监督管理部门应当将收到一级药品召回的调查评估报告和召回计划报告国家食品药品监督管理局。'可被翻译为：Article 17 After starting the drug recall procedure, the drug manufacturer shall submit the investigation and assessment reports and recall plan to the local drug regulatory department of the province, autonomous region or municipality directly under the Central Government for record within 1 day in the case of Class 1 recall, 3 days in the case of Class 2 recall and 7 days in the case of Class 3 recall. The local drug regulatory department of the province, autonomous region or municipality directly under the Central Government shall submit the received investigation and assessment reports and plan for Class 1 recall to the State Food and Drug Administration.\n\n根据上述已知信息，请将'第二十一条 药品生产企业在实施召回的过程中，一级召回每日，二级召回每3日，三级召回每7日，向所在地省、自治区、直辖市药品监督管理部门报告药品召回进展情况。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 21 During implementation of the recall, the drug manufacturer shall give updates to the local drug regulatory department of the province, autonomous region or municipality directly under the Central Government on the recall progress daily in the case of Class 1 recall, every 3 days in the case of Class 2 recall and every 7 days in the case of Class 3 recall."
    },
    {
        "instruction":"已知信息：\n'第六十四条 实验室的设计应当确保其适用于预定的用途，并能够避免混淆和交叉污染，应当有足够的区域用于样品处置、留样和稳定性考察样品的存放以及记录的保存。'可被翻译为：Article 64: Laboratories should be designed to suit its intended use and avoid mixups and cross-contamination. There should be adequate space for samples handling, storage of retention and stability samples, and storage of records.\n\n根据上述已知信息，请将'第二百二十五条 企业按规定保存的、用于药品质量追溯或调查的物料、产品样品为留样。用于产品稳定性考察的样品不属于留样。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 225: The reference samples are materials or products that are being kept by the manufacturer according to the operation procedures for quality traceability or investigation. Samples for product stability study are not reference samples."
    },
    {
        "instruction":"已知信息：\n'（二）因化妆品质量安全违法行为被公安机关拘留或者给予其他治安管理处罚的；'可被翻译为：(2) those who are arrested or receive other public security punishment by the public security authorities due to illegal act related with quality and safety of cosmetics;\n\n根据上述已知信息，请将'（一）因化妆品质量安全相关犯罪被人民法院判处刑罚的；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(1) those who are sentenced to penalties by the People’s Court due to crime related with quality and safety of cosmetics;"
    },
    {
        "instruction":"已知信息：\n'第八十条 应当制定设备的预防性维护计划和操作规程，设备的维护和维修应当有相应的记录。'可被翻译为：Article 80: Preventive maintenance plans and procedures should be established, and the maintenance and repair activities should be recorded.\n\n根据上述已知信息，请将'预防性维护——按照确保没有额外污染风险的标准，对设备、公用设施和厂房进行维护（包括计划内和计划外维护）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Preventative maintenance - maintaining equipment, utilities and premises (planned and unplanned\nmaintenance) to a standard that will ensure there is no additional risk of contamination."
    },
    {
        "instruction":"已知信息：\n'含有原液并通常与辅料放在一起的一种药品类型。'可被翻译为：A pharmaceutical product type that contains a drug substance, generally, in association with excipients.\n\n根据上述已知信息，请将'可与辅料一起生产制剂的未经配方的药物。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The unformulated drug substance that may subsequently be formulated with excipients to produce the dosage form."
    },
    {
        "instruction":"已知信息：\n'已经备案的产品不再生产或者进口的，备案人应当及时报告承担备案管理工作的药品监督管理部门取消备案。'可被翻译为：If the products that have been filed are no longer produced or imported, the filing person shall promptly report to the drug regulatory department responsible for the filing administration for cancelling the filing.\n\n根据上述已知信息，请将'第四十二条 已经注册的产品不再生产或者进口的，注册人应当主动申请注销注册证。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 42 If the registered product is no longer produced or imported, the registrant shall take the initiative to apply for cancellation of the registration license."
    },
    {
        "instruction":"已知信息：\n'在生产、取样、包装或重新包装、贮存或运输等操作过程中，原辅料、中间产品、待包装产品、成品受到具有化学或微生物特性的杂质或异物的不利影响。'可被翻译为：Adverse impacts of impurities with chemical or microbiological properties or foreign matters, into starting materials, intermediate, bulk, or finished products during production, sampling, packaging or repackaging, storage or transport.\n\n根据上述已知信息，请将'在生产、抽样，包装或重新包装、贮存或运输过程中混入原材料、中间体或 API 中，具有化学或微生物性质的杂质或外来物质。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The undesired introduction of impurities of a chemical or microbiological nature, or of foreign matter, into or onto a raw material, intermediate, or API during production, sampling, packaging or repackaging, storage or transport."
    },
    {
        "instruction":"已知信息：\n'质谱进样器之一。由阀、贮槽和针孔漏组成。'可被翻译为：One of the mass spectrometry sampler. It consists of a valve, a storage tank and a pinhole leak.\n\n根据上述已知信息，请将'质谱进样器之一。主要用于固体样品及高沸点液体样品的进样。将微克(Rg)量样品置于末端封闭的毛细管底部，插入进样杆顶端。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"One of the mass spectrometry samplers. It is mainly used for solid samples and high boiling point liquid samples. Place the microgram (Rg) measure sample at the bottom of the capillary tube with closed end and insert it into the top of the injector rod."
    },
    {
        "instruction":"已知信息：\n'活性药物成分 （API）：准备用于制剂生产成为其中活性成分的物质或其混合物。此类物质用于改变药效活性或其它直接影响诊断、治愈、缓解、治疗或预防疾病影响或影响人体结构和功能。'可被翻译为：active pharmaceutical ingredient (API). Any substance or mixture of substances intended to be used in the manufacture of a pharmaceutical dosage form and that, when so used, becomes an active ingredient of that pharmaceutical dosage form. Such substances are intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease, or to affect the structure and function of the body.\n\n根据上述已知信息，请将'任何旨在供生产一种药物(医疗用品)制剂，并作为其活性成份的物质或混合物。这类物质旨在疾病的诊断，治疗、缓减，处置或预防以及影响人体的结构和功能等方面发挥药理作用或其它的直接效应。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Any substance or mixture of substances intended to be used in the manufacture of a drug (medicinal) product and that, when used in the production of a drug, becomes an active ingredient of the drug product. Such substances are intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure and function of the body."
    },
    {
        "instruction":"已知信息：\n'（三）每批药品均应当由质量受权人签名批准放行。'可被翻译为：3. The release of each batch of products should be approved with signature by the Qualified Person.\n\n根据上述已知信息，请将'（三）物料应当由指定人员签名批准放行。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"3. The release of materials should be approved with signature by a designated person."
    },
    {
        "instruction":"已知信息：\n'除菌级过滤器：一种经过适当验证、可以去除液体或气体中的特定微生物以得到无菌滤液的过滤器。通常这种过滤器的孔径等于或小于 0.22μm。'可被翻译为：Sterilising grade filter - A filter that, when appropriately validated, will remove a defined microbial challenge\nfrom a fluid or gas producing a sterile effluent. Usually such filters have a pore size equal or less than 0.22μm.\n\n根据上述已知信息，请将'一种过滤器，经过适当验证后，将从产生无菌流出物的流体或气体中去除特定的微生物挑战。通常这种过滤器的孔径等于或小于0.22微米(µm)。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A filter that, when appropriately validated, will remove a defined microbial challenge from a fluid or gas producing a sterile effluent. Usually such filters have a pore size equal to or less than 0.22 micrometres (µm)."
    },
    {
        "instruction":"已知信息：\n'第五十六条 化妆品、化妆品新原料注册人未按照本办法规定申请特殊化妆品、化妆品新原料变更注册的，由原发证的药品监督管理部门责令改正，给予警告，处1万元以上3万元以下罚款。'可被翻译为：Article 56 If the registrant of cosmetics and new cosmetic ingredients fails to apply for the change of registration for special cosmetics and new cosmetic ingredients in accordance with the requirements of these Provisions, the drug regulatory department that originally issued the license shall give an order for rectification, give a disciplinary warning, and impose a fine of not less than 10,000 yuan but no more than 30,000 yuan.\n\n根据上述已知信息，请将'化妆品、化妆品新原料备案人未按照本办法规定更新普通化妆品、化妆品新原料备案信息的，由承担备案管理工作的药品监督管理部门责令改正，给予警告，处5000元以上3万元以下罚款。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"If the filing person of cosmetics and new cosmetics ingredients fails to update the filing information of general cosmetics and new cosmetics ingredients in accordance with the requirements of these Provisions, the drug regulatory department responsible for the filing administration shall order corrections, give warnings, and impose a fine of no less than 5,000 yuan but no more than 30,000 yuan."
    },
    {
        "instruction":"已知信息：\n'计算机科学与心理学相结合而产生的研究用计算机实现人的智能行为和功能的一门学科。人工智能的智能范畴一般包括人的智能行为，如图像和声音识别、学习、计划、决策、解决问题、自然语言理解等。'可被翻译为：The combination of computer science and psychology is the study of the use of computers to implement human intelligent behavior and function. The intelligence category of artificial intelligence generally includes human intelligent behavior, such as image and sound recognition, learning, planning, decision making, problem solving, natural language understanding, etc.\n\n根据上述已知信息，请将'运用特定领域的专门知识，通过推理来模拟通常由人类专家才能解决的各种复杂的、具体的问题，达到与专家具有同等解决问题能力的计算机智能程序系统。它能对决策的过程做出解释，并有学习功能，即能自动增长解决问题所需的知识。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The use of specialized knowledge in a specific field, through reasoning to simulate a variety of complex, specific problems usually solved by human experts, to achieve and experts have the same problem-solving ability of the computer intelligent program system. It can explain the decision-making process, and has a learning function, that is, it can automatically increase the knowledge needed to solve the problem."
    },
    {
        "instruction":"已知信息：\n'第三十四条 普通化妆品上市或者进口前，备案人按照国家药品监督管理局的要求通过信息服务平台提交备案资料后即完成备案。'可被翻译为：Article 34 Before a general cosmetic is marketed or imported, the filing person shall complete the filing by submitting the filing dossiers through the information service platform as required by the NMPA.\n\n根据上述已知信息，请将'第三十八条 特殊化妆品生产或者进口前，注册申请人应当按照国家药品监督管理局的要求提交申请资料。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 38 Before a special cosmetic is produced or imported, the registrant shall submit the application dossiers as required by the NMPA."
    },
    {
        "instruction":"已知信息：\n'第十五条 国家鼓励疫苗上市许可持有人加大研制和创新资金投入，优化生产工艺，提升质量控制水平，推动疫苗技术进步。'可被翻译为：Article 15 To facilitate the progress of vaccine technology, the State encourages vaccine MAHs to increase capital investment on research, development and innovation, to optimize production process, and to promote quality control level.\n\n根据上述已知信息，请将'国家制定疫苗行业发展规划和产业政策，支持疫苗产业发展和结构优化，鼓励疫苗生产规模化、集约化，不断提升疫苗生产工艺和质量水平。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The State formulates development planning and industry policies for the vaccine industry to support development and structural optimization of the vaccine industry, and encourages scale and intensive production and constant improvement on the production process and quality of vaccines."
    },
    {
        "instruction":"已知信息：\n'中药饮片生产企业销售其生产的中药饮片，应当履行药品上市许可持有人相关义务。'可被翻译为：The manufacturer of prepared slices of Chinese crude drugs shall perform relevant obligations as the MAH of the drug when selling the prepared slices of Chinese crude drugs.\n\n根据上述已知信息，请将'第三十九条 中药饮片生产企业履行药品上市许可持有人的相关义务，对中药饮片生产、销售实行全过程管理，建立中药饮片追溯体系，保证中药饮片安全、有效、可追溯。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 39 Manufacturers of decoction pieces of Chinese medicine shall fulfill relevant obligations of an MAH, and shall implement whole chain management for the manufacture and distribution of decoction pieces of Chinese medicine and establish a traceability system for decoction pieces of Chinese medicine to ensure the safety, efficacy, and traceability thereof."
    },
    {
        "instruction":"已知信息：\n'（四）拆零销售应当使用洁净、卫生的包装，包装上注明药品名称、规格、数量、用法、用量、批号、有效期以及药店名称等内容；'可被翻译为：(IV) For dismantling sales, clean and sanitary package shall be used, on which the name, strength, quantity, usage, dosage, lot number, and expiry date of the drug, and name of the drug store shall be indicated;\n\n根据上述已知信息，请将'贴于药品包装上用于指示药物名称、剂型、装量、用法用量等信息的标志。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A mark affixed to the package of a drug to indicate the name, dosage form, dosage, usage, and other information."
    },
    {
        "instruction":"已知信息：\n'6.临床试验各环节参与人员具有能够承担临床试验工作相应的教育、培训和经验，并得到主要研究者的授权。'可被翻译为：6. The participants in all aspects of clinical trials shall be qualified in education, training and experience correspondingly to undertake the work of clinical trials, and shall be authorized by the principal investigator.\n\n根据上述已知信息，请将'6.参与研究人员应具有研究所需专业知识和资格、工作 经验和培训经历，并应完整保留主要研究人员档案；参与研究的人员应与申报资料一致。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"6. The study personnel should be of adequate knowledge, qualifications, working experience and training to perform their duties in the study, and the personnel files of those who play important roles in the study should be retained completely; the personnel involved in the study should be consistent with that specified in the application dossiers."
    },
    {
        "instruction":"已知信息：\n'新药研制单位依法向药品监督管理部门提出新药相关科学研究结果的一系列申请。新药申请分申请临床研究和申请生产上市两个阶段。'可被翻译为：The research and development unit for a new drug shall submit a series of applications for the results of scientific research related to the new drug to the drug regulatory department in accordance with law. A new drug application is divided into two stages: application for clinical research and application for production and marketing.\n\n根据上述已知信息，请将'生产新药必须经国家药品监督管理部门批准，取得批准文号的过程。新药的申报和审批分为临床研究和生产上市两个阶段。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The process in which the production of a new drug must be approved by the State drug regulatory department and the approval number is obtained. The application and approval of a new drug is divided into two stages: clinical research and production and listing."
    },
    {
        "instruction":"已知信息：\n'主要以机械方式与物料结合的水分。结合力很弱，干燥速度较快。'可被翻译为：Moisture that is mainly mechanically bound to the material. The binding force is very weak and the drying speed is fast.\n\n根据上述已知信息，请将'主要以物理化学方式与物料结合的水分。结合力较强，干燥速度缓慢。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Moisture that binds primarily to the material in a physicochemical manner. The binding force is strong and the drying speed is slow."
    },
    {
        "instruction":"已知信息：\n'疾病预防控制机构、接种单位在接收或者购进疫苗时，应当索取前款规定的证明文件，并保存至疫苗有效期满后不少于五年备查。'可被翻译为：When accepting or purchasing vaccines, disease prevention and control institutions and immunization entities shall ask for the abovementioned supporting documents and keep such documents for no less than five years upon the expiration date of vaccines for reference.\n\n根据上述已知信息，请将'疾病预防控制机构、接种单位、疫苗配送单位应当按照规定，建立真实、准确、完整的接收、购进、储存、配送、供应记录，并保存至疫苗有效期满后不少于五年备查。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Disease prevention and control institutions, immunization entities and vaccine distribution entities shall establish authentic, accurate and complete records of acceptance, purchase, storage, distribution and supply as required, and keep such records for no less than five years upon the expiration date of vaccines for reference."
    },
    {
        "instruction":"已知信息：\n'研究在0.1〜100nm之间的物质组成体系的运动规律、相互作用以及实际应用中相关技术问题的学科。'可被翻译为：The discipline of studying the movement law, interaction and related technical problems in practical application of the material composition system between 0.1 and 100nm.\n\n根据上述已知信息，请将'研究大量粒子（原子、分子）集合的宏观运动规律的学科。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The study of macroscopic laws of motion of large collections of particles (atoms, molecules)."
    },
    {
        "instruction":"已知信息：\n'第六十条  设区的市级负责药品监督管理的部门应当建立并及时更新辖区内医疗器械经营企业信用档案。信用档案中应当包括医疗器械经营企业许可备案、监督检查结果、违法行为查处、质量抽查检验、自查报告、不良行为记录和投诉举报等信息。'可被翻译为：Article 60 The department in charge of drug supervision and administration at the level of a city divided into districts shall establish and promptly update credit files of the medical device distributors within their administrative areas. The credit files shall include information such as a medical device distributor’s licensing or filing, supervision and inspection results, investigation and punishment of illegal acts, sample testing of quality, self-inspection report, records of misconducts, and compliant reporting, etc.\n\n根据上述已知信息，请将'第六十七条  省、自治区、直辖市药品监督管理部门应当建立并及时更新辖区内第二类、第三类医疗器械注册人、受托生产企业信用档案，设区的市级负责药品监督管理的部门应当依法按照职责建立并及时更新辖区内第一类医疗器械备案人、受托生产企业信用档案。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 67 The drug regulatory department of the province, autonomous region, or municipality directly under the central government shall establish and timely update the credit files of the registrant or the contract manufacturer of Class II and Class III medical devices within the jurisdiction area, the department in charge of drug supervision and administration at the level of a city divided into districts shall establish and promptly update the credit files of Class I medical device filing entity or the contract manufacturer within the jurisdiction area according to its duties."
    },
    {
        "instruction":"已知信息：\n'第七条 国家药品监督管理局加强信息化建设，为公众查询化妆品信息提供便利化服务。'可被翻译为：Article 7 The NMPA shall enhance informatization construction, to provide convenient services for the public in inquiring information on cosmetics.\n\n根据上述已知信息，请将'第十条 国家药品监督管理局加强信息化建设，为注册人、备案人提供便利化服务。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 10 The NMPA shall strengthen informatization to provide convenient services for registrants and filing persons."
    },
    {
        "instruction":"已知信息：\n'一个批次的待包装品或成品的所有生产记录。批生产记录能提供该批产品的生产历史，以及与质量有关的情况。'可被翻译为：All production records for a batch of goods to be packaged or finished. Batch production records provide the production history of the batch, as well as information related to quality.\n\n根据上述已知信息，请将'文件记录—审核并取得显示被污染的批次的所有记录副本；确定在“不良”批次前后是否生产了其它批次。审核与受污染批次相关的所有活动和设备。可能有普通水源、混合罐、管着、原料、灭菌器、过滤器等被交叉污染了，将微生物转给后续产品批次。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1. Documentation- Review and obtain copies of all records for lots indicating contamination; determine if there are other lots manufactured either before or after the “bad” lot(s). Review all associated activity and equipment related to the contaminated lot. There may be common water sources, mixing tanks, piping, raw material, sterilizers, filters, etc. that may have been cross contaminated and transferred microbes to subsequent lots of products."
    },
    {
        "instruction":"已知信息：\n'一分子氨基酸的a-竣基和一分子氨基酸的a-氨基脱水缩合形成的酰胺键，即—CO—NH—。'可被翻译为：An amide bond formed by the dehydration condensation of the A-carboxyl group of an amino acid with the A-amino group of an amino acid, that is, -CO-NH --.\n\n根据上述已知信息，请将'由多个氨基酸借肽键线性连接而成。肽键就是氨基酸的a-竣基与相邻的另一氨基酸的a-氨基脱水缩合的共价键。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"It is formed by a linear connection of multiple amino acids by peptide bonds. a peptide bond is a covalent bond in which the A-carboxyl group of an amino acid is dehydrated and condensed with the A-amino group of another adjacent amino acid."
    },
    {
        "instruction":"已知信息：\n'质量体系应包括GXP要求，应用于产品和工艺，包括技术转移的生命周期阶段中。'可被翻译为：6.3. The quality system should incorporate GxP which should be applied to the life cycle stages of the products and processes, including the technology transfer.\n\n根据上述已知信息，请将'技术转移要求由经过培训的具备丰富知识并在质量体系内工作的人员进行规划，有适当的文件记录、有包括所有开发、生产和质量控制（QC）（适用时）的数据和信息。同时还要考虑产品所处生命周期阶段。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.4. A technology transfer requires a planned approach by trained, knowledgeable personnel working within a quality system, with appropriate documentation, data and information covering all aspects of development, production and quality control (QC), as applicable, and considering the stage of the product life cycle."
    },
    {
        "instruction":"已知信息：\n'根据《中华人民共和国广告法》规定，经商国家卫生健康委，同意将《阿尔茨海默病及相关病杂志》列入允许发布处方药广告的医学、药学专业刊物名单'可被翻译为：According to the Advertisement Law of the People's Republic of China, upon the consultation with the National Health Commission, the Journal of Alzheimer’s Disease and Related Diseases is approved to be included in the list of medical and pharmaceutical journals approved to advertise prescription drugs.\n\n根据上述已知信息，请将'国家药监局关于公布允许发布处方药广告的医学药学专业刊物名单的通告'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"NMPA Announcement on Issuing the List of Medical and Pharmaceutical Journals Approved to Advertise Prescription Drugs"
    },
    {
        "instruction":"已知信息：\n'质量风险管理应作为系统性流程执行，用于评估、控制、沟通和回顾风险。'可被翻译为：6.5. Quality risk management should be implemented as a systematic process for the assessment, control, communication and review of risks.\n\n根据上述已知信息，请将'质量风险管理流程的工作水平、正式程度和文件应与风险水平相称。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"6.8. The level of effort, formality and documentation of the quality risk management process should be commensurate with the level of risk."
    },
    {
        "instruction":"已知信息：\n'药品批准上市后，持有人应当按照国家药品监督管理局核准的生产工艺和质量标准生产药品，并按照药品生产质量管理规范要求进行细化和实施。'可被翻译为：After the drug is approved for marketing, the MAH shall manufacture the drug in accordance with the manufacturing process and specifications approved by NMPA, and follow the requirements of Good Manufacturing Practice (GMP) for specifics and implementation.\n\n根据上述已知信息，请将'疫苗上市许可持有人应当按照规定向国家药品监督管理局进行年度报告。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The vaccine MAHs shall, in accordance with the provisions, submit an annual report to the NMPA."
    },
    {
        "instruction":"已知信息：\n'氨基糖'可被翻译为：amino sugar\n\n根据上述已知信息，请将'由氨基糖或氨基环醇与糖组成的抗生素。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"An antibiotic consisting of amino sugars or aminocyclic alcohols combined with sugars."
    },
    {
        "instruction":"已知信息：\n'被吸收入血的毒物随血流转运至组织器官的过程。'可被翻译为：The process by which poison absorbed into the bloodstream is transported by the bloodstream to tissues and organs.\n\n根据上述已知信息，请将'药物吸收后随血液循环到各组织器官中的过程。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The process by which a drug is absorbed and circulates through the bloodstream to various tissues and organs."
    },
    {
        "instruction":"已知信息：\n'信用档案中应当包括生产许可备案和生产产品品种、委托生产、监督检查结果、违法行为查处、质量抽查检验、不良行为记录和投诉举报等信息。'可被翻译为：The credit file shall include manufacturing licensing filing and manufactured product variety, entrusted manufacturing, supervision and inspection results, investigation of illegal acts, sample testing of quality, records of dishonest behaviors and complaint report, etc.\n\n根据上述已知信息，请将'第六十条  设区的市级负责药品监督管理的部门应当建立并及时更新辖区内医疗器械经营企业信用档案。信用档案中应当包括医疗器械经营企业许可备案、监督检查结果、违法行为查处、质量抽查检验、自查报告、不良行为记录和投诉举报等信息。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 60 The department in charge of drug supervision and administration at the level of a city divided into districts shall establish and promptly update credit files of the medical device distributors within their administrative areas. The credit files shall include information such as a medical device distributor’s licensing or filing, supervision and inspection results, investigation and punishment of illegal acts, sample testing of quality, self-inspection report, records of misconducts, and compliant reporting, etc."
    },
    {
        "instruction":"已知信息：\n'第八条 召回药品的生产企业所在地省、自治区、直辖市药品监督管理部门负责药品召回的监督管理工作，其他省、自治区、直辖市药品监督管理部门应当配合、协助做好药品召回的有关工作。'可被翻译为：Article 8 The local drug regulatory department of the province, autonomous region or municipality directly under the Central Government where the manufacturer of the recalled drug is located is responsible for supervising and managing recall of the drug. The drug regulatory departments of other provinces, autonomous regions or municipalities directly under the Central Government shall cooperate and assist in work relating to recall of the drug.\n\n根据上述已知信息，请将'第八条 召回医疗器械的生产企业所在地省、自治区、直辖市食品药品监督管理部门负责医疗器械召回的监督管理，其他省、自治区、直辖市食品药品监督管理部门应当配合做好本行政区域内医疗器械召回的有关工作。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 8 The food and drug regulatory department of the province, autonomous region and municipality directly under the Central Government where the manufacturer of the recalled medical device is located shall be responsible for the supervision and administration of the recall, and the food and drug regulatory departments of other provinces, autonomous regions and municipalities directly under the Central Government shall cooperate in the recall of medical devices within their respective administrative areas."
    },
    {
        "instruction":"已知信息：\n'非脂溶性小分子物质，在特殊膜蛋白质帮助下，由高浓度向低浓度一侧转运的过程。'可被翻译为：The process by which a non-fat-soluble small molecule is transported from one side of the biofilm to the other with the help of special membrane proteins.\n\n根据上述已知信息，请将'非脂溶性或脂溶性很小的物质，借助于细胞膜上的运载蛋白或通道蛋白的帮助，顺浓度梯度和（或）顺电位梯度（电位差）通过细胞膜的转运过程。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Non-fat soluble or very little fat soluble substances, with the help of carrier proteins or channel proteins on the cell membrane, along the concentration gradient and\/or along the potential gradient (potential difference) of the transport process through the cell membrane."
    },
    {
        "instruction":"已知信息：\n'药理毒理学研究现场核查主要是对药理毒理学研究情况，包括药理和(或)毒理研究的条件、方案执行情况、数据记录和结果报告等方面进行的核查。'可被翻译为：The on-site inspection of Pharmacological and Toxicological study is mainly to inspect the Pharmacological and Toxicological study, including the conditions of pharmacology and\/or toxicology study, protocol implementation situation, data records and result reports etc.\n\n根据上述已知信息，请将'(二)药理毒理学研究现场核查主要是对药理毒理学研 究情况，包括研究条件、方案执行情况、数据记录和结果报 告等方面进行核查。基于注册需要和风险原则，可仅对部分药理毒理学试验项目的部分内容进行核查。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(II) On-site inspection of Pharmacological and Toxicological study is mainly to inspect the study conditions of Pharmacological and Toxicological, including study conditions, protocol implementation, data records and result reports. Based on registration requirements and risk principles, only part of the content of some Pharmacological and Toxicological trial items can be inspected."
    },
    {
        "instruction":"已知信息：\n'国家药品监督管理局食品药品审核查验中心（以下简称核查中心）承担批签发过程中的境外现场检查等工作。'可被翻译为：Center for Food and Drug Inspection of NMPA (hereinafter referred to as CFDI) shall be responsible for overseas on-site inspection during lot release.\n\n根据上述已知信息，请将'二、国家药品监督管理局食品药品审核查验中心将在其网站公示现场核查计划，并通知药品注册申请人及其所在地省级药品监管部门，公示10个工作日后，该中心将通知现场核查日期，不再接受药品注册申请人的撤回申请。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"II. NMPA Center for Food and Drug Inspection shall publicize on its website and inform the applicants of drug registration and the competent local provincial drug regulatory authority of the on-site verification plan. The Center shall, 10 working days after the public notification, inform the date for on-site verification and no longer accept the applicants' withdrawal of drug registration applications."
    },
    {
        "instruction":"已知信息：\n'第一百零五条 申请仿制的药品属于按非处方药管理的，申请人应当在《药品注册申请表》的“附加申请事项”中标注非处方药项。'可被翻译为：Article 105 Where the applied generic drug is regulated as a non-prescription drug, the applicant shall indicate the item of non-prescription drug in the \"additional application items\" of the Application Form for Drug Registration.\n\n根据上述已知信息，请将'第一百零九条 进口的药品属于非处方药的，适用进口药品的申报和审批程序，其技术要求与境内生产的非处方药相同。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 109 For the registration application of an import drug categorized as non-prescription drug, the application, review and approval procedures for import drugs shall apply, and the technological requirements shall be the same as those for the domestically produced non-prescription drugs."
    },
    {
        "instruction":"已知信息：\n'第三节 持续稳定性考察'可被翻译为：Section 3 On-going Stability Program\n\n根据上述已知信息，请将'13.确保完成产品的持续稳定性考察计划，提供稳定性考察的数据；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"13) To ensure the implementation of on-going stability study and make the stability data available;"
    },
    {
        "instruction":"已知信息：\n'（二）新《办法》发布至实施前受理的药品注册申请，按照新《办法》规定的范围和《关于鼓励药品创新实行优先审评审批的意见》（食药监药化管〔2017〕126号）规定的程序执行。'可被翻译为：(2) Drug registration applications accepted between the issuance and the implementation of the new Provisions shall be handled in accordance with the scope stipulated in the new Provisions and the Opinions on Encouraging Priority Review and Examination and procedures prescribed in the Opinions on Fueling Pharmaceutical Innovation via Prioritized Review & Approval (CFDA Department of Drug and Cosmetics Supervision [2017] No.126) .\n\n根据上述已知信息，请将'（三）新《办法》实施后受理的药品注册申请，按照新《办法》规定的范围和程序执行。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(3) Drug registration applications accepted after the implementation of the new Provisions shall be executed in accordance with the scope and procedures prescribed by the new Provisions."
    },
    {
        "instruction":"已知信息：\n'开放式系统系指由负责系统中电子记录内容的人员不对使用访问进行管理的计算环境。'可被翻译为：(9) Open system means an environment in which system access is not controlled by persons who are responsible for the content of electronic records that are on the system.\n\n根据上述已知信息，请将'封闭系统系指由负责系统中电子记录内容的人员管理系统访问的计算机环境。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(4) Closed system means an environment in which system access is controlled by persons who are responsible for the content of electronic records that are on the system."
    },
    {
        "instruction":"已知信息：\n'二、口服固体制剂每剂量单位含羟考酮碱不超过5毫克，且不含其它麻醉药品、精神药品或药品类易制毒化学品的复方制剂列入第二类精神药品管理；'可被翻译为：2. Oral solid preparations containing no more than 5 mg of oxycodone base perdose unit, barring other narcotic drugs,psychotropic drugs or pharmaceutical precursor chemicals, shall be subject to the management of Class II psychotropic drugs;\n\n根据上述已知信息，请将'三、丁丙诺啡与纳洛酮的复方口服固体制剂列入第二类精神药品管理。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"3. Compound oral solid preparations of buprenorphine and naloxone shall be subject to the management of Class II psychotropic drugs."
    },
    {
        "instruction":"已知信息：\n'研究化学药物及天然活性成分的化学结构、理化性质、化学合成、体内代谢、化学结构与药效的相互关系，药物作用的化学机制，以及寻找新药的途径和方法的一门学科。与创制和发展新药有关的化学规律和方法均属药物化学研究的范畴。'可被翻译为：The study of chemical drugs and natural active ingredients of chemical structure, physical and chemical properties, chemical synthesis, in vivo metabolism, chemical structure and efficacy of the relationship between the chemical mechanism of drug action, as well as the search for new ways and methods of a discipline. The chemical laws and methods related to the creation and development of new drugs belong to the category of pharmaceutical chemistry research.\n\n根据上述已知信息，请将'研究用微生物发酵或与化学合成方法结合制取药物的一门学科。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A discipline that studies the preparation of drugs by microbial fermentation or in combination with chemical synthesis."
    },
    {
        "instruction":"已知信息：\n'第二十八条 技术审评过程中需要申请人补正资料的，技术审评机构应当一次告知需要补正的全部内容。申请人应当在1年内按照补正通知的要求一次提供补充资料。技术审评机构应当自收到补充资料之日起40个工作日内完成技术审评。申请人补充资料的时间不计算在审评时限内。'可被翻译为：Article 28 Where supplementary and correction materials are required during technical evaluation, the technical evaluation institution shall inform the applicant one-off of all the supplements to be completed. The applicant shall submit all necessary supplementary and correction materials one-off within one year according to the supplementation notice. The technical evaluation institution shall complete the technical evaluation within 40 workdays from the date of acceptance of the supplements. The time spent by applicant for supplementing such materials shall not be calculated in the overall evaluation time.\n\n根据上述已知信息，请将'（三）需要申请人补充资料的，应当一次告知需要补充的全部内容；申请人应当在90个工作日内按照要求一次提供补充资料，技术审评机构收到补充资料后审评时限重新计算；未在规定时限内补充资料的，技术审评机构应当作出技术审评不通过的审评结论。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(3) Where supplementary documents are required from the applicant, the applicant shall be notified once of all the contents to be supplemented; the applicant shall provide supplementary documents at one time as required within 90 working days, and the evaluation time limit shall be recalculated after the technical assessment agency receives the supplementary documents; if the supplementary documents are not submitted within the specified timeline, the technical assessment agency shall make an evaluation conclusion of disapproval."
    },
    {
        "instruction":"已知信息：\n'(良好的贸易和分销规范)是质量保证的一部分，通过对贸易和分销过程中发生的众多活动进行充分控制，确保药品质量得到保持。'可被翻译为：(Good trade and distribution practices are) that part of quality assurance that ensures that the quality of pharmaceutical products is maintained by means of adequate control throughout the numerous activities which occur during the trade and the distribution process.\n\n根据上述已知信息，请将'1.(良好贮存规范)是质量保证的一部分，通过在整个贮存过程中适当的控制来确保药品的质量得到保持。\n2.质量保证的一部分，通过在医疗产品的整个储存过程中进行适当的控制，确保保持医疗产品的质量。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.(Good storage practices are) that part of quality assurance that ensures that the quality of pharmaceutical products is maintained by means of adequate control throughout the storage thereof.\n2.That part of quality assurance that ensures that the quality of medical products is maintained by means of adequate control throughout the storage thereof."
    },
    {
        "instruction":"已知信息：\n'菌落的生长表明可能存在大肠杆菌，应通过鉴定试验证实。应使用快速鉴定试剂盒或 DNA 测序将分离株鉴定至属，如有可能，鉴定至种。如果不存在菌落或鉴定测试为 阴性，则产品符合测试要求。'可被翻译为：Growth of colonies indicates the possible presence of E. coli. This is confirmed by identification test. Isolates should be identified to genus and, if possible, species using rapid identification kits or DNA sequencing. The product complies with the test if no colonies are present or if the identification tests are negative.\n\n根据上述已知信息，请将'菌落的生长表明可能存在铜绿假单胞菌，应通过鉴定试验证实。应使用快速鉴定试剂 盒或 DNA 测序将分离株鉴定至属，如有可能，鉴定至种。如果未检出菌落或鉴定测 试为阴性，则产品符合测试要求。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Growth of colonies indicates the possible presence of P. aeruginosa. This is confirmed by identification test. Isolates should be identified to genus and, if possible, species using rapid identification kits or DNA sequencing. The product complies with the test if no colonies are present or if the identification tests are negative."
    },
    {
        "instruction":"已知信息：\n'国家药监局关于发布医用康复器械通用名称命名指导原则等6项指导原则的通告'可被翻译为：NMPA Announcement on Issuing 6 Guidance including the Guidance for Nomenclature of the Generic Names of Medical Rehabilitation Devices\n\n根据上述已知信息，请将'国家药监局关于发布神经和心血管手术器械通用名称命名指导原则等2项指导原则的通告'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"NMPA Announcement on Issuing 2 Guidance including the Guidance for Nomenclature of the Generic Names of Neurosurgical and Cardiovascular Surgical Devices"
    },
    {
        "instruction":"已知信息：\n'（一）法定代表人（企业负责人）、质量负责人身份证明、学历或者职称相关材料复印件；'可被翻译为：(1) copies of the identity and the academic degree or professional title of the legal representative (the person in charge of the enterprise) and the person in charge of quality;\n\n根据上述已知信息，请将'（三）生产、质量和技术负责人的身份、学历、职称相关材料复印件；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(3) copies of related materials such as identities, academic degrees and professional titles of the persons in charge of manufacturing, quality and technology;"
    },
    {
        "instruction":"已知信息：\n'第七十三条 省、自治区、直辖市食品药品监督管理部门按照属地管理原则，对进口体外诊断试剂代理人注册与备案相关工作实施日常监督管理。'可被翻译为：Article 73 The food and drug regulatory departments of the provinces, autonomous regions and municipalities directly under the central government shall, in accordance with the principle of territorial administration, perform routine supervision and administration over the work concerning registration and filing done by agents for import in-vitro diagnostic reagents.\n\n根据上述已知信息，请将'第六十三条 省、自治区、直辖市食品药品监督管理部门按照属地管理原则，对进口医疗器械代理人注册与备案相关工作实施日常监督管理。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 63 The food and drug regulatory departments of the provinces, autonomous regions and municipalities directly under the central government shall, in accordance with the principle of territorial administration, perform routine supervision and administration over the work concerning registration and filing done by agents for import medical devices."
    },
    {
        "instruction":"已知信息：\n'1.质量管理的一部分侧重于设定质量目标，规定必要的操作过程和相关资源以实现质量目标。\n2.作为质量管理的一部分，质量策划需要设定质量目标，并规定实现质量目标所需的操作过程和相关资源。'可被翻译为：1.Part of quality management focused on setting quality objectives and specifying necessary operational processes and related resources to fulfil the quality objectives.\n2.Part of quality management, quality planning entails setting quality objectives and specifying necessary operational processes and related resources to fulﬁl the quality objectives.\n\n根据上述已知信息，请将'质量规划：质量管理的一部分，主要是设置质量目标和指定必要的操作流程和相关的资源以达成质量目标'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"quality planning. Part of quality management, focused on setting quality objectives and specifying necessary operational processes and related resources to fulfil the quality objectives."
    },
    {
        "instruction":"已知信息：\n'第二十一条 化妆品新原料注册人、备案人应当建立化妆品新原料上市后的安全风险监测和评价体系，对化妆品新原料的安全性进行追踪研究，对化妆品新原料的使用和安全情况进行持续监测和评价。'可被翻译为：Article 21 Registrants and filing persons of new cosmetic ingredients shall establish a safety risk monitoring and evaluation system after the launch of new cosmetic ingredients, conduct follow-up research on the safety of new cosmetic ingredients, and continue to monitor and evaluate the use and safety of new cosmetic ingredients.\n\n根据上述已知信息，请将'（三）其他与化妆品新原料安全有关的情况。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(3) Other circumstances related to the safety of new cosmetic ingredients."
    },
    {
        "instruction":"已知信息：\n'第十九条    疫苗批签发应当逐批进行资料审核和抽样检验，其他生物制品批签发可以采取资料审核的方式，也可以采取资料审核和样品检验相结合的方式进行，并可根据需要进行现场核实。对不同品种检验项目和检验比例，由中检院负责组织论证，并抄报国家药品监督管理局。批签发机构按照确定的检验要求进行检验。'可被翻译为：Article 19  For the lot release of vaccines, dossier review and sample testing shall be conducted lot by lot. For other biological products, lot release may be conducted by means of independent dossier review or by combining dossier review with sample testing, and on-site verification may be conducted as required. For the testing items and testing proportion for different varieties, the NIFDC shall organize the demonstration and submit a copy to the NMPA. Each lot release institution shall conduct test in accordance with the determined specifications.\n\n根据上述已知信息，请将'第十八条 批签发可以采取资料审核的方式，也可以采取资料审核和样品检验相结合的方式进行，并可根据需要进行现场核实。对不同品种所采用的批签发方式及检验项目和检验比例，由中检院负责组织论证，各批签发机构按照确定的批签发方式和检验要求进行检验。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 18 Lot release may be conducted by means of independent dossier review or by combining dossier review with sample test, and on-site inspection may be conducted as required. For the lot release mode as well as the testing items and testing proportion for different products, the NIFDC shall organize the demonstration and each lot release institution shall conduct test in accordance with the determined mode for lot release and specifications."
    },
    {
        "instruction":"已知信息：\n'一组相互关联或相互作用的活动，它们使用输入来交付预期的结果。在nra的背景下，生产和服务提供过程应与基本监管功能相一致。'可被翻译为：A set of interrelated or interacting activities that use inputs to deliver an intended result. In the context of NRAs, the production and service provision processes should coincide with basic regulatory functions.\n\n根据上述已知信息，请将'过程或子过程无法提供预期结果的不同方式。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Different ways that a process or subprocess can fail to provide the anticipated result."
    },
    {
        "instruction":"已知信息：\n'以下均为只含有与检查有关的微生物信息的 FDA 指南文件。大多情况下，放在CBER 通用信息或 CBER 指南网页中。'可被翻译为：Listed below are all the FDA guidance documents that contain only microbiological information relevant to inspection. In most cases these will be listed in the general website for CBER or CBER guidelines.\n\n根据上述已知信息，请将'标题为“检查”和“分析”的章节与“附件 A”与 FDA 微生物学家有关。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The sections entitled “Inspectional” and “Analytical” and “Attachment A” are pertinent to an FDA microbiologist."
    },
    {
        "instruction":"已知信息：\n'三、申请人应当充分评估其拟申报药械组合产品的属性。对于药械组合产品不能确定管理属性的，申请人应当在申报注册前向国家药品监督管理局医疗器械标准管理中心（以下简称标管中心）申请药械组合产品属性界定。'可被翻译为：III. The Applicant shall fully evaluate the attributes of the drug-device combination products to be applied for. For the drug device combination products whose attribute cannot be determined, the applicants shall apply for attribute definition to Center for Medical Device Standards Management, NMPA (hereinafter referred to as the \"CMDSM\")prior to registration application.\n\n根据上述已知信息，请将'第一百二十二条 拟申报注册的药械组合产品，已有同类产品经属性界定为药品的，按照药品进行申报；尚未经属性界定的，申请人应当在申报注册前向国家药品监督管理局申请产品属性界定。属性界定为药品为主的，按照本办法规定的程序进行注册，其中属于医疗器械部分的研究资料由国家药品监督管理局医疗器械技术审评中心作出审评结论后，转交药品审评中心进行综合审评。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 122 For a drug-device combination product, where other products of the same category have been defined as drugs, drug registration application shall be submitted; where attribute of a product has not been defined, the applicant shall apply for product attribute definition to the NMPA before submitting the registration application. For a drug-device combination product defined as one with drug as the predominant part, its registration shall comply with the procedures specified in these Provisions; study data on the medical device part shall be reviewed by the Center of Medical Device Evaluation of NMPA (CMDE), which shall then forward its review conclusions to the CDE for comprehensive review."
    },
    {
        "instruction":"已知信息：\n'为贯彻落实《化妆品注册备案管理办法》，规范和指导化妆品新原料注册与备案工作，国家药监局制定了《化妆品新原料注册备案资料管理规定》，现予公布，自2021年5月1日起施行。'可被翻译为：In order to implement the Provisions for Registration and Notification of Cosmetics and standardize and guide the registration and notification of new cosmetic ingredients, the NMPA has developed the Rules for Registration and Notification Dossiers of New Cosmetic Ingredients, which is hereby issued and shall take effect as of May 1,2021.\n\n根据上述已知信息，请将'为指导化妆品和新原料注册人、备案人规范开展注册备案和提交注册备案资料，依据《化妆品监督管理条例》《化妆品注册备案管理办法》《化妆品注册备案资料管理规定》《化妆品新原料注册备案资料管理规定》等相关规定，国家药监局组织制定了《化妆品注册备案资料提交技术指南（试行）》，于2021年4月12日予以发布。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In order to guide registrants and filing applicants of cosmetics and new raw materials to carry out registration and notification and submit relevant documents in a standardized manner, according to the Regulations for the Supervision and Administration of Cosmetics, Provisions for Registration and Notification of Cosmetics, Provisions for Registration and Notification Dossier of Cosmetics, Provisions for Registration and Notification Dossier of New Cosmetic Raw Materials and other relevant provisions, NMPA has organized to formulate the Technical Guidelines for Submitting Registration and Notification Dossier of Cosmetics (Interim), which was issued on 2021, April 12."
    },
    {
        "instruction":"已知信息：\n'第一百五十七条 国家食品药品监督管理局接到复审申请后，应当在50日内作出复审决定，并通知申请人。维持原决定的，国家食品药品监督管理局不再受理再次的复审申请。'可被翻译为：Article 157 The State Food and Drug Administration shall make a second review decision, and notify the applicant the decision within 50 days after receiving an application for second review. Where the original decision is affirmed, the State Food and Drug Administration shall not accept any further application for second review thereof.\n\n根据上述已知信息，请将'第一百五十八条 复审需要进行技术审查的，国家食品药品监督管理局应当组织有关专业技术人员按照原申请时限进行。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 158 Where there is any need for technical review in second review, the State Food and Drug Administration shall organize relevant technical personnel to conduct review within the timeline as that for the original application."
    },
    {
        "instruction":"已知信息：\n'第三十二条 批签发机构应当对批签发工作情况进行年度总结，由中检院汇总分析后，于每年3月底前向食品药品监管总局报告。'可被翻译为：Article 32 Lot release institutions shall summarize their annual lot release work. The NIFDC, after summarization and analysis, shall report to the CFDA before the end of March each year.\n\n根据上述已知信息，请将'第三十三条    批签发机构应当对批签发工作情况进行年度总结，由中检院汇总分析后，于每年3月底前向国家药品监督管理局报告。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 33 Lot release institutions shall summarize their annual lot release work. The NIFDC, after summarization and analysis, shall report to the NMPA before the end of March each year."
    },
    {
        "instruction":"已知信息：\n'构成生物大分子结构单元的排列次序。如DNA分子是由4种核昔酸（A,T,G,C）排列组成，DNA序列就是组成某一DNA分子的核昔酸的排列次序。'可被翻译为：The arrangement of the structural units of biomacromolecules. For example, the DNA molecule is composed of four nucleotides (A,T,G,C), and the DNA sequence is the sequence of nucleotides that make up a DNA molecule.\n\n根据上述已知信息，请将'由核昔酸聚合而成的生物大分子。包括脱氧核糖核酸(DNA)和核糖核酸(RNA)。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A biomacromolecule polymerized from nucleotide. Includes deoxyribonucleic acid (DNA) and ribonucleic acid (RNA)."
    },
    {
        "instruction":"已知信息：\n'申请资料不齐全或者不符合规定形式的，批签发机构应当在5日内一次性书面告知批签发申请人需要补正的全部内容及资料补正时限。逾期不告知的，自收到申请资料和样品之日起即为受理。'可被翻译为：If the application dossiers are incomplete or nonconforming to the prescribed form, the lot release institution shall inform the lot release applicant of all contents to be supplemented and corrected and the time limit for supplementation in writing all at once within 5 days. Where the lot release institution fails to notify the applicant within the time limit, it shall be regarded as acceptance as of the date of receipt of application dossiers and samples.\n\n根据上述已知信息，请将'申请资料不齐全或者不符合规定形式的，批签发机构应当在5日内一次性书面告知批签发申请人需要补正的全部内容及资料补正时限。逾期不告知的，自收到申请资料之日起即为受理。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"If the application dossiers are incomplete or nonconforming to the prescribed form, the lot release institution shall inform the lot release applicant of all contents to be supplemented and corrected and the time limit for supplementation in writing all at once within 5 days. Where the lot release institution fails to notify the applicant within the time limit, it shall be regarded as acceptance as of the date of receipt of application dossiers."
    },
    {
        "instruction":"已知信息：\n'有毒成分是化学定义的物质或物质群，其毒性占主导地位，尽管它们可能有助于草药材料或草药制剂的治疗活性。'可被翻译为：Toxic constituents are substances or group(s) of substances that are chemically defined and their toxic property is predominant, although they may contribute to the therapeutic activities of the herbal material or herbal preparation.\n\n根据上述已知信息，请将'1.标记物(标记物质)是中草药中化学定义的成分的参比物质。它们可能对治疗活性有贡献，也可能没有。然而，即使它们对治疗活动有贡献，也可能没有证据表明它们对临床疗效负有全部责任。\n2.参考物质:指草药的化学成分。它们可能有助于也可能不有助于其治疗活性。然而，即使它们有助于治疗活性，也可能没有证据表明它们对材料的临床疗效负全部责任(10)。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.Markers (marker substances) are reference substances that are chemically defined constituents of a herbal material. They may or may not contribute to the therapeutic activity. However, even when they contribute to the therapeutic activity, evidence that they are solely responsible for the clinical efficacy may not be available.\n2.Reference substances that are chemically defined constituents of a herbal material. They may or may not contribute to their therapeutic activity. However, even when they contribute to the therapeutic activity, evidence that they are solely responsible for the material’s clinical efficacy may not be available (10)."
    },
    {
        "instruction":"已知信息：\n'一种或一种以上含药物粒子经特殊的给药装置给药后以气溶胶形式进入呼吸道的吸入制剂。按用途可分为吸入粉雾剂、非吸入粉雾剂和外用粉雾剂。'可被翻译为：An inhalation preparation in which one or more drug-containing particles are administered by a special drug delivery device and then enter the respiratory tract in aerosol form. It can be divided into inhaled powder, non-inhaled powder and external powder according to its use.\n\n根据上述已知信息，请将'一种或一种以上含药物粒子经特殊的给药装置给药后以气溶胶形式进入呼吸道的吸入制剂。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"An inhaled preparation in which one or more drug-containing particles are administered by a special drug delivery device and enter the respiratory tract in aerosol form."
    },
    {
        "instruction":"已知信息：\n'只有一套冲模，适用于实验室试制或小批量生产的一种小型台式压片设备。'可被翻译为：A small benchtop tablet pressing device with only one set of dies suitable for laboratory trial production or small batch production.\n\n根据上述已知信息，请将'常用的压片设备。旋转台上具有多套冲模，适合进行片剂的批量生产。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A commonly used tablet pressing device. The rotary table has multiple sets of stamping dies, suitable for mass production of tablets."
    },
    {
        "instruction":"已知信息：\n'如果产品的阶段式生产在 CCS 中经过适当论证并经过验证，过滤器使用人员应：'可被翻译为：Where campaign manufacture of a product has been appropriately justified in the  CCS and validated, the filter user should:\n\n根据上述已知信息，请将'液体的除菌过滤应按照相关药典要求进行验证。验证可以根据产品的不同规格或种类进行分组，但应在最差条件下进行。分组的基本依据应经过论证并用文件记录。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Sterile  filtration  of liquids  should be validated  in  accordance with relevant Pharmacopeia requirements. Validation can be grouped by different strengths or variations of a product but should be done under worst-case conditions. The rationale for grouping should be justified and documented."
    },
    {
        "instruction":"已知信息：\n'RABS 的设计应通过具有单向流和关键区域初始气流保护确保 A 级条件。应保持从关键区到支持性背景环境的正向气流。'可被翻译为：RABS:\nThe design of RABS should ensure grade A conditions with unidirectional airflow and first air protection in thecritical zone. A positive airflow from the critical zone to the supporting background environment should be maintained.\n\n根据上述已知信息，请将'洁净区中对生产过程不重要的活动应保持在最低限度，特别是在进行无菌操作时。人员移动应缓慢、受控\n并有条不紊，以避免由于过度活动导致的微粒和微生物的过量脱落。执行无菌操作的操作人员应始终遵循\n无菌技术，以防止气流的变化可能将较低质量的空气引入关键区域。应限制关键区附近的移动，应避免单\n向流（初始气流）通路的阻塞。应考虑将气流可视化研究的回顾作为培训计划的一部分。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Activities in clean areas that are not critical to the production processes should be kept to a minimum,\nespecially when aseptic operations are in progress. Movement of personnel should be slow, controlled and\nmethodical to avoid excessive shedding of particles and organisms due to over-vigorous activity. Operators\nperforming aseptic operations should adhere to aseptic technique at all times to prevent changes in air currents\nthat may introduce air of lower quality into the critical zone. Movement adjacent to the critical zone should be\nrestricted and the obstruction of the path of the unidirectional (first air) airflow should be avoided. A review of\nairflow visualisation studies should be considered as part of the training programme."
    },
    {
        "instruction":"已知信息：\n'第一百零六条 企业应当制定冷藏、冷冻药品运输应急预案，对运输途中可能发生的设备故障、异常天气影响、交通拥堵等突发事件，能够采取相应的应对措施。'可被翻译为：Article 106 Enterprises shall formulate a contingency plan for the transportation of refrigerated and frozen drugs, and be able to take corresponding measures to deal with such emergencies as equipment failure, abnormal weather influence and traffic congestion that may occur during the transportation.\n\n根据上述已知信息，请将'（四）有防止室外装卸、搬运、接收、发运等作业受异常天气影响的措施。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(IV) Protective measures against the impact of abnormal weather during outdoor loading and unloading, handling, receiving, shipment, and other operations shall be in place."
    },
    {
        "instruction":"已知信息：\n'第七条 化妆品、化妆品新原料注册人、备案人依法履行产品注册、备案义务，对化妆品、化妆品新原料的质量安全负责。'可被翻译为：Article 7 The registrant and filing person of cosmetics and new cosmetic ingredients shall perform product registration and filing obligations in accordance with law and shall be responsible for the quality and safety of cosmetics and new cosmetic ingredients.\n\n根据上述已知信息，请将'（四）按照与注册人、备案人的协议，对投放境内市场的化妆品、化妆品新原料承担相应的质量安全责任；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(4) In accordance with the agreement with the registrants and filing persons, assuming corresponding quality and safety responsibilities for cosmetics and new cosmetic ingredients released in the domestic market; and"
    },
    {
        "instruction":"已知信息：\n'2019年8月26日，经第十三届全国人大常委会第十二次会议修订通过，修订后的《中华人民共和国药品管理法》（以下称药品管理法）自2019年12月1日起施行。国家药监局正在抓紧开展配套规章、规范性文件和技术指南的制修订工作，并将按程序陆续发布。现就贯彻实施新修订的药品管理法有关事项公告如下：'可被翻译为：Revised and adopted by the Twelfth Session of the Standing Committee of the 13th National People's Congress on August 26,2019, the revised Drug Administration Law of the People's Republic of China(hereinafter referred to as DAL) shall be implemented as from December 1,2019. NMPA is stepping up work on the development, formulation and revision of supporting regulations, normative documents and technical guidelines, which will be released in accordance with procedures. We hereby announce the issues pertaining to the implementation of the newly revised DALas follows:\n\n根据上述已知信息，请将'2018年10月，《药品管理法（修正草案）》提交第十三届全国人大常委会第六次会议进行初次审议，并于会后公开征求社会公众意见。审议中，有意见提出现行《药品管理法》自2001年修订以来，没有进行大的修改，建议将历年来药品领域改革成果和行之有效的做法上升为法律，将修正草案改为修订草案。2019年4月，第十三届全国人大常委会第十次会议对《药品管理法（修订草案）》进行审议。2019年8月26日，第十三届全国人大常委会第十二次会议进行第三次审议并表决通过。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In October 2018, the DAL Amendment Draft was submitted to the Sixth Session of the Standing Committee of the 13thNational People's Congress for initial deliberation, and subsequent solicitation of public comments. During the deliberation,taken into account that no major revisions have been made since the DAL revision in2001, it was recommended that the results of the reform of the pharmaceutical sector and effective practices over the years be raised to the law, and the draft amendments be changed to the revised drafts. In April2019, the Tenth Session of the Standing Committee of the 13th National People'sCongress deliberated the Revised Draft of DAL, which has been passed by voting on August 26, 2019 at the third deliberation of the Twelfth Session of the Standing Committee of the 13th National People'sCongress."
    },
    {
        "instruction":"已知信息：\n'为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药监局组织制定了影像型超声诊断设备同品种临床评价技术审查指导原则等2项注册技术审查指导原则，于2021年1月15日予以发布。'可被翻译为：In order to strengthen the supervision and guidance over medical device registration and further improve the quality of registration review, the NMPA has organized to formulate 2 technical review guidelines for registration including the Guidelines for Technical Review of Clinical Evaluation of Ultrasound Diagnostic Imaging Equipment Based on Predicate Products, which are hereby promulgated on January 15, 2021.\n\n根据上述已知信息，请将'国家药监局关于发布影像型超声诊断设备同品种临床评价技术审查指导原则等2项注册技术审查指导原则的通告'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"NMPA Announcement on Issuing of Two Registration Technical Review Guidelines Including the Guidelines for Technical Review of Clinical Evaluation of Ultrasound Diagnostic Imaging Equipment Based on Predicate Products"
    },
    {
        "instruction":"已知信息：\n'（五）供应商和生产商（如不同）标识的批号；'可被翻译为：5. The batch number of the supplier, and of the producer if different;\n\n根据上述已知信息，请将'1.产品或物料的名称、剂型、规格、批号或供货批号，必要时注明供应商和生产商（如不同）的名称或来源；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1) Name of the material or product, dosage form, strength, batch number or shipping batch number, where appropriate, the name of the manufacturer and\/or supplier;"
    },
    {
        "instruction":"已知信息：\n'如果上市许可持有人（MAH）不是制造商，则双方之间应达成技术协议，确定他们各自在生产产品质量回顾方面的责任。最终批放行的授权人员（AP）与上市许可持有人(MAH)应确保及时进行质量回顾和回顾准确性。'可被翻译为：Where the Marketing Authorisation holder is not the manufacturer, there should be a technical agreement in place between the various parties that defines their respective responsibilities in producing the product quality review. The Authorised Person responsible for final batch certification together with the Marketing Authorisation holder should ensure that the quality review is performed in a timely manner and is accurate.\n\n根据上述已知信息，请将'第二百六十八条 药品委托生产时，委托方和受托方之间应当有书面的技术协议，规定产品质量回顾分析中各方的责任，确保产品质量回顾分析按时进行并符合要求。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 268: For contract manufacturing, a written technical agreement should be in place between contract giver and contract acceptor, which defines their respective responsibilities of the product quality review to ensure that the quality review is performed on schedule according to the requirements."
    },
    {
        "instruction":"已知信息：\n'质量控制（QC） 为确保起始物料、中间体、包材和成品（FPP）符合既定的鉴别、含量、纯度和其它属性标准所执行的所有工作，包括设置标准、取样、检测和分析清场。'可被翻译为：quality control (QC). All measures taken, including the setting of specifications, sampling, testing and analytical clearance, to ensure that starting materials, intermediates, packaging materials and finished pharmaceutical products (FPP) conform with established specifications for identity, strength, purity and other characteristics.\n\n根据上述已知信息，请将'对于包材QC检测，应提供质量标准，包括图纸、原图和材料。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"12.21. For QC testing of packaging components, specifications should be provided including drawings, artwork and material."
    },
    {
        "instruction":"已知信息：\n'第六十一条  进口医疗器械注册人、备案人应当指定我国境内企业法人作为代理人，代理人应当协助注册人、备案人履行医疗器械监督管理条例和本办法规定的义务。'可被翻译为：Article 61 The registrant or filing entity of imported medical devices shall designate the domestic enterprise legal person as the agent, who shall assist the registrant or filing entity to fulfill the obligations prescribed in the Regulations on Supervision and Administration of Medical Devices and these Provisions.\n\n根据上述已知信息，请将'第八条 注册人、备案人在境外的，应当指定我国境内的企业法人作为境内责任人。境内责任人应当履行以下义务：'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 8 Overseas registrants and filing persons shall designate an enterprise legal person within the territory of China as the domestic responsible person. The domestic responsible person shall fulfill the following obligations:"
    },
    {
        "instruction":"已知信息：\n'在一个设备内同时进行多次部分气化和部分冷凝以分离液体混合物组分的方法。'可被翻译为：The method of partially vaporizing and partially condensing several times at the same time in a device to separate the liquid mixture components.\n\n根据上述已知信息，请将'以压力为推动力，依靠膜的选择性将液体中的组分进行分离的方法。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A method of separating the components of a liquid by means of the selectivity of the membrane, driven by pressure."
    },
    {
        "instruction":"已知信息：\n'容器和密闭器不应对药品有析出性、反应性或吸收性'可被翻译为：f. Containers and closures should not be additive, reactive, or absorptive to the drug product\n\n根据上述已知信息，请将'设备表面不应该具有反应性、析出或吸收性'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"ii. Equipment surfaces should not be reactive, additive, or absorptive"
    },
    {
        "instruction":"已知信息：\n'低温保护剂溶液通常是高渗的而不是生理的。例如，通常用于细胞冻存的10% DMSO溶液的浓度大约为1.4摩尔渗透压浓度(Osm\/L)。随着细胞失水，引入这种类型溶液中的细胞迅速脱水，以减少细胞内外的渗透压差。DMSO缓慢渗透到细胞内使其重新平衡。这可能会导致体积偏移，从而导致细胞活力的丧失。因此，冷冻保存溶液通常是逐步添加或逐渐地(如使用注射泵)或从容器的侧面缓慢添加到细胞悬浮液中，以防止由于渗透压造成细胞损失。应开发引入或去除冷冻保存液的方法并评估其对细胞活力和功能的影响。'可被翻译为：Cryoprotectant solutions typically are hypertonic and are not physiological. For example, a10% DMSO solution used commonly in cell preservation has a concentration of approximately 1.4 osmolarity (Osm\/L). Cells introduced into this type of solution rapidly dehydrate as water leaves the cell in order to reduce the difference in osmotic potential between the inside and outside of the cell. DMSO slowly permeates the cell to re-equilibrate. This may cause excursions in volume that can result in a loss of cell viability. Therefore, cryopreservation solutions commonly are added to a cell suspension in stepwise additions or gradually(e.g.,using asy ringe pump) or slowly dispensing down the side of the container to prevent cell losses resulting from osmotic stress. The method for introducing or removing a cryopreservation solution should be developed and evaluated for its impact on cell viability and functionality.\n\n根据上述已知信息，请将'对于DMSO，当两种溶液混合时，会产生较大的混合焓导致样品加热。这种加热的温度可能会高到足以损坏细胞的程度，因此通常将包含DMSO的溶液在混合前进行预冷。预冷可减少溶液混合过程中产生的热量，减少细胞渗透体积的变化，并减少细胞暴露于DMSO中的损伤。在冷冻之前，对细胞暴露于冷冻保护剂的时间应加以限制，并且常规研发工作中确定允许无有害影响的最大允许时间。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In thecase of DMSO, a large latent enthalpy of mixing results in sample heating whenthe two solutions are mixed. This heating can be high enough to damage the cells, so solutions that contain DMSO commonly are precooled before mixing.Prechilling the solution reduces heating associated with mixing of the solution, reducesthe osmotic volume changes that the cells experience, and reduces cell lossesassociated with exposure to DMSO. The time that cells are exposed to the cryoprotectant,prior to freezing, should be limited and the maximum time allowable, withoutdeleterious effects, should be determined during development work for routineuse."
    },
    {
        "instruction":"已知信息：\n'污水'可被翻译为：sewage\n\n根据上述已知信息，请将'照明、饮用水、清洗和厕所设施，污水和废物处置'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"v. Lighting, potable water, washing and toilet facilities, sewage and refuse disposal"
    },
    {
        "instruction":"已知信息：\n'至少采用两种不同的识别方式，例如识别码和密码。'可被翻译为：(1) Employ at least two distinct identification components such as an identification code and password.\n\n根据上述已知信息，请将'保证定期检查、收回或修订识别码和密码（例如，解决密码老化）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(b) Ensuring that identification code and password issuances are periodically checked, recalled, or revised (e.g., to cover such events as password aging)."
    },
    {
        "instruction":"已知信息：\n'第七十四条  有下列情形之一的，依照医疗器械监督管理条例第八十一条的规定处罚：'可被翻译为：Article 74 In one of the following circumstances, punishment shall be imposed in accordance with provisions in Article 81 of the Regulations on Supervision and Administration of Medical Devices:\n\n根据上述已知信息，请将'第六十一条 有下列情形之一的，属于化妆品监督管理条例规定的情节严重情形：'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 61 Any of the following circumstances shall belong to the serious circumstances stipulated in the Regulations on Supervision and Administration of Cosmetics:"
    },
    {
        "instruction":"已知信息：\n'医疗机构未按照规定报告疑似药品不良反应的，责令限期改正，给予警告；逾期不改正的，处五万元以上五十万元以下的罚款。'可被翻译为：Where a medical institution fails to report suspected adverse drug reactions, the offender shall be ordered to make correction within the time limit and be given a disciplinary warning. Where correction is not made within the prescribed period, it shall be subject to a fine of not less than RMB 50,000 but not more than RMB 500,000.\n\n根据上述已知信息，请将'第一百二十七条 违反本法规定，有下列行为之一的，责令限期改正，给予警告；逾期不改正的，处十万元以上五十万元以下的罚款：'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 127 In any of the following circumstances in violation of this Law, the offender shall be ordered to make correction within the time limit and be given a disciplinary warning. Where correction is not made within the prescribed period, it shall be subject to a fine of not less than RMB 100,000 but not more than RMB 500,000."
    },
    {
        "instruction":"已知信息：\n'化妆品电子商务平台经营者知道或者应当知道平台内化妆品经营者被依法禁止从事化妆品生产经营活动的，不得向其提供电子商务平台服务。'可被翻译为：If the operators of cosmetic e-commerce platform know or shall know that the cosmetic marketers in the platform are prohibited from engaging in manufacturing and marketing of cosmetics according to law, they shall not provide e-commerce platform services to such marketers.\n\n根据上述已知信息，请将'第四十五条 化妆品电子商务平台经营者应当对申请入驻的平台内化妆品经营者进行实名登记，要求其提交身份、地址、联系方式等真实信息，进行核验、登记，建立登记档案，并至少每6个月核验更新一次。化妆品电子商务平台经营者对平台内化妆品经营者身份信息的保存时间自其退出平台之日起不少于3年。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 45 The operators of cosmetic e-commerce platform shall register the real names of the cosmetic marketers who apply for being stationed in the platform, ask them to submit authentic information on their identity, address and contact information, etc., conduct verification and registration, establish registration files, and carry out verification and updating at least once every 6 months. Operator of an e-commerce platform shall keep identity information of the cosmetic marketers inside the platforms for not less than 3 years from the date of their withdrawal from the platform."
    },
    {
        "instruction":"已知信息：\n'1.工作范围是经过验证的关键参数的范围，在该范围内可生产可接受的产品。\n2.经验证的关键参数范围，在此范围内可生产可接受的产品。'可被翻译为：1.Operating range is the range of validated critical parameters within which acceptable products can be manufactured.\n2.The range of validated critical parameters within which acceptable products can be manufactured.\n\n根据上述已知信息，请将'制造商在正常操作期间选择作为参数可接受值的范围。这个范围必须在工作范围内。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The range that the manufacturer selects as the acceptable values for a parameter during normal operations. This range must be within the operating range."
    },
    {
        "instruction":"已知信息：\n'分析测试报告'可被翻译为：analytical test report\n\n根据上述已知信息，请将'分析测试报告通常包括对所采用的测试程序的描述、分析结果、讨论、结论和\/或对一个或多个的建议'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"An analytical test report usually includes a description of the test procedure(s) employed, results of the analysis, discussion and conclusions and\/or recommendations for one or more"
    },
    {
        "instruction":"已知信息：\n'第二百七十二条 应当有专人及足够的辅助人员负责进行质量投诉的调查和处理，所有投诉、调查的信息应当向质量受权人通报。'可被翻译为：Article 272: There should be designated person(s) supported by sufficient staff for investigating and handling of the quality complaints, and the Qualified Person should be made aware of any complaints and investigations.\n\n根据上述已知信息，请将'第二百九十九条 应当指定专人负责组织协调召回工作，并配备足够数量的人员。产品召回负责人应当独立于销售和市场部门；如产品召回负责人不是质量受权人，则应当向质量受权人通报召回处理情况。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 299: A person should be designated as responsible for execution and coordination of recalls and should be supported by sufficient staff. This responsible person should be independent of the sales and marketing organization. If this person is not the Authorized Person, the latter should be made aware of any recall activity."
    },
    {
        "instruction":"已知信息：\n'第三十八条  持有人应当对上市医疗器械安全性进行持续研究，对产品的不良事件报告、监测资料和国内外风险信息进行汇总、分析，评价该产品的风险与受益，记录采取的风险控制措施，撰写上市后定期风险评价报告。'可被翻译为：Article 38 MAHs shall conduct continuous research on the safety of medical devices once they are on the market, summarize and analyze the adverse event reports, monitoring data and domestic and overseas risk profile of products, evaluate its  risks and benefits, record the risk control measures taken and completepost-market periodic risk evaluation report.\n\n根据上述已知信息，请将'第十四条  持有人应当对其上市的医疗器械进行持续研究，评估风险情况，承担医疗器械不良事件监测的责任，根据分析评价结果采取有效控制措施，并履行下列主要义务：'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 14 MAHs shall carry out continuous research on the medical devices already marketed, evaluate the risks, assume the responsibilities of medical device adverse event monitoring, take effective control measures based on the analysis and evaluation results, and fulfill the following main obligations:"
    },
    {
        "instruction":"已知信息：\n'某一时点某人群中患有某种疾病的频率。'可被翻译为：The frequency of a disease in a population at a given point in time.\n\n根据上述已知信息，请将'一种由结果探索病因的回顾性研究方法。其基本原理是以现在确诊的患有某特定疾病'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A retrospective study method in which the cause is explored by the results. It is based on the present diagnosis of a particular disease"
    },
    {
        "instruction":"已知信息：\n'管理药品监管活动的全部范围的国家机构，根据国家药品立法至少包括以下所有职能:■新产品和现有产品的上市许可;\n■质量控制实验室检测;\n■药物不良反应监测;\n■提供药品信息，促进合理用药;\n■对制造商、批发商和分销渠道进行良好生产规范(GMP)检查和许可;\n■执行操作;\n■监测药物使用情况。'可被翻译为：A national body that administers the full spectrum of medicine regulatory activities, including at least all of the following functions in conformity with national medicine legislation:■marketing authorization of new products and variations of existing products;\n■quality control laboratory testing;\n■monitoring of adverse drug reactions;\n■provision of information on medicines and promotion of rational use of medicines;\n■good manufacturing practice (GMP) inspections and licensing of manufacturers, wholesalers and distribution channels;\n■enforcement operations;\n■monitoring of drug utilization.\n\n根据上述已知信息，请将'1.药监局:由成员国政府指定的管理药品在该国上市许可的机构\n2.负责药品注册和其他监管活动的国家机构。\n3.药监局:管理包括药监局在内的所有药品管理活动的国家机构\n至少符合国家药品立法的下列所有职能:\n•新产品的上市许可和现有产品的变型;\n•质量控制实验室检测;\n•药物不良反应监测;\n•提供药品信息，促进合理用药;\n•良好生产规范(GMP)检查和对制造商、批发商的许可\n以及分销渠道;\n•执法行动;\n•监测药物使用情况。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.An authority appointed by the government of a Member State to administer the granting of marketing authorizations for pharmaceutical products in that country.\n2.The national agency responsible for the registration of and other regulatory activities concerning pharmaceutical products.\n3.A national body that administers the full spectrum of drug regulatory activities, including at \nleast all of the following functions in conformity with national drug legislation:\n •  marketing authorization of new products and variation of existing products; \n•  quality control laboratory testing; \n•  adverse drug reaction monitoring; \n•  provision of drug information and promotion of rational drug use; \n•  good manufacturing practice (GMP) inspections and licensing of manufacturers, wholesalers \nand distribution channels; \n•  enforcement operations; \n•  monitoring of drug utilization."
    },
    {
        "instruction":"已知信息：\n'三、药品经营企业申请换发药品经营许可证的，药品监督管理部门按照换证工作程序和开办有关要求进行审查，符合《药品经营质量管理规范》和换发要求（或经整改后符合换发要求）的，予以换证；经整改后，仍不符合要求的，不予换证。'可被翻译为：3. Where a drug distributor applies for renewal of a drug distribution license, the drug administration departments shall conduct a review in accordance with the procedures for renewal of licenses and relevant requirements for establishment. The license shall be renewed if the conditions comply with the GSP and the renewal requirements (or conditions met after rectification). Where the requirements are still not met after rectification, the license shall not be renewed.\n\n根据上述已知信息，请将'二、新开办药品经营企业申请核发药品经营许可证的，药品监督管理部门可将筹建和验收程序合并执行，按照《药品经营质量管理规范》及现场检查指导原则等有关要求，对申办企业组织检查。符合要求的，发给药品经营许可证。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2. Where a newly establishing drug distributor applies for the issuance of a Drug Distribution License, the drug administration departments may combine  the examination & approval procedures for establishment preparation and acceptance, and organize inspection over the applicant pursuant to the relevant requirements of the Good Supply Practice for Pharmaceutical Products (GSP) and on-site inspection guidelines. A Drug Distribution License shall be issued if requirements are met."
    },
    {
        "instruction":"已知信息：\n'用火焰或干热空气进行灭菌的方法。'可被翻译为：Method of sterilization by flame or dry hot air.\n\n根据上述已知信息，请将'又称\"过滤灭菌”。用滤过方法除去活的或死的微生物的方法。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Also known as \"filtration sterilization\". A method of removing living or dead microorganisms by filtration."
    },
    {
        "instruction":"已知信息：\n'申请人应按照eCTD技术文件（附件1—4）要求准备和提交eCTD申报资料光盘，并在eCTD注册申请新报资料受理后5个工作日内，提交纸质资料。申请人如未按照规定时间提交纸质资料，按终止药品注册程序处理。同时，申请人应承诺所提交的电子资料与纸质资料内容完全一致，如因资料一致性产生的任何问题由申请人自行承担。'可被翻译为：Applicants should prepare and submit the eCTD application dossiers on CD-ROM as required by the eCTD technical documents(Attachments 1-4), and submit the paper dossiers within 5 working days upon the acceptance of the eCTD registration application dossiers. If an applicant fails to submit the paper dossiers within the specified time, the drug registration process will be terminated. At the same time, the applicant should make commitment that the electronic dossiers submitted is completely consistent with the paper dossiers. The applicant should bear the responsibilities for any problem arising from the inconsistency.\n\n根据上述已知信息，请将'采用eCTD申报的注册申请，申请人无需再单独提交核查检验用申报资料光盘和临床试验数据库光盘。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"For registrations application with eCTD submission, there is no need for applicants to submit the CD-ROM of the application dossiers for verification and inspection and theCD-ROM of clinical trial database separately."
    },
    {
        "instruction":"已知信息：\n'静脉药物集中配置'可被翻译为：pharmacy intravenous admixture service\n\n根据上述已知信息，请将'为保证静脉输液用药的特殊质量要求和安全，将传统分散于各病区护理站配置输液的方式，改为集中到药房管理的、输液配置室中配置的管理方式。细胞毒类药物和肠外营养输液是集中配制的重点。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In order to ensure the special quality requirements and safety of intravenous infusion, the traditional distribution of intravenous infusion distributed in nursing stations in each ward was changed to the centralized management of the pharmacy and the distribution of intravenous infusion room. Infusion of cytotoxic drugs and parenteral nutrition is the focus of centralized preparation."
    },
    {
        "instruction":"已知信息：\n'将不同的医疗干预措施进行对比时，计算一种干预措施相对于另一种干预措施增加的成本与相对增加的效果的比值的一种分析方法。'可被翻译为：A method of analysis that calculates the ratio of the increased cost of one intervention relative to another to the relative increased effect when comparing different medical interventions.\n\n根据上述已知信息，请将'计算并给出可供选择的医疗干预措施的成本和健康结果的分析方法。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A method of calculating and providing an analysis of the costs and health outcomes of alternative medical interventions."
    },
    {
        "instruction":"已知信息：\n'国际性药学学术组织，成立于1912年，总部设在荷兰海牙。国际药学联合会除有药学学术科研团体外，还吸收制药企业、教育及个人会员。'可被翻译为：International pharmaceutical academic organization, founded in 1912, headquartered in The Hague, Netherlands. In addition to pharmaceutical academic research groups, the International Pharmaceutical Federation also attracts members from pharmaceutical enterprises, education and individuals.\n\n根据上述已知信息，请将'国际标准化组织-成立于1946 年，是制定国际标准的主要组织。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"International Standards Organization - founded in 1946, it is the principal international standards-setting organization."
    },
    {
        "instruction":"已知信息：\n'先将容器或系统中的残余气体排出，然后将容器或系统加压至2bar，然后将用于净化的气体排出至1.013 bar，以清除容器或系统中的残余气体。'可被翻译为：To remove the residual gas from a container or system by first venting the residual gas from the container or system, then pressurizing the container or system to 2 bar and thereafter venting the gas used for purging to 1.013 bar.\n\n根据上述已知信息，请将'通过打开容器或系统使其进入大气，将容器或系统中的残余气体降至1.013巴。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"To remove the residual gas from a container or system down to 1.013 bar by opening the container or system to the atmosphere."
    },
    {
        "instruction":"已知信息：\n'供体和受体区室的孔口面积可以用游标卡尺确定。供体隔室的体积可以用供体隔室的直径和高度来计算。'可被翻译为：Orifice area for the donor and receptor compartments can be determined using vernier calipers. Volume of the donor compartment can be calculated using the donor compartment diameter and height.\n\n根据上述已知信息，请将'FDC的部件如图8-10所示。将皮肤置于受体隔室上方，并由供体隔室和夹紧机构保持在原位。皮肤应保持在供体和受体间室之间的水平面上。供体和受体隔室应由惰性材料制成。供体室的孔的表面积，它定义了试验的药物输送表面积，尺寸应该在标称值的±5%以内。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The components of the FDC are displayed in Figures 8–10. The skin is placed above the receptor compartment and kept in place by the donor compartment and a clamping mechanism. The skin should be held in a horizontal plane between the donor and receptor compartments. The donor and receptor compartments should be made out of an inert material. The surface area of the orifices of the donor compartment, which define the dosage delivery surface area for the test, should be sized within ±5% of the nominal value."
    },
    {
        "instruction":"已知信息：\n'分子力学'可被翻译为：molecular mechanics\n\n根据上述已知信息，请将'建立在牛顿力学基础上的分子模拟方法。通过求解分子中每个原子的牛顿力学方程来模拟分子运动和分子的行为，通过时间的微小增量，求解每个原子的位置和运动速度。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A method of molecular simulation based on Newtonian mechanics. Simulate the motion of molecules and the behavior of molecules by solving the equations of Newtonian mechanics for each atom in the molecule, solving the position and speed of motion of each atom by small increments of time."
    },
    {
        "instruction":"已知信息：\n'用生物活性来表示某些生物活性物质，如抗生素、激素、疫苗、血液制品、维生素及酶的量值，以国际公认的单位表示。'可被翻译为：The amount of certain bioactive substances, such as antibiotics, hormones, vaccines, blood products, vitamins, and enzymes, expressed in internationally recognized units.\n\n根据上述已知信息，请将'世界卫生组织经过国际协作标定后，对生物或合成来源的物质用国际单位表示生物活性的生物标准物质。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"After the World Health Organization has been calibrated by international collaboration, the biological reference material of biological or synthetic origin is expressed in international units of biological activity."
    },
    {
        "instruction":"已知信息：\n'分子中含有能吸收紫外-可见光而产生电子跃迁结构的基团。'可被翻译为：The molecule contains groups that can absorb UV-visible light and produce electronic transition structures.\n\n根据上述已知信息，请将'原子或分子中的电子从一个原子轨道向另一轨道的跃迁。电子跃迁需要极大的能量，并可被可见光、紫外光和X射线诱发。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The transition of electrons in an atom or molecule from one atomic orbital to another. Electron transitions require great energy and can be induced by visible, ultraviolet, and X-ray light."
    },
    {
        "instruction":"已知信息：\n'第九十一条 国家食品药品监督管理局药品审评中心应当在规定的时间内组织药学、医学及其他技术人员对申报资料进行审评，必要时可以要求申请人补充资料，并说明理由。'可被翻译为：Article 91 The Center for Drug Evaluation of the State Food and Drug Administration shall organize pharmaceutical, medical and other technical personnel to conduct technical review of the submitted dossiers within the specified timeline, and may request, with reasons, applicants to provide supplementary materials when necessary.\n\n根据上述已知信息，请将'第六十条 国家食品药品监督管理局药品审评中心收到申报资料后，应当在规定的时间内组织药学、医学及其他技术人员对申报资料进行审评，必要时可以要求申请人补充资料，并说明理由。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 60 After receiving submitted dossiers, the Center for Drug Evaluation of the State Food and Drug Administration shall organize pharmaceutical, medical and other technical personnel to conduct technical review of the submitted dossiers within the specified timeline, and may request, with reasons, applicants to provide supplementary materials when necessary."
    },
    {
        "instruction":"已知信息：\n'以稳定的速度和近似平行的流线流过洁净区的整个横截面积的整流气流(现代标准不再指层流，而是采用了术语“单向气流”)。'可被翻译为：A rectified airflow over the entire cross-sectional area of a clean zone with a steady velocity and approximately parallel streamlines (modern standards no longer refer to laminar flow, but have adopted the term unidirectional airflow).\n\n根据上述已知信息，请将'1.单向气流是在洁净区的整个横截面积上以稳定的速度和近似平行的流线进行整流的气流(另见紊流)。(现代标准不再指层流，而是采用了“单向气流”一词。)\n2.以稳定的速度和近似平行的流线流过洁净区的整个横截面积的整流气流(参见紊流)。(现代标准不再指层流，而采用了单向气流这一术语。)\n3.一种以强劲和均匀的方式沿单一方向移动的气流，并以足够的速度可重复地将颗粒从关键加工或测试区域扫走。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.Unidirectional airflow is a rectified airflow over the entire cross-sectional area of a clean zone with a steady velocity and approximately parallel streamlines (see also turbulent flow).(Modern standards no longer refer to laminar flow, but have adopted the term unidirectional airflow.)\n2.A rectified airflow over the entire cross-sectional area of a clean zone with a steady velocity and approximately parallel streamlines (see also turbulent air flow). (Modern standards no longer refer to laminar flow, but have adopted the term unidirectional airflow.)\n3.An airflow moving in a single direction in a robust and uniform manner and at sufficient speed to reproducibly sweep particles away from the critical processing or testing area."
    },
    {
        "instruction":"已知信息：\n'(1) 色谱使用自动积分， 同一个分析批中采用相同的积分参数。如果色谱重积分和手动积分， 记录修改理由并保留原始和重积分的图谱和数据， 与申报资料一致。'可被翻译为：(1) Chromatogram adopts automatic integration; the same integration parameters are used in the same analysis batch. If reintegration and manual integration of chromatogram are adopted, record the reason of modification and retain the original and reintegrated chromatogram and data, which are consist with the application dossier.\n\n根据上述已知信息，请将'抽查药(毒)代动力学生物样本分析数据，包括申报资 料中提交的纸质图谱是否与原始图谱一致，申报资料中提交的分析数据是否与原始分析数据一致；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"To sample and audit the pharmacokinetic (toxicokinetic) data, including chromatograms and analytical data, for the purpose of verifying consistency with those submitted in the application;"
    },
    {
        "instruction":"已知信息：\n'在一段时间内，给药剂量、给药途径、频率和给药间隔。'可被翻译为：The route, frequency and duration of administration of the dose of a medicine over a period of time.\n\n根据上述已知信息，请将'在一级动力学药物中，按固定间隔时间给予固定剂量，在每次给药时体内总有前次给药存留量，多次给药形成不断蓄积，随着给药次数的增加，体内总药量的蓄积率逐渐增力口，直至在剂量间隔内消除的药量等于给药剂量，从而达到平衡时的浓度。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In primary kinetic drugs, a fixed dose is given at a fixed interval, and there is always a residual amount of the previous administration in the body during each administration, and multiple administration forms continuous accumulation. With the increase of administration times, the accumulation rate of the total amount of drug in the body gradually increases until the amount of drug eliminated in the dose interval is equal to the dose given, so as to achieve the equilibrium concentration."
    },
    {
        "instruction":"已知信息：\n'当无菌灌装的无菌产品的轧盖作为洁净工艺在 A 级送风保护下进行时，应在轧盖前剔除无塞或跳塞的西林瓶作报废处理。应有经适当确认的自动化方法检测胶塞高度。'可被翻译为：Where capping of aseptically filled sterile product is conducted as a clean process with grade A air supply\nprotection, vials with missing or displaced stoppers should be rejected prior to capping. Appropriately qualified,\nautomated methods for stopper height detection should be in place.\n\n根据上述已知信息，请将'修订：调整洁净室分级表，新增培养基模拟灌装、生物负载监测和西林瓶轧盖相关指南。2005年11月-2007年12月'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Revision to align classification table of clean rooms, to include guidance on media simulations,bioburden monitoring and capping of vials November 2005 to December 2007"
    },
    {
        "instruction":"已知信息：\n'国家药监局药审中心关于发布《低分子量肝素类仿制药免疫原性研究指导原则(试行)》的通告'可被翻译为：NMPA CDE Announcement on Issuing the Guidance for Immunogenicity Study of Generic Drugs of Low Molecular Weight Heparin (Interim)\n\n根据上述已知信息，请将'国家药监局药审中心关于发布《皮肤外用化学仿制药研究技术指导原则（试行）》的通告'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Notice of CDE of China NPMA on Issuing the Technical Guidance for Studies of Dermatological Generic Drugs for Topical Use (Interim)"
    },
    {
        "instruction":"已知信息：\n'10件以内，抽样1件；11件－50件，每增加10件加抽1件，不足10件者以10件计；51件－100件，每增加20件加抽1件，不足20件者以20件计；101件以上，每增加50件加抽1件，不足50件者以50件计；1001件以上，每增加100件加抽1件，不足100件者以100件计；'可被翻译为：If the quantity is less than 10, take 1 product for sampling; if the quantity is 11 to 50, take additional 1 product for sampling for every additional 10, and the odd less than 10 shall be counted as 10; if the quantity is 51 to 100, take additional 1 product for sampling for every additional 20, and the odd less than 20 shall be counted as 20; if the quantity is more than 101, take additional 1 product for sampling for every additional 50, and the odd less than 50 shall be counted as 50; if the quantity is more than 1001, take additional 1 product for sampling for every additional 100, and the odd less than 100 shall be counted as 100;\n\n根据上述已知信息，请将'100－1000毫升（含1000毫升）的注射液，每1万瓶抽样1件，不足1万瓶的按1万瓶计。1000毫升以上的注射液（含透析液），每5000瓶（袋）抽样1件，不足5000瓶（袋）的按5000瓶计。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"If the injection is 100 ml to 1000 ml (including), take 1 product for sampling for every 10,000 vials, and the odd less than 10,000 vials shall be counted as 10,000. If the injection (including dialysate) is more than 1000 ml, take 1 product for sampling for every 5,000 vials (bags), and the odd less than 5,000 vials (bags)shall be counted as 5,000."
    },
    {
        "instruction":"已知信息：\n'药物粉末在自下而上的气流中保持悬浮状态，再喷入润湿剂或黏合剂的液体使粉末聚结成颗粒的方法。'可被翻译为：The method in which the drug powder is kept suspended in the bottom-up air flow and then sprayed with the liquid of wetting agent or binder to condense the powder into particles.\n\n根据上述已知信息，请将'可使物料聚结成颗粒或压缩成型的具有黏性的固体粉末或液体。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A viscous solid powder or liquid that condenses materials into particles or compresses them."
    },
    {
        "instruction":"已知信息：\n'西门子医学诊断产品（上海）有限公司报告，由于涉及产品存在特定批次检查出现结果偏差，但质控无法检测到的问题，生产商Siemens Healthcare Diagnostics Inc.对高敏C反应蛋白校准液High Sensitivity C Reactive Protein Calibrator (hsCRP CAL)主动召回。召回级别为三级。涉及产品的型号、规格及批次等详细信息见《医疗器械召回事件报告表》。'可被翻译为：According to a report of Siemens Healthcare Diagnostics Inc., due to discrepancy in the testing results of particular batches of High Sensitivity C Reactive Protein Calibrator (hsCRP CAL) which cannot be identified in quality control, the manufacturer initiated the voluntary recall of the product. The recall is identified as a Class III recall. For details on product models, specifications and batches, see the Report Form of Medical Device Recall.\n\n根据上述已知信息，请将'Siemens Healthcare Diagnostics Inc.对高敏C反应蛋白校准液主动召回'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Siemens Healthcare Diagnostics Inc. voluntarily recalls High Sensitivity C Reactive Protein Calibrator"
    },
    {
        "instruction":"已知信息：\n'（六）药品生产厂房不得用于生产对药品质量有不利影响的非药用产品。'可被翻译为：6. The production of non-drugs with adverse effects on drug should not be allowed in premises used for drugs.\n\n根据上述已知信息，请将'药品上市许可持有人和药品生产企业不得在药品生产厂房生产对药品质量有不利影响的其他产品。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Drug MAHs and manufacturers shall not manufacture other products having negative influence on drug quality in drug manufacturing workshops."
    },
    {
        "instruction":"已知信息：\n'第十一条    新批准上市的生物制品首次申请批签发前，批签发申请人应当在生物制品批签发管理系统内登记建档。登记时应当提交以下资料：'可被翻译为：Article 11 Before the initial application for lot release of the new biological product approved for marketing, the lot release applicant shall register and file in the Information Management System for Lot Release (hereinafter referred to as IMS). The following materials shall be submitted for registration:\n\n根据上述已知信息，请将'第十一条 新批准上市的生物制品首次申请批签发前，批签发申请人应当在批签发信息管理系统内登记建档。登记时应当提交以下资料：'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 11 Before the initial application for lot release of the new biological product approved for marketing, the lot release applicant shall register and file in the Information Management System for Lot Release. The following materials shall be submitted for registration:"
    },
    {
        "instruction":"已知信息：\n'（二）在使用医疗器械过程中是否发生过故障或者伤害；'可被翻译为：(2) whether any malfunction or injury occurred during the use of the medical device;\n\n根据上述已知信息，请将'（三）在现有使用环境下是否会造成伤害，是否有科学文献、研究、相关试验或者验证能够解释伤害发生的原因；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(3) whether it would cause injury under the existing use environment, and whether there are scientific literatures, researches, relevant tests, or verifications that can explain the cause of the injury;"
    },
    {
        "instruction":"已知信息：\n'国家药监局关于发布影像型超声诊断设备同品种临床评价技术审查指导原则等2项注册技术审查指导原则的通告'可被翻译为：NMPA Announcement on Issuing of Two Registration Technical Review Guidelines Including the Guidelines for Technical Review of Clinical Evaluation of Ultrasound Diagnostic Imaging Equipment Based on Predicate Products\n\n根据上述已知信息，请将'为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药监局组织制定了影像型超声诊断设备同品种临床评价技术审查指导原则等2项注册技术审查指导原则，于2021年1月15日予以发布。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In order to strengthen the supervision and guidance over medical device registration and further improve the quality of registration review, the NMPA has organized to formulate 2 technical review guidelines for registration including the Guidelines for Technical Review of Clinical Evaluation of Ultrasound Diagnostic Imaging Equipment Based on Predicate Products, which are hereby promulgated on January 15, 2021."
    },
    {
        "instruction":"已知信息：\n'为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药品监督管理局于2020年3月10日组织制定并发布了《用于放射治疗的X射线图像引导系统注册技术审查指导原则》和《正电子发射\/X射线计算机断层成像系统注册技术审查指导原则》。'可被翻译为：To strengthen the supervision and guidance over the registration of medical device products and further improve the quality of registration review, NMPA has organized the formulation of and released on March 10, 2020 the Guidelines for Technical Review of the Registration of X-ray Image Guided Systems for Radiotherapy and Guidelines for Technical Review of the Registration of Positron Emission \/ X-Ray Computed Tomography Systems.\n\n根据上述已知信息，请将'为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药品监督管理局组织制定了《视力筛查仪注册技术审查指导原则》和《乳腺X射线系统注册技术审查指导原则》，并于6月24日发布。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"To strengthen the supervision and guidance of medical device registration, and further improve the quality of registration review, the NMPA organized to formulation of the Guidelines for Technical Review of Vision Screener Registration and the Guidelines for Technical Review of Mammography System Registration, which were published on June 24."
    },
    {
        "instruction":"已知信息：\n'2019年，注册基层用户总数比上年增长15.69%。其中，注册人注册基层用户比上年增长41.92%，经营企业和使用单位的注册基层用户分别比上年增长24.22%和2.28%。'可被翻译为：In 2019, the total number of registered grassroots users increased by 15.69 percent over the previous year. Among them, the registered grassroots users of registrants, distributors and user units have increased by 41.92 percent, 24.22 percent and 2.28 percent over 2017, respectively.\n\n根据上述已知信息，请将'2020年，注册基层用户总数比上年增长10.03%。其中，注册人注册基层用户比上年增长38.31%，经营企业和使用单位的注册基层用户分别比上年增长11.52%和3.24%。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In 2020, the total number of registered grassroots users increased by 10.03% compared with the previous year. Among them, the registered grassroots users of registrants, distributors and using units have increased by 38.31%, 11.52% and 3.24% compared with the previous year, respectively."
    },
    {
        "instruction":"已知信息：\n'申请人应当对申报资料的真实性负责。'可被翻译为：The applicant shall be responsible for the authenticity of application dossiers.\n\n根据上述已知信息，请将'申请人应当对其申请材料全部内容的真实性负责。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The applicant shall be responsible for the authenticity of all information on the materials for application."
    },
    {
        "instruction":"已知信息：\n'稳定性，是指医疗器械唯一标识应当与产品基本特征相关，产品的基本特征未变化的，产品标识应当保持不变。'可被翻译为：Stability means that UDI shall be co-related to the basic features of the corresponding product, and UDI-DI shall remain the same unless basic characteristics of the product are changed.\n\n根据上述已知信息，请将'生长过程中尺寸的变化保持比例关系。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Isometric growth occurs when proportional relationships are preserved as size changes during growth."
    },
    {
        "instruction":"已知信息：\n'选择最佳接收液作为IVRT方法开发初始步骤的一个优点是，在使用接收液对不同膜评估前，可先采用选定的接收液对样品分析方法进行优化。'可被翻译为：One advantage of selecting an optimal receptor solution as an initial step in IVRT method development is that it allows for the sample analysis method to be optimized for the selected receptor solution sample matrix before proceeding to an evaluation of different membranes using that receptor solution.\n\n根据上述已知信息，请将'一般情况下，在IVRT方法开发中，（使用相同的接收介质）对不同的膜进行评估；通常采用合成膜过滤溶液中的微粒物质。在IVRT膜的选择中，可根据膜的有效孔径（如0.45μm），以及它们对药物的预期惰性。应在IVRT方法开发报告中，提供每种膜对化合物结合的信息和膜本身对IVRT方法中所选接收液的惰性（根据IVRT方法开发的前一阶段），以及在IVRT中所用的每种膜的药物释放线性和精密度信息，这些信息有助于解释IVRT方法中膜选择的合理性。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"It is conventional to evaluate different membranes during IVRT method development (all using the same receptor solution); these membranes are frequently synthetic membranes used for the filtration of particulate matter in solutions. IVRT membranes are selected based upon their effective pore size (e.g., 0.45 micrometers (μm)), as well as their expected inertness to binding the drug. Information should be provided in the IVRT method development report on each membrane’s binding to the drug and its chemical compatibility with relevant receptor solution(s) selected for the IVRT method (based on the preceding phase of IVRT method development), as well as information on the linearity and precision of the resulting release rate when each membrane is used in an IVRT, as this information can help to explain why a specific membrane is optimal for the IVRT method."
    },
    {
        "instruction":"已知信息：\n'第一百四十六条 药品监督管理部门或者其设置、指定的药品检验机构在药品监督检验中违法收取检验费用的，由政府有关部门责令退还，对直接负责的主管人员和其他直接责任人员依法给予处分；情节严重的，撤销其检验资格。'可被翻译为：Article 146 Where a drug regulatory department or its designated drug control institution illegally collects inspection fees during drug supervision and inspection, the relevant government department shall order it to return the fees and punish the persons directly in charge and other directly responsible persons in accordance with the law. In serious circumstances, the qualification for testing shall be annulled.\n\n根据上述已知信息，请将'第一百四十五条 药品监督管理部门或者其设置、指定的药品专业技术机构参与药品生产经营活动的，由其上级主管机关责令改正，没收违法收入；情节严重的，对直接负责的主管人员和其他直接责任人员依法给予处分。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 145 Where a drug regulatory department or its designated drug professional and technical institutions participate in drug manufacturing and business activities, it shall be ordered by its higher-level competent administrative department to make correction, and its illegal income shall be confiscated. In serious circumstances, the persons directly in charge and other directly responsible persons shall be punished in accordance with the law."
    },
    {
        "instruction":"已知信息：\n'第四十四条 食品药品监督管理部门在组织产品技术审评时可以调阅原始研究资料,并组织对申请人进行与产品研制、生产有关的质量管理体系核查。'可被翻译为：Article 44 The food and drug regulatory department may refer to the original research data when organizing a technical evaluation for product registration, and organize an inspection of the applicant’s quality management system concerning product research, development and production.\n\n根据上述已知信息，请将'第三十四条 食品药品监督管理部门在组织产品技术审评时可以调阅原始研究资料，并组织对申请人进行与产品研制、生产有关的质量管理体系核查。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 34 The food and drug regulatory department may refer to the original research data when organizing a technical evaluation for product registration, and organize an inspection of the applicant's quality management system concerning product research, development and production."
    },
    {
        "instruction":"已知信息：\n'指包装中直接接触原料药或制剂的包装，包括包装上的标签。'可被翻译为：Immediate (primary) pack is that constituent of the packaging that is in direct contact with the drug substance or drug product, and includes any appropriate label.\n\n根据上述已知信息，请将'（七）药品说明书及包装、标签的式样（原料药和制剂中间体除外）；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(VII) insert sheet, patterns of its packaging and labeling(except for drug substances and intermediate preparations);"
    },
    {
        "instruction":"已知信息：\n'七、新《办法》实施前附条件批准的药品，应当按照新修订《药品管理法》第七十八条有关附条件批准药品上市后管理的规定执行。'可被翻译为：7. Drugs approved with conditions before the implementation of the new Provisions shall follow the provisions in Article 78 of the newly revised Drug Administration Law concerning post-marketing management of conditionally approved drugs.\n\n根据上述已知信息，请将'（七）不具备《药品管理法》规定的生产条件的；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(7) the production conditions prescribed in the Drug Administration Law are not met;"
    },
    {
        "instruction":"已知信息：\n'（五）与经营的医疗器械相适应的专业指导、技术培训和售后服务的质量管理机构或者人员。'可被翻译为：(5) having quality management agencies or personnel providing professional guidance, technical training, and after-sales services compatible with the distributed medical devices.\n\n根据上述已知信息，请将'（三）有与所经营药品相适应的质量管理机构或者人员；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(3) have the units or personnel necessary for quality control of the drugs to be distributed; and"
    },
    {
        "instruction":"已知信息：\n'第八条 注册核查遵循公开、公平、公正的原则，以临床价值或者问题为导向，促进药物的研发和上市。'可被翻译为：Article 8 Registration inspection shall follow the principles of openness, fairness, and justice, and be guided by clinical value or problems to promote the drug development and approval.\n\n根据上述已知信息，请将'第七条 药品注册管理遵循公开、公平、公正原则，以临床价值为导向，鼓励研究和创制新药，积极推动仿制药发展。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 7 The administration of drug registration shall follow the principles of openness, fairness and impartiality, emphasize clinical values, and aim at encouraging the research and development of new drugs and facilitating the development of generic drugs."
    },
    {
        "instruction":"已知信息：\n'通过膜的运动而转运大分子物质的过程。包括胞饮和胞吐。'可被翻译为：The process of transporting macromolecular substances through the motion of a membrane. Including pinocytosis and exocytosis.\n\n根据上述已知信息，请将'大分子物质通过膜的内陷形成小泡而进入细胞的过程。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The process by which macromolecules enter a cell through the invagination of a membrane to form vesicles."
    },
    {
        "instruction":"已知信息：\n'第一百零五条 在冷藏、冷冻药品运输途中，应当实时监测并记录冷藏车、冷藏箱或者保温箱内的温度数据。'可被翻译为：Article 105 During the transportation of refrigerated or frozen drugs, real-time monitoring and recording of temperature data in refrigerated vehicles, refrigerated container or thermal insulation container shall be conducted.\n\n根据上述已知信息，请将'第七十四条 冷藏、冷冻药品到货时，应当对其运输方式及运输过程的温度记录、运输时间等质量控制状况进行重点检查并记录。不符合温度要求的应当拒收。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 74 Upon arrival of refrigerated and frozen drugs, the inspection shall focus on the status of quality control over the means of transportation, temperature record during the transportation, and transportation time, records shall be taken, and those failing to meet temperature requirements shall be rejected."
    },
    {
        "instruction":"已知信息：\n'以一个产品名称申请注册或者进行备案的配合使用产品或者组合包装产品，任何一剂的最后一道接触内容物的工序在境外完成的，按照进口产品管理。'可被翻译为：For products used in conjunction or combination products that apply for registration or file for filing under one product name, if any of the last process touching the contents are produced overseas, the set shall be regulated as imported products.\n\n根据上述已知信息，请将'第六十一条 化妆品最后一道接触内容物的工序在境内完成的为国产产品，在境外完成的为进口产品，在中国台湾、香港和澳门地区完成的参照进口产品管理。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 61 Cosmetics of which the last process touching the contents completes in China are domestic products, and those that completes overseas are imported products. Those that completes in Taiwan, Hong Kong SAR and Macau SAR shall be regulated by the reference of imported products."
    },
    {
        "instruction":"已知信息：\n'以治疗目的拟递送至细胞中的具有转录或翻译活性的遗传物质。不包括或化学合成的寡核苷酸。'可被翻译为：Transcriptionally or translationally active genetic material transferred by a vector intended to confer biological  activity following expression in cells\n\n根据上述已知信息，请将'通过转导的遗传物质的表达（转录\/翻译）或通过特异性改变人类细胞目的基因组来发挥作用的治疗产品。此定义用于本指导原则。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Therapeutic products that mediate their effect by the expression (transcription\/translation) of transferred genetic  materials, or by specifically altering the target genome of human cells.This definition is for the purpose of this guideline."
    },
    {
        "instruction":"已知信息：\n'（三）医疗器械注册人、备案人和受托生产企业名称、生产许可证号或者备案编号；'可被翻译为：(3) name of the registrant, filing entity and contract manufacturer of the medical device, manufacturing license number or filing number;\n\n根据上述已知信息，请将'（三）医疗器械注册人、备案人和受托生产企业名称、生产许可证编号或者备案编号。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(3) name of the registrant, filing entity and contract manufacturer of the medical device, manufacturing license number or filing number."
    },
    {
        "instruction":"已知信息：\n'可用于存储ttspp的总容量，考虑到所采用的负载支撑系统的类型(地板支撑托盘，可调节托盘货架或货架单元)，根据可以在商店中实现的利用率进行修改。'可被翻译为：The total volume available for storing TTSPPs, taking account of the type of load support system employed (floor-standing pallets, adjustable pallet racking or shelving units), as modified by the utilization factor that can be achieved in the store.\n\n根据上述已知信息，请将'考虑到库存单位(SKU)的类型、负载支持系统的类型和仓库中使用的库存管理系统，在实践中可以可靠地实现的可用于存储温度敏感药品(TTSPPS)的总体容量的百分比。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The percentage of the total volume available for storing temperature-sensitive pharmaceutical products (TTSPPS) that can reliably be achieved in practice, taking account of the types of stock-keeping unit (SKU), the types of load support system and the stock management systems used in the store."
    },
    {
        "instruction":"已知信息：\n'药物通过口服或注射，进入血液后再作用于病变部位的给药方式。'可被翻译为：The drug is administered orally or by injection, enters the blood stream, and then acts on the lesion site.\n\n根据上述已知信息，请将'需要药物主要作用于中枢神经系统时，把药物直接注入脊髓蛛网膜下腔的方法。注射点定位以左右韶后上棘的连线与后正中线的交接处，穿过韧带和硬脑脊膜、有脑脊液溢出的部位。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A method of injecting a drug directly into the subarachnoid space of the spinal cord when it is required to act primarily on the central nervous system. The injection point is located at the intersection of the line of the superior spine of the left and right Shao Shao and the median line of the back, through the ligament and the dura, where there is cerebrospinal fluid overflow."
    },
    {
        "instruction":"已知信息：\n'流动相的极性大于固定相极性的色谱方法。'可被翻译为：Chromatographic method in which the polarity of mobile phase is greater than that of stationary phase.\n\n根据上述已知信息，请将'采用高压输液系统，将具有不同极性的单一溶剂或不同比例的混合溶剂、缓冲液等流动相泵入固定相的色谱柱，对供试品进行分离测定的方法。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Using high pressure infusion system, the single solvent with different polarity or different proportion of mixed solvent, buffer and other mobile phase is pumped into the stationary phase column, and the test product is separated and determined."
    },
    {
        "instruction":"已知信息：\n'第五条 药品生产企业应当按照本办法的规定建立和完善药品召回制度，收集药品安全的相关信息，对可能具有安全隐患的药品进行调查、评估，召回存在安全隐患的药品。'可被翻译为：Article 5 Drug manufacturers shall establish and improve the drug recall system according to these Provisions, collect relevant drug safety information, investigate and assess drugs with potential safety hazards and recall drugs with safety hazards.\n\n根据上述已知信息，请将'第十五条 药品生产企业应当对收集的信息进行分析，对可能存在安全隐患的药品按照本办法第十二条、第十三条的要求进行调查评估，发现药品存在安全隐患的，应当决定召回。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 15 Drug manufacturers shall analyze information collected, investigate and assess drugs with potential safety hazards according to requirements of Article 12 and Article 13 of these Provisions and recall the drugs found to have safety hazards immediately."
    },
    {
        "instruction":"已知信息：\n'第三十五条 技术审评过程中需要申请人补正资料的，技术审评机构应当一次告知需要补正的全部内容。申请人应当在１年内按照补正通知的要求一次提供补充资料；技术审评机构应当自收到补充资料之日起60个工作日内完成技术审评。申请人补充资料的时间不计算在审评时限内。'可被翻译为：Article 35 Where supplementary and correction materials are required during technical evaluation, the technical evaluation institution shall inform the applicant one-off of all the supplements to be completed. The applicant shall submit all necessary supplementary and correction materials one-off within one year according to the supplementation notice. The technical evaluation institution shall complete the technical evaluation within 60 workdays from the date of acceptance of the supplements. The time spent by applicant for supplementing such materials shall not be calculated in the overall evaluation time.\n\n根据上述已知信息，请将'第二十八条 技术审评过程中需要申请人补正资料的，技术审评机构应当一次告知需要补正的全部内容。申请人应当在1年内按照补正通知的要求一次提供补充资料。技术审评机构应当自收到补充资料之日起40个工作日内完成技术审评。申请人补充资料的时间不计算在审评时限内。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 28 Where supplementary and correction materials are required during technical evaluation, the technical evaluation institution shall inform the applicant one-off of all the supplements to be completed. The applicant shall submit all necessary supplementary and correction materials one-off within one year according to the supplementation notice. The technical evaluation institution shall complete the technical evaluation within 40 workdays from the date of acceptance of the supplements. The time spent by applicant for supplementing such materials shall not be calculated in the overall evaluation time."
    },
    {
        "instruction":"已知信息：\n'定量研究毒物在体内吸收、分布、生物转化、排泄等过程随时间变化的动态规律的学科。'可被翻译为：The subject of quantitative study of the dynamic laws of the absorption, distribution, biotransformation and excretion of toxicants in the body over time.\n\n根据上述已知信息，请将'全称\"药物代谢动力学”。主要研究机体对药物的处置的动态变化，包括药物在机体内的吸收、分布、生物转化及排泄的过程，尤其是血药浓度随时间变化规律的学科。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Full name \"Pharmacokinetics\". It mainly studies the dynamic changes of the body's treatment of drugs, including the absorption, distribution, biotransformation and excretion processes of drugs in the body, especially the discipline of blood drug concentration changes with time."
    },
    {
        "instruction":"已知信息：\n'又称“C8柱二一种常用的高效液相色谱键合硅胶填料，是一种化学键合硅胶固定相。'可被翻译为：Also known as \"C8 column two, a commonly used high performance liquid chromatography bonded silica gel filler, is a chemically bonded silica gel stationary phase.\n\n根据上述已知信息，请将'又称“C]8柱\"。最常用的反相色谱键合硅胶填料。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Also known as \"C]8 column\". Most commonly used reversed phase chromatography bonding silica gel fillers."
    },
    {
        "instruction":"已知信息：\n'第五十二条 对于因品种特性或者注册核查工作遇到特殊情况，确需延长时限的，书面告知申请人延长时限，并通知药品审评中心，必要时通知其他相关专业技术机构。延长时限不超过原时限的二分之一。'可被翻译为：Article 52 If it is necessary to extend the time limit due to the variety characteristics or special circumstances of registration inspection, the applicant shall be informed in writing of the extension of the time limit, and CDE shall be notified, or other relevant professional and technical institutions shall be notified when necessary. The extension time limit shall not exceed one half of the original time limit.\n\n根据上述已知信息，请将'第一百零二条 因品种特性及审评、核查、检验等工作遇到特殊情况确需延长时限的，延长的时限不得超过原时限的二分之一，经药品审评、核查、检验等相关技术机构负责人批准后，由延长时限的技术机构书面告知申请人，并通知其他相关技术机构。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 102 Where it is necessary to extent the timeline due to product characteristics and special circumstances in review, inspection and\/or testing, the extension shall not be longer than 1\/2 of the original timeline. After the extension is approved by the person in charge of a technical institution for drug review, inspection or testing, the technical institution which extends the timeline shall inform the applicant in a written notice and notify other relevant technical institutions."
    },
    {
        "instruction":"已知信息：\n'5.经批准的工艺规程和操作规程；'可被翻译为：5) Approved master manufacturing documents and operation procedures;\n\n根据上述已知信息，请将'（一）审核和批准产品的工艺规程、操作规程等文件；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1. The review and approval of master manufacturing documents, procedures, etc;"
    },
    {
        "instruction":"已知信息：\n'（1）降低或阻碍某一化学反应的物质。（2）降低或抑制另一种物质（如酶）活性的物质。'可被翻译为：(1) A substance that reduces or hinders a chemical reaction. (2) A substance that reduces or inhibits the activity of another substance, such as an enzyme.\n\n根据上述已知信息，请将'能降低机体内胆固醇水平的物质。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A substance that lowers the level of cholesterol in the body."
    },
    {
        "instruction":"已知信息：\n'国家药监局关于发布《已上市生物制品变更事项及申报资料要求》的通告'可被翻译为：NMPA Announcement on Issuing the Requirements for Change Items and Application Dossiers of Marketed Biological Products\n\n根据上述已知信息，请将'国家药监局关于发布已上市化学药品变更事项及申报资料要求的通告'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"NMPA Notice on Issuing the Requirements for Change Items of Marketed Chemicals and Application Dossier"
    },
    {
        "instruction":"已知信息：\n'测定粉体比表面积的最基本方法，系将烘干脱气处理后的样品置于液氮中，由覆满粉体表面所需气体分子的值换算出粉体比表面积。'可被翻译为：The most basic method to determine the specific surface area of the powder is to place the sample after drying and degassing treatment in liquid nitrogen, and convert the specific surface area of the powder from the value of the gas molecules required to cover the surface of the powder.\n\n根据上述已知信息，请将'物质的表面具有表面张力6在恒温恒压下可逆地增大表面积必，则需功。必，因为所需的功等于物系自由能的增加，且这一增加是由于物系的表面积增大所致，故称为表面能。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The surface of a substance has surface tension 6 If the surface area is reversibly increased at constant temperature and pressure, work is required. Yes, because the work required is equal to the increase in the free energy of the system of matter, and this increase is caused by the increase in the surface area of the system of matter, it is called the surface energy."
    },
    {
        "instruction":"已知信息：\n'（五）组织检查本行政区域内药品生产、经营企业的药品不良反应报告和监测工作的开展情况，并与同级卫生行政部门联合组织检查本行政区域内医疗机构的药品不良反应报告和监测工作的开展情况；'可被翻译为：(V)  Organize inspection of ADR reporting and monitoring carried out by drug manufacturers and distributors within their administrative regions; jointly with the health administrative departments at the same level, organize inspection of ADR reporting and monitoring carried out by medical institutions within their administrative regions.\n\n根据上述已知信息，请将'（五）组织检查药品生产、经营企业的药品不良反应报告和监测工作的开展情况，并与卫生部联合组织检查医疗机构的药品不良反应报告和监测工作的开展情况。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(V)  Organize inspection of ADR reporting and monitoring carried out by drug manufacturers and distributors; organize inspection of ADR reporting and monitoring carried out by medical institutions jointly with the Ministry of Health."
    },
    {
        "instruction":"已知信息：\n'第三十三条 申办者应当在开展药物临床试验前在药物临床试验登记与信息公示平台登记药物临床试验方案等信息。药物临床试验期间，申办者应当持续更新登记信息，并在药物临床试验结束后登记药物临床试验结果等信息。登记信息在平台进行公示，申办者对药物临床试验登记信息的真实性负责。'可被翻译为：Article 33 The sponsor shall, before carrying out the drug clinical trial, submit the drug clinical trial protocol and other information on the drug clinical trial registry and information disclosure platform. During the drug clinical trial, the sponsor shall continually update the registered information and, after the drug clinical trial ends, submit results of the drug clinical trial and other related information. Information posted on the platform shall be disclosed to the public. The sponsor is responsible for the authenticity of registered information about the drug clinical trial.\n\n根据上述已知信息，请将'（三）药物临床试验结束后未登记临床试验结果等信息。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(3) Fail to register the clinical trial results and other information after completion of clinical trials."
    },
    {
        "instruction":"已知信息：\n'业务连续性计划'可被翻译为：business continuity plan\n\n根据上述已知信息，请将'定义由管理层支持和资助的持续过程的文件化计划，以确保采取必要步骤来识别潜在损失的影响，维持可行的恢复策略和恢复计划，并通过人员培训、计划测试和维护确保服务的连续性。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A documented plan that defines the ongoing process supported by management and funded to ensure that the necessary steps are taken to identify the impact of potential losses, maintain viable recovery strategies and recovery plans, and assure continuity of services through personnel training, plan testing and maintenance."
    },
    {
        "instruction":"已知信息：\n'第八十七条 生产设备应当有明显的状态标识，标明设备编号和内容物（如名称、规格、批号）；没有内容物的应当标明清洁状态。'可被翻译为：Article 87: Production equipment should be clearly labeled to indicate the equipment reference number and the contents (e.g. product name, strength, batch number, etc.). The equipment without contents should be labeled to indicate its cleaning status.\n\n根据上述已知信息，请将'第八十九条 主要固定管道应当标明内容物名称和流向。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 89: Main fixed pipes should be clearly labeled to indicate the contents and the direction of flow."
    },
    {
        "instruction":"已知信息：\n'与药物具有相同的分子式，但其分子中原子的空间排列不同并且为不能重合的镜像的化合物。'可被翻译为：A compound with the same molecular formula as the drug substance that differs in the spatial arrangement of atoms within the molecule and is a non-superimposable mirror image.\n\n根据上述已知信息，请将'组合化学中表示包含数量较多且为不同结构的化合物集合。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Combinatorial chemistry refers to a collection of compounds containing a large number and different structures."
    },
    {
        "instruction":"已知信息：\n'以临床效果指标作为健康产出，对两个或多个可选择的医疗干预进行经济学评价的方法。'可被翻译为：A method for the economic evaluation of two or more alternative medical interventions using clinical outcome indicators as health outcomes.\n\n根据上述已知信息，请将'以质量生命调整年作为健康产出，对两个或多个可选择的医疗干预进行经济学评价方法。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Quality life adjustment years (QLS) were used as health outcomes to evaluate two or more alternative medical interventions."
    },
    {
        "instruction":"已知信息：\n'药审中心受理1类创新药注册申请共700件（319个品种），（化学药的品种数以活性成分统计，中药和生物制品的品种数均以药品通用名称统计，下同），品种数较2018年增长了20.8%。其中，受理1类创新药的新药临床试验（IND）申请302个品种，较2018年增长了26.4%；受理1类创新药的新药上市申请（NDA）17个品种，较2018年减少了8个品种。'可被翻译为：CDE has accepted a total of 700 applications(involving 319 varieties, increased by 20.8% as compared with those in 2018) for the registration of Class 1 innovative drugs(the number of varieties of chemical drugs is based on the statistical analysis of active ingredients, while the varieties of TCMs and biological products are all counted by their generic names, the same below), covering 302 INDs (increased by 26.4% as compared with those in 2018) and 17 NDAs (decreased by 8 varieties as compared with those in 2018) for Class 1 innovative drugs.\n\n根据上述已知信息，请将'药审中心受理1类化药创新药注册申请157个品种，整体较2017年略有增加，其中受理创新药NDA 16个品种，较2017年增长了一倍。2018年受理的157个化药创新药注册申请中，国产化药创新药注册申请为115个品种，进口化药创新药注册申请为42个品种，2015年至2018年创新药注册申请受理情况详见图4。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"CDE accepted registration applications for 157 varieties of Class 1 innovative chemicals, covering 16 innovative NDAs (up by 100% YOY), 115 varieties of domestically produced innovative chemicals, and 42 imported ones. For such details from 2015 to 2018, see Figure 4."
    },
    {
        "instruction":"已知信息：\n'×1械注×2××××3×4××5××××6。其中：'可被翻译为：×1 XZ ×2××××3×4××5××××6. Among which,\n\n根据上述已知信息，请将'核磁共振谱中出现的一类多重峰。其峰数为5,峰高比为1：4：6：4：1。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A class of multimodal peaks occurring in NMR spectra. It has a peak number of 5 and a peak-to-height ratio of 1:4:6:4:1."
    },
    {
        "instruction":"已知信息：\n'用于对样品进行测量的设备应该有适当的验证和频繁的核查，确保结果可靠和可重复， 此类设备的例子包括称重天平、pH计、灭菌器、微生物计数器、手动\/自动读板器和紫 外可见光分光计。手动和自动读板器更多信息参见标题为抗生素效价测定章节：管碟法。'可被翻译为：Equipment used to provide a unit of measurement should have the appropriate validation and frequent verification checks to ensure reliable and reproducible results; examples of such equipment include a weight scale, pH meter, autoclave, micrometer, manual\/automatic plate reader and UV-VIS spectrophotometer. For more information on manual and automatic plate readers, see section titled Antibiotic Potency Testing: Plate Method.\n\n根据上述已知信息，请将'经过指定的培养时间后，取掉小管，灭活（即灭菌）并用肥皂和水清洗。小管再次用于检测之前要加热灭菌。使用手动\/自动读碟器测量每个 ZOI 的直径。ZOI 应由经过资格确认的实验室员工测量。使用手动\/自动读碟器测量 ZOI。手动读碟器的示例包括 Fisher_x0002_Lily 读碟器或手动\/电子圆规；手动读取需要将数据录入（例如手写和\/或电子）纸质记录和\/或电子日志和\/或数据表。自动读碟器的例子包括 OMNICON 或 Trinity V3。与手动读取不同，自动读碟器允许计算机化系统对培养碟进行测量，不需要录入原始数据。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"After the specified incubation time, the penicylinders are removed, decontaminated (i.e. \nautoclaved) and washed with soap and water. The penicylinders are then heat sterilized prior to \nre-use in test. The diameter of each ZOI is measured with a manual\/automatic plate reader. ZOIs should only be measured by qualified laboratory personnel. ZOI measurements are taken with the use of a manual or automatic plate reader. Examples of a manual reader include a Fisher_x0002_Lily zone reader or manual\/electronic calipers; manual reads require data entry (e.g. handwritten and\/or electronic) onto hardcopy and\/or into electronic logbooks and\/or spreadsheets. Examples \nof automated plate readers include OMNICON or Trinity V3. Unlike manual reads, automated \nplate readers allow a computerized system to measure the plates and do not require data entry of \nraw data."
    },
    {
        "instruction":"已知信息：\n'第一百七十七条 批包装记录应当依据工艺规程中与包装相关的内容制定。记录的设计应当注意避免填写差错。批包装记录的每一页均应当标注所包装产品的名称、规格、包装形式和批号。'可被翻译为：Article 177: A batch packaging record should be based on the relevant parts of the Packaging Instructions, and avoid transcription errors. The record should carry the product name, strength, package size and batch number on every page.\n\n根据上述已知信息，请将'第一百七十二条 批生产记录应当依据现行批准的工艺规程的相关内容制定。记录的设计应当避免填写差错。批生产记录的每一页应当标注产品的名称、规格和批号。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 172: A batch processing record should be based on the relevant parts of the currently approved master manufacturing documents. Such records should be designed to avoid transcription errors. The record should carry the product name, dosage form, strength and batch number on every page."
    },
    {
        "instruction":"已知信息：\n'第五十八条 疫苗上市许可持有人应当对疫苗进行质量跟踪分析，持续提升质量控制标准，改进生产工艺，提高生产工艺稳定性。'可被翻译为：Article 58 Vaccine MAHs shall carry out quality tracking analysis for vaccines and continuously improve quality control standards, production process and stability of the production process.\n\n根据上述已知信息，请将'第二十一条 国务院药品监督管理部门在批准疫苗注册申请时，对疫苗的生产工艺、质量控制标准和说明书、标签予以核准。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 21 The drug regulatory department under the State Council shall examine and approve the production process, quality control standards, package inserts and labels of vaccines during the approval process of the vaccine registration application."
    },
    {
        "instruction":"已知信息：\n'第一条 为规范药品生产质量管理，根据《中华人民共和国药品管理法》、《中华人民共和国药品管理法实施条例》，制定本规范。'可被翻译为：Article 1: These provisions of Good Manufacturing Practice (GMP) for Drugs, in accordance with the Drug Administration Law of the People's Republic of China and the Regulations for Implementation of the Drug Administration Law of the People's Republic of China, are enacted to regulate the manufacturing and quality management of Drugs.\n\n根据上述已知信息，请将'第一条 为加强药品经营质量管理，规范药品经营行为，保障人体用药安全、有效，根据《中华人民共和国药品管理法》、《中华人民共和国药品管理法实施条例》，制定本规范。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 1 To strengthen quality management of drug distribution, standardize drug distribution activities, and guarantee safe and effective use of drugs on human body, the Good Supply Practice for Drugs (GSP) is formulated in accordance with the Drug Administration Law of the People's Republic of China and the Regulations for Implementation of the Drug Administration Law of the People's Republic of China."
    },
    {
        "instruction":"已知信息：\n'注意，如果在需氧碟上发现有生长，则应与厌氧碟上的生长情况进行比较。在 分离完成之后进一步对其进行鉴别。'可被翻译为：Note if any growth is observed on aerobic plate and compare to growth on anaerobic plates. Proceed with identification when isolation is complete.\n\n根据上述已知信息，请将'注意，如果在通用生长培养碟中发现生长，则在分离完成后进一步进行鉴别。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Note if any growth is observed on general growth medium plate. Proceed with identification when isolation is complete."
    },
    {
        "instruction":"已知信息：\n'为推动药品注册技术标准与国际接轨，经研究，国家药品监督管理局决定适用《Q2（R1）：分析方法论证：正文和方法学》等11个国际人用药品注册技术协调会（ICH）指导原则（详见附件）。现就有关事项公告如下。'可被翻译为：To keep pace with the international technical standards for drug registration, NMPA has decided to apply 11 ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) guidelines, including the Q2(R1): Validation of Analytical Procedures: Text and Methodology. The relevant matters are hereby announced as follows.\n\n根据上述已知信息，请将'国家药监局关于适用《Q2（R1）：分析方法论证：正文和方法学》等11个国际人用药品注册技术协调会指导原则的公告'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Announcement of NMPA on Applying 11 ICH Guidelines Including Q2 (R1): Validation of Analytical Procedures: Text and Methodology"
    },
    {
        "instruction":"已知信息：\n'药代动力学'可被翻译为：Pharmacokinetics\n\n根据上述已知信息，请将'在该指导原则的全文中均用术语“动力学”表达其含义，该术语在此并不是具体指药代和\/或毒代动力学。尚无可更好地表达该术语的单词。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The term \"kinetics\" is used consistently throughout this guideline, irrespective of intending to mean pharmaco- and\/or toxicokinetics. No better single term was available."
    },
    {
        "instruction":"已知信息：\n'重伤(也称为健康状况严重恶化)是:——危及生命的疾病或伤害;——身体功能的永久性损伤或对身体的永久性损伤;—需要医疗或手术干预以防止身体功能永久性损伤或身体结构永久性损伤的情况(28)。'可被翻译为：Serious injury (also known as serious deterioration in state of health) is either: –– life- threatening illness or injury; –– permanent impairment of a body function or permanent damage to a body; –– a condition necessitating medical or surgical intervention to prevent permanent impairment of a body function or permanent damage to a body structure (28).\n\n根据上述已知信息，请将'严重不良事件，是指临床试验过程中发生的导致死亡或者健康状况严重恶化，包括致命的疾病或者伤害、身体结构或者身体功能的永久性缺陷、需住院治疗或者延长住院时间、需要进行医疗或者手术介入以避免对身体结构或者身体功能造成永久性缺陷；导致胎儿窘迫、胎儿死亡或者先天性异常、先天缺损等事件。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The serious adverse event refers to event of death or serious deterioration of physical health during the clinical trial, including deadly illnesses or injuries, permanent defect in body structure or body function, and event where hospitalization or prolonged hospitalization, medical or surgical intervention is needed to avoid permanent defect to body structure or body function; and events that causes fetal distress, fetal death, or congenital anomalies or defects."
    },
    {
        "instruction":"已知信息：\n'（一）未履行监督检查职责，或者发现违法行为不及时查处；'可被翻译为：(1) failing to perform duties of supervision and inspection, or failing to promptly investigate and punish any illegal act that has been identified;\n\n根据上述已知信息，请将'（二）对发现的药品安全违法行为未及时查处；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(2) failing to promptly investigate and deal with drug safety violation upon discovery;"
    },
    {
        "instruction":"已知信息：\n'修订内容涉及药品标签的，应当一并进行修订；说明书及标签其他内容应当与原批准内容一致。在补充申请备案后9个月内对所有已出厂的药品说明书及标签予以更换。'可被翻译为：If the modification relates to the label of the drug, the latter shall be modified together; the other content of the package insert and the label shall be consistent with the original approved ones. All the insert sheets and labels of exfactory drugs shall be changed within 9 months after the record filing of the supplementary application.\n\n根据上述已知信息，请将'一、相关品种的上市许可持有人可依据《药品注册管理办法》等有关规定，按照相应修订建议，向国家药监局药品审评中心提出补充申请，修订说明书【适应症】和【用法用量】项有关内容，并同时完善说明书安全性信息等相关内容。修订内容涉及药品标签的，应当一并进行修订。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"I. The marketing authorization holders of relevant varieties may, based on the Provisions for Drug Registration and in accordance with corresponding revision suggestions, submit the supplementary application to the Center for Drug Evaluation of NMPA, revise the [Indications] and [Usage and Dosage] of the package insert, and simultaneously improve the safety information and other relevant contents in the package insert. If revision relates to the drug label, the latter shall be modified together."
    },
    {
        "instruction":"已知信息：\n'毛细管色谱分析中，在毛细管柱的出口端引入的一路气流。其作用是减少柱后的死体积，改善柱效，满足检测器的最佳气体流速，以提高检测器的灵敏度。'可被翻译为：In capillary chromatography, a stream of air introduced at the exit of a capillary column. Its role is to reduce the dead volume behind the column, improve the column efficiency, meet the best gas flow rate of the detector, in order to improve the sensitivity of the detector.\n\n根据上述已知信息，请将'一种与电离装置结合在一起的接口。以喷雾探针为进样渠道，色谱柱后流出物以l~2ml\/min流速，经过喷雾探针中心部位的不锈钢毛细管流入，形成气溶胶，并在毛细管出口前被加热管剧烈加热，其溶剂迅速蒸发，体积迅速膨胀后以超音速喷出毛细管，从而形成由微小液滴、粒子和蒸气组成的雾状混合物。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"An interface that is combined with an ionization device. With the spray probe as the sample channel, the effluent after the chromatograph column flows through the stainless steel capillary in the center of the spray probe at the flow rate of l~2ml\/min, forming an aerosol, and is heated violently by the heating tube before the capillary outlet, the solvent evaporates rapidly, and the volume expands rapidly after ejecting the capillary tube at supersonic speed. Thus forming a mist mixture composed of tiny droplets, particles and vapors."
    },
    {
        "instruction":"已知信息：\n'国家药品监督管理局化妆品技术审评机构（以下简称技术审评机构）负责特殊化妆品、化妆品新原料注册的技术审评工作，进口普通化妆品、化妆品新原料备案后的资料技术核查工作，以及化妆品新原料使用和安全情况报告的评估工作。'可被翻译为：The cosmetic technical assessment agency of the NMPA (hereinafter referred to as the technical assessment agency) is responsible for the technical assessment of the registration of special cosmetics and new cosmetic ingredients, the technical verification of imported general cosmetics and the new cosmetic ingredients after filing, and the evaluation of the use and safety reports of new cosmetic ingredients.\n\n根据上述已知信息，请将'第二十五条 技术审评机构收到省、自治区、直辖市药品监督管理部门或者化妆品新原料注册人、备案人的反馈或者报告后，应当结合不良反应监测机构的化妆品年度不良反应统计分析结果进行评估，认为通过调整化妆品新原料技术要求能够消除安全风险的，可以提出调整意见并报告国家药品监督管理局；认为存在安全性问题的，应当报请国家药品监督管理局撤销注册或者取消备案。国家药品监督管理局应当及时作出决定。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 25 The technical assessment agency shall, after receiving the feedback or report from the drug regulatory department of the province, autonomous region, or municipality, or the registrant and filing person of new cosmetic ingredients, assess the situation in accordance with the annual statistical analysis results of cosmetic adverse reactions from the adverse reaction monitoring agency. When believing that the safety risks can be eliminated by adjusting technical requirements of the new cosmetic ingredients, the technical assessment agency may propose opinions of adjustment and report to the NMPA; when believing that there are safety issues, the technical assessment agency shall report to the NMPA and request to revoke the registration or nullify the filing. The NMPA shall make decisions in a timely manner."
    },
    {
        "instruction":"已知信息：\n'两方或多方之间的正式协议。公司和组织可以使用谅解备忘录建立正式的合作伙伴关系。谅解备忘录不具有法律约束力，但它们具有一定程度的严肃性和相互尊重，比君子协议更有力。'可被翻译为：A formal agreement between two or more parties. Companies and organizations can use MoUs to establish official partnerships. MoUs are not legally binding but they carry a degree of seriousness and mutual respect, stronger than a gentlemen’s agreement.\n\n根据上述已知信息，请将'正式的商业文件，概述了与另一个个人、团体或实体达成的协议的基本条款。这是签订更详细合同的第一步。其他名称包括但不限于谅解备忘录、合作合同或合作协议。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A formal business document outlining the basic terms of an agreement with another individual, group or entity. It is one of the first steps towards a more detailed contract. Alternative names include, but are not limited to, memorandum of understanding, cooperation contract or collaboration agreement."
    },
    {
        "instruction":"已知信息：\n'境内第一类体外诊断试剂备案，备案人向设区的市级食品药品监督管理部门提交备案资料。'可被翻译为：To apply for filing of class I in-vitro diagnostic reagent, the filing entity shall submit the filing documents to the food and drug regulatory department of the city consisting of districts .\n\n根据上述已知信息，请将'境内第一类医疗器械备案，备案人向设区的市级食品药品监督管理部门提交备案资料。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"To apply for filing of class I domestic medical devices, the filing entity shall submit the filing documents to the food and drug regulatory department of the city consisting of districts ."
    },
    {
        "instruction":"已知信息：\n'为贯彻落实《中华人民共和国疫苗管理法》规定，按照《关于药品信息化追溯体系建设的指导意见》（国药监药管〔2018〕35号）等文件要求，国家药监局组织制订了3项信息化标准：《药品追溯系统基本技术要求》《疫苗追溯基本数据集》《疫苗追溯数据交换基本技术要求》于2019年8月27日发布，自发布之日起实施。'可被翻译为：To implement the provisions of the Vaccine Administration Law of the People's Republic of China, per the Guiding Opinions on the Construction of Drug Informationization Traceability System (NMPA Department of Drug Supervision (2018) No. 35) and other documents, NMPA has organized the formulation of three Informationization Standards: the Basic Technical Requirements for Drug Traceability System, Basic Dataset for Vaccine Traceability, and Basic Technical Requirements for Vaccine Traceability Data Exchange, which were released on August 27, 2019, and effective as of the date of publication.\n\n根据上述已知信息，请将'为贯彻落实《中华人民共和国药品管理法》的规定，按照《国家药品监督管理局关于药品信息溯源系统建设的指导意见》(国家药品监督管理局[2018]35号)等文件要求，国家药监局组织编制了《药品上市许可持有人和生产企业溯源基本数据集》。《药品经营企业可追溯性基本数据集》、《使用单位可追溯性基本数据集》、《消费者可追溯性药品基本数据集》、《药品可追溯性数据交换基本技术要求》于2020年3月11日发布，自发布之日起施行。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"To implement the provisions of the Drug Administration Law of the People's Republic of China, in accordance with the requirements of the Guiding Opinions of the China National Drug Administration on the Construction of Drug Information Traceability System (CNDA Department of Drug Supervision [2018] No. 35) and other documents, NMPA organized the formulation of the Basic Data Sets for Traceability of Drug Marketing Authorization Holders and Manufacturers, Basic Data Sets for Traceability of Drug Distributors, Basic Data Sets for Traceability of Drug Using Units, Basic Data Sets for Traceable Drugs for Consumers, and Basic Technical Requirements for Traceability Data Exchange of Drugs, which were issued on March 11, 2020, and effective as of the issuing date."
    },
    {
        "instruction":"已知信息：\n'第一百零五条 药品监督管理部门应当依照法律、法规的规定对药品研制活动进行监督检查，必要时可以对为药品研制提供产品或者服务的单位和个人进行延伸检查，有关单位和个人应当予以配合，不得拒绝和隐瞒。'可被翻译为：Article 105 Drug regulatory departments shall, in accordance with laws and regulations, supervise and inspect drug R&D activities and, when necessary, carry out extended inspection of entities and individuals providing products or services for drug R&D. Relevant entities and individuals shall provide cooperation and shall not refuse inspection or conceal information.\n\n根据上述已知信息，请将'药品监督管理部门应当加强对疫苗上市许可持有人的现场检查；必要时，可以对为疫苗研制、生产、流通等活动提供产品或者服务的单位和个人进行延伸检查；有关单位和个人应当予以配合，不得拒绝和隐瞒。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The drug regulatory departments shall strengthen the on-site inspection on vaccine MAHs. If necessary, regulatory departments may conduct extended inspections on entities or individuals who provide products or services for vaccine development, manufacture and distribution, and relevant entities and individuals shall cooperate and not reject the inspection or conceal any information."
    },
    {
        "instruction":"已知信息：\n'进口麻醉药品、精神药品,海关凭国家食品药品监督管理局核发的麻醉药品、精神药品《进口准许证》办理报关验放手续。'可被翻译为：To import narcotic drugs and psychotropic substances, the customs shall perform customs clearance on the basis of the Import License for narcotic drugs and psychotropic substances issued by the State Food and Drug Administration.\n\n根据上述已知信息，请将'为落实国务院常务会议关于进出口环节监管证件实现网上申报、网上办理的工作要求，国家药监局整合开发了药品业务应用系统，用于进出口环节药品监管证件业务办理，包括药品出口销售证明、出口欧盟原料药证明文件、麻醉药品和精神药品进出口准许证、首次进口药材等事项。该系统同时具备麻醉药品和精神药品研制立项、中药提取物备案的网上申请与办理功能。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In order to implement the requirements of the Executive meeting of The State Council on the implementation of online declaration and online processing of import and export regulatory documents, the State Food and Drug Administration has integrated and developed a drug business application system for the import and export process of drug regulatory documents. Including drug export sales certificates, export documents of EU raw material drugs, narcotics and psychotropic drugs import and export permits, first import of medicinal materials and other matters. The system also has the function of online application and management for the development of narcotic drugs and psychotropic drugs and the filing of traditional Chinese medicine extracts."
    },
    {
        "instruction":"已知信息：\n'关键质量属性（CQA）、关键工艺参数（CPP）和中控；'可被翻译为：critical quality attributes (CQAs), critical process parameters (CPPs) and in-process controls;\n\n根据上述已知信息，请将'高风险公用设施的关键参数和关键质量属性的结果应定期进行趋势分析，以确保系统性能保持适当。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Results for critical parameters and critical quality attributes of high risk utilities should be subject to regular trend analysis to ensure that system capabilities remain appropriate."
    },
    {
        "instruction":"已知信息：\n'由于不同DNA链的断裂和连接而产生DNA片段的交换和重新组合，形成新DNA分子的过程。'可被翻译为：The process of the exchange and recombination of DNA fragments resulting from the breaking and joining of different DNA strands to form new DNA molecules.\n\n根据上述已知信息，请将'除去并连接DNA、RNA或多肽链片段，形成新的遗传重组体或改变原有的遗传结构的过程。如DNA重组时的剪接过程。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The process of removing and joining fragments of a DNA, RNA, or polypeptide chain to form a new genetic recombination or to alter the original genetic structure. The process of splicing, as in DNA recombination."
    },
    {
        "instruction":"已知信息：\n'一种用于软膏剂溶出研究的装置。'可被翻译为：The invention relates to an apparatus for studying the dissolution of ointment.\n\n根据上述已知信息，请将'用于度量两个药品溶出特性的方法。常用相似因子仪）表示。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A method for measuring the dissolution characteristics of two drugs. Commonly used similitude factor meter) representation."
    },
    {
        "instruction":"已知信息：\n'就本指南而言，无菌产品是指暴露于无菌条件下的一种或多种灭菌元件，并最终构成无菌原料药或无菌成品。这些要素包括成品药品的容器、瓶盖和组分。或者，通过终端灭菌过程实现无菌的产品。'可被翻译为：For the purpose of this guidance, sterile product refers to one or more of the sterilized elements exposed to aseptic conditions and, ultimately, making up the sterile active substance or finished sterile product. These elements include the containers, closures and components  of the finished drug product. Or, a product that is rendered sterile by a terminal sterilization process.\n\n根据上述已知信息，请将'把整个制备过程控制在无菌条件下进行的一种操作方法。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A process in which the entire preparation process is controlled under sterile conditions."
    },
    {
        "instruction":"已知信息：\n'质量管理的一部分，着重于设定质量目标，并详细规定必要的操作程序和相关资源以实 现质量目标。(ISO 9000:2005)'可被翻译为：Part of quality management focused on setting quality objectives and specifying necessary operational processes and related resources to fulfil the quality objectives. (ISO 9000:2005)\n\n根据上述已知信息，请将'1.质量管理的一部分侧重于设定质量目标，规定必要的操作过程和相关资源以实现质量目标。\n2.作为质量管理的一部分，质量策划需要设定质量目标，并规定实现质量目标所需的操作过程和相关资源。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.Part of quality management focused on setting quality objectives and specifying necessary operational processes and related resources to fulfil the quality objectives.\n2.Part of quality management, quality planning entails setting quality objectives and specifying necessary operational processes and related resources to fulﬁl the quality objectives."
    },
    {
        "instruction":"已知信息：\n'下表是技术转移通常所需文件举例'可被翻译为：The table below provides an example of documentation commonly required for the transfer of technology.\n\n根据上述已知信息，请将'技术转移通常所需文件举例'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Example of documentation commonly required for the transfer of technology*"
    },
    {
        "instruction":"已知信息：\n'醛糖还原酶抑制药'可被翻译为：aldose reductase inhibitors\n\n根据上述已知信息，请将'能抑制醛糖还原酶，阻止体内葡萄糖转化为山梨醇积聚而引发的糖尿病性外周神经病症状的一药物。如依帕司他。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A drug that inhibits aldose reductase and prevents the conversion of glucose in the body to the accumulation of sorbitol in diabetic peripheral neuropathy symptoms. Such as epalrestat."
    },
    {
        "instruction":"已知信息：\n'一种通过选择3个合适的波长，经过计算消除共存组分的分光光度法。'可被翻译为：A spectrophotometric method for calculating the elimination of coexisting components by selecting three suitable wavelengths.\n\n根据上述已知信息，请将'两种以上组分共存时，根据各组分吸收光谱相互重叠的程度分别考虑建立的光谱分析方法。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"When more than two kinds of components coexist, the spectral analysis method is respectively considered according to the degree of overlap of the absorption spectra of each component."
    },
    {
        "instruction":"已知信息：\n'证明当局是否对该药品的实际生产企业进行定期检查'可被翻译为：Does the certifying authority arrange for periodic inspections of the manufacturing plant in which the dosage form is produced\n\n根据上述已知信息，请将'申请人所提供的信息是否满足证明当局的要求'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Does the information submitted by the applicant satisfy the certifying authority on all aspects of the manufacture of the product"
    },
    {
        "instruction":"已知信息：\n'是指出现在治疗期间的、但在治疗前未曾发生或比治疗\n前明显恶化的事件。'可被翻译为：An event that emerges during treatment having been absent pre-treatment, or worsens relative to the pre-treatment state.\n\n根据上述已知信息，请将'根据所有治疗中的潜在发生情况，对受试者进行的分类。以两种治疗为例 ，针对特定的，有四个主层：任一治疗期间均不会发生事件的受试者，在 A 治疗期间会发生事件但在 B 治疗期间不会发生事件的受试者，在 B 治疗期间会发生事件但在 A 治疗期间不会发生事件的受试者，以及在两种治疗期间均会发生事件的受试者。在本文件中，主层是指主分层定义的任何分层（或分层组合）'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Classification of subjects according to the potential occurrence of an intercurrent event on all treatments. With two treatments, there are four principal strata with respect to a given intercurrent event: subjects who would not experience the event on either treatment, subjects who would experience the event on treatment A but not B, subjects who would experience the event on treatment B but not A, and subjects who would experience the event on both treatments. In this document a principal stratum refers to any of the strata (or combination of strata) defined by principal stratification."
    },
    {
        "instruction":"已知信息：\n'第五条 国家药品监督管理局负责特殊化妆品、进口普通化妆品、化妆品新原料的注册和备案管理，并指导监督省、自治区、直辖市药品监督管理部门承担的化妆品备案相关工作。国家药品监督管理局可以委托具备相应能力的省、自治区、直辖市药品监督管理部门实施进口普通化妆品备案管理工作。'可被翻译为：Article 5 The National Medical Products Administration (NMPA) is responsible for the registration and filing administration of special cosmetics, imported general cosmetics and new cosmetic ingredients, and guiding and supervising the related cosmetic filing work undertaken by the drug regulatory departments of provinces, autonomous regions, and municipalities. The NMPA may entrust the drug regulatory departments of provinces, autonomous regions, and municipalities directly under the Central Government that have corresponding capabilities to implement the filing administration of imported general cosmetics.\n\n根据上述已知信息，请将'第六条 省、自治区、直辖市药品监督管理部门负责本行政区域内国产普通化妆品备案管理工作，在委托范围内以国家药品监督管理局的名义实施进口普通化妆品备案管理工作，并协助开展特殊化妆品注册现场核查等工作。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 6 The drug regulatory departments of provinces, autonomous regions and municipalities are responsible for the filing administration of domestic general cosmetics within their administrative areas, implementing the filing administration of imported general cosmetics in the name of the NMPA within the scope of entrustment, and assisting in the on-site inspection for registration of special cosmetics etc."
    },
    {
        "instruction":"已知信息：\n'为一组蛋白酶，使纤溶酶原激活生成有活性的纤溶酶。包括：①组织纤溶酶激动剂，如阿替普酶（tPA）等；②尿激酶：③链激酶。'可被翻译为：For a group of proteases, plasminogen is activated to produce an active plasminase. It includes: ① tissue plasminase agonists, such as Alteplase (tPA); ② urokinase: ③ streptokinase.\n\n根据上述已知信息，请将'可使血管中血栓纤维蛋白凝块溶解、恢复血供的药物。如阿替普酶、尿激酶、链激酶、瑞替普酶、拉诺替普酶等。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"It can dissolve thrombus fibrin clot in blood vessels and restore blood supply. Such as alteplase, urokinase, streptokinase, Reteplase, Lanoteplase, etc."
    },
    {
        "instruction":"已知信息：\n'包装操作的转移应该遵守与产品工艺相同的程序原则。'可被翻译为：12.25. The transfer of packaging operations should follow the same procedural principles as those of the product processing.\n\n根据上述已知信息，请将'RU应该确定是否需要对包装工艺进行确认和验证。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"12.26. RU should determine the need for qualification and validation for the packaging process."
    },
    {
        "instruction":"已知信息：\n'又称\"碳水化合物”。多羟基醛、多羟基酮以及能水解而生成多羟基醛或多羟基酮的有机化合物。由碳、氢、氧三种元素组成的一类化合物，其中氢和氧的比例与水分子中氢和氧的比例相同。'可被翻译为：Also known as \"carbohydrate\". Polyhydroxy aldehydes, polyhydroxy ketones, and organic compounds capable of hydrolysis to produce polyhydroxy aldehydes or polyhydroxy ketones. A class of compounds consisting of three elements, carbon, hydrogen, and oxygen, in which the ratio of hydrogen to oxygen is the same as in the water molecule.\n\n根据上述已知信息，请将'药物与含有多羟基化合物载体（如聚乙烯毗咯烷酮（PVP）等）以恰当比例形成的非结晶性无定型物。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"An amorphous substance formed in appropriate proportions with a carrier containing polyhydroxyl compounds, such as polyvinylpirolidone (PVP)."
    },
    {
        "instruction":"已知信息：\n'第三十二条 药品监督管理部门可以采取暂停生产、销售、使用或者召回药品等控制措施。卫生行政部门应当采取措施积极组织救治患者。'可被翻译为：Article 32 Drug regulatory departments may take such control measures as suspension of production, sales and use or recall of drugs. Health administrative departments shall take active measures to organize treatment of patients.\n\n根据上述已知信息，请将'同级卫生行政部门应当在本行政区域内暂停医疗机构使用相关医疗器械，采取措施积极组织救治患者。相关持有人应当予以配合。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The health administrative departments at the same level shall suspend the use of relevant medical devices in the medical institutions within their respective administrative regions and take measures to actively organize the treatment for patients. The relevant MAHs shall be cooperative."
    },
    {
        "instruction":"已知信息：\n'（二）协助注册人、备案人开展化妆品不良反应监测、化妆品新原料安全监测与报告工作；'可被翻译为：(2) Assisting the registrants and filing persons in carrying out cosmetic adverse reaction monitoring, safety monitoring and reporting of new cosmetic ingredients;\n\n根据上述已知信息，请将'（三）协助注册人、备案人实施化妆品、化妆品新原料召回工作；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(3) Assisting the registrants and filing persons in implementing the recall of cosmetics and new cosmetic ingredients;"
    },
    {
        "instruction":"已知信息：\n'每个容器接种一个准备好的标准化接种菌并混合。所用混悬液接种菌的体积为产品体积的0.5% 到1.0%。加入1，2和3类产品的测试微生物浓度使得接种后立即测试的制备物浓度在每毫升产 品含1105至1106 CFU之间。加入4类产品（抗酸性产品）的最终测试微生物浓度在每毫升 产品含1103至1104CFU之间。'可被翻译为：of the prepared and standardized inoculums and mix. The volume of the suspension inoculums used is 0.5% to 1.0% of the volume of the product. The concentration of the test organisms added to the product for Categories 1, 2 and 3 is such that concentration of the test preparation immediately after inoculation is between 1x105 and 1x106 colony forming organisms (CFU) per mL of product. For category 4 products (antacids) the final concentration of the test organisms is between 1x103 and 1x104 CFU\/mL of product.\n\n根据上述已知信息，请将'立即测定每个接种混悬液中活菌的浓度，并通过平板计数法计算CFU\/mL的初始浓度（参见微 生物计数测试和特定微生物测试）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Immediately determine the concentration of viable organisms in each inoculum suspension and calculate the initial concentration of CFU\/mL by the plate count method (see Microbial Enumeration Tests )."
    },
    {
        "instruction":"已知信息：\n'IVRT灵敏度是检测释放速率变化的能力，其中，释放速率为配方制剂中药物浓度的函数。如果在相同的日期，对RS、较高规格和较低规格的配方制剂进行平行研究，相对于RS，较高规格或较低规格的配方制剂能分别呈现出较高或较低释放速率，则认为IVRT方法是灵敏的。'可被翻译为：IVRT sensitivity is the ability to detect changes in the release rate, as a function of drug concentration in the formulation. If the IVRT method consistently identifies higher or lower rates of release for test formulations with increased or decreased drug concentrations, respectively, relative to the formulation at the nominal strength of the RS run in parallel on the same day, the IVRT method would generally be considered sensitive.\n\n根据上述已知信息，请将'IVRT专属性是不同规格制剂产品释放速率变换比例的函数，其中一些或可能所有配方制剂均是小批量实验室批次，每种规格的配方成分略有不同，以适应不同规格产品中活性成分的不同含量。这种不同规格制剂产品配方的轻微变化可能影响不同规格制剂产品释放速率的理想变化比例。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"IVRT specificity is a function of the proportionality of release rates across different strengths of the product, some, or all of which may be formulated as small-scale laboratory batches, with each strength having a slightly different formulation composition to accommodate for the different amount of the active ingredient in that strength of the product. These slight formulation differences across the different strengths of the product may impact the ideal proportionality of release rates across the different strengths of the product."
    },
    {
        "instruction":"已知信息：\n'预先确定每种抗生素的中值标准品（【S3】）的吸光度。参考USP<81>中测试参数 和可接受数据要求'可被翻译为：Absorbance values of the media reference standard ([S3]) are predetermined per antibiotic. Refer USP<81> for testing parameters and acceptable data requirements.\n\n根据上述已知信息，请将'预先测定培养基对照标准（【S3】）的单位抗生素吸光度值。参见 USP<81>中检测\n参数和可接受的数据要求'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2. Absorbance values of the media reference standard ([S3]) are predetermined per antibiotic. \nRefer USP <81> for testing parameters and acceptable data requirements."
    },
    {
        "instruction":"已知信息：\n'（七）禁忌症、注意事项、警示以及提示的内容；'可被翻译为：(7) Contraindications, precautions, warnings and suggestive descriptions.\n\n根据上述已知信息，请将'（十五）临床试验结果分析、讨论，尤其是适应症、适用范围、禁忌症和注意事项；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(15) Analysis and discussion of clinical trial results, in particular, indications, scope of application, contraindications and precautions;"
    },
    {
        "instruction":"已知信息：\n'医疗器械说明书和标签中的文字、符号、表格、数字、图形等应当准确、清晰、规范。'可被翻译为：Words, symbols, tables, figures and graphics in the instructions and labels of medical devices shall be accurate, clear and standardized.\n\n根据上述已知信息，请将'（一）文字、符号、数字的字号不规范，或者出现多字、漏字、错别字、非规范汉字的；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(1) the font size of characters, symbols, and numbers is not standardized, or there are multiple characters, missing characters, wrongly written characters, and non-standard Chinese characters;"
    },
    {
        "instruction":"已知信息：\n'一种应用天然蛋白质阵列分析技术进行结构测定的蛋白质组学学科。'可被翻译为：A discipline of proteomics that uses natural protein array analysis techniques for structural determination.\n\n根据上述已知信息，请将'高密度的蛋白质阵列，是蛋白质阵列的发展。在几平方厘米的面积中可以包含几万个不同的蛋白质点，可用于大规模的分析。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"High-density protein arrays are the development of protein arrays. Tens of thousands of different protein spots can be contained in an area of a few square centimeters, which can be used for large-scale analysis."
    },
    {
        "instruction":"已知信息：\n'4.对于涉及微生物限度、无菌等项目的规范，为避免样品污染，还应提供用于该检验的独立包装样品。'可被翻译为：4.For specifications involving microbial limits, sterility and other test items, to avoid sample contamination, the individually packaged samples for this test shall also be provided.\n\n根据上述已知信息，请将'4.对于涉及微生物限度、无菌等项目的标准，为避免样品污染，还应提供用于该检验的独立包装样品。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"4.For specifications involving microbial limits, sterility and other test items, to avoid sample contamination, the individually packaged samples for this test shall also be provided."
    },
    {
        "instruction":"已知信息：\n'核查，是指由申办者组织的对临床试验相关活动和文件进行系统性的独立检查，以确定此类活动的执行、数据的记录、分析和报告是否符合临床试验方案、标准操作规程、本规范和有关适用的管理要求。'可被翻译为：The verification refers to the systematic independent inspection of relevant clinical trial activities and documents organized by the sponsor, so as to determine whether the implementation of such activities, data recording, analysis and reporting conform to the clinical trial protocol, standard operating procedures, the GCP and applicable management requirements.\n\n根据上述已知信息，请将'检查，是指监管部门对临床试验的有关文件、设施、记录和其他方面进行的监督管理活动。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The inspection refers to the supervision and administration activities carried out by the regulatory department for inspecting relevant clinical trial documents, facilities, records and other aspects."
    },
    {
        "instruction":"已知信息：\n'未鉴定的降解产物'可被翻译为：unidentified degradation product\n\n根据上述已知信息，请将'已被列入新药制剂质量标准中并规定了认可标准的降解产物。一个特定的降解产物可以是结构已经鉴定或未鉴定的。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A degradation product that is individually listed and limited with a specific acceptance criterion in the new drug product specification. A specified degradation product can be either identified or unidentified."
    },
    {
        "instruction":"已知信息：\n'现场核查过程中认为有必要进行样品检验的，经报核查中心同意后，核查组按照药品抽样的有关要求，抽取样品并封样，抽样情况应当在核查报告中进行描述；样品按要求送交药品检验机构进行样品检验。'可被翻译为：If it is deemed necessary to conduct sample inspection during the on-site inspection, the inspection team shall, with the approval of CFDI, take samples and seal them in accordance with the relevant requirements on drug sampling, and the sampling situation shall be described in the inspection report. The samples shall be sent to the drug testing institution for sample testing as required.\n\n根据上述已知信息，请将'第三十一条 有因检查需要由核查组抽取样品进行检验的，核查组按照药品抽样的有关要求，抽取样品并封样；抽取的样品按要求送交药品检验机构进行样品检验。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 31 If the inspection team needs to take samples for cause-related inspection, the inspection team shall take samples and seal them in accordance with the relevant requirements for drug sampling; the samples shall be sent to the drug testing institution for sample testing as required."
    },
    {
        "instruction":"已知信息：\n'第一百三十条 在营业场所内，企业工作人员应当穿着整洁、卫生的工作服。'可被翻译为：Article 130 In the business premises, personnel of enterprises shall wear neat and hygienic working clothes.\n\n根据上述已知信息，请将'第一百四十四条 营业场所应当具有相应设施或者采取其他有效措施，避免药品受室外环境的影响，并做到宽敞、明亮、整洁、卫生。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 144 Business premises shall be equipped with appropriate facilities or other effective measures shall be taken to prevent drugs from being affected by the outdoor environment, and the premises shall also be spacious, bright, clean and hygienic."
    },
    {
        "instruction":"已知信息：\n'第三十六条 药品经营企业、使用单位违反本办法第六条规定的，责令停止销售和使用，并处1000元以上5万元以下罚款；造成严重后果的，由原发证部门吊销《药品经营许可证》或者其他许可证。'可被翻译为：Article 36 Drug distributors and users who violate the provisions in Article 6 of these Provisions shall be ordered to stop selling and using the drug and fined an amount more than 1,000 Yuan and less than 50 ,000Yuan; for those who have caused serious consequences, the original certificate-issuing department shall revoke their Drug Supply Certificate or other certificates.\n\n根据上述已知信息，请将'第三十二条 医疗器械经营企业、使用单位违反本办法第七条第一款规定的，责令停止销售、使用存在缺陷的医疗器械，并处5000元以上3万元以下罚款；造成严重后果的，由原发证部门吊销《医疗器械经营许可证》。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 32 A medical device distributor or using unit that violates the Provisions of the Paragraph 1, Article 7 of these Provisions shall be ordered to stop the sale and use of defective medical devices, and a fine of not less than 5,000 Yuan but not more than 30,000 Yuan shall be imposed concurrently; for those who have caused serious consequences, the former license issuing department shall revoke their Medical Device Distribution License."
    },
    {
        "instruction":"已知信息：\n'根据监管机构制定的要求，对制造商产生的证据和采取的程序进行系统检查，以确定医疗器械是安全的，并按制造商的预期运行，因此符合医疗器械安全和性能的基本原则(32)。'可被翻译为：The systematic examination of evidence generated, and procedures undertaken, by the manufacturer, under requirements established by the regulatory authority, to determine that a medical device is safe and performs as intended by the manufacturer and, therefore conforms to the Essential principles of safety and performance for medical devices (32).\n\n根据上述已知信息，请将'文件化证据，通常是质量管理体系的输出，证明医疗器械符合立法规定的相关安全、性能和标签原则(32)。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The documented evidence, normally an output of the quality management system that demonstrates the medical device complies with the relevant principles of safety, performance and labelling specified through legislation (32)."
    },
    {
        "instruction":"已知信息：\n'（三）首营企业：采购药品时，与本企业首次发生供需关系的药品生产或者经营企业。'可被翻译为：(III) First commercial enterprise: the drug manufacturer or distributor that has the supply and demand relation with the enterprise in the purchase of drugs;\n\n根据上述已知信息，请将'（四）首营品种：本企业首次采购的药品。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(IV) First commercial varieties: drugs purchased by the enterprise for the first time;"
    },
    {
        "instruction":"已知信息：\n'第九条 国家食品药品监督管理总局可以组织医疗器械分类专家委员会制定、调整医疗器械分类目录。'可被翻译为：Article 9 The China Food and Drug Administration may organize a medical device classification experts committee to formulate and adjust the medical device classification catalogue.\n\n根据上述已知信息，请将'第八条 国家食品药品监督管理总局根据医疗器械生产、经营、使用情况，及时对医疗器械的风险变化进行分析、评价，对医疗器械分类目录进行调整。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 8 The China Food and Drug Administration shall analyze and evaluate the risk changes timely according to the situation in medical device production, distribution and use, and adjust the medical device classification catalogue."
    },
    {
        "instruction":"已知信息：\n'第一条 为规范药品注册生产现场核查(以下简称注册核查)和上市前药品生产质量管理规范符合性检查(以下简称上市前 GMP 检查) 的衔接，保证注册核查和上市前 GMP 检查同步实施工作的质量和效率， 根据《中华人民共和国药品管理法》《中华人民共和国疫苗管理法》《药品注册管理办法》《药品生产监督管理办法》，制定本程序。'可被翻译为：Article 1 In order to standardize the work procedure for collaborative drug registration inspection of manufacturing site (hereinafter referred to as registration inspection) and Pre-market Good Manufacturing Practice (GMP) compliance inspection (hereinafter referred to as Pre-market GMP inspection), and to ensure the quality and efficiency of collaborative registration inspection and Pre-market GMP inspection, this Procedures is formulated in accordance with the Drug Administration Law of the People's Republic of China, Vaccine Administration Law of the People's Republic of China, Measures for Administration of Drug Registration and Measures for Supervision and Administration of Drug Production.\n\n根据上述已知信息，请将'第九条 检查组依据现场检查情况，分别撰写注册核查、上市前 GMP 检查报告，分别作出注册核查、上市前GMP 检查结论。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 9 The inspection team shall write registration inspection and Pre-market GMP inspection reports and draw conclusions on registration inspection and Pre-market GMP inspection respectively based on the on-site inspection."
    },
    {
        "instruction":"已知信息：\n'在一定条件下，把特定的基因（群）加以大量复制的现象。'可被翻译为：The phenomenon of making a large number of copies of specific genes (groups) under certain conditions.\n\n根据上述已知信息，请将'药物与材料在一定条件下形成新相析出的现象。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The phenomenon of the formation of new phase precipitation between the drug and the material under certain conditions."
    },
    {
        "instruction":"已知信息：\n'一种独立分析方法的定量限是样品中某待测物能以适当的精密度和准确度被定量检出的最低量。定量限是一种针对样品中低含量物质定量分析的参数，特别用于杂质和\/或降解产物的测定。（ICH Q2）'可被翻译为：Limit of Quantitation: The quantitation limit of an individual analytical procedure is the lowest amount of analyte in a sample which can be quantitatively determined with suitable precision and accuracy. The quantitation limit is a parameter of quantitative assays for low levels of compounds in sample matrices, and is used particularly for the determination of impurities and\/or degradation products. (ICH Q2)\n\n根据上述已知信息，请将'某一分析方法的定量限度是指在合适的准确性和精密度下，能够定量测定样品中被分析物的最低量。它是样品中含量下，能够定量测定样品中被分析物的最低量。它是样品中含量低的化合物定量测定的参数，特别适用于杂质和\/或降解产物的测定。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The quantitation limit of an individual analytical procedure is the lowest amount of analyte in a sample which can be quantitatively determined with suitable precision and accuracy. The quantitation limit is a parameter of quantitative assays for low levels of compounds in sample matrices, and is used particularly for the determination of impurities and\/or degradation products."
    },
    {
        "instruction":"已知信息：\n'（一）对符合法定条件的药品注册申请不予受理的；'可被翻译为：(1) not accepting a drug registration application that is in conformity with regulatory requirements;\n\n根据上述已知信息，请将'（一）对符合法定条件的批签发申请不予受理的；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(I) Not accepting the lot release application that is in conformity with statutory requirements;"
    },
    {
        "instruction":"已知信息：\n'柱色谱分离法中用于将待分离物质从色谱柱中解吸或洗脱出来的试剂。'可被翻译为：A reagent used in column chromatography to desorption or eluate the substance to be separated from the column.\n\n根据上述已知信息，请将'1975年由美国陶氏化学公司(DowChemical)的斯莫尔(Small),史蒂文斯(Stevens)和鲍曼(Bowman)发明的一种色谱技术。采用电导检测器的离子交换色谱，用于无机离子的分析，是一项新的液相色谱分析技术。已有多种分离方式和多种检测器可分为带有抑制柱的离子色谱(双柱离子色谱)和单柱离子色谱。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A chromatographic technique invented in 1975 by Small, Stevens and Bowman of DowChemical in the United States. Ion exchange chromatography with conductance detectors, for the analysis of inorganic ions, is a new analytical technique for liquid chromatography. There are a variety of separation methods and a variety of detectors that can be divided into ion chromatography with suppression columns (double column ion chromatography) and single column ion chromatography."
    },
    {
        "instruction":"已知信息：\n'第一百六十条 企业应当定期进行卫生检查，保持环境整洁。存放、陈列药品的设备应当保持清洁卫生，不得放置与销售活动无关的物品，并采取防虫、防鼠等措施，防止污染药品。'可被翻译为：Article 160 Enterprises shall carry out regular sanitary inspection and keep the environment clean and tidy. The equipment used for the storage or display of drugs shall be kept clean and sanitary, and shall not be placed with any item unrelated to the sales activities. Insect-proof and rat-proof measures shall be taken to prevent the contamination to drugs.\n\n根据上述已知信息，请将'第四十条 企业应当有整洁的生产环境；厂区的地面、路面及运输等不应当对药品的生产造成污染；生产、行政、生活和辅助区的总体布局应当合理，不得互相妨碍；厂区和厂房内的人、物流走向应当合理。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 40: The manufacturer should have a neat manufacturing environment. The ground, roads, and transportation in plant area should not introduce contamination to the manufacturing. The general layout of production, administration, living and ancillary areas should be well designed to avoid interference from each other. Premises and buildings should be well designed to ensure the logical flow of materials and personnel."
    },
    {
        "instruction":"已知信息：\n'第三十五条 疫苗上市许可持有人应当按照采购合同约定，向疾病预防控制机构供应疫苗。'可被翻译为：Article 35 Vaccine MAHs shall supply vaccines to disease prevention and control institutions in accordance with the procurement contract.\n\n根据上述已知信息，请将'第三十六条 疫苗上市许可持有人应当按照采购合同约定，向疾病预防控制机构或者疾病预防控制机构指定的接种单位配送疫苗。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 36 Vaccine MAHs shall deliver vaccines to disease prevention and control institutions or immunization entities designated by disease prevention and control institutions in accordance with the procurement contract."
    },
    {
        "instruction":"已知信息：\n'第十九条 用于运输、储藏的包装的标签，至少应当注明药品通用名称、规格、贮藏、生产日期、产品批号、有效期、批准文号、生产企业，也可以根据需要注明包装数量、运输注意事项或者其他标记等必要内容。'可被翻译为：Article 19    The label on the package for transportation and storage shall bear at least the adopted name in China, strength, storage, production date, batch number, expiry date, approval number and manufacturer. Other information such as packaging quantity, precautions for transportation or other marks may be included when necessary.\n\n根据上述已知信息，请将'第二十条 原料药的标签应当注明药品名称、贮藏、生产日期、产品批号、有效期、执行标准、批准文号、生产企业，同时还需注明包装数量以及运输注意事项等必要内容。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 20    The label for drug substance shall include the adopted name in China, storage, production date, batch number, expiry date, applied specifications, approval number and manufacturer. Other necessary information such as packaging quantity and precautions for transportation shall also be indicated."
    },
    {
        "instruction":"已知信息：\n'中药材销售记录应当包括品名、规格、产地、购货单位、销售数量、单价、金额、销售日期等内容；中药饮片销售记录应当包括品名、规格、批号、产地、生产厂商、购货单位、销售数量、单价、金额、销售日期等内容。'可被翻译为：The sales records of Chinese crude drugs shall include the name of the product, strength, place of production, purchaser, sales quantity, unit price, amount and sales date; those of Prepared Slices shall include the name of product, strength, lot number, place of production, manufacturer, purchaser, sales quantity, unit price, amount and sales date, etc.\n\n根据上述已知信息，请将'（三）做好拆零销售记录，内容包括拆零起始日期、药品的通用名称、规格、批号、生产厂商、有效期、销售数量、销售日期、分拆及复核人员等；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(III) The records of dismantling sales shall be made, including the starting date of dismantling, adopted name, strength, lot number, manufacturer, and expiry date of drugs, sales quantity, sales date, dismantling and checking personnel, etc.;"
    },
    {
        "instruction":"已知信息：\n'组织药品活动的法律条件。(另见下文立法。)'可被翻译为：The legal conditions under which pharmaceutical activities should be organized. (See also legislation below.)\n\n根据上述已知信息，请将'组织药品活动的法律条件(另见上文立法)'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The legal conditions under which pharmaceutical activities should be organized (see also legislation above)"
    },
    {
        "instruction":"已知信息：\n'第三十条  医疗器械经营企业应当建立并实施产品追溯制度，保证产品可追溯。'可被翻译为：Article 30 The medical device distributors shall establish and implement product traceability system, to guarantee traceability of the products.\n\n根据上述已知信息，请将'医疗器械经营企业应当按照国家有关规定执行医疗器械唯一标识制度。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The medical device distributors shall execute Unique Device Identification (UDI) system of medical devices in accordance with relevant regulations of the State."
    },
    {
        "instruction":"已知信息：\n'由于化合物的结构改变，如发生共瓶作用、引入助色团，以及溶剂改变等原因，使紫外吸收峰向长波方向移动的现象。'可被翻译为：Due to the structural change of the compound, such as the occurrence of co-bottling, the introduction of chromophores, and the change of solvents, the phenomenon that the ultraviolet absorption peak moves in the direction of long wave.\n\n根据上述已知信息，请将'化合物的结构改变时或受溶剂影响使紫外吸收峰向短波方向移动的现象。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The phenomenon in which the ultraviolet absorption peak shifts to the shortwave direction when the structure of the compound is changed or affected by the solvent."
    },
    {
        "instruction":"已知信息：\n'精神药物公约'可被翻译为：convention on psychotropic substances\n\n根据上述已知信息，请将'联合国于1971年为保证精神药物仅限于医疗及科研的需用，并防止非法使用而产生依懒性，危害健康而制定的文件。我国于1985加入该公约。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The United Nations issued a document in 1971 to ensure that psychotropic substances are limited to medical and scientific needs, and to prevent the illegal use of psychotropic substances resulting in laziness and harm to health. China acceded to the Convention in 1985."
    },
    {
        "instruction":"已知信息：\n'乙型肝炎病毒(HBV)'可被翻译为：hepatitis b virus(hbv)\n\n根据上述已知信息，请将'乙型肝炎病毒周围的抗原。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The antigen on the periphery of the hepatitis B virus."
    },
    {
        "instruction":"已知信息：\n'IVRT选择性是指IVRT方法区分对照外用制剂和改变规格的配方制剂（50%和150%规格）之间，释放速率差异的能力，应证明改变配方制剂规格后，其释放速率与对照外用制剂相比，在统计学上不等效。可以根据USP<1724>中描述的统计学方法，对释放速率的不等效性进行评估。'可被翻译为：IVRT selectivity is the ability of the IVRT method to discriminate the drug release rates between the reference topical product and the altered (50% and 150% nominal strength) concentration test formulations such that their release rates are determined to be statistically inequivalent compared to that from the nominal reference strength formulation. Determination of inequivalence between release rates should be evaluated using the statistical approach described in USP General Chapter<1724>.\n\n根据上述已知信息，请将'IVRT或IVPT之间的选择应基于制剂评估的预期目标，如表2所示。表3进一步描述了两种方法内在的实验差异。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The selection between IVRT or IVPT should be based on the intended objective(s) of the formulation assessment, as described in Table 2. Intrinsic experimental differences between the two methodologies are further described in Table 3."
    },
    {
        "instruction":"已知信息：\n'用于测试的培养基需要通过用适当微生物的培养基接种来测试促菌生长能力。最好选择测试微 生物用于促菌生长能力试验（D部分）。'可被翻译为：Media used for testing needs to be tested for growth promotion by inoculating the medium with appropriate microorganisms. It is preferable that test microorganisms be chosen for growth promotion testing (Section D).\n\n根据上述已知信息，请将'试剂和培养基适当存贮、有效期和促生长试验'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"4. Reagents and media- proper storage, expiration date, and growth promotion"
    },
    {
        "instruction":"已知信息：\n'基因疗法'可被翻译为：gene therapy\n\n根据上述已知信息，请将'虽然本文重点在于药品，但其原则应可应用于其它产品如生物制品、先进疗法药品\/细胞和基因疗法产品、疫苗、医疗器械和病媒控制产品的生产、相关工艺和控制的转移。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2.4. Although this document focuses on pharmaceutical products, the principles can also be applied to the transfer of production, related processes and controls for other products such as biopharmaceutical products, advanced therapy medicinal products\/cellular and gene therapy products, vaccines, medical devices and vector control products."
    },
    {
        "instruction":"已知信息：\n'采用经过验证的有效抑菌剂，用无菌抹布清洁样品容器外表。放在经过消毒的托盘 或放在经过适当消毒的层流罩或生物安全柜表面上，让容器干燥。'可被翻译为：Cleanse outer surfaces of sample containers with sterile wipes using a validated effective antimicrobial agent. Place on a disinfected tray or surface in a properly disinfected laminar flow hood or biosafety cabinet. Allow containers to dry.\n\n根据上述已知信息，请将'如可能的话，在无菌条件下打开容器，在层流罩中或生物安全柜中称重。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Aseptically open containers and perform weighing procedures in a laminar flow hood or biological safety cabinet if possible."
    },
    {
        "instruction":"已知信息：\n'（一）在试验前确认临床试验机构已具有适当的条件，包括人员配备与培训符合要求，实验室设备齐全、工作情况良好，预期有足够数量的受试者，参与研究人员熟悉试验要求。'可被翻译为：(1) Before the trial, confirm that the clinical trial institution has appropriate conditions, where the staffing and training meets requirements, laboratory equipment is complete and works properly, there are sufficient subjects as expected and the investigators involved are familiar with the trial requirements.\n\n根据上述已知信息，请将'（二）临床试验机构的人员配备以及设备条件等是否符合试验要求。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(2) Whether the staffing and equipment conditions of clinical trial institutions meet the trial requirements."
    },
    {
        "instruction":"已知信息：\n'原材料（起始物料，试剂、溶剂）、工艺辅助材料、中间体，APIs 和包装及标签材料的总称。'可被翻译为：A general term used to denote starting materials, reagents, and solvents intended for use in the production of intermediates or APIs.\n\n根据上述已知信息，请将'原材料(起始物料，试剂、溶剂)、工艺辅助材料、中间体，APIs 和包装及标签材料的总称。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A general term used to denote raw materials (starting materials, reagents, solvents), process aids, intermediates, APIs and packaging and labelling materials."
    },
    {
        "instruction":"已知信息：\n'第九十五条 申请进口药品制剂，必须提供直接接触药品的包装材料和容器合法来源的证明文件、用于生产该制剂的原料药和辅料合法来源的证明文件。原料药和辅料尚未取得国家食品药品监督管理局批准的，应当报送有关生产工艺、质量指标和检验方法等规范的研究资料。'可被翻译为：Article 95 To apply for importation of pharmaceutical preparations, approved documents for the lawful sources of the immediate packaging materials and containers and those of the drug substances and the excipients used for the pharmaceutical preparations shall be provided. Where drug substances and excipients are not yet approved by the State Food and Drug Administration, relevant data of manufacturing processes, specifications and testing methods, etc. shall be submitted.\n\n根据上述已知信息，请将'1.具有试验用药品的来源证明、检验报告和在符合 GMP 条件下生产的证明文件。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1. There are proof of origin, certificate of analysis, and documentation of manufacture under GMP conditions of investigational medicinal products."
    },
    {
        "instruction":"已知信息：\n'省级药品监督管理部门与同级卫生行政部门联合对设区的市级、县级的调查进行督促、指导，对药品群体不良事件进行分析、评价，对本行政区域内发生的影响较大的药品群体不良事件，还应当组织现场调查，评价和调查结果应当及时报国家食品药品监督管理局和卫生部。'可被翻译为：Provincial drug regulatory departments, jointly with the health administrative departments at the same level, shall supervise and guide the investigation conducted by drug regulatory departments of municipalities with districts and counties, analyze and evaluate ADE clusters, and organize on-site investigation on ADE clusters that occur within their administrative regions and have a major impact. The evaluation and investigation results shall be reported to the SFDA and the Ministry of Health in a timely manner.\n\n根据上述已知信息，请将'第二十八条 设区的市级、县级药品监督管理部门获知药品群体不良事件后，应当立即与同级卫生行政部门联合组织开展现场调查，并及时将调查结果逐级报至省级药品监督管理部门和卫生行政部门。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 28 Drug regulatory departments of municipalities with districts and counties shall, upon knowing of ADE clusters, immediately conduct on-site investigation jointly with the health administrative departments at the same level, and promptly report the investigation results level by level to the provincial drug regulatory departments and health administrative departments."
    },
    {
        "instruction":"已知信息：\n'医疗器械注册人、备案人、经营企业经营条件发生重大变化，不再符合医疗器械经营质量管理体系要求的，应当立即采取整改措施；可能影响医疗器械安全、有效的，应当立即停止经营活动，并向原经营许可或者备案部门报告。'可被翻译为：In case of significant changes in distribution conditions of the registrant, filing entity and distributor of the medical devices, thus not conforming to requirements of the quality management system for medical device distribution, rectification measures shall be taken immediately; if safety and effectiveness of the medical devices might be influenced, distribution activities shall be suspended immediately, and report shall be made to the former licensing department or filing department.\n\n根据上述已知信息，请将'第四十四条  医疗器械注册人、备案人、受托生产企业的生产条件发生变化，不再符合医疗器械质量管理体系要求的，应当立即采取整改措施；可能影响医疗器械安全、有效的，应当立即停止生产活动，并向原生产许可或者生产备案部门报告。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 44 Where changes occur in the manufacturing conditions of the registrant, filing entity, and contract manufacturer of medical devices, so that the conditions cease to meet the requirements of the quality management system for medical devices, measures for rectification shall be taken immediately; where the safety and effectiveness of the medical devices may possibly be affected, the enterprise shall immediately stop manufacturing and report the matter to the former department that issued the Manufacturing License or accepted for filing."
    },
    {
        "instruction":"已知信息：\n'（四）生产步骤操作人员的签名；必要时，还应当有操作（如称量）复核人员的签名。'可被翻译为：4. Signatures of the operator of different steps of production and, where appropriate, of the person who checked each of these operations (e.g. weighing);\n\n根据上述已知信息，请将'（四）包装工序的操作人员签名。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"4. The signatures of the operators of the different steps;"
    },
    {
        "instruction":"已知信息：\n'第四十三条 药品审评中心在审评药品制剂注册申请时，对药品制剂选用的化学原料药、辅料及直接接触药品的包装材料和容器进行关联审评，需补充资料的，按照补充资料程序要求药品制剂申请人或者化学原料药、辅料及直接接触药品的包装材料和容器登记企业补充资料，可以基于风险提出对化学原料药、辅料及直接接触药品的包装材料和容器企业进行延伸检查。'可被翻译为：Article 43 When evaluating a drug registration application, the CDE conducts bundling review of the chemical active drug ingredients, excipients and primary packaging materials and containers of the drug product. Where supplementary dossiers are needed, the drug product applicant or the enterprise that registers chemical active drug ingredients, excipients and primary packaging materials and containers shall be required to provide supplementary dossiers in compliance with relevant procedures. When necessary, extended inspection on enterprises of chemical active drug ingredients, excipients and primary packaging materials and containers may be proposed based on risks.\n\n根据上述已知信息，请将'第四十一条 药品审评中心在审评药品制剂注册申请时，对药品制剂选用的化学原料药、辅料及直接接触药品的包装材料和容器进行关联审评。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 41 When evaluating a drug registration application, the CDE shall conduct bundling review of the chemical active drug ingredients, excipients and primary packaging materials and containers used for the drug products."
    },
    {
        "instruction":"已知信息：\n'一种高效液相色谱一质谱联用的仪器接口。属于大气压电离的范畴，包括电喷雾、离子的形成及离子的传递三个步骤。'可被翻译为：An instrument interface for high performance liquid chromatography-mass spectrometry. It belongs to the category of atmospheric pressure ionization, including electrospray, ion formation and ion transfer three steps.\n\n根据上述已知信息，请将'一种液相色谱一质谱联用的接口。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The utility model relates to a liquid chromatography-mass spectrometry interface."
    },
    {
        "instruction":"已知信息：\n'<1223>替代微生物方法的验证'可被翻译为：l. <1223> Validation of alternative microbiological methods\n\n根据上述已知信息，请将'已被验证为适合目的的方法，可与替代方法进行比较。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A method which has been validated as being fit for purpose, with which an alternative method may be compared."
    },
    {
        "instruction":"已知信息：\n'附录 C 对于重复回收和产品接种方法的验证作了更深入的解释。'可被翻译为：Annex C has a more in-depth explanation of the validation of the repetitive recovery and product inoculation methods.\n\n根据上述已知信息，请将'附录 A 包括一个决策树“阐述基于被测产品性质设计生物负载方法，并且包括用于选择诸如搅拌技术或过滤与直接电镀之类的指南”。附录 A 还阐述了可用于确定生物负载方法验证的程序（重复回收方法、产品接种方法等）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Annex A contains a decision tree “that addresses designing a bioburden method based on the nature of the product being tested and includes guidance for choosing such things as agitation techniques or filtration versus direct plating.”2 Annex A also addresses the procedures (repetitive recovery method, product inoculation method) available for the validation of the method for determining bioburden."
    },
    {
        "instruction":"已知信息：\n'用于特定化学和物理检测的经过检定、性质均匀的物质。在检测中需要化学对照品的一个或多个性质与待测样品进行比较，化学对照品应具有满足其用途的适当纯度。'可被翻译为：A certified, homogeneous substance used for specific chemical and physical tests. One or more properties of the chemical reference required in the test to be compared with the sample to be tested, and the chemical reference should be of an appropriate purity for its purpose.\n\n根据上述已知信息，请将'1.本文所用的“化学对照物质”一词是指一种经过认证的、统一的材料，用于特定的化学和物理测试，其性能与被检查产品的性能进行比较，并具有足以满足其预期用途的纯度。\n2.一种经过认证的、统一的材料，用于特定的化学和物理测试，其性能与被检查产品的性能进行比较，并具有适合其预期用途的纯度。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.The term chemical reference substances, as used in this text, refers to an authenticated, uniform material that is intended for use in specified chemical and physical tests, in which its properties are compared with those of the product under examination, and which possesses a degree of purity adequate for its intended use.\n2.An authenticated, uniform material that is intended for use in specified chemical and physical tests, in which its properties are compared with those of the product under examination, and which possesses a degree of purity adequate for its intended use."
    },
    {
        "instruction":"已知信息：\n'使排便通畅的药物。包括多种盐类，如镁盐、磷酸盐、枸椽酸盐等，如硫酸镁。'可被翻译为：Drugs that make bowel movements unimpeded. Include a variety of salts such as magnesium salts, phosphates, citrate salts, etc., such as magnesium sulfate.\n\n根据上述已知信息，请将'治疗和防止惊厥的药物。如地西泮、镁盐注射剂等。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Drugs to treat and prevent convulsions. Such as diazepam, magnesium salt injections, etc."
    },
    {
        "instruction":"已知信息：\n'为进一步保障公众用药安全，2020年6月9日，国家药品监督管理局发布公告，决定对垂体后叶注射液说明书【不良反应】、【注意事项】等项进行修订。'可被翻译为：To further protect drug safety for the people, on June 9, 2020, NMPA issued an Announcement with decisions made to revise the [adverse reactions], [precautions], etc. in the package insert of Posterior Pituitary Injection.\n\n根据上述已知信息，请将'根据药品不良反应评估结果，为进一步保障公众用药安全，国家药品监督管理局于2020年6月9日发布公告，决定对川贝枇杷制剂（包括糖浆剂、膏剂、颗粒剂、片剂、胶囊剂）说明书【不良反应】【禁忌】和【注意事项】项进行统一修订。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In accordance with the results of AD Revaluation, to further protect drug safety for the people, NMPA issued an Announcement on June 9, 2020, with decisions made to uniformly revise the [adverse reactions],[contraindications] and [precautions] in the package inserts of Chuanbei Pipa Preparations (including syrups, ointments, granules, tablets and capsules)."
    },
    {
        "instruction":"已知信息：\n'国家药监局关于发布医疗器械分类目录动态调整工作程序的公告'可被翻译为：NMPA Announcement on Issuing the Working Procedures for Dynamic Adjustment of Classification Catalogue for Medical Devices\n\n根据上述已知信息，请将'为加强医疗器械分类管理，规范《医疗器械分类目录》动态调整工作，根据《医疗器械监督管理条例》《医疗器械分类规则》，国家药监局组织制定了《医疗器械分类目录动态调整工作程序》，并于4月27日发布。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In order to strengthen the classification management of medical devices and standardize the dynamic adjustment of the Classification Catalogue for Medical Devices, according to the Regulations for the Supervision and Administration of Medical Devices and the Classification Rules for Medical Devices, NMPA has organized to formulate the Working Procedures for Dynamic Adjustment of Classification Catalogue for Medical Devices, which was issued on April 27."
    },
    {
        "instruction":"已知信息：\n'三、临床医师、药师应当仔细阅读甲巯咪唑制剂说明书的修订内容，在选择用药时，应当根据新修订说明书进行充分的获益\/风险分析。'可被翻译为：III. The clinicians and pharmacists shall carefully read the revised content of the package inserts for methimazole preparations. Drug options should be based on comprehensive benefit\/risk analysis as per the new revisions.\n\n根据上述已知信息，请将'三、临床医师、药师应当仔细阅读上述药品说明书的修订内容，在选择用药时，应当根据新修订说明书进行充分的获益\/风险分析。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"III. The clinicians and pharmacists shall carefully read the revised contents of the package inserts for Vitamin B6 injection. Drug options should be based on comprehensive benefit\/risk analysis a sper the new revisions."
    },
    {
        "instruction":"已知信息：\n'省级药品监管部门依职责负责辖区内持有人药品上市后生产监管事项变更的许可、登记和注册管理事项变更的备案、报告等管理工作；依法组织实施对药品上市后变更的监督管理。'可被翻译为：Provincial drug regulatory departments shall be responsible for the permit and registration of the post-approval change of supervision items for production, and the filing and reporting of the post-approval change of administrative items for registration for the drugs of MAHs within their respective administrative regions in accordance with their responsibilities; and organize the supervision and administration of post-approval changes of drugs in accordance with law.\n\n根据上述已知信息，请将'各省级药品监管部门应当落实辖区内药品上市后变更监管责任，细化工作要求，制定工作文件，明确工作时限，药品注册管理和生产监管应当加强配合，互为支撑，确保药品上市后变更监管工作平稳有序开展。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Each provincial drug regulatory department shall implement the responsibility for supervision over change management of post-approval drugs at its administrative area, by specifying requirements, formulating working documents, and clarifying time limits. The cooperation between drug registration administration and production supervision should be consolidated for mutual support, to ensure the smooth and orderly implementation of change management of post-approval drugs."
    },
    {
        "instruction":"已知信息：\n'第八十条 伪造、变造、买卖、出租、出借医疗器械注册证的，按照《医疗器械监督管理条例》第六十四条第二款的规定予以处罚。'可被翻译为：Article 80 Where a medical device registration certificate is falsified, altered, bought or sold, leased or lent, punishments shall be made according to Paragraph 2, Article 64 of the Regulations on Supervision and Administration of Medical Devices.\n\n根据上述已知信息，请将'第七十条 伪造、变造、买卖、出租、出借医疗器械注册证的，按照《医疗器械监督管理条例》第六十四条第二款的规定予以处罚。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 70 Where a medical device registration certificate is falsified, altered, bought or sold, leased or lent, punishments shall be made according to Paragraph 2, Article 64 of the Regulations on Supervision and Administration of Medical Devices."
    },
    {
        "instruction":"已知信息：\n'（五）进口单位未取得《药品经营许可证》（生产企业应当取得《药品生产许可证》）和《企业法人营业执照》的；'可被翻译为：(V) the importer has not obtained the Drug Supply License (in the case of a drug manufacturer, Drug Manufacturing Certificate shall be obtained) and the Business License for Legal Person;\n\n根据上述已知信息，请将'（二）报验单位的《药品经营许可证》和《企业法人营业执照》复印件；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(II) photocopies of Drug Supply Certificate and Business License for Legal Person of the applicant for testing;"
    },
    {
        "instruction":"已知信息：\n'第九十九条 纯化水、注射用水的制备、贮存和分配应当能够防止微生物的滋生。纯化水可采用循环，注射用水可采用70℃以上保温循环。'可被翻译为：Article 99: Purified water and water for injection should be produced, stored and distributed in a manner that prevents microbial growth. Purified water can be circulated, and water for injection can be circulated at a temperature above 70℃.\n\n根据上述已知信息，请将'第一百零一条 应当按照操作规程对纯化水、注射用水管道进行清洗消毒，并有相关记录。发现制药用水微生物污染达到警戒限度、纠偏限度时应当按照操作规程处理。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 101: The pipes for purified water and water for injection should be cleaned and sanitized according to operation procedures and recorded accordingly. If bioburden of water for pharmaceutical use exceeds alert or action limits, actions should be taken according to operation procedures."
    },
    {
        "instruction":"已知信息：\n'1.按ISO 2859-1规定的批次检验程度。检验程度越高，检测的样品越多，因此，到达最终用户的有缺陷产品的风险越低。\n2.按ISO 2859-1规定的批次检验程度。检验程度越高，需要检测的样品越多，因此，缺陷产品到达消费者手中的风险就越低。'可被翻译为：1.The degree of examination of the lot, as specified in ISO 2859-1. The higher the inspection level, the more samples will be tested and, hence, the lower the risk of faulty products reaching the end-user.\n2.The degree of examination of the lot, as specified in ISO 2859-1. The higher the inspection level, the more samples that will be tested and, hence, the lower the risk of faulty products reaching the consumer.\n\n根据上述已知信息，请将'连续一系列批次提交接受抽样时的最差可容忍过程平均值的质量水平(ISO 2859-1)。注:制造商应始终达到比AQL更好的工艺平均水平。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The quality level that is the worst tolerable process average when a continuing series of lots is submitted for acceptance sampling (ISO 2859-1). Note: Manufacturers should be consistently achieving a process average that is better than the AQL."
    },
    {
        "instruction":"已知信息：\n'（一）质量管理部门的人员有权进入生产区和仓储区进行取样及调查。'可被翻译为：1. Personnel of quality management department should have the authority to access to production and storage areas for sampling and investigation.\n\n根据上述已知信息，请将'第六十九条 更衣室和盥洗室应当方便人员进出，并与使用人数相适应。盥洗室不得与生产区和仓储区直接相通。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 69: Facilities for changing clothes and for washing and toilet purposes should be easily accessible and appropriate for the number of users. Toilets should not communicate directly with production or storage areas."
    },
    {
        "instruction":"已知信息：\n'无菌处理后采用的一种终端湿热工艺，该工艺已被证明可提供≤10-6的无菌保证水平，但不满足蒸汽灭菌的要求(例如，F0≥8分钟)。这也可能有利于破坏可能无法通过过滤去除的病毒。'可被翻译为：A terminal moist heat process employed after aseptic processing that has been demonstrated to provide a sterility assurance level of ≤ 10–6 but where the requirements of steam sterilization (for example, F0 ≥ 8 minutes) are not fulfilled. This may also be beneficial in the destruction of viruses that may not be removed through filtration.\n\n根据上述已知信息，请将'无菌工艺后最终热处理：无菌工艺后采用的最终湿热工艺，已被证明可提供无菌保证水平（SAL）≤10-6 但不满足蒸汽灭菌的要求（例如 F0≥8 分钟）。这也可能有利于破坏可能无法过滤去除的病毒。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Post-aseptic  processing  terminal  heat  treatment—  A  terminal  moist  heat  process   employed  after  aseptic processing  which  has  been  demonstrated  to  provide  a  sterility  assurance  level  (SAL)  ≤10-6   but  where  the requirements of steam sterilisation (for example, Fo≥8 min) are not fulfilled. This may also be beneficial in the destruction of viruses that may not be removed through filtration."
    },
    {
        "instruction":"已知信息：\n'药品注册现场核查(药物临床试验) 的目的主要是通过对注册申报资料与临床试验的原始记录和文件的核对和\/或实地确证， 评价试验实施、数据记录和结果报告是否符合试验方案和药物临床试验相关法规， 核实相关申报资料的真实性、一致性，同时关注受试者保护。'可被翻译为：On-site inspection for drug registration (Drug Clinical Trials) is mainly aimed at evaluating whether the clinical trial execution, data recording and result reporting conform to the trial protocol and relevant regulations of drug clinical trial, verifying the authenticity and consistency of relevant application dossiers, and paying attention to subject protection, by checking and\/or on-site inspection of the original data and documents of the application dossier and clinical trials.\n\n根据上述已知信息，请将'药物临床试验现场核查主要是核对注册申报资料与临床试验的原始记录和文件，评价试验实施、数据记录和结果报告是否符合试验方案和药物临床试验相关法规，同时关注受试者保护。必要时可对临床试验用药物进行抽查检验。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The on-site inspection of drug clinical trials is mainly to check the registration application dossiers and the original records and documents of clinical trials, evaluate whether the implementation of the trial, data records and result reports comply with the trial protocol and relevant laws and regulations of drug clinical trials, and pay attention to the protection of subjects. If necessary, random sample and test can be conducted on drugs used in clinical trials."
    },
    {
        "instruction":"已知信息：\n'接种单位接种非免疫规划疫苗，除收取疫苗费用外，还可以收取接种服务费。接种服务费的收费标准由省、自治区、直辖市人民政府价格主管部门会同财政部门制定。'可被翻译为：When administering non-immunization program vaccines, immunization entities may charge an immunization service fee in addition to the fee for vaccines. The criteria for immunization service fee shall be formulated by the pricing departments of the people's governments of provinces, autonomous regions and municipalities directly under the Central Government jointly with the financial departments.\n\n根据上述已知信息，请将'疾病预防控制机构配送非免疫规划疫苗可以收取储存、运输费用，具体办法由国务院财政部门会同国务院价格主管部门制定，收费标准由省、自治区、直辖市人民政府价格主管部门会同财政部门制定。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Disease prevention and control institutions may charge storage and transportation fee for distributing non-immunization program vaccines; the specific measures shall be formulated by the financial department under the State Council in conjunction with the competent pricing department under the State Council; and the charging criteria shall be formulated by the competent pricing departments of the people's governments of provinces, autonomous regions and municipalities directly under the Central Government in conjunction with the financial departments at the same level."
    },
    {
        "instruction":"已知信息：\n'用于定量测定生物基质中待测物的分析方法。'可被翻译为：Analytical method used in the quantitative determination of analytes in biological matrices.\n\n根据上述已知信息，请将'加入已知量待测物的生物基质，用于监测生物分析方法的性能，并评估单个处理批或分析批中分析的未知样品结果的完整性和有效性。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A biological matrix spiked with a known quantity of analyte that is used to monitor the performance of a bioanalytical method and assess the integrity and validity of the results of the unknown samples analysed in an individual batch or run."
    },
    {
        "instruction":"已知信息：\n'第一百四十七条 应当根据确认或验证的对象制定确认或验证方案，并经审核、批准。确认或验证方案应当明确职责。'可被翻译为：Article 147: The qualification or validation protocol should be prepared based on its object. The protocol should be reviewed and approved. Responsibilities should be specified in the protocol.\n\n根据上述已知信息，请将'9.确保完成各种必要的确认或验证工作，审核和批准确认或验证方案和报告；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"9) To ensure the necessary qualifications or validations are done appropriately, and to review and approve validation protocols and reports;"
    },
    {
        "instruction":"已知信息：\n'由申办者设立一个独立的数据监查委员会，它定期对研究进展、安全性数据和关键疗效终点进行评估，向申办者建议是否继续、调整或停止试验。'可被翻译为：An independent data monitoring committee that may be established by the sponsor to assess at intervals the progress of a clinical trial, the safety data, and the critical efficacy endpoints, and to recommend to the sponsor whether to continue, modify, or stop a trial.\n\n根据上述已知信息，请将'1.对控制参数进行有计划的一系列观察或测量，以评估CCP是否受到控制的行为。\n2.由申办方指定并对其负责的人员，负责监测和报告试验的进展情况，并对数据进行核实。\n3.由申办者或CRO任命并对其负责的人，负责监测和报告试验的进展情况并核实数据。\n4.由申办者指定的负责监测和报告试验进展及数据核查的人员。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.The act of conducting a planned sequence of observations or measurements of control parameters to assess whether a CCP is under control.\n2.A person appointed by, and responsible to, the sponsor for monitoring and reporting the progress of the trial and for the verification of data.\n3.A person appointed by, and responsible to, the sponsor or CRO for the monitoring and reporting of progress of the trial and for verification of data.\n4.A person appointed by the sponsor who is responsible for monitoring and reporting the progress of the trial and for the verification of data."
    },
    {
        "instruction":"已知信息：\n'国家药监局关于药物临床试验数据自查核查注册申请情况的公告'可被翻译为：NMPA Issued the Announcement on Registration Application Situation and Self-Examination & Verification of Drug Clinical Trial Data\n\n根据上述已知信息，请将'2019年10月15日，国家药监局发布《关于药物临床试验数据自查核查注册申请情况的公告》，决定核实7份已完成临床试验并申请生产的药品的临床试验数据，现将有关事宜公告如下：'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"On October 15, 2019, NMPA released the Announcement on Registration Application Situation and Self-Examination &Verification of Drug Clinical Trial Data with decision made to verify the clinical trial data of 7 newly received registration applications for drugs that have completed the clinical trials and are applying for production, the relevant issues are hereby announced:"
    },
    {
        "instruction":"已知信息：\n'（二）企业内部所用物料名称和（或）代码；'可被翻译为：2. The \"in-house\" name and\/or code of material;\n\n根据上述已知信息，请将'（一）指定的物料名称和企业内部的物料代码；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1. The designated name and the internal code reference of the material;"
    },
    {
        "instruction":"已知信息：\n'染色体数目与原来的染色体单倍体或二倍体不同；对于细胞系，其染色体数目与原型染色体不同。'可被翻译为：Chromosome numbers different from the original haploid or diploid set of chromosomes; for cell lines, chromosome numbers differe nt from the modal chromosome set.\n\n根据上述已知信息，请将'细胞中染色体倍数的数目变化，大致为单倍体数目的整数倍。核内复制是多倍体的一种形态类型，其为染色体对在中期相进行联合成为“双分染色体 ”。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Numerical deviation of the modal number of chromosomes in a cell, with approximately whole multiples of the haploid number. Endoreduplication is a morphological form of polyploidy in which chromosome pairs are associated at metaphase as “diplochromosomes”."
    },
    {
        "instruction":"已知信息：\n'能溶解气体、固体、液体而成为均匀混合物的一种液体。'可被翻译为：A liquid capable of dissolving a gas, solid, or liquid into a uniform mixture.\n\n根据上述已知信息，请将'将某种物质溶解在一溶剂中，使该物质从一种固体或一种液体混合物中分离出来。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Dissolving a substance in a solvent separates the substance from a solid or a liquid mixture."
    },
    {
        "instruction":"已知信息：\n'分析方法应根据现行WHO技术报告系列中发布的指南进行验证。'可被翻译为：10.6. Analytical procedures should be validated according to the guidelines as published in current WHO Technical Report Series (7).\n\n根据上述已知信息，请将'工艺验证应依据现行WHO TRS中发布的指南执行。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"10.3. Process validation should be done according to guidelines as published in current WHO Technical Report Series (3)."
    },
    {
        "instruction":"已知信息：\n'促进液体在固体表面铺展或渗透的过程。'可被翻译为：The process of promoting the spread or penetration of liquid on a solid surface.\n\n根据上述已知信息，请将'固体表面被液体润湿的难易程度。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The ease with which a solid surface can be wetted by a liquid."
    },
    {
        "instruction":"已知信息：\n'为进一步保障公众用药安全，国家药品监督管理局决定对氨酚麻美口服溶液、氨酚麻美糖浆、小儿氨酚烷胺颗粒、氨酚伪麻那敏咀嚼片、小儿复方氨酚烷胺片、小儿氨咖黄敏颗粒、氨金黄敏颗粒、氨咖愈敏溶液、儿童复方氨酚肾素片、氨咖黄敏口服溶液、氨酚伪麻那敏分散片（Ⅲ）、小儿氨酚那敏片、小儿氨酚黄那敏片、小儿氨酚黄那敏颗粒等14个品种药品说明书进行修订。'可被翻译为：In order to further protect the medication safety for the public, NMPA decided to revise the package inserts of 14 drug varieties including the Paracetamol, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution, Paracetamol, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Syrup, Pediatric Paracetamol and Amantadine Hydrochloride Granules, Paracetamol, Pseudoephedrine Hydrochloride and Chlorpheniramine Maleate Chewable Tablets, Pediatric Compound Paracetamol and Amantadine Hydrochloride Tablets, Pediatric Paracetamol, Caffein, Artificial Cow-bezoar and Chlorphenamine Maleate Granules, Paracetamol, Amantadine Hydrochloride, Artificial Cow-bezar and Chlorphenamine Mdeate Granules, Paraceramol Caffeine Guaifenfsin and Chlorphenamine Maleate Solution, Pediatric Compound Paracetamol and Phenylephrine Tablets, Paracetamol, Caffeine, Artificial Cow-Bezoar, Chlorphenamine Maleate Oral Solution, Paracetamol, Pseudoephedrine Hydrochloride and Chlorphenamine Maleate Dispersible Tablets (III), Compound Paracetamol and Chlorphenamine Tablets for Infant, Pediatric Paracetamol, Artificial Cow-bezoar and Chlorphenamine Maleate Tablets, and Pediatric Paracetamol, Artificial Cow-bezoar and Chlorphenamine Maleate Granules.\n\n根据上述已知信息，请将'国家药监局关于修订氨酚麻美口服溶液等14个品种药品说明书的公告'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"NMPA Announcement on Revising the Package Inserts of 14 Drug Varieties Including Paracetamol, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution"
    },
    {
        "instruction":"已知信息：\n'国家药监局 国家知识产权局关于发布《药品专利纠纷早期解决机制实施办法（试行）》的公告'可被翻译为：Announcement of National Medical Products Administration and National Intellectual Property Administration on the Issuance of the Measures for the Implementation of the Mechanism for Early Settlement of Drug Patent Disputes (Interim)\n\n根据上述已知信息，请将'国家药监局关于实施《药品专利纠纷早期解决机制实施办法（试行）》相关事宜的通告'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"NMPA Announcement on the Issues Related to the Implementation of the Measures for the Implementation of the Mechanism for Early Settlement of Drug Patent Disputes (interim)"
    },
    {
        "instruction":"已知信息：\n'《中华人民共和国疫苗管理法》已由中华人民共和国第十三届全国人民代表大会常务委员会第十一次会议于2019年6月29日通过，现予公布，自2019年12月1日起施行。'可被翻译为：The Vaccine Administration Law of the People's Republic of China, adopted at the 11th Meeting of the Standing Committee of the Thirteenth National People's Congress on June 29, 2019, is hereby promulgated and shall go into effect as of December 1, 2019.\n\n根据上述已知信息，请将'《中华人民共和国药品管理法》已由中华人民共和国第十三届全国人民代表大会常务委员会第十二次会议于2019年8月26日修订通过，现予公布，自2019年12月1日起施行。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The Drug Administration Law of the People's Republic of China adopted at the 12th Meeting of the Standing Committee of the Thirteenth National People's Congress on August 26, 2019 is hereby promulgated and shall go into effect as of December 1, 2019."
    },
    {
        "instruction":"已知信息：\n'（一）正常使用情况下存在可能危及人体健康和生命安全的不合理风险的产品；'可被翻译为：(1) products with unreasonable risks that may cause hazards to human health and life safety under normal use;\n\n根据上述已知信息，请将'第四条 本办法所称安全隐患，是指由于研发、生产等原因可能使药品具有的危及人体健康和生命安全的不合理危险。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 4 Safety hazards mentioned in these Provisions mean unreasonable drug-related hazards to human health and life caused by problems associated with research & development, production and other factors."
    },
    {
        "instruction":"已知信息：\n'细胞的冷冻保存'可被翻译为：CRYOPRESERVATION OF CELLS\n\n根据上述已知信息，请将'使用受控速率冷冻装置可更精确地控制冷冻环境，从而在细胞外冰晶形成时为冷却速率范围狭窄（与最大存活率相关）或敏感的细胞提供更一致（且更高）的解冻后恢复能力。将温度探针放置在要冷冻的细胞附近或同时进行低温保存的模拟细胞悬液中，用于监视冷冻过程并提供过程控制。如果融合潜热的释放被延迟或控制不当，则进行冷冻保存的细胞可能会受到破坏，并且复苏后的活力可能会降低。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The useof controlled-rate freezing provides more precise control of the freezingenvironment and therefore may provide more consistent (and higher) post-thaw recoveryfor cells that may have a narrow range of cooling rates associated with maximum survival or cells that are sensitive to the temperature at which ice forms in theextracellular solution. Temperature probes placed near the cells being frozen,or in a mock cell suspension that undergoes cryopreservation simultaneously, areused to monitor the freezing process and to provide process control. If releaseof the latent heat of fusion is delayed or poorly controlled, cells undergoing cryopreservationmay be damaged and may have diminished viability after thaw."
    },
    {
        "instruction":"已知信息：\n'导致蛋白质活性构象和信号转导变化的蛋白质之间的作用。如多肽配体与蛋白酶、多肽激素与受体之间的相互作用。'可被翻译为：Interactions between proteins that cause changes in the active conformation and signal transduction of proteins. Such as interactions between polypeptide ligands and proteases, polypeptide hormones and receptors.\n\n根据上述已知信息，请将'结合物是指一个活性成分(如多肽、碳水化合物等) 通过共价键或非共价键与载体(如蛋白质、多肽、无机盐等)连接，以增强制品的效力或稳定性。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A conjugated product is made up of an active ingredient (for example, peptide, carbohydrate) bound covalently or noncovalently to a carrier (for example, protein, peptide, inorganic mineral) with the objective of improving the efficacy or stability of the product."
    },
    {
        "instruction":"已知信息：\n'（四）产品原液、半成品和成品的检验项目、检验方法和结果是否符合药典和药品注册标准的要求；'可被翻译为：(IV) Whether the testing items, testing methods and results of bulk, final bulk and finished products meet the requirements stipulated by the ChP and the drug registration specifications;\n\n根据上述已知信息，请将'1.用于医学判断的检验项目和作为疗效和安全性指标的检验项目通过国家级室间质评或经其他方法验证以保证检测结果的可靠性。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1. For relevant inspection items used for medical judgement and used as efficacy and safety index, the reliability of the test results is verified by national inter-laboratory quality assessment or other methods."
    },
    {
        "instruction":"已知信息：\n'碱基与糖相连组成的抗生素。'可被翻译为：An antibiotic consists of a base attached to a sugar.\n\n根据上述已知信息，请将'糖与肽相连组成的抗生素。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"An antibiotic consisting of a sugar attached to a peptide."
    },
    {
        "instruction":"已知信息：\n'熔距'可被翻译为：melting range\n\n根据上述已知信息，请将'一种物质初熔至终熔时的温度范围。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The temperature range of a substance from initial to final melting."
    },
    {
        "instruction":"已知信息：\n'第三十五条  医疗器械注册人、备案人应当建立并实施产品追溯制度，保证产品可追溯。受托生产企业应当协助注册人、备案人实施产品追溯。'可被翻译为：Article 35 The registrant or filing entity of medical devices shall establish and implement the procedures for tracing products, to guarantee the traceability of the products. The contract manufacturer shall assist with the registrant and the filing entity in tracing the products.\n\n根据上述已知信息，请将'第三十条  医疗器械注册人、备案人应当开展设计开发到生产的转换活动，并进行充分验证和确认，确保设计开发输出适用于生产。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 30 The registrant or filing entity of medical devices shall carry out transition activities from design and development to manufacturing, and make full verification and validation, so as to ensure that the output of design and development is applicable to the manufacturing."
    },
    {
        "instruction":"已知信息：\n'（六）国家药品监督管理局规定其他优先审评审批的情形。'可被翻译为：(6) Other circumstances of priority review and approval specified by the NMPA.\n\n根据上述已知信息，请将'（三）国家药品监督管理局规定应当开展再评价的其他情形。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(III) Other situations under which re-evaluation shall be performed as specified by the National Medical Products Administration."
    },
    {
        "instruction":"已知信息：\n'安装完成，所有服务连接并运行，但没有生产设备，材料或人员在场的状态。'可被翻译为：Condition where the installation is complete with all services connected and functioning but with no production equipment, materials, or personnel present.\n\n根据上述已知信息，请将'设备安装完毕，设备按客户和供应商商定的方式安装和运行，但没有人员在场的状态。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Condition where the installation is complete with equipment installed and operating in a manner agreed upon by the customer and supplier, but with no personnel present."
    },
    {
        "instruction":"已知信息：\n'第二百零六条 有数条包装线同时进行包装时，应当采取隔离或其他有效防止污染、交叉污染或混淆的措施。'可被翻译为：Article 206: Appropriate segregation or other precautions to effectively prevent contamination, cross-contamination or mixups should be adopted if several packaging lines are working simultaneously.\n\n根据上述已知信息，请将'第二百零二条 包装操作规程应当规定降低污染和交叉污染、混淆或差错风险的措施。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 202: Packaging operation procedures should specify the measures to minimize the risk of contamination, cross-contamination, mixups or errors."
    },
    {
        "instruction":"已知信息：\n'细菌、酵母或其他微生物细胞丧失细胞壁中部分坚硬的肽聚糖时所形成的球状体。'可被翻译为：Globules formed when bacterial, yeast, or other microbial cells lose part of the hard peptidoglycan in their cell walls.\n\n根据上述已知信息，请将'微生物菌株通过酶解作用，脱除细胞壁，细胞在高渗溶液中释放出只含细胞膜的球状体。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The process by which microbial strains remove their cell walls by enzymatic hydrolysis, and the cells release spheroids containing only the cell membrane in a hypertonic solution."
    },
    {
        "instruction":"已知信息：\n'阻滞正常生殖过程，达到避孕或终止妊娠目的的女用药物。有不同剂型,如短效口服片、长效口服片、长效注射药、埋植剂、多相片剂、阴道栓剂和胶冻剂等。'可被翻译为：A female drug used to block the normal reproductive process and to prevent or terminate pregnancy. There are different dosage forms, such as short-acting oral tablets, long-acting oral tablets, long-acting injectable drugs, implants, multiphase tablets, vaginal suppositories and gels.\n\n根据上述已知信息，请将'1.FPP的形式，如片剂、胶囊、酏剂或栓剂。\n2.药品成品的形态，如片剂、胶囊、酏剂、注射剂、栓剂。\n3.完整的药物制剂形式，如片剂、胶囊、酏剂、栓剂。\n4.制剂的形式，如片剂、胶囊、酏剂或栓剂。\n5.制成品的形式，如片剂、胶囊、酏剂或栓剂。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.The form of the FPP, e.g. tablet, capsule, elixir or suppository.\n2.The form of the completed pharmaceutical product, e.g. tablet, capsule, elixir, injection, suppository.\n3.The form of the completed pharmaceutical preparation, e.g. tablet, capsule, elixir, suppository.\n4.The form of the completed pharmaceutical product, e.g. tablet, capsule, elixir or suppository.\n5.The form of the finished pharmaceutical product, e.g. tablet, capsule, elixir or suppository."
    },
    {
        "instruction":"已知信息：\n'初始和定期的设备检测，例如含有或生成识别码或密码信息的记号或卡，以确保其运行正常，且未遭受未经授权的修改。'可被翻译为：(e) Initial and periodic testing of devices, such as tokens or cards, that bear or generate identification code or password information to ensure that they function properly and have not been altered in an unauthorized manner.\n\n根据上述已知信息，请将'按照损失管理过程对丢失、失窃、遗漏或存在其他损坏可能的记号、卡及其他含有或生成识别码或密码信息装置采取电子失效，并采用适当和严格的管理发生临时或永久的代用品。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(c) Following loss management procedures to electronically deauthorize lost, stolen, missing, or otherwise potentially compromised tokens, cards, and other devices that bear or generate identification code or password information, and to issue temporary or permanent replacements using suitable, rigorous controls."
    },
    {
        "instruction":"已知信息：\n'第十三条  省、自治区、直辖市药品监督管理部门应当对申请资料进行审核，按照国家药品监督管理局制定的医疗器械生产质量管理规范的要求进行核查，并自受理申请之日起20个工作日内作出决定。现场核查可以与产品注册体系核查相结合，避免重复核查。需要整改的，整改时间不计入审核时限。'可被翻译为：Article 13 The drug regulatory department of the province, autonomous region, or municipality directly under the central government shall examine the application dossiers, and conduct inspection in compliance with the requirements of the Good Manufacturing Practice for medical devices formulated by NMPA, and make decisions within 20 working days from the date of acceptance. The on-site inspection shall be combined with inspection of the product registration system, to avoid repeated inspection. If rectification is necessary, the rectification time shall not be included in the review time.\n\n根据上述已知信息，请将'第十二条 省、自治区、直辖市药品监督管理部门应当对申请人提交的申请资料进行审核，对申请人的生产场所进行现场核查，并自受理化妆品生产许可申请之日起30个工作日内作出决定。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 12 The drug regulatory department of the province, autonomous region, or municipality directly under the central government shall review the application documents submitted by the applicant, and conduct on-site inspection on manufacturing premises of the applicant, and make a decision within 30 working days beginning from the date of acceptance of the application for cosmetics manufacturing license."
    },
    {
        "instruction":"已知信息：\n'（二）有与药品生产相适应的厂房、设施、设备和卫生环境；'可被翻译为：(2) having the premises, facilities, equipment and hygienic environment required for drug manufacturing;\n\n根据上述已知信息，请将'（二）有与药品生产相适应的厂房、设施和卫生环境；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(2) have the premises, facilities, and hygienic environment required for drug manufacturing;"
    },
    {
        "instruction":"已知信息：\n'泛指各种机制导致发生的任何有害的遗传物质改变。'可被翻译为：A broad term that refers to any deleterious change in the genetic material regardless of the mechanism by which the change is induced.\n\n根据上述已知信息，请将'对生物体的遗传物质进行人为的操作，使之发生修饰和改变的过程。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The process of artificially manipulating the genetic material of an organism so that it is modified or altered."
    },
    {
        "instruction":"已知信息：\n'原发证部门应当结合企业遵守医疗器械管理法律法规、医疗器械生产质量管理规范情况和企业质量管理体系运行情况进行审查，必要时开展现场核查，在医疗器械生产许可证有效期届满前作出是否准予延续的决定。'可被翻译为：The former license issuing department shall make review in combination with the enterprise’s compliance with laws and regulations on administration of medical devices, the Good Manufacturing Practice for Medical Devices, and operation condition of the enterprise’s quality management system, and carry out on-site inspection if necessary, and then make a decision on whether granting renewal or not before expiration of valid term of the Medical Device Manufacturing License.\n\n根据上述已知信息，请将'原发证部门应当按照本办法第十三条的规定对延续申请进行审查，必要时开展现场核查，在医疗器械经营许可证有效期届满前作出是否准予延续的决定。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The former license issuing department shall review the application for renewal as stipulated in Article 13 of these Provisions, carry out on-site inspection if necessary, and make a decision on whether granting renewal or not before expiration of the valid term of the Medical Device Distribution License."
    },
    {
        "instruction":"已知信息：\n'进入 A 级和 B 级区的人员应接受无菌更衣和无菌行为的培训。应通过评估和至少每年定期再评估来确认符合无菌更衣程序，并应包括目检和微生物评估（使用戴手套的手指、前臂、胸部和头罩（口罩\/额头）等监测位置。预期限度参见 9.30 节）。对于正在或即将进行无菌操作的 A 级和 B 级区，无监督进入应仅限于经过适当资质确认、已通过更衣评估并参与过成功的 APS 的人员。'可被翻译为：The personnel accessing grade A and B areas should be trained for aseptic gowning and aseptic behaviours.\nCompliance with aseptic gowning procedures should be confirmed by assessment and periodic reassessment at\nleast annually, and should involve both visual and microbial assessment (using monitoring locations such as\ngloved fingers, forearms, chest and hood (facemask \/ forehead). See paragraph 9.30 for the expected limits). The\nunsupervised access to the grade A and grade B areas where aseptic operations are or will be conducted should be\nrestricted to appropriately qualified personnel, who have passed the gowning assessment and have participated in\na successful APS.\n\n根据上述已知信息，请将'注 3：对于人员更衣的确认，应采用表 6 中的表面微生物和五指手套的限度要求。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Note 3: For the qualification of personnel gowning, the limits given for contact plates and glove prints in Table 6 should apply."
    },
    {
        "instruction":"已知信息：\n'食品药品监督管理部门应当自受理复审申请之日起30个工作日内作出复审决定，并书面通知申请人。维持原决定的，食品药品监督管理部门不再受理申请人再次提出的复审申请。'可被翻译为：The food and drug regulatory department shall make a re-evaluation decision within 30 workdays after accepting the re-evaluation application and inform the applicant. Where the original decision shall be maintained, the food and drug regulatory department shall not accept further application for re-evaluation by the applicant.\n\n根据上述已知信息，请将'第四十三条 食品药品监督管理部门应当自受理复审申请之日起30个工作日内作出复审决定，并书面通知申请人。维持原决定的，食品药品监督管理部门不再受理申请人再次提出的复审申请。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 43 The food and drug regulatory department shall make a re-evaluation decision within 30 workdays after accepting the re-evaluation application and inform the applicant. Where the original decision shall be maintained, the food and drug regulatory department shall not accept further application for re-evaluation by the applicant."
    },
    {
        "instruction":"已知信息：\n'（六）内部审核、管理评审、变更控制、年度自查报告等情况；'可被翻译为：(6) internal audit, management review, change control, annual self-inspection report and other conditions;\n\n根据上述已知信息，请将'（七）内部审核、管理评审、年度自查报告等情况；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(7) internal audit, management review, annual self-inspection report and other conditions;"
    },
    {
        "instruction":"已知信息：\n'第二百二十七条 标准品或对照品的管理应当至少符合以下要求：'可被翻译为：Article 227: The management of the standard substances or reference substances should meet at least the following requirements:\n\n根据上述已知信息，请将'第二百二十条 质量控制实验室应当配备药典、标准图谱等必要的工具书，以及标准品或对照品等相关的标准物质。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 220: Necessary reference books such as pharmacopeias and standards spectrum, and primary reference substances such as reference standards and reference substances, should be available in quality control laboratories."
    },
    {
        "instruction":"已知信息：\n'现场核查过程中认为有必要进行样品检验的，经报核查中心同意后，核查组按照药品抽样的有关要求，抽取样品并封样，抽样情况应当在核查报告中进行描述；样品按要求送交药品检验机构进行样品检验。'可被翻译为：If it is deemed necessary to conduct sample inspection during the on-site inspection, the inspection team shall, with the approval of CFDI, take samples and seal them in accordance with the relevant requirements on drug sampling, and the sampling situation shall be described in the inspection report. The samples shall be sent to the drug testing institution for sample testing as required.\n\n根据上述已知信息，请将'第五十七条 本程序所指的抽样是指药品监督管理部门在注册核查过程中进行的取样、封样和通知检验。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 57 The sampling referred to in the Procedures refers to the sampling, sample sealing and notified inspection conducted by the drug regulatory authority during the registration inspection process."
    },
    {
        "instruction":"已知信息：\n'所有已灌装容器 100%完整性测试的方法和参数（参见第 8.22 节）。'可被翻译为：Methods and parameters for integrity testing of 100% of all filled containers (see paragraph 8.22).\n\n根据上述已知信息，请将'已灌装容器完整性测试的方法和参数（参见第 8.22 节）。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Methods and parameters for integrity testing of filled containers (see paragraph 8.22)."
    },
    {
        "instruction":"已知信息：\n'血清中所含特定药物的浓度。'可被翻译为：The concentration of a particular drug contained in the serum.\n\n根据上述已知信息，请将'血浆中所含特定药物的浓度。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The concentration of a specific drug contained in the plasma."
    },
    {
        "instruction":"已知信息：\n'1.不被视为新活性物质的API，先前已通过严格的监管机构或WHO的成品批准，但需要提交档案。例如，这将包括新的pd和多源产品的变体。\n2.不被视为新活性物质的API，以前已通过SRA或WHO的成品批准，但需要提交档案。例如，这将包括新的pd和多源产品的变体。'可被翻译为：1.An API that is not considered a new active substance, which has been previously approved through a finished product by a stringent regulatory authority or by WHO, but requires the filing of a dossier. This would include, for example, new PDs and variations to multisource products.\n2.An API that is not considered a new active substance, that has been previously approved through a finished product by an SRA or WHO, but requires the filing of a dossier. This would include, for example, new PDs and variations to multisource products.\n\n根据上述已知信息，请将'不被视为新活性物质的活性药物成分，先前已通过严格的监管机构或世界卫生组织的成品批准，但需要提交档案。这将包括，例如，新产品档案和多源产品的变体。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"An active pharmaceutical ingredient that is not considered a new active substance, which has been previously approved through a finished product by a stringent regulatory authority or by the World Health Organization, but requires the filing of a dossier. This would include, for example, new product dossiers and variations to multisource products."
    },
    {
        "instruction":"已知信息：\n'在电子未占有的分子轨道中，能量最低的分子轨道。'可被翻译为：In molecular orbitals that are not occupied by electrons, the ones with the lowest energy.\n\n根据上述已知信息，请将'原子或分子中电子激发前存在的低能量轨道。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"A low energy orbital in an atom or molecule that exists before the electrons are excited."
    },
    {
        "instruction":"已知信息：\n'1.全国医疗器械不良事件报告数量。2019年，国家医疗器械不良事件监测信息系统共收到可疑医疗器械不良事件报告396345份，比上年减少2.61%（图1）。'可被翻译为：1. Number of Medical Device Adverse Event Report. In 2019, the National Medical Device Adverse Event Monitoring Information System has received a total of 396,345 reports of suspected medical device adverse events, a decrease of 2.61 percent YOY(See Figure 1) .\n\n根据上述已知信息，请将'2020年，国家医疗器械不良事件监测信息系统共收到医疗器械不良事件报告536,055份，比上年增加35.25%。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In 2020, the National Medical Device Adverse Event Monitoring Information System has received a total of 536,055 reports of medical device adverse events, showing an increase of 35.25% compared with the previous year."
    },
    {
        "instruction":"已知信息：\n'进口疫苗类制品和血液制品应当同时提交生产企业所在国家或者地区的原产地证明以及药品管理当局出具的批签发证明文件，并提供经公证的中文译本。进口产品在本国免予批签发的，应当提供免予批签发的证明性文件。'可被翻译为：For an imported vaccine product or blood product, the certificate of origin of the country or region where the manufacturer is located and the lot release supporting documents issued by the local drug regulatory authority shall be provided at the same time, as well as their Chinese translations notarized. If an imported product is exempted from lot release in the country of origin, supporting documents for exemption of lot release shall be provided.\n\n根据上述已知信息，请将'第二十七条 申请疫苗批签发应当按照规定向批签发机构提供批生产及检验记录摘要等资料和同批号产品等样品。进口疫苗还应当提供原产地证明、批签发证明；在原产地免予批签发的，应当提供免予批签发证明。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 27 To apply for vaccine lot release, materials such as summary protocol of manufacturing and control and samples shall be provided to the lot release institutions as required. For imported vaccines, the certificate of country of origin and certificate of lot release shall also be provided; and if the imported vaccines are exempted from lot release in the country of origin, the exemption certificate of lot release shall be provided."
    },
    {
        "instruction":"已知信息：\n'使设计具备良好地接受旧版本输入信息的能力。本概念可用于整个系统、数据通信、协议、文件格式和计算机编程语言。例如，如果使用新标准设计的产品可以接收、阅读、查看或播放使用旧标准或格式设计的产品信息，那么就说该产品是向下兼容的。'可被翻译为：The ability of the design to gracefully accept input created with older versions of itself. The concept can be applied to entire systems, data \ncommunications, protocols, file formats and computer programming languages. For example, if products designed for the new standard can \nreceive, read, view or play older standards or formats, then the product is said to be Backward Compatible.\n\n根据上述已知信息，请将'使设计具备良好地接受新版本输入信息的能力。本概念适用于整个系统、数据通信、协议、文件格式和计算机编程语言。例如，如果按照旧标准设计的产品收、阅读、查看或播放新标准或格式（不包括新功能）下的信息，则认为该产品是具备“向上兼容性”的。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The ability of the design to gracefully accept input intended for newer versions of itself. The concept can be applied to entire systems, data \ncommunications, protocols, file formats and computer programming languages. For example, if products designed for the older standard can \nreceive, read, view or play the newer standard or format (excluding new functionality), then the product is said to be Forward Compatible."
    },
    {
        "instruction":"已知信息：\n'封闭系统系指由负责系统中电子记录内容的人员管理系统访问的计算机环境。'可被翻译为：(4) Closed system means an environment in which system access is controlled by persons who are responsible for the content of electronic records that are on the system.\n\n根据上述已知信息，请将'（十）负责指导设定计算机系统质量控制功能；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(X) Guiding the setting of quality control function of the computer system;"
    },
    {
        "instruction":"已知信息：\n'第四十八条 生物制品批签发证明、生物制品不予批签发通知书、生物制品批签发复审结果通知书由批签发机构按照顺序编号，其格式为“批签X（进）检XXXXXXXX”，其中，前X符号代表批签发机构所在地省、自治区、直辖市行政区域或者机构的简称，进口生物制品使用“进”字；后8个X符号的前4位为公元年号，后4位为年内顺序号。'可被翻译为：Article 48 The Certificate for Lot Release of Biological Products, the Notice of Disapproval of Lot Release of Biological Products and the Notice of Re-review Result of Lot Release of Biological Products shall be numbered by the lot release institution in sequence with a format of “Lot Release X (Import) Test XXXXXXXX”, wherein the first X symbol represents the abbreviation of the administrative region of the province, autonomous region or municipality directly under the Central Government in the place where the lot release institution is located or abbreviation of the institution; for imported biological products, “Import” shall be used; and in the last 8 X symbols, the former 4 X symbols represent the AD year, and the latter 4 X symbols represent the sequence number within the year.\n\n根据上述已知信息，请将'第四十七条    生物制品批签发证明、生物制品不予批签发通知书、生物制品批签发复审结果通知书由批签发机构按照国家药品监督管理局规定的顺序编号，其格式为“批签X（进）检XXXXXXXX”，其中，前X符号代表批签发机构所在地省、自治区、直辖市行政区域或者机构的简称，进口生物制品使用“进”字；后8个X符号的前4位为公元年号，后4位为年内顺序号。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 47 The Certificate for Lot Release of Biological Products, the Notice of Disapproval of Lot Release of Biological Products and the Notice of Re-review Result of Lot Release of Biological Products shall be numbered by the lot release institution in sequence specified by the NMPA, with a format of \"Lot release X (Import) Test XXXXXXXX\", wherein the first X symbol represents the abbreviation of the administrative region of provinces, autonomous regions or municipalities directly under the Central Government in the place where the lot release institution is located or abbreviation of the institution; for imported biological products, \"Import\" shall be used; and in the last 8 X symbols, the former 4 X symbols represent the AD year, and the latter 4 X symbols represent the sequence number within the year."
    },
    {
        "instruction":"已知信息：\n'（一）未按照规定建立药品不良反应报告和监测管理制度，或者无专门机构、专职人员负责本单位药品不良反应报告和监测工作的；'可被翻译为：(I) Having not established an ADR reporting and monitoring management system as required, or having no specialized department or full-time personnel in charge of ADR reporting and monitoring within the enterprise;\n\n根据上述已知信息，请将'（一）未按照本办法规定建立医疗器械召回管理制度的；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(1) fail to establish a medical device recall management system in accordance with these Provisions;"
    },
    {
        "instruction":"已知信息：\n'第三十一条 药品上市许可持有人、药品生产企业在药品生产中，应当开展风险评估、控制、验证、沟通、审核等质量管理活动，对已识别的风险及时采取有效的风险控制措施，以保证产品质量。'可被翻译为：Article 31 Drug MAHs and manufacturers shall conduct risk assessment, control, validation, communication, review and other quality management activities, and promptly take effective risk control measures for identified risks to ensure product quality.\n\n根据上述已知信息，请将'（四）对药品生产企业、供应商等相关方与药品生产相关的活动定期开展质量体系审核，保证持续合规；'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(4) regularly carry out quality system audits of drug manufacturing related activities of related parties including drug manufacturers and suppliers to ensure continuous regulatory compliance;"
    },
    {
        "instruction":"已知信息：\n'细胞内代谢终产物的积累或某些中间产物的过量积累，阻止代谢途径中某些酶合成的现象。'可被翻译为：The accumulation of metabolic end products or excessive accumulation of certain intermediates in the cell prevents the synthesis of certain enzymes in the metabolic pathway.\n\n根据上述已知信息，请将'酶促系列反应中，某些中间产物或终产物对催化起始步骤反应的酶活性和酶合成进行调节的作用。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"In a series of enzymatic reactions, some intermediates or end products regulate the activity and synthesis of enzymes that catalyze the initial step of the reaction."
    },
    {
        "instruction":"已知信息：\n'研究角度'可被翻译为：research perspective\n\n根据上述已知信息，请将'药物经济学评价和研究的视角，主要包括社会角度、患者角度、医疗机构角度和保险方角度。不同的研究角度需要测量的成本和产出范围不同。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"The perspectives of pharmacoeconomic evaluation and research mainly include the social perspective, the patient perspective, the medical institution perspective and the insurance perspective. Different research perspectives need to measure different ranges of costs and outputs."
    },
    {
        "instruction":"已知信息：\n'中国境内企业投资的境外注册人在境内生产已获进口医疗器械注册证的第二类、第三类医疗器械产品的，参照本公告执行，由投资境外注册人的中国境内企业作为注册申请人申请该产品注册。'可被翻译为：The production of Class II and Class III medical devices with imported medical device registration certificates in China by overseas registrants invested by domestic enterprises in China can be implemented with reference to this Announcement. The domestic enterprises in China that invest the overseas registrants should apply for product registration as the registration applicants.\n\n根据上述已知信息，请将'进口医疗器械注册人通过其在境内设立的外商投资企业在境内生产第二类、第三类已获进口医疗器械注册证产品的有关事项，适用本公告。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"This Announcement is applicable to the matters concerning the production of Class II and Class III medical devices with imported medical device registration certificates in China by the imported medical device registrants through their foreign invested enterprises established in China."
    },
    {
        "instruction":"已知信息：\n'第一百一十五条 应当由指定人员按照操作规程进行配料，核对物料后，精确称量或计量，并作好标识。'可被翻译为：Article 115: Dispensing should only be carried out by designated personnel according to operation procedures. After being checked, materials should be accurately weighed or measured, and well labeled.\n\n根据上述已知信息，请将'第一百一十七条 用于同一批药品生产的所有配料应当集中存放，并作好标识。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Article 117: Materials dispensed for each batch should be kept together and conspicuously labeled as such."
    },
    {
        "instruction":"已知信息：\n'应建立适当机制，发现不符合验证参数的灭菌循环。应对任何失败的灭菌或不符合经验证工艺过程的灭菌（例如加热循环等阶段较长或较短）进行调查。'可被翻译为：There should be mechanisms in place to detect a sterilisation cycle that does not conform to the validated parameters. Any failed sterilisation or sterilisation that deviated from the validated process (e.g. have longer or shorter phases such as heating cycles) should be investigated.\n\n根据上述已知信息，请将'液体循环的验证应包括温度，时间和\/或 F0值。关键操作参数应符合规定的限度（包括适当的公差），并作为灭菌验证和常规循环可接受标准的一部分予以确认。'翻译为英文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":" Validation of fluid cycles should include temperature, time and\/or Fo. Critical processing parameters should be subject to defined limits (including appropriate tolerances) and be confirmed as part of the sterilisation validation and routine cycle acceptance criteria."
    }
]